

Reseptregisteret
2009–2013

The Norwegian
Prescription Database
2009–2013



Reseptregisteret 2009–2013

The Norwegian Prescription Database 2009–2013

Christian Berg
Øystein Karlstad
Milada Mahic
Ingvild Odsbu

Rapport 2014:2
Nasjonalt folkehelseinstitutt /
The Norwegian Institute of Public Health

Tittel/Title:

Reseptregisteret 2009–2013

The Norwegian Prescription
Database 2009–2013

Redaktør/Editor:

Christian Berg

Forfattere/Authors:

Christian Berg
Øystein Karlstad
Milada Mahic
Ingvild Odsbu

Publisert av / Published by:

Nasjonalt folkehelseinstitutt
Postboks 4404 Nydalen
NO-0403
Norway

Tel: + 47 21 07 70 00

E-mail: folkehelseinstituttet@fhi.no

www.fhi.no

Design/Layout

Houston911

Acknowledgement:

Julie D.W. Johansen (English version)

Forsideillustrasjon / Front page illustration:

iStockPhoto

Trykk/Print:

www.wj.no

Opplag / Number printed:

300

Bestilling/Order:

publikasjon@fhi.no

Fax: +47-21 07 81 05

Tel: +47-21 07 82 00

ISSN: 1890-9647

ISBN: 978-82-8082-618-3 trykt utgave/printed version

ISBN: 978-82-8082-619-0 elektronisk utgave/electronic version

Tidligere utgave / Previous edition:

2008: Reseptregisteret 2004–2007 / The Norwegian Prescription Database 2004–2007

2009: Legemiddelstatistikk 2009:2: Reseptregisteret 2004–2008 / The Norwegian Prescription Database 2004–2008

2010: Legemiddelstatistikk 2010:2: Reseptregisteret 2005–2009. Tema: Vanedannende legemidler / The Norwegian Prescription Database 2005–2009. Topic: Addictive drugs

2011: Legemiddelstatistikk 2011:2: Reseptregisteret 2006–2010 / The Norwegian Prescription Database 2006–2010

2012: Legemiddelstatistikk 2012:2: Reseptregisteret 2007–2011 / The Norwegian Prescription Database 2007–2011

2013: Legemiddelstatistikk 2013:2: Reseptregisteret 2008–2012 / The Norwegian Prescription Database 2008–2012



Forord

Bruken av legemidler i befolkningen er økende. En viktig målsetting for norsk legemiddelpolitikk er rasjonell legemiddelbruk. En forutsetning for arbeidet med å optimalisere legemiddelbruken i befolkningen er kunnskap om hvilke legemidler som brukes, hvem som bruker legemidlene og hvordan de brukes. For å få bedre kunnskap på dette området, vedtok Stortinget i desember 2002 å etablere et nasjonalt reseptbasert legemiddelregister (Reseptregisteret). Oppgaven med å etablere registeret ble gitt til Folkehelseinstituttet som fra 1. januar 2004 har mottatt månedlige opplysninger fra alle apotek om utlevering av legemidler til pasienter, leger og institusjoner.

Denne rapporten er syvende utgave av den årlige statistikken fra Reseptregisteret. Generell informasjon om Reseptregisteret, legemiddelstatistikk, klassifikasjon av legemidler og målemetoder finnes i rapportens del 1. Del 2 inneholder noen nøkkeltall fra Reseptregisteret og et omfattende tabellverk med opplysninger om antall individer som har fått utlevert legemidler etter resept fra apotekene i Norge i siste femårsperiode (2009–2013). Opplysningene er fordelt på enkeltlegemidler og legemiddelgrupper. ATC (Anatomisk Terapeutisk Kjemisk) -klassifikasjon er benyttet i tabellene. For 2013 er informasjon om alders- og kjønnsfordeling og kostnader inkludert i tabellene. ATC-/DDD-versjon gjeldende fra januar 2014 er benyttet i rapporten, se også www.whocc.no

Reseptregisteret har også en nettside der man kan finne kompletterende informasjon. Nettstedet er: www.norpd.no (engelsk versjon) eller www.reseptregisteret.no (norsk versjon).

Det er også mulig å søke om utlevering av data fra Reseptregisteret til forskning eller til andre formål som er i henhold til formålet for Reseptregisteret. Mer informasjon om dette finnes i bokens del 2 og på nettsiden til Folkehelseinstituttet (www.fhi.no).

Avdeling for legemiddelepideologi
Folkehelseinstituttet
April 2014

Preface

The use of drugs in the population is increasing. An important goal of the health policies regarding pharmaceuticals in Norway is rational drug use. In order to improve drug use, knowledge about which drugs are used, how they are used and who uses them is vital. In December 2002, the Parliament decided to establish a national prescription database in Norway (NorPD). The task of building up the register was given to the Norwegian Institute of Public Health (NIPH). Since 1st January 2004, the institute has received monthly data on prescriptions from all Norwegian pharmacies.

This report is the seventh edition of the annual statistics from NorPD. General information about NorPD, drug statistics, classification of drug and measurement methods is included in part 1 of the report. Part 2 contains some key figures from NorPD and the main tables with information about the number of individuals who had prescriptions dispensed from pharmacies in Norway during the latest five years period (2009–2013). The information includes particular drug substances as well as drug groups. ATC (Anatomical Therapeutic Chemical) classification is used in the tables. For 2013, information about age, gender and costs are included in the tables. The ATC/DDD version of January 2014 has been used in the report, see also www.whooc.no

NorPD also has a website where you can find complementary information. The website is: www.norpd.no (English version) or www.reseptregisteret.no (Norwegian version). It is also possible to apply for data from NorPD for research or for other purposes which are according to the objectives of NorPD. More information about this can be found in part 2 of the report, and at the website of the Norwegian Institute of Public Health (www.fhi.no).

Department of Pharmacoepidemiology
Norwegian Institute of Public Health
April 2014

Innhold

| | |
|--|------------|
| Forord | 6 |
| 1. Generelt om Reseptregisteret og legemiddelstatistikk | 11 |
| 1.1 Reseptregisteret (NorPD) | 11 |
| 1.2 Nordiske reseptregistre | 14 |
| 1.3 Grossistbasert legemiddelstatistikk | 15 |
| 1.4 Anatomisk Terapeutisk Kjemisk (ATC)-klassifisering | 15 |
| 1.5 Definert Døgndose (DDD) | 16 |
| 1.6 WHO Collaborating Centre for Drug Statistics Methodology..... | 17 |
| 2. Reseptregisteret 2009–2013 | 19 |
| 2.1 Utvalgte nøkkeltall fra Reseptregisteret | 19 |
| 2.2 Reseptkategorier og refusjon av utgifter til legemidler | 23 |
| 2.3 Beskrivelse av hovedtabellene | 27 |
| 2.4 ATC main groups..... | 31 |
| 2.5 ATC group A – Alimentary tract and metabolism..... | 32 |
| 2.6 ATC group B – Blood and bloodforming organs..... | 43 |
| 2.7 ATC group C – Cardiovascular system..... | 46 |
| 2.8 ATC group D – Dermatologicals | 54 |
| 2.9 ATC group G – Genito urinary system and sex hormones..... | 60 |
| 2.10 ATC group H – Systemic hormonal preparations, excl. sex hormones and insulins | 65 |
| 2.11 ATC group J – Antiinfectives for systemic use | 68 |
| 2.12 ATC group L – Antineoplastic and immunomodulating agents | 74 |
| 2.13 ATC group M – Musculo-skeletal system | 77 |
| 2.14 ATC group N – Nervous system | 81 |
| 2.15 ATC group P – Antiparasitic products, insecticides and repellents..... | 91 |
| 2.16 ATC group R – Respiratory system | 93 |
| 2.17 ATC group S – Sensory organs | 97 |
| 2.18 ATC group V – Various..... | 101 |
| Noen forkortelser og definisjoner | 102 |
| Folkemengde i Norge 2009–2013 (per 1. juli) | 103 |
| Folkemengde etter alder i 2013 (per 1. juli) | 103 |
| Liste over publikasjoner basert på data fra Reseptregisteret per mars 2014..... | 104 |

Contents

| | |
|---|------------|
| Preface | 6 |
| 1. General information about the Norwegian Prescription Database and drug statistics | 11 |
| 1.1 About the NorPD | 11 |
| 1.2 Prescription statistic in the other Nordic countries | 14 |
| 1.3 The Norwegian Drug Wholesales Statistics | 15 |
| 1.4 The Anatomical Therapeutic Chemical (ATC) classification system | 15 |
| 1.5 The Defined Daily Dose (DDD)..... | 16 |
| 1.6 The WHO Collaborating Centre for Drug Statistics Methodology..... | 17 |
| 2. The Norwegian Prescription Database (NorPD) 2009–2013..... | 19 |
| 2.1 Selected key figures from NorPD | 19 |
| 2.2 Prescription categories and reimbursement of medicinal expenses | 23 |
| 2.3 Description of the main tables..... | 27 |
| 2.4 ATC main groups..... | 31 |
| 2.5 ATC group A – Alimentary tract and metabolism..... | 32 |
| 2.6 ATC group B – Blood and bloodforming organs..... | 43 |
| 2.7 ATC group C – Cardiovascular system..... | 46 |
| 2.8 ATC group D – Dermatologicals | 54 |
| 2.9 ATC group G – Genito urinary system and sex hormones..... | 60 |
| 2.10 ATC group H – Systemic hormonal preparations, excl. sex hormones and insulins | 65 |
| 2.11 ATC group J – Antiinfectives for systemic use | 68 |
| 2.12 ATC group L – Antineoplastic and immunomodulating agents | 74 |
| 2.13 ATC group M – Musculo-skeletal system | 77 |
| 2.14 ATC group N – Nervous system | 81 |
| 2.15 ATC group P – Antiparasitic products, insecticides and repellents..... | 91 |
| 2.16 ATC group R – Respiratory system | 93 |
| 2.17 ATC group S – Sensory organs | 97 |
| 2.18 ATC group V – Various..... | 101 |
| Some abbreviations and definitions | 102 |
| Population in Norway 2009–2013 (as of 1st July) | 103 |
| Population by age in 2013 (as of 1st July)..... | 103 |
| List of publications based on data from the Norwegian Prescription Database (NorPD) as of March 2014 | 104 |

1. Generelt om Reseptregisteret og legemiddelstatistikk

1.1 Reseptregisteret (NorPD)

Datainnsamling og variabler i Reseptregisteret

Ny apoteklov trådte i kraft 1. mars 2001, og ifølge den nye loven ble apotek forpliktet til å videresende reseptdata til en ny nasjonal legemiddeldatabase. I oktober 2003 ble ny detaljert forskrift for Reseptregisteret (hjemlet i Helseregisterloven) vedtatt av Kongen i Statsråd (1). Formålet med Reseptregisteret (jf. forskriftens § 1-3) er å samle inn og behandle data om legemiddelbruk hos mennesker og dyr for å:

1. kartlegge forbruket i landet og belyse endringer over tid
2. fremme og gi grunnlag for forskning og utredning for å kunne belyse positive og negative effekter av legemiddelbruk
3. gi myndighetene et statistisk grunnlag for kvalitetssikring av legemiddelbruk og overordnet tilsyn, styring og planlegging
4. gi legemiddelrevirer et grunnlag for internkontroll og kvalitetsforbedring

Forskriftens formål bestemmer hva Reseptregisteret kan brukes til. Forskriften bestemmer også hva slags data som kan samles inn fra apotek og administrative registre.

1. General information about the Norwegian Prescription Database and drug statistics

1.1 About the NorPD

Data collection and variables in NorPD

New legislation in the Norwegian pharmacy sector came into force on March 1st 2001. According to the new act, pharmacies were obliged to forward prescription data to a new national drug database. In October 2003, new, detailed regulations for the NorPD were approved (1). The objectives of the NorPD, as defined in authoritative regulations, are to collect and prepare data on drug use in individuals and animals in order to:

1. describe drug use patterns, highlighting changes over time
2. promote and form a basis for research and review of the safety and effectiveness of drug use
3. serve as a management tool for the authorities in order to assure prescribing quality in addition to general surveillance, control and planning
4. give the prescribing doctors a basis for internal control, as part of an audit method to improve the quality of prescribing practices

All NorPD data use must be in accordance with these objectives. The regulation also determines what kind of data can be collected from the pharmacies and administrative registers.

Reseptregisteret inneholder følgende variabler:

Pasient

Personidentifikasjon (kryptert), fødselsmåned /-år, døds måned/- år, kjønn, bosted (kommune og fylke)

Forskriver

Personidentifikasjon (kryptert), fødselsår, kjønn, yrke, spesialitet

Legemiddel

Nordisk varenummer (merkenavn, styrke, legemiddelform, pakningsstørrelse), antall pakninger, ATC-kode, antall definerte døgndoser (DDD), reseptkategori, kode for refusjon (fra mars 2008: ICD10, ICPC koder og enkelte koder definert av Legemiddelverket, fullstendig implementert fra mars 2009), bruksområde og forskrevet dose (fritekst), utleveringsdato, pris (apotekets utsalgspris)

Apotek

Apoteknavn, konsesjonsnummer, kommune og fylke

Det nordiske varenummeret er en unik identifikasjon for hver pakning av et legemiddel og muliggjør kobling til andre registre som gir detaljert informasjon om legemidlene. Indikasjon for forskrivning ble de første årene ikke registrert i databasen, kun overordnede refusjonskoder som for enkelte legemidler fungerte som grov diagnosekode. Fra mars 2008 ble forskriver pålagt å angi mer spesifikke diagnosekoder på blåresepter som erstatning for de gamle sykdomspunktene. Det skal benyttes enten International Classification of Diseases versjon 10 (ICD-10) eller International Classification of Primary Care (ICPC). I tillegg har Legemiddelverket på enkelte områder definert egne koder. Ordningen er fullstendig implementert fra mars 2009.

Fra 1. januar 2004 har Folkehelseinstituttet mottatt månedlig informasjon om reseptutleveringer fra alle apotek i Norge (2). I alle apotek er det tilrettelagt for automatisk innsending av rapport til Reseptregisteret til fast tidspunkt hver måned, slik at apotekene kan oppfylle sin rapporteringsplikt uten vesentlig ekstra arbeid. Reseptregisteret inneholder informasjon om alle legemidler som er forskrevet og utlevert til enkeltpasienter utenom sykehus og institusjoner. Legemidler forskrevet på godkjeningsfritak er også inkludert, men legemidler som selges reseptfritt er ikke registrert i Reseptregisteret. Hvis reseptfrie legemidler er forskrevet på resept vil de imidlertid bli registrert i databasen.

De viktigste dataene i Reseptregisteret er basert på resepter forskrevet til enkeltpersoner, men også forskrivning av legemidler fra veterinærer til dyr og forskrivning til egen praksis registreres i Reseptregisteret. Når det gjelder pasienter som er innlagt i sykehus eller sykehjem, samler registeret kun inn

The NorPD contains the following variables:

Patient

Person-identifier (encrypted), month/year of birth, month/year of death, gender, place of residence (municipality & county)

Prescriber

Person-identifier (encrypted), year of birth, gender, profession, speciality

Drug

Nordic article number (unique product identifier stating brand name, strength, pharmaceutical form and pack size), number of packs, ATC code, number of Defined Daily Doses (DDD), prescription category, reimbursement code (from March 2008: ICD10, ICPC codes or codes defined by the Norwegian Medicines Agency, completely implemented from March 2009), intended use and prescribed dose (free-text according to pharmacy label), dispensing date, price (pharmacy retail price)

Pharmacy

Name, licence number, municipality and county

The Nordic article number is the important link to other registries providing detailed information about the drugs. The indication for prescribing was in the first years not recorded in the database, only the code of reimbursement which in some cases, acted as a proxy of diagnosis. From March 2008, prescribers had to use either the International Classification of Diseases version 10 (ICD10), or the International Classification of Primary Care Codes (ICPC) or special codes assigned by the Norwegian Medicines Agency as the code of reimbursement on the prescriptions. This was fully implemented from March 2009.

Since 1st January 2004, the NIPH has received monthly data on prescriptions from all Norwegian pharmacies (2). Monthly electronically reports are automatically generated in all pharmacies, thus avoiding extra work for the pharmacy. NorPD contains information about all drugs prescribed (reimbursed or not) and dispensed at pharmacies to individual patients living outside institutions, i.e. ambulant care. Unlicensed drugs are also included, but drugs sold over-the-counter (OTC) are not recorded in NorPD. However, if the OTC drugs are prescribed by a physician and dispensed, then they will be recorded in the database.

The main data in NorPD are based on prescriptions to individual humans, but also prescribed drugs by veterinarians to animals and prescribing to a physician's own practice are collected in NorPD. For patients in nursing homes and hospitals, the register collects figures on drug use at the level of the institution or the department, i.e. on an aggregate level.



Figure 1.1: Data flow, the Norwegian Prescription Database (NorPD)

aggregerte data på institusjons- eller avdelingsnivå basert på informasjon som apotekene registrerer når de leverer legemidler til institusjoner.

Datasikkerhet

Som illustrert i figur 1.1 blir registreringer av utleverte legemidler fra apotek elektronisk og automatisk overført til Statistisk sentralbyrå (SSB) før de kommer til FHI og inkluderes i Reseptregisteret. SSB fungerer som en såkalt tiltrodd tredjepart og er en del av datasikkerheten for å ivareta konfidensialitet og informasjonssikkerhet for all personlig informasjon. SSB har tilgang til pasientens personnummer og forskrivers helsepersonellnummer, og erstatter begge med et pseudonym. SSB kan ikke lese noen annen informasjon fra reseptene, fordi denne informasjonen er kryptert før SSB mottar dataene. Når SSB sender data er fødselsnummer og forskrivers helsepersonellnummer fjernet, og FHI kan dekryptere helseopplysningene som fremgår av resepten igjen. Prinsippet for pseudonymisering er at ingen, heller ikke den som tildeler og forvalter pseudonymer, skal kunne ha samtidig tilgang til både pseudonym, helseopplysninger og personens identitet. Begrepet "Pseudonymiserte helsedata" er definert i Helseregisterloven: "Personlig helsedata som identitet er kryptert, eller på annen måte skjult, men likevel individuell, slik at det er mulig å følge hver person gjennom helsesystemet uten at vedkommendes identitet blir avslørt" (3). Dette betyr at identiteten til pasienter og forskrivere har blitt kryptert i henhold til norsk lovgivning, men likevel er individuell, slik at det er mulig å følge enkeltpersoner over tid, og gjøre registerkoblingsstudier.

Kvalitetssikring

For kvalitetssikring blir et antall søk gjennomført månedlig eller halvårlig for å identifisere mulige feil eller uoverensstemmelser. FHI gjør ulike rutinemessige

Data protection

As illustrated in figure 1.1 the pharmacy records of dispensed drugs are electronically and automatically transferred through Statistics Norway before they arrive at NIPH and are included in NorPD. Statistics Norway acts as a so-called "trusted third party centre" and is a part of the data protection to ensure confidentiality of personal information. Statistics Norway only has access to the patient personal identification number and the prescriber's health personnel number and replaces both with a pseudonymised identifier. Statistics Norway cannot read any other prescription data because this information is encrypted before Statistics Norway receives the data. When Statistics Norway sends the data including the pseudonymised identifiers to the NIPH, the NIPH is allowed to decrypt the prescription information again. The term "Pseudonymous health data" is defined in the Personal Health Data Filing System Act (in Norwegian: Helseregisterloven): "personal health data in which the identity has been encrypted or otherwise concealed, but nonetheless individualized so that it is possible to follow each person through the health system without his identity being revealed" (3). This means that the identity of patients and prescribers has been encrypted according to Norwegian legislation, but nonetheless individualized, so that it is possible to follow individuals over time and perform record-linkage studies. Data linkage is based on the unique identification number system which is available in all the Nordic countries.

Quality checks

For quality assurance, a number of queries are carried out monthly or half-yearly to identify possible errors or inconsistencies. NIPH performs different routine checks on the data before they are transferred to the NorPD. In the NorPD, the Nordic article number is linked to the national register of medicinal products with validated

kontroller på data før de overføres til Reseptregisterets database. I Reseptregisteret er det nordiske varenummeret knyttet til det nasjonale vareregisteret for legemidler med gyldige ATC-koder og DDD-verdier (4). Dette registeret oppdateres månedlig. FHI sjekker også om dataleveranser fra hvert apotek er av rimelig størrelse. Det totale antallet reseptbelagte poster, totalt antall pasienter og forskrivere blir sjekket hver måned. Statistikk for apotekene blir rutinemessig kjørt. Denne rutinen vil identifisere uvanlige variasjoner i størrelsen på dataleveranser fra måned til måned, og fange opp manglende leveranser av spesielle typer data, eller hvis en datalevering fra ett apotek er tom i en måned på grunn av tekniske feil på apoteket eller hos tiltrodd tredjepart (SSB). Fødselsnummeret kontrolleres hos SSB mot Folkeregisteret. Når fødselsnummeret er ugyldig eller mangler, lager SSB et spesielt pseudonym. Disse personene er ikke mulig å følge over tid, og heller ikke mulig å koble til andre datakilder, men det rapporterte antall ordinasjoner og DDD knyttet til disse personene kan likevel inkluderes i totalstatistikken.

1.2 Nordiske reseptregistre

På slutten av 1980-tallet, tok apotek i de nordiske landene gradvis i bruk elektroniske systemer ved ekspedering av resepter. Dette gjorde det mulig å samle inn reseptdata fra apotek på en enklere og mer effektiv måte. Selv om helsevesenet ikke er organisert likt i de nordiske landene, har alle fem land et helsevesen med universell dekning for helseutgifter. Alle borgere, uavhengig av sosioøkonomisk status, har ubegrenset tilgang til helsetjenester, inkludert delvis eller fullstendig refusjon av kjøpte legemidler. Nasjonale reseptdatabaser, som er basert på data fra ekspederte og utleverte legemidler fra apotek til individer utenfor sykehus/sykehjem, har vært tilgjengelig siden 1994 i Finland og Danmark, siden 2004 i Norge, siden 2005 i Sverige og siden 2006 på Island. Databasene dekker til sammen 25 millioner innbyggere (Danmark: 5,6 millioner, Finland: 5,4 millioner; Island: 0,3 millioner; Norge: 5,1 millioner og Sverige: 9,6 millioner). Det er mulig å koble disse dataene til ulike helseutfall og andre data basert på det unike fødselsnummeret/-koden som alle innbyggere i disse landene har. Databasene er en viktig ressurs for å kunne gjennomføre longitudinelle og registerkoblede studier med helseundersøkelser og andre registre. Databasene representerer også et godt kunnskapgrunnlag for nasjonale beslutninger innen legemiddelbruk. En artikkel fra 2010 gir en oversikt over datainnsamlingsprosedyrer og innhold i de nordiske landenes reseptregistre (5).

ATC codes and DDD values (4). This register is updated monthly. NIPH also checks if the data deliveries from each pharmacy are of a reasonable size. The total number of prescription records and the total number of patients and prescribers are checked every month. Statistics for the pharmacies are checked by routine. Unusual variations in size of data files from month to month are identified and any missing data is caught, such as missing special data type deliveries or empty data files caused by technical error at the pharmacy or at the trusted third party. The Personal Identification Number is checked in Statistics Norway against the Central Population Registry. If the Personal Identification Number is invalid or missing, Statistics Norway creates a special pseudonym, but it is not possible to track these individuals or link them to other data sources. However, the reported total number of ordinations and DDDs can be included in the total statistics.

1.2 Prescription statistic in the other Nordic countries

During the late 1980s, pharmacies in the Nordic countries gradually computerized their records of dispensed prescriptions which made it possible to collect data efficiently. Although healthcare systems are not organized identically in the Nordic countries, all five countries have a tax-supported public health service with universal coverage. All citizens, independent of socioeconomic status, have unrestricted access to health services, including partial or complete reimbursement of purchased medicines. National prescription databases, containing data on drugs dispensed at pharmacies (exposure data) to individuals receiving ambulatory care, have been available since 1994 in Finland and Denmark, since 2004 in Norway, since 2005 in Sweden and since 2006 in Iceland. The databases together cover 25 million inhabitants (Denmark: 5.6 million; Finland: 5.4 million; Iceland: 0.3 million; Norway: 5.1 million; and Sweden: 9.6 million) and have the potential to link these data to different health outcomes and other data based on the unique personal identity code which all residents in these countries have. The databases serve as a resource for conducting longitudinal and record-linkage studies with health surveys and other registries. They also offer a sound evidence base for national decision-making in the field of drug utilization. An article from 2010 provides an overview of the data collection procedures and content of the Nordic countries' prescription databases (5). In addition, the article discusses their unique potential for cross-national record linkage and for analytical pharmacoepidemiological studies.

1.3 Grossistbasert legemiddelstatistikk

Statistikk basert på totalt salg av legemidler fra grossist til apotek, sykehus/sykehjem har vært tilgjengelig i Norge siden 1970-tallet. Grossistbasert legemiddelstatistikk omfatter alt salg av legemidler fra grossist til apotek, sykehus/sykehjem, dagligvaredetaljister og andre med tillatelse til å omsette legemidler. Legemidler til dyr og mennesker, både reseptfrie og reseptbelagte, er inkludert i statistikken. Statistikken gir en oversikt over utviklingen i legemiddelomsetningen over tid, både totalt og på fylkesnivå. Statistikken inneholder imidlertid ikke opplysninger om den enkelte legemiddelbruker.

Legemiddelforbruket i Norge – årlig publikasjon

Årlig publiseres data fra den Grossistbaserte legemiddelstatistikken i publikasjonen Legemiddelforbruket i Norge. Hver utgave omfatter 5-årsoversikter over totalsalget av reseptfrie og reseptbelagte legemidler i Norge (6). Boken er tilgjengelig på nettsiden www.legemiddelforbruk.no. Nærmere informasjon vedrørende utlevering av data fra den grossistbaserte legemiddelstatistikken finnes på Folkehelseinstituttets nettside www.fhi.no.

1.4 Anatomisk Terapeutisk Kjemisk (ATC)-klassifisering

Alle legemidler som er registrert i Norge er gruppert etter ATC-systemet. I ATC-systemet inndeles legemidlene i grupper på 5 nivåer: På 1. nivå fordeles legemidlene på 14 anatomiske hovedgrupper. Det neste nivået (2. nivå) er en terapeutisk eller farmakologisk undergruppe. 3. nivå og 4. nivå er terapeutiske, farmakologiske eller kjemiske undergrupper, mens 5. nivå representerer den kjemiske substansen.

ATC- koden

En fullstendig klassifisering av legemiddelsubstansen spironolaktone (vanndrivende middel) med ATC-koden C03DA01 kan illustrere oppbyggingen av ATC-systemet:

| | |
|---------|---|
| C | Hjerte og kretsløp (1. nivå, anatomisk hovedgruppe) |
| C03 | Diuretika (2. nivå, terapeutisk undergruppe) |
| C03D | Kaliumsparende midler (3. nivå, farmakologisk undergruppe) |
| C03DA | Aldosteronantagonister (4. nivå, farmakologisk undergruppe) |
| C03DA01 | Spironolaktone (5. nivå, kjemisk substans) |

1.3 The Norwegian Drug Wholesales Statistics

Statistics based on total sales of drugs from wholesalers to pharmacies, hospitals/nursing homes has been available in Norway since the 1970s. The Norwegian Drug Wholesales Statistics database includes total sales of drugs from wholesalers to pharmacies, hospitals/nursing homes and non-pharmacy outlets and others with permission to sell medicines. Total sales of prescription and non-prescription human and veterinary medicines are included in the statistics. The statistics give an overview of developments in drug consumption over time, both at county and country level. The statistics, however, contain no information about the individual drug user.

Drug Consumption in Norway – published annually

Data from the Norwegian Drug Wholesales Statistics Database have been published annually in *Drug Consumption in Norway (6)* since 1977. Each issue includes total sales data for 5 year periods for both prescription- and non-prescription drugs in Norway. The book is available from the website www.drugconsumption.no. Further information on the Norwegian Drug Wholesales Statistics database, including how to apply for data, can be found at the Norwegian Institute of Public Health's website www.fhi.no.

1.4 The Anatomical Therapeutic Chemical (ATC) classification system

In the ATC system the drug substances are classified into groups at 5 different levels. The drugs are divided into fourteen main groups (1st level), with pharmacological/ therapeutic sub-groups (2nd levels). The 3rd and 4th levels are chemical/pharmacological/ therapeutic sub-groups and the 5th level is the chemical substance.

The ATC code

A complete classification of the drug spironolactone (diuretic) with the ATC code C03DA01 illustrates the structure of the ATC system:

| | |
|---------|---|
| C | Cardiovascular system (1st level, anatomical main group) |
| C03 | Diuretics (2nd level, therapeutic sub-group). |
| C03D | Potassium-sparing agents (3rd level, pharmacological sub-group) |
| C03DA | Aldosterone antagonists (4th level, pharmacological sub-group) |
| C03DA01 | Spironolactone (5th level, chemical substance) |

Alle spironolakton preparater (Aldactone® og Spirix®) gis i dette systemet koden C03DA01.

Ved hjelp av dette klassifikasjonssystemet kan man lage statistikker over legemiddelforbruk gruppert på fem ulike nivåer, fra tall som viser totalforbruket av alle preparater klassifisert f.eks. under hovedgruppe C – *Hjerte og kretsløp* (1. nivå), tall for de ulike undergruppene (2., 3. og 4. nivå) og ned til tall som viser forbruket av det enkelte virkestoff.

ATC-kode for hvert enkelt preparat er angitt i *apotekenes vareregister*, og i preparatomtalene (SPC) som er publisert i *Felleskatalogen*. Ved å bruke "Anatomisk terapeutisk kjemisk legemiddelregister" (Felleskatalogens gule del), vil man få en oversikt over hvilke produktnavn hver enkelt ATC-kode omfatter.

1.5 Definert Døgndose (DDD)

I enkelte tabeller i del 2 i boken er volum av legemiddelforbruk angitt i antall DDD. Ved å benytte definerte døgndoser (DDD) som måleenhet, får man bedre mulighet for sammenligninger mellom alternative legemidler uavhengig av prisdifferanser. Vurdering av volum av legemiddelforbruket gjennom lengre tidsperioder, nasjonalt og internasjonalt, blir enklere og bedre ved bruk av definerte døgndoser. Måleenheten DDD er definert som *den antatt gjennomsnittlige døgndose brukt ved preparatets hovedindikasjon hos voksne*.

Døgndosene fastsettes på bakgrunn av en vurdering av bruken internasjonalt, selv om de nasjonale terapitradisjonene kan variere fra et land til et annet (f.eks. bruksområde og doseringsanbefalinger). Den definerte døgndose (DDD) bør derfor betraktes som en teknisk måleverdi.

Legemidler som benyttes ved forskjellige indikasjoner kan by på spesielle problemer som det må tas hensyn til ved vurdering av døgndosestatistikk. Dosen ved hovedindikasjonen benyttes normalt ved fastsettelse av DDD. Med unntak for noen få spesielle barnepreparater benyttes doseringer for voksne. Ofte vil DDD for ulike administrasjonsformer være like med unntak av der biotilgjengeligheten er svært forskjellig. For preparater der man benytter en støtdose og en vedlikeholdsdose, vil døgndosen være basert på vedlikeholdsdosen. Hvis mulig er DDD angitt i mengde aktiv substans. Er det umulig, som f.eks. ved kombinasjonspreparater og enkelte flytende preparater, angis DDD som antall enkeltdoser (antall tabletter, kapsler, milliliter osv.).

All medicinal products containing plain spironolactone (Aldactone® and Spirix®) are thus assigned the code C03DA01.

The ATC classification system makes it possible to compile drug consumption statistics on 5 different levels, i.e., figures showing total consumption of all preparations classified in main group C – *Cardiovascular system* (1st level), figures for the various subgroups (2nd, 3rd and 4th levels), and down to figures showing consumption of each active ingredient.

The ATC code for all pharmaceuticals on the Norwegian market can be retrieved from *the pharmacy medicinal product register* and in the monographs of the national drug catalogue "*Felleskatalogen*". The yellow section of the latter, entitled *The Anatomical Therapeutic Chemical Medicines Register*, lists all medicinal products belonging to each of the ATC 5th level codes.

1.5 The Defined Daily Dose (DDD)

In some tables in part 2 in this book the sales volume of drug consumption is given in number of DDDs. Using DDDs as the unit of measurement allows better comparison between alternative medications, regardless of price differences. The evaluation of drug consumption volumes over time, nationally and internationally, is simplified and improved by the use of DDDs. A DDD is defined as *the assumed average maintenance dose per day for a drug used on its main indication in adults*.

The DDDs are determined on the basis of evaluation of international use of the substance in question, bearing in mind that national therapy traditions (indications, dosages) often differ greatly. Each DDD should therefore be regarded as a technical measuring unit.

Drugs used for more than one indication may cause particular problems which are important to consider when evaluating statistics based on DDDs. With the exception of a very few specially formulated pediatric preparations, adult dosages are used. The DDD for a substance will often be one and the same, irrespective of the route of administration. However, drugs with different bioavailabilities depending on their administration route will have more than one DDD, each of them linked to a specific dosage form. For medications where a booster dose is followed by a smaller maintenance dosage, the maintenance dose will form the basis for determining the DDD. Whenever possible, the DDD is indicated as the quantity of active substance.

DDD representer ikke nødvendigvis den mest forskrevne eller brukte dose, noe som må tas i betraktning når tallene vurderes. Det vil derfor ofte være vanskelig å beregne antall brukere ved kun å bruke DDD som måleenhet. Dette gjelder særlig der doseringsanbefalingene kan variere mye etter bruksområde. Salgstallene kan angis i DDD/1000 innbyggere/døgn og beregnes på følgende måte:

$$\frac{\text{Samlet forbruk i antall DDD x 1000}}{365 \text{ x antall innbyggere}}$$

Dette tallet vil gi et estimat av andelen av befolkningen i promille som får en bestemt medikamentell behandling. Et estimert salg av et legemiddel på 10 DDD/ 1000 innbyggere /døgn indikerer at 10 av 1000 personer (dvs. 1 % av befolkningen) daglig kan bruke dette legemidlet. Dette estimatet blir imidlertid kun riktig dersom det er samsvar mellom DDD og dosen som faktisk brukes.

1.6 WHO Collaborating Centre for Drug Statistics Methodology

ATC/DDD systemet administreres og videreutvikles av WHO Collaborating Centre for Drug Statistics Methodology. Dette senteret er en del av Avdeling for legemiddelepidemiologi ved Nasjonalt folkehelseinstitutt. Nærmere beskrivelse av systemet finnes i publikasjonen Guidelines for ATC classification and DDD assignment (7). ATC Index with DDDs, som inneholder en liste over alle fastsatte DDD, kan bestilles fra WHO senteret (8). Begge publikasjonene finnes i engelsk og spansk versjon. Senterets webside har følgende adresse: www.whocc.no. ATC og DDD endringer som er vedtatt blir publisert årlig og gjort gjeldende ved årsskiftet. ATC/DDD versjon gjeldende fra januar 2014 er benyttet i rapporten. Publikasjonene kan bestilles fra WHO Collaborating Centre for Drug Statistics Methodology.

When this is impossible, as is the case with combination preparations and some liquid preparations, the DDD is indicated as the number of single doses (number of tablets, capsules, millilitres etc.). The DDDs are not necessarily the most frequently prescribed or used doses. This must be considered when evaluating the data. Accordingly it will often be difficult to estimate the number of users by using the DDD as the measuring unit. The sales can be given as the number of DDDs/1000 inhabitants/day, calculated as follows:

$$\frac{\text{Total consumption measured in number of DDDs x 1000}}{365 \text{ x number of inhabitants}}$$

This figure offers an estimation of what proportion of the population that may receive a certain drug treatment. An estimated drug consumption of 10 DDDs/1000 inhabitants/day corresponds to a daily use of this drug by 1% of the population. This estimate is, however, only valid if there is good correlation between the DDD and the actual consumed dose.

1.6 The WHO Collaborating Centre for Drug Statistics Methodology

The WHO Collaborating Centre for Drug Statistics Methodology is responsible for the administration and development of the ATC/DDD system. The Centre is located at the Department of Pharmacoepidemiology at the NIPH. Further information about the ATC/DDD system is given in the publication Guidelines for ATC classification and DDD assignment (7). The ATC Index with DDDs which includes a list of all assigned DDDs can be ordered from the Centre (8). Both publications are available in English and Spanish. The website for the Centre is www.whocc.no. ATC and DDD changes are published annually and are made official by the end of the year. ATC/DDD version from January 2014 has been used in the book. The ATC/DDD publications can be ordered from the WHO Collaborating Centre for Drug Statistics Methodology.

Referanser/References:

1. Forskrift om innsamling og behandling av helseopplysninger i reseptbasert legemiddelregister (Reseptregisteret). 20-10-2003.
2. Strøm H. Reseptbasert legemiddelregister: et viktig verktøy for å oppnå detaljert legemiddelstatistikk. *Nor J Epidemiol.* 2004;14(1):53-55.
3. Helseregisterloven [Personal Health Data Filing System Act]. Lov av 18.mai 2001
4. Rønning M, Litleskare I, Addis A et al. Recommendations for national registers of medicinal products with validated ATC codes and DDD values. *Italian J Public Health* 2006;3(1):30-35.
5. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sørensen HT. The Nordic countries as a cohort for pharmacoepidemiological research. *Basic Clin Pharmacol Toxicol* 2010;106(2):86-94.
6. Sakshaug S (Ed). Drug Consumption in Norway 2009–2013. [Legemiddelforbruket i Norge 2009–2013] Oslo: Norwegian Institute of Public Health, 2014.
7. WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment 2014. Oslo, 2013.
8. WHO Collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs 2014. Oslo 2013.



Mylan
50mg
50 tabletter

50 tabletter
Mylan 50mg
50 tabletter

50 tabletter

Mylan 50mg

| ATC level | | Number of individuals | | | | | | | | | | |
|-----------|--|-----------------------|-------|-------|-------|-----|----|----|-----|-----|-----|-----|
| A03BA03 | hyoscyamine | 2 978 | 2 973 | 2 242 | 1 017 | 832 | 56 | <5 | 313 | 366 | 151 | 536 |
| A03BB | Belladonna alkaloids, semisynthetic, quaternary ammonium compounds | 151 | 167 | 231 | 259 | 239 | 67 | <5 | 80 | 116 | 41 | 153 |
| A03BB01 | butylscopolamine | 13 | 152 | 210 | 238 | 220 | 67 | <5 | 73 | 107 | 38 | 134 |
| | | 9 | <5 | 0 | 0 | 0 | 19 | 8 | 7 | 9 | <5 | 19 |

Del 2 Part 2

2. Reseptregisteret 2009–2013

2.1 Utvalgte nøkkeltall fra Reseptregisteret

Reseptregisteret inneholder opplysninger fra alle landets apotek om utlevering av legemidler på resept, til forskrivers egen praksis og til institusjoner. I 2013 ble rundt 95 % av legemidlene i Reseptregisteret (målt i DDD) utlevert til enkeltpersoner. Leveransene til institusjoner (sykehus og sykehjem) utgjorde 4,5 % av det totale antall DDD og ca. 0,4 % av totalt antall DDD ble utlevert til bruk i forskrivers egen praksis. Salg av reseptfrie legemidler er ikke inkludert i Reseptregisteret. Reseptfritt salg utgjorde i 2013 15 % av totalt salg av legemidler i Norge målt i DDD (Kilde: Grossistbasert legemiddelstatistikk, Folkehelseinstituttet).

2. The Norwegian Prescription Database (NorPD) 2009–2013

2.1 Selected key figures from NorPD

NorPD contains information from all Norwegian pharmacies of prescriptions to individuals, to a prescriber's own practice and to institutions. In 2013, about 95% of DDDs in NorPD were dispensed to individuals in ambulatory care. Deliveries to institutions (hospitals and nursing homes) amounted to 4.5% of the DDDs and about 0.4% of the DDDs were dispensed for use in the physician's practice. Sales of OTC medicines are not included in NorPD. OTC sales constitute 15% of total sales of pharmaceuticals in Norway in 2013, measured in DDDs (source: Norwegian Drug Wholesale Statistics, Norwegian Institute of Public Health).

Table 2.1.a: Number of individuals and one-year prevalence (%) of the population who had at least one prescription dispensed in Norway 2009–2013

| | Women n (%) | Men n (%) | Both genders n (%) |
|------|------------------|------------------|-----------------------|
| 2009 | 1 839 960 (76,1) | 1 523 065 (63,2) | 3 363 025 (69,6) |
| 2010 | 1 842 575 (75,4) | 1 510 186 (61,8) | 3 352 761 (68,6) |
| 2011 | 1 879 445 (76,0) | 1 551 598 (62,6) | 3 431 043 (69,3) |
| 2012 | 1 897 957 (75,9) | 1 571 092 (62,4) | 3 469 049 (69,1) |
| 2013 | 1 910 199 (75,5) | 1 574 389 (61,7) | 3 484 588 (68,6) |




Figure 2.1: One-year prevalence (%) of the population who had at least one prescription dispensed in 2013 in Norway according to age and gender

Reseptregisteret ble opprettet 1. januar 2004 og i perioden 2004–2013 har 5,2 millioner individer blitt inkludert i NorPD med minst ett legemiddel utlevert på resept fra apotek. Antall legemiddelutleveringer etter resept til pasienter i samme periode er 373 millioner.

I 2013 fikk 68,6 % av den norske befolkningen utlevert minst ett legemiddel på resept, 75,5 % av kvinnene og 61,7 % av mennene (tabell 2.1.a). Krav om at pasientens fødselsnummer skal påføres resepten ble innført 1. oktober 2003. I 2004, det første driftsåret for NorPD, var andelen av resepter med ugyldig eller manglende 11-sifret fødselsnummer 3,7 %. I årene 2006–2007 lå denne andelen på rundt 2 %, og i 2008 og 2009 har den ligget på i underkant av 1,4 %. I 2010–2013 var andelen uten gyldig fødselsnummer under 1 % (0,44 % i 2013).

Ettårsprevalensen for å få utlevert legemiddel etter resept i 2013 var lavest for begge kjønn i aldersgruppen 10–14 år (figur 2.1). Rundt 90 % av individene i alderen 70 år og eldre fikk utlevert medisiner etter resept. Hvis vi ekskluderer kvinner som kun fikk utlevert hormonelle prevensjonsmidler (ATC-kode G03A), blir prevalensen av legemiddelbruk redusert med ca. 10–15 prosentpoeng hos kvinner i alderen 15–29 år, men fortsatt var andelen av legemiddelbrukere blant kvinner over 15 år høyere enn blant menn.

Since January 2004 5.2 million individuals have been included in NorPD with at least one prescription medication dispensed from a pharmacy. The number of prescriptions dispensed to patients in the same period (2004–2013) is 373 million.

In 2013, 68.6% of the Norwegian population had at least one prescription dispensed, 75.5% of women and 61.7% of men (table 2.1.a). In 2004, the first operational year of NorPD, the proportion of prescriptions having invalid or missing personal identification number was 3.7%. In the period 2005–2007, the proportion was around 2%. The proportion of prescriptions with an invalid personal identification number has declined further to just below 1.4 % in 2008 and 2009. In 2010–2013 the proportion was less than 1% (0.44% in 2013).

The age-specific one year prevalence for having a drug dispensed in 2013 was lowest in both genders at about 10–14 years of age (figure 2.1). About 90 % of individuals aged 70 years and older received prescription medications. Excluding women who received only hormonal contraception for systemic use (ATC code G03A), the prevalence of drug use was reduced by about 10–15 percentage points in women aged 15–29, although the proportion of drug users among women over 15 years of age was still higher than in men.

Table 2.1.b: One-year prevalence (%) of the population who had at least one prescription dispensed in Norway in 2013 according to the main ATC groups

| ATC | Women % | Men % | Both genders % |
|---|---------|-------|----------------|
| A Alimentary tract and metabolism | 18,8 | 14,1 | 16,4 |
| B Blood and blood forming organs | 12,3 | 12,5 | 12,4 |
| C Cardiovascular system | 20,9 | 20,1 | 20,5 |
| D Dermatologicals | 13,9 | 11,6 | 12,7 |
| G Genito urinary system and sex hormones | 24,9 | 6,1 | 15,5 |
| H Systemic hormonal preparations, excl. sex hormones and insulins | 11,2 | 5,4 | 8,3 |
| J Anti-infectives for systemic use | 30,3 | 20,5 | 25,4 |
| L Anti-neoplastic and immunomodulating agents | 1,9 | 1,6 | 1,8 |
| M Musculo-skeletal system | 20,9 | 15,5 | 18,2 |
| N Nervous system | 31,1 | 21,2 | 26,1 |
| P Anti-parasitic products, insecticides and repellents | 2,4 | 1,4 | 1,9 |
| R Respiratory system | 27,1 | 20,9 | 24,0 |
| S Sensory organs | 13,8 | 10,3 | 12,1 |
| V Various | 0,5 | 0,5 | 0,5 |

Tabell 2.1.b viser ettårsprevalens for hele befolkningen som har fått utlevert minst ett legemiddel etter resept innen hver av de 14 ATC-hovedgruppene, totalt og fordelt på kvinner og menn. De tre legemiddelgruppene som er mest brukt blant begge kjønn er midler mot infeksjoner til systemisk bruk (ATC-gruppe J), legemidler med virkning på nervesystemet (ATC-gruppe N) og legemidler som brukes for sykdommer i luftveiene (ATC-gruppe R).

Tabell 2.1.c viser en oversikt over legemidler (definert som ATC 5.nivåer) med flest brukere i Norge i 2013. Fenoxymetylpenicillin (antibakterielt middel) har flest brukere etterfulgt av tre smertestillende midler (diklofenak, paracetamol og kombinasjonen kodein / paracetamol). Paracetamol og diklofenak selges også i reseptfrie pakninger. Denne bruken telles ikke i Reseptregisteret. For øvrig inneholder listen i hovedsak de samme legemidlene som tidligere år, men med noen endringer i rekkefølgen.

Table 2.1.b shows the one-year prevalence of the entire population, and among men and women, who received at least one prescription in each of the main ATC groups. The three drug groups most used in both men and women are anti-infectives (ATC group J), drugs affecting the nervous system (ATC group N) and drugs used for respiratory diseases (ATC group R).

Table 2.1.c lists the medicines (defined as ATC 5th levels) with most users in Norway in 2013. Phenoxymethylpenicillin (antibacterial) is used by the highest number of individuals followed by three analgesics (diclofenac, paracetamol, and the combination codeine / paracetamol). Paracetamol and diclofenac are also sold OTC. This use is not covered by NorPD. In general the list comprises mainly the same medicines as previous years, but with some changes in the sequence.

Table 2.1.c: Drugs with the highest number of users in Norway 2013

| | ATC code | Active ingredient | Use | Number of individuals | Proportion (%) of the population |
|----|----------|---|--|-----------------------|----------------------------------|
| 1 | J01CE02 | phenoxymethylpenicillin | Antibacterial | 438 508 | 8,6 |
| 2 | M01AB05 | diclofenac ¹⁾ | NSAID/analgesic | 417 775 | 8,2 |
| 3 | N02BE01 | paracetamol ¹⁾ | Analgesic | 384 388 | 7,6 |
| 4 | N02AA59 | codeine, combinations excl. psycholeptics | Analgesic | 383 925 | 7,6 |
| 5 | B01AC06 | acetylsalicylic acid | Antithrobotic | 378 066 | 7,4 |
| 6 | N05CF01 | zopiclone | Hypnotic | 303 992 | 6,0 |
| 7 | C10AA01 | simvastatin | Cholesterol lowering | 290 634 | 5,7 |
| 8 | R06AE07 | cetirizine ¹⁾ | Anti-allergic | 274 382 | 5,4 |
| 9 | C07AB02 | metoprolol | Antihypertensive/ cardiac disease | 270 550 | 5,3 |
| 10 | R05DA01 | ethylmorphine | Cough suppresant | 250 796 | 4,9 |
| 11 | R03AC02 | salbutamol | Asthma/COPD | 219 571 | 4,3 |
| 12 | M01AE01 | ibuprofen ¹⁾ | NSAID/analgesic | 217 264 | 4,3 |
| 13 | J01CA08 | pivmecillinam | Antibacterial | 200 464 | 3,9 |
| 14 | H03AA01 | levothyroxine sodium | Thyroxine supplement | 192 528 | 3,8 |
| 15 | C10AA05 | atorvastatin | Cholesterol lowering | 189 401 | 3,7 |
| 16 | S01AA01 | chloramphenicol | Antibacterial eye drops | 185 720 | 3,7 |
| 17 | N02AX02 | tramadol | Analgesic | 172 161 | 3,4 |
| 18 | A02BC02 | pantoprazole ¹⁾ | Reflux oesofagitis | 171 451 | 3,4 |
| 19 | H02AB06 | prednisolone | Antiinflammatory/corticosteroid | 168 968 | 3,3 |
| 20 | R01AD09 | mometasone | Inflammatory skin disorders / eczema/psoriasis | 152 995 | 3,0 |
| 21 | J01AA02 | doxycycline | Antibacterial | 145 943 | 2,9 |
| 22 | A02BC05 | esomeprazole | Reflux oesofagitis | 142 299 | 2,8 |
| 23 | J01CA04 | amoxicillin | Antibacterial | 134 844 | 2,7 |
| 24 | N05BA04 | oxazepam | Anxiolytic | 134 612 | 2,6 |
| 25 | R06AX27 | desloratadine | Anti-allergic | 129 266 | 2,5 |
| 26 | C08CA01 | amlodipine | Antihypertensive/ cardiac disease | 129 021 | 2,5 |
| 27 | G03AA07 | levonorgestrel and ethinylestradiol | Hormonal contraception | 125 595 | 2,5 |
| 28 | J01FA01 | erythromycin | Antibacterial | 120 963 | 2,4 |
| 29 | N05BA01 | diazepam | Anxiolytic | 120 562 | 2,4 |
| 30 | A12AX | Calcium, combinations with vitamin D and/or other drugs ¹⁾ | Calcium supplement | 112 275 | 2,2 |

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

2.2 Reseptkategorier og refusjon av utgifter til legemidler

Reseptregisteret inneholder opplysninger om antall individer som fikk utlevert minst ett legemiddel innenfor de ulike reseptkategorier. Reseptkategorier har følgende hovedinndeling:

- Hvit resept
- Blå resept
- Helseforetaksresept

Følgende er ikke inkludert i tabellene som presenteres i dette kapittelet (tabell 2.2.a–2.2.d): Bidragsordningen hjemlet i Lov om folketrygd (folketrygdloven) § 5.22 hvor bidrag kan ytes til dekning av utgifter til helsetjenester når utgiftene ikke ellers dekkes etter andre lover, og støtte til legemidler for vernepliktige og jernbanepersonell.

Hvite resepter

Resepter hvor pasienten betaler hele kostnaden for legemidlet selv.

Blå resept

Resepter som rekvireres i henhold til Blåreseptforskriften (FOR-2007-06-28-814), der staten betaler deler av kostnaden for legemidlet. I tabellene 2.2.a–2.2.d er Blåreseptordningene slått sammen (§§ 2, 3a, 3b, 4, 5).

Refusjon etter § 2

Legemidler som er ført opp på refusjonslista tilknyttet § 2 refunderes pliktmessig når brukt ved de diagnoser (angitt med ICPC eller ICD diagnosekoder) spesifisert i refusjonslista. Legemiddelverket avgjør hvilke legemidler som skal føres opp i refusjonslista, og hvilke diagnosekoder/vilkår legemidlet skal underlegges ved rekvirering på blå resept.

Refusjon etter §§ 3a og 3b

HELFO kan fatte vedtak om refusjon av utgifter til legemidler som ikke er ført opp i refusjonslista tilknyttet § 2, forutsatt at bruken av legemidlene er dekket av en diagnosekode i refusjonslista (§3a). Vedtak fattes for hver enkelt pasient på grunnlag av søknad fra behandlende legen. For andre kostbare legemidler mot kroniske sykdommer som ikke er nevnt i refusjonslista, kan HELFO unntaksvis fatte vedtak om refusjon for hver enkelt pasient på grunnlag av legens søknad (§3b). Reseptregisteret gir ikke en komplett oversikt over refusjon etter §§ 3a og 3b.

Refusjon etter § 4

Legemidler som benyttes ved allmennfarlige smittsomme sykdommer, refunderes etter § 4 etter en nærmere angitt sykdomsliste. Det ytes stønad til utgifter til legemidler mot infeksjoner, immunstimulerende legemidler og vaksiner. Denne støtten ytes til alle som

2.2 Prescription categories and reimbursement of medicinal expenses

NorPD contains information about the number of individuals having at least one drug dispensed in the various prescription categories. Prescription categories are divided into:

- Non-reimbursable prescriptions
- Reimbursement prescriptions
- Health Trust prescriptions (HELFO)

The following is not included: Contribution according to National Insurance Act § 5.22 in which a contribution may be granted to cover the cost of healthcare when expenses are not otherwise covered by other laws and medicinal support during military service and railway personnel.

Non-reimbursable prescriptions

These are prescriptions paid in full by the patient.

Reimbursement prescriptions ("Blue Prescription")

The costs under the various reimbursement schemes are combined in the tables (§§ 2, 3a, 3b, 4, 5).

Reimbursement according to § 2

Drugs listed on the reimbursement list § 2 will always be reimbursed when prescribed for the diagnoses (indicated by the ICPC and ICD codes) specified in the reimbursement list. The Norwegian Medicines Agency decides which medicines are included in the list and which diagnostic codes/conditions should be subject to reimbursement prescribing.

Reimbursement according to §§ 3a and 3b

HELFO can decide to reimburse drugs that are not listed in the reimbursement list attached to § 2, provided that use of the drug is covered by a diagnostic code in the reimbursement list (§ 3a). Decisions are made for the individual patient based on an application from the treating physician. For other expensive drugs for chronic diseases not mentioned in the reimbursement list, in special cases HELFO may grant reimbursement for an individual patient based on the physician's application (§ 3b). NorPD will not contain a complete listing of reimbursement according to §§ 3a and 3b.

Reimbursement according to § 4

Drugs used for communicable diseases are reimbursed according to § 4 according to a specified disease list. The reimbursement is granted for anti-infective, immunostimulants and vaccines.

bor i Norge, uavhengig av medlemskap i folketrygden. Legen har mulighet til å rekvirere flere av legemidlene i denne paragrafen til seg selv for å bevare pasientenes anonymitet. Slike resepter vil følgelig ikke kunne følges på individnivå i Reseptregisteret.

Informasjon om egenbetaling (egenandel og eventuell tilleggsbetaling ved reservasjon mot generisk bytte) er ikke tilgjengelig i Reseptregisteret.

Helseforetaksresept

De regionale helseforetakene er gitt et særskilt finansieringsansvar for enkelte kostbare legemidler. Dette gjelder blant annet immunmodulerende legemidler til behandling av revmatiske lidelser (TNF α -hemmerne), multipel sklerose og kreft. Bare legemidler som er ekspedert på resept til individer er tatt med i tabellen.

This support is provided to all who live in Norway, regardless of citizenship. The physician may prescribe these drugs for use in their own practice without giving the person-identifier of the patient. Such prescriptions will not be available on an individual level in the NorPD.

Information regarding self-payment is not available in NorPD.

Health Trust Prescription

The regional health trusts provide a dedicated funding for certain expensive drugs. These include immunomodulating drugs for the treatment of rheumatic disorders (TNF α inhibitors), multiple sclerosis and cancer. Only drugs that are dispensed by prescription to individuals are included in the table.

Table 2.2.a Sales of drugs by prescription categories, overview 2013

| | Number of individuals | Proportion (%) of the population | Number of DDDs | Sales in 1000 NOK |
|--------------------------------|-----------------------|----------------------------------|----------------|-------------------|
| Non-reimbursable prescriptions | 3 004 244 | 59,1 | 589 451 070 | 2 677 229 |
| Reimbursement prescriptions | 2 203 509 | 43,4 | 1 622 828 376 | 9 558 223 |
| Health Trust prescriptions | 18 023 | 0,4 | 5 332 102 | 1 466 709 |

Table 2.2.b: Sales of reimbursed drugs (§§ 2, 3a, 3b, 4, 5) by ATC main groups 2013

| ATC main groups | Number of individuals | Proportion (%) of the population | Number of DDDs | Sales in 1000 NOK |
|---|-----------------------|----------------------------------|----------------|-------------------|
| A Alimentary tract and metabolism | 457 966 | 9,0 | 179 509 294 | 1 230 641 |
| B Blood and blood forming organs | 285 213 | 5,6 | 89 630 902 | 890 187 |
| C Cardiovascular system | 974 074 | 19,2 | 724 305 734 | 1 532 996 |
| D Dermatologicals | 247 034 | 4,9 | 489 715 | 122 181 |
| G Genito urinary system and sex hormones | 118 860 | 2,3 | 37 582 020 | 271 394 |
| H Systemic hormonal preparations, excl. sex hormones and insulins | 332 031 | 6,5 | 62 457 368 | 407 145 |
| J Antiinfectives for systemic use | 110 667 | 2,2 | 10 313 908 | 537 271 |
| L Antineoplastic and immunomodulating agents | 76 203 | 1,5 | 22 354 230 | 1 184 494 |
| M Musculo-skeletal system | 266 847 | 5,3 | 53 585 049 | 200 093 |
| N Nervous system | 595 732 | 11,7 | 185 342 791 | 1 660 731 |
| P Antiparasitic products, insecticides and repellents | 6 422 | 0,1 | 751 893 | 4 219 |
| R Respiratory system | 759 815 | 15,0 | 223 449 555 | 1 222 738 |
| S Sensory organs | 260 115 | 5,1 | 32 795 009 | 215 377 |
| V Various | 15 027 | 0,3 | 260 913 | 78 732 |

Table 2.2.c: Reimbursed drugs (§§ 2, 3a, 3b, 4, 5) with the highest number of users 2013

| | ATC code | Active ingredient | Use | Number of individuals | Proportion (%) of the population | Number of DDDs | Sales in 1000 NOK |
|----|----------|----------------------------|---|-----------------------|----------------------------------|----------------|-------------------|
| 1 | C10AA01 | simvastatin | Cholesterol lowering | 288 629 | 5,7 | 91 629 126 | 117 931 |
| 2 | C07AB02 | metoprolol | Antihypertensive/ cardiac disease | 267 637 | 5,3 | 43 681 441 | 126 833 |
| 3 | R06AE07 | cetirizine | Anti-allergic | 236 248 | 4,7 | 47 348 931 | 51 615 |
| 4 | H03AA01 | levothyroxine sodium | Thyroxine supplement | 191 492 | 3,8 | 40 900 239 | 53 977 |
| 5 | C10AA05 | atorvastatin | Cholesterol lowering | 188 729 | 3,7 | 103 780 967 | 160 013 |
| 6 | R03AC02 | salbutamol | Asthma/COPD | 183 418 | 3,6 | 18 290 452 | 67 330 |
| 7 | C08CA01 | amlodipine | Antihypertensive/ cardiac disease | 128 353 | 2,5 | 57 460 532 | 54 550 |
| 8 | N02BE01 | paracetamol | Analgesic | 125 298 | 2,5 | 13 819 518 | 32 888 |
| 9 | R06AX27 | desloratadine | Anti-allergic | 113 156 | 2,2 | 18 536 709 | 29 218 |
| 10 | R01AD09 | mometasone | Anti-allergic nose spray | 111 844 | 2,2 | 13 289 824 | 39 941 |
| 11 | N06AB10 | escitalopram | Antidepressant | 108 238 | 2,1 | 34 669 614 | 72 570 |
| 12 | A10BA02 | metformin | Diabetes | 103 901 | 2,0 | 25 488 942 | 46 836 |
| 13 | A02BC02 | pantoprazole | Reflux oesofagitis | 103 451 | 2,0 | 21 985 342 | 48 620 |
| 14 | A02BC05 | esomeprazole | Reflux oesofagitis | 96 545 | 1,9 | 29 413 400 | 150 468 |
| 15 | H02AB06 | prednisolone | Antiinflammatory/ corticosteroid | 96 272 | 1,9 | 14 605 650 | 22 223 |
| 16 | R03AK06 | salmeterol and fluticasone | Asthma/COPD | 92 901 | 1,8 | 20 776 117 | 303 501 |
| 17 | B01AA03 | warfarin | Antitrombotic | 87 624 | 1,7 | 18 558 355 | 69 064 |
| 18 | C09CA06 | candesartan | Antihypertensive/ cardiac disease | 85 509 | 1,7 | 40 945 220 | 62 235 |
| 19 | C03CA01 | furosemide | Antihypertensive/ cardiac disease | 83 757 | 1,6 | 21 763 014 | 18 801 |
| 20 | R03AK07 | formoterol and budesonide | Asthma/COPD | 81 476 | 1,6 | 15 422 555 | 224 096 |
| 21 | S01GX02 | levocabastine | Anti-allergic, eyedrops | 69 812 | 1,4 | * | 17 342 |
| 22 | C09DA01 | losartan and diuretics | Antihypertensive/ cardiac disease | 67 143 | 1,3 | 21 964 284 | 46 554 |
| 23 | R01AD12 | fluticasone furoate | Anti-allergic, nose spray | 65 840 | 1,3 | 5 049 876 | 15 472 |
| 24 | C09CA01 | losartan | Antihypertensive/ cardiac disease | 63 320 | 1,2 | 23 957 835 | 38 383 |
| 25 | C09AA05 | ramipril | Antihypertensive/ cardiac disease | 62 503 | 1,2 | 50 171 254 | 24 680 |
| 26 | R06AX13 | loratadine | Anti-allergic | 57 685 | 1,1 | 11 480 480 | 15 137 |
| 27 | D07AC13 | mometasone | Inflammatory skin disorders / eczema/psoriasis | 56 492 | 1,1 | * | 13 332 |
| 28 | R03BA05 | fluticasone | Asthma/COPD | 55 721 | 1,1 | 4 764 335 | 37 339 |
| 29 | C09DA06 | candesartan and diuretics | Antihypertensive/ cardiac disease | 55 596 | 1,1 | 17 944 808 | 48 834 |
| 30 | M05BA04 | alendronic acid | Osteoporosis | 52 516 | 1,0 | 14 711 498 | 35 999 |

* No DDD assigned for this ATC 5th level

Table 2.2.d: Reimbursed drugs (§§ 2, 3a, 3b, 4, 5) with highest sales in NOK 2013

| | ATC code | Active ingredient | Use | Number of individuals | Proportion (%) of the population | Number of DDDs | Sales in 1000 NOK |
|----|----------|---|--------------------------------------|-----------------------|----------------------------------|----------------|-------------------|
| 1 | R03AK06 | salmeterol and fluticasone | Asthma/COPD | 92 901 | 1,8 | 20 776 117 | 303 501 |
| 2 | R03AK07 | formoterol and budesonide | Asthma/COPD | 81 476 | 1,6 | 15 422 555 | 224 096 |
| 3 | B02BD02 | coagulation factor VIII | Bleeding disorder | 176 | 0,0 | 66 505 | 221 029 |
| 4 | C10AA05 | atorvastatin | Cholesterol lowering | 188 729 | 3,7 | 103 780 967 | 160 013 |
| 5 | R03BB04 | tiotropium bromide | COPD | 41 186 | 0,8 | 11 534 196 | 152 389 |
| 6 | A02BC05 | esomeprazole | Reflux oesofagitis | 96 545 | 1,9 | 29 413 400 | 150 468 |
| 7 | H01AC01 | somatropin | Growth hormone deficiency | 1 895 | 0,0 | 790 214 | 146 293 |
| 8 | N06BA04 | methylphenidate | ADHD | 28 197 | 0,6 | 11 934 390 | 130 124 |
| 9 | L02BX03 | abiraterone | Cancer | 749 | 0,0 | 119 189 | 127 473 |
| 10 | C07AB02 | metoprolol | Antihypertensive/ cardiac disease | 267 637 | 5,3 | 43 681 441 | 126 833 |
| 11 | C10AA01 | simvastatin | Cholesterol lowering | 288 629 | 5,7 | 91 629 126 | 117 931 |
| 12 | L01XE01 | imatinib | Cancer | 492 | 0,0 | 54 390 | 100 853 |
| 13 | A10AC01 | insulin (human) | Diabetes | 32 519 | 0,6 | 11 527 383 | 97 006 |
| 14 | A10AB05 | insulin aspart | Diabetes | 28 283 | 0,6 | 9 023 648 | 84 878 |
| 15 | N02CC01 | sumatriptan | Migraine | 45 719 | 0,9 | 2 742 843 | 84 190 |
| 16 | L03AA13 | pegfilgrastim | Cancer | 2 341 | 0,0 | 170 640 | 80 127 |
| 17 | N03AX09 | lamotrigine | Epilepsy/ bipolar disorders | 26 770 | 0,5 | 6 889 720 | 79 996 |
| 18 | B01AE07 | dabigatran etexilate | Antitrombotic | 13 671 | 0,3 | 3 811 247 | 79 036 |
| 19 | A07EC02 | mesalazine | Ulcerative colitis / Crohn's disease | 15 813 | 0,3 | 5 982 157 | 78 523 |
| 20 | J05AR03 | tenofovir disoproxil and emtricitabine | HIV infections | 1 524 | 0,0 | 430 891 | 73 653 |
| 21 | N06AB10 | escitalopram | Antidepressant | 108 238 | 2,1 | 34 669 614 | 72 570 |
| 22 | C10AX09 | ezetimibe | Cholesterol lowering | 20 725 | 0,4 | 5 994 991 | 70 377 |
| 23 | N03AX16 | pregabalin | Neuropathic pain /epilepsy | 9 465 | 0,2 | 3 456 935 | 70 357 |
| 24 | B01AA03 | warfarin | Antitrombotic | 87 624 | 1,7 | 18 558 355 | 69 064 |
| 25 | R03AC02 | salbutamol | Asthma/COPD | 183 418 | 3,6 | 18 290 452 | 67 330 |
| 26 | B01AF01 | rivaroxaban | Antitrombotic | 13 218 | 0,3 | 5 697 248 | 67 277 |
| 27 | J05AR06 | emtricitabine, tenofovir disoproxil and efavirenz | HIV infections | 792 | 0,0 | 245 417 | 62 663 |
| 28 | H01CB02 | octreotide | Cancer | 512 | 0,0 | 215 990 | 62 492 |
| 29 | C09CA06 | candesartan | Antihypertensive/ cardiac disease | 85 509 | 1,7 | 40 945 220 | 62 235 |
| 30 | N05AH04 | quetiapine | Schizophrenia/psychoses | 25 799 | 0,5 | 3 269 035 | 61 452 |

2.3 Beskrivelse av hovedtabellene

Tabellene i del 2 i denne boken gir en oversikt over antall individer som har fått utlevert legemidler etter resept fra apotekene i Norge. Alle som har hentet ut minst ett legemiddel er inkludert og opplysningene er fordelt på enkeltlegemidler og legemiddelgrupper. Selv om et individ har fått utlevert samme legemiddel flere ganger, telles vedkommende som bruker bare én gang. Det er kun utleveringer til individer med fullt fødselsnummer som er inkludert i tabellene i boken. I Reseptregisteret er 0,44 % av utleveringene til individer hvor fullstendig fødselsnummer ikke er angitt i 2013.

Tabellene inneholder tall for perioden 2009–2013. I tillegg er følgende opplysninger for 2013 inkludert:

- Andel kvinner (%) av totalt antall individer som har hentet ut minst én resept
- Antall individer som har hentet ut minst ett legemiddel etter resept fordelt på følgende aldersgrupper: <15, 15–44, 45–69, ≥70
- Salg i kroner fra apotek for utvalget i tabellen, dvs. til individer med fullt fødselsnummer. Kronebeløpet tilsvarer reell utsalgspris fra apotek.

Tabellene er sortert i henhold til ATC-systemet (se nærmere beskrivelse på s. 15). De aller fleste ATC-grupper med legemidler på det norske markedet er inkludert. Legemidler til pasienter i sykehus eller sykehjem er ikke tilgjengelig på individnivå i Reseptregisteret. Det totale antall legemiddelbrukere vil derfor være høyere enn det som fremgår av tabellene for en del legemidler, og spesielt for legemidler som brukes mye i sykehus. Vi har valgt å utelate noen ATC-grupper. Dette er legemidler som hovedsaklig brukes i sykehus eller institusjoner. Følgende ATC-grupper er utelatt:

| | |
|------|--|
| B05 | Blodsubstitutter og infeksjonsløsninger |
| J06 | Immunsera og immunglobuliner |
| J07 | Vaksiner |
| L01 | Antineoplastiske midler |
| M03A | Perifert virkende muskelrelakserende midler |
| N01 | Anestetika |
| S01H | Lokalanestetika |
| S01J | Diagnostika |
| S01L | Midler ved okulær vaskulær sykdom |
| V | Varia (kun ATC-gruppe V01 <i>Allergener</i> er inkludert i tabellen) |

Reseptfrie legemidler skrives i noen tilfeller også ut på resept, men i hovedsak vil salg av reseptfrie legemidler ikke være inkludert i denne boken. Salg av reseptfrie

2.3 Description of the main tables

The tables in section 2 of this book provide an overview of the number of individuals who have had prescriptions dispensed from pharmacies in Norway. Anyone who has had at least one prescription dispensed is included and the data are given for each medicinal substance and for groups of medicines. Even if an individual has been given the same medicine several times, he or she is counted as a user only once. Only dispensing data to individuals with a personal identification number are included in the tables. In NorPD the complete personal identification number is missing for 0.44% of the dispensed medicines to individuals in 2013.

The tables contain figures for the period 2009–2013. In addition, the following information for 2013 includes:

- Share of women (%) of the total number of individuals who have had at least one prescription dispensed
- The number of individuals who have had at least one prescription dispensed in the following age groups: <15, 15–44, 45–69, ≥70
- Sales in million Norwegian kroner (mNOK), i.e. for prescriptions dispensed to individuals with a personal identification number. The amount in NOK corresponds to the actual retail price from the pharmacy.

The tables are arranged according to the ATC system (see further description in p. 15). The majority of ATC groups containing drugs on the Norwegian market are included. Medicine use by individuals in hospitals and nursing homes is not included at the individual level in the Norwegian Prescription Database. The total number of medicine users will therefore be higher than the figures in the tables for a number of drugs, particularly for drugs that are frequently used in hospitals or institutions. We have chosen to exclude some ATC groups in this book that are mainly used in hospitals or institutions. The following ATC groups have been omitted:

| | |
|------|--|
| B05 | Blood substitutes and perfusion solutions |
| J06 | Immune sera and immunoglobulins |
| J07 | Vaccines |
| L01 | Antineoplastic agents |
| M03A | Muscle relaxants, peripherally acting agents |
| N01 | Anesthetics |
| S01H | Local anesthetics |
| S01J | Diagnostic agents |
| S01L | Ocular vascular disorder agents |
| V | Various (ATC group V01 Allergens is included in the table) |



Figure 2.2: The report generator at www.reseptregisteret.no (English version at www.norpd.no)

legemidler, både i og utenom apotek, er med i den grossistbaserte legemiddelstatistikken, hvor tallmaterialet blir publisert i publikasjonen Legemiddelforbruket i Norge (se også s. 15). I tabellene i del 2 i denne boken er det tatt med en fotnote tilknyttet de ulike ATC-kodene hvor det i tillegg også selges reseptfrie pakninger. I 2013 utgjorde reseptfrie legemidler en andel på 15 % av totalt antall solgte doser (DDD). Disse andelene har holdt seg relativt konstant over tid.

De fleste legemidler som forskrives på resept, har godkjent markedsføringstillatelse i Norge. Leger har imidlertid anledning til å forskrive legemidler uten markedsføringstillatelse. Det må da søkes om spesielt godkjenningstiltak fra Statens legemiddelverk. Det finnes også enkelte legemidler som inngår i en såkalt negativliste, og som bare kan utleveres etter spesiell tillatelse fra Legemiddelverket. Legemidler som er forskrevet på resept etter søknad om godkjenningstiltak eller etter spesiell tillatelse fra Legemiddelverket, er inkludert i tabellene i boken. Antall individer som behandles med disse legemidlene vil ofte være lavt. Dersom antall individer er lavere enn fem, angis < 5 i tabellene.

Mange individer bruker flere legemidler. Vær derfor oppmerksom på at man ikke kan summere antall brukere av ulike legemidler, eller legemiddelgrupper i tabellene, for å finne totalt antall brukere av to eller flere legemidler. Statistikk på aggregert nivå i tabellene vil imidlertid inneholde brukere av minst ett av

Non-prescription medicines are sometimes prescribed, but the majority of the OTC medicine sales will not be included in the tables in this book. Sales of OTC medicines are, however, included in the Norwegian Drug Wholesales Statistics database and the figures are published in "Drug Consumption in Norway" (see also p. 15). A footnote is used in the tables in part 2 of this book in the various ATC codes where OTC medicines are available in Norway. In 2013, OTC medicines had a share of 15% of total sales measured in DDDs. These shares have remained almost unchanged over time.

Most prescribed medicines have an approved marketing authorisation in Norway. However, physicians can prescribe drugs without approved marketing authorisation. They must then apply for a licence from the Norwegian Medicines Agency. There are also some medicines that are part of a so-called "negative list" which can only be prescribed by special permission from the Medicines Agency. Drugs that are prescribed on licence or by special permission are included in the tables in the book. The number of individuals who are prescribed these medicines is often low. If the number of individuals is less than five, <5 is used in the tables.

Many individuals use more than one medicine. Please be aware that it is not possible to add together the number of users of various drugs or drug groups in the tables to find the total number of users of two or more drugs. Statistics on the aggregate level in the

legemidlene i undernivåene. For eksempel viser tallene at totalt antall brukere av sovemidler (ATC-gruppe N05C) er lavere enn summen av antall brukere av de enkelte legemidlene som er klassifisert i N05C. Det betyr at noen individer har fått utlevert mer enn en type sovemiddel i løpet av et år, enten ved bruk av flere sovemidler samtidig eller ved bytte fra ett middel til et annet.

Reseptregisterets nettsider: www.reseptregisteret.no
Reseptregisteret har eget nettsted som kan brukes sammen med tabellene i denne rapporten for å få kompletterende informasjon. På søkesidene (figur 2.2) kan man selv lage rapporter over antall brukere av et bestemt legemiddel eller en legemiddelgruppe. Dette kan gjøres ved søk på forhåndsdefinerte legemiddelgrupper, via ATC-systemet eller ved søk på virkestoff eller produktnavn.

Følgende data om legemiddelbruk kan hentes ut fra nettstedet:

- Antall brukere, eventuelt fordelt på kjønn, 5 års aldersgrupper, fylke eller helseregion
- Antall brukere per 1 000 innbyggere (prevalens per 1 000)
- Omsetning i kroner
- Omsetning i doser (DDD – definerte døgndoser)
- Befolkningsgrunnlag i statistikken, eventuelt fordelt på kjønn, alder, fylke eller helseregion

Data er tilgjengelige fra 2004, og nettstedet oppdateres årlig med foregående års tall.

Tallene i denne rapporten kan avvike noe fra tallene som finnes på nettstedet. Årsaken er at uttrekket av data til boken er gjort på et noe senere tidspunkt enn datagrunnlaget for nettsiden. Rapporteringen av data fra apotek til Reseptregisteret er for en liten andel av reseptutleveringene forsinket. Forsinkelsen kan være på noen måneder, og dette innebærer at noen data fra foregående år blir rapportert på etterskudd. I tillegg er individer uten kjent bostedsadresse utelatt fra nettsiden, men inkludert i tabellene i denne rapporten. Nettstedet finnes også i engelsk versjon (www.norpd.no).

Utlevering av data fra Reseptregisteret

Det er mulig å søke om data fra Reseptregisteret til forskning eller til andre formål som er i henhold til formålet for Reseptregisteret. Søknadsskjema er tilgjengelige på nettstedet til FHI (www.fhi.no), og alle søknader om tilgang til data fra FHI skal sendes til datatilgang@fhi.no. Dataene er gratis, men kostnader i forbindelse med administrativ håndtering og filbehandling må påregnes.

tables will, however, include the use of at least one of the drugs in the included drug groups. For example, the figures in the tables show that the total number of users of sleeping pills (ATC group N05C) is lower than the sum of the number of users of the individual medicines that are classified in N05C. This means that some individuals have been given more than one type of sleeping pill during a year, either through the use of more than one simultaneously or by switching from one agent to another.

The NorPD website: www.norpd.no

The Norwegian Prescription Database has its own website which can be used together with the tables in this report for complementary information. On the website (figure 2.2), one can create reports on the number of users of a particular drug or drug group. This can be done by searching for pre-defined drug groups, through the ATC system or by searching the active substance or product name.

The following data on drug use can be extracted from the website:

- Number of users, split by gender, 5-year age groups, county or health region
- Number of users per 1 000 population (prevalence per 1 000)
- Turnover in NOK (pharmacy retail price)
- Turnover in doses (DDD – defined daily doses)
- Population base for the statistics, split by gender, age, county or health region

Data are available from 2004 with an annual update for the preceding year.

The figures in this book may differ slightly from the numbers found on the website. This is because the data extraction for the book was made at another date than the data on the website. Reporting of data from the pharmacy to NorPD is delayed for a minor number of prescriptions. The delay may be a few months, meaning that reports of data from a year can arrive the following year. Besides, individuals without known address are included in the tables in this book but not on the website.

Access to data from NorPD

It is possible to apply for data from the Norwegian Prescription Database for research or for other purposes which are according to the objectives of NorPD. Application forms are available on the website of NIPH (www.fhi.no) and all applications for access to data from NIPH should be sent to datatilgang@fhi.no. The data is free of charge, but fees for administration and file processing will be required.

Beregning av prevalens per 1000 innbyggere

Prevalens er ofte definert som antall individer som har fått utlevert ett legemiddel per 1000 innbyggere. Antall individer oppgitt i tabellene kan benyttes til å beregne prevalens av legemiddelbruken i befolkningen. Hvordan dette kan gjøres er vist i eksemplet nedenfor.

Antall individer som fikk minst ett hjerte-/karmiddel (ATC-gruppe C) i Norge i 2013: 1 040 279

Antall innbyggere i Norge per 1. juli 2013: 5 080 148

Beregning av prevalens (per 1000) for brukere av hjerte-/karmidler i Norge i 2013:

$$\frac{\text{Antall individer} \times 1000}{\text{Antall innbyggere}} = \frac{1\,040\,279 \times 1000}{5\,080\,148} = 204,8 \text{ individer per 1000 innbyggere}$$

På s. 105 finnes tabeller over befolkningstallet i Norge for årene 2009–2013. Befolkningstallet for de fire aldersgruppene i tabellene er også angitt. Det brukes middelfolkemengden for hvert år, dvs folketallet per 1. juli, beregnet ut fra Statistisk Sentralbyrås folketall 1.1 og 31.12. Alder er definert som den alder individet har ved slutten av året (utleveringsår minus fødselsår).

Calculation of prevalence per 1000 inhabitants

Prevalence is often defined as the number of individuals per 1000 inhabitants who have had at least one prescription dispensed in a pharmacy during a specific time period. The number of individuals listed in the tables can be used to calculate the prevalence of drug users in the population. Please read the following example:

The number of individuals who had at least one cardiovascular drug dispensed (ATC group C) in Norway in 2013: 1 040 279

The number of inhabitants in Norway as of 1st July 2013: 5 080 148

Calculation of the prevalence (per 1000) of users of cardiovascular drugs in Norway in 2013:

$$\frac{\text{The number of individuals} \times 1000}{\text{The number of inhabitants}} = \frac{1\,040\,279 \times 1000}{5\,080\,148} = 204.8 \text{ individuals per 1000 inhabitants}$$

The population in Norway for the years 2009–2013 is shown on p. 105. The population of the four age groups in the tables is also provided. The population as of 1st July each year is used, calculated from the population figures by Statistics Norway from 1st January and 31st December. Age is defined as the age of the individual at the end of the year (year of dispensing minus birth year).

2.4 ATC main groups

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|-----------|-----------|-----------|-----------|--------------------|-------------------------------------|---------|---------|---------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | | | | | | | <15 | 15-44 | 45-69 | ≥70 | |
| A ALIMENTARY TRACT AND METABOLISM | 678 403 | 702 509 | 742 204 | 791 540 | 832 956 | 57 | 26 048 | 194 571 | 372 083 | 240 254 | 1 502 917 |
| B BLOOD AND BLOOD FORMING ORGANS | 562 344 | 581 349 | 597 921 | 617 386 | 629 097 | 49 | 3 070 | 61 114 | 272 750 | 292 163 | 1 045 480 |
| C CARDIOVASCULAR SYSTEM | 945 886 | 975 141 | 998 461 | 1 019 237 | 1 040 279 | 51 | 6 903 | 99 153 | 542 497 | 391 726 | 1 571 794 |
| D DERMATOLOGICALS | 587 812 | 611 440 | 624 493 | 632 680 | 645 684 | 54 | 79 769 | 246 820 | 216 869 | 102 226 | 245 500 |
| G GENITO URINARY SYSTEM AND SEX HORMONES | 703 423 | 721 846 | 745 367 | 761 600 | 785 598 | 80 | 3 475 | 431 263 | 242 798 | 108 062 | 897 948 |
| H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS | 375 465 | 387 821 | 402 923 | 414 206 | 422 537 | 67 | 16 419 | 109 977 | 183 711 | 112 430 | 444 841 |
| J ANTIINFECTIVES FOR SYSTEMIC USE | 1 394 508 | 1 252 392 | 1 326 405 | 1 336 787 | 1 288 914 | 59 | 148 972 | 513 276 | 429 761 | 196 905 | 816 142 |
| L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | 72 795 | 76 656 | 81 612 | 86 336 | 90 729 | 54 | 1 264 | 19 959 | 43 089 | 26 417 | 2 668 185 |
| M MUSCULO-SKELETAL SYSTEM | 891 127 | 901 910 | 927 355 | 937 937 | 925 319 | 57 | 14 318 | 327 053 | 427 476 | 156 472 | 331 706 |
| N NERVOUS SYSTEM | 1 230 918 | 1 248 505 | 1 279 676 | 1 304 344 | 1 327 510 | 59 | 30 708 | 421 950 | 580 132 | 294 720 | 2 600 528 |
| P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS | 86 714 | 88 743 | 92 296 | 95 141 | 96 547 | 62 | 3 632 | 43 659 | 38 204 | 11 052 | 36 412 |
| R RESPIRATORY SYSTEM | 1 183 767 | 1 183 735 | 1 223 490 | 1 239 078 | 1 220 116 | 56 | 159 501 | 441 102 | 449 667 | 169 846 | 1 363 495 |
| S SENSORY ORGANS | 596 290 | 609 467 | 617 742 | 618 314 | 612 715 | 57 | 110 059 | 175 648 | 194 853 | 132 155 | 301 674 |

2.5 ATC group A – Alimentary tract and metabolism

| | | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|--------------|---|-----------------------|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|----------------|----------------|----------------|-------------------|
| | | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | | <15 | 15–44 | 45–69 | ≥70 | | | | | | | |
| A | ALIMENTARY TRACT AND METABOLISM | 678 403 | 702 509 | 742 204 | 791 540 | 832 956 | 57 | 26 048 | 194 571 | 372 083 | 240 254 | 1 502 917 |
| A01 | STOMATOLOGICAL PREPARATIONS | 11 205 | 6 463 | 9 155 | 15 109 | 18 958 | 57 | 450 | 7 723 | 6 281 | 4 504 | 3 398 |
| A01A | STOMATOLOGICAL PREPARATIONS | 11 205 | 6 463 | 9 155 | 15 109 | 18 958 | 57 | 450 | 7 723 | 6 281 | 4 504 | 3 398 |
| A01AA | Caries prophylactic agents | 665 | 776 | 4 792 | 10 862 | 14 642 | 57 | 142 | 5 865 | 4 796 | 3 839 | 2 533 |
| A01AA01 | sodium fluoride ¹⁾ | 665 | 776 | 4 792 | 10 862 | 14 642 | 57 | 142 | 5 865 | 4 796 | 3 839 | 2 533 |
| A01AB | Antiinfectives and antiseptics for local oral treatment | 8 998 | 4 088 | 2 553 | 2 415 | 2 440 | 52 | 161 | 1 025 | 827 | 427 | 247 |
| A01AB02 | hydrogen peroxide ¹⁾ | 0 | <5 | <5 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| A01AB03 | chlorhexidine ¹⁾ | 2 293 | 2 540 | 2 482 | 2 360 | 2 390 | 52 | 155 | 1 010 | 812 | 413 | 220 |
| A01AB04 | amphotericin B | 6 690 | 1 529 | 52 | 36 | 25 | 60 | 0 | 8 | 11 | 6 | 19 |
| A01AB09 | miconazole | 5 | <5 | 5 | 8 | 10 | 60 | <5 | <5 | 0 | 5 | 6 |
| A01AB11 | various ¹⁾ | 22 | 26 | 14 | 11 | 16 | 75 | <5 | <5 | <5 | <5 | 2 |
| A01AB17 | metronidazole | 45 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| A01AC | Corticosteroids for local oral treatment | 1 026 | 1 155 | 1 379 | 1 409 | 1 465 | 64 | 116 | 511 | 599 | 239 | 392 |
| A01AC01 | triamcinolone | 1 026 | 1 155 | 1 379 | 1 398 | 1 435 | 64 | 115 | 507 | 577 | 236 | 344 |
| A01AC03 | hydrocortisone | 0 | 0 | 0 | 0 | <5 | 0 | 0 | 0 | <5 | 0 | 6 |
| A01AD | Other agents for local oral treatment | 598 | 508 | 516 | 532 | 519 | 58 | 32 | 359 | 98 | 30 | 226 |
| A01AD01 | epinephrine | 6 | 9 | 10 | 10 | 14 | 36 | 0 | <5 | 6 | <5 | 16 |
| A01AD02 | benzydamine | 562 | 475 | 494 | 496 | 477 | 59 | 18 | 346 | 90 | 23 | 207 |
| A01AD11 | various | 30 | 24 | 12 | 26 | 28 | 54 | 14 | 9 | <5 | <5 | 3 |
| A02 | DRUGS FOR ACID RELATED DISORDERS | 316 609 | 338 746 | 366 465 | 393 798 | 417 708 | 55 | 7 648 | 92 424 | 200 287 | 117 349 | 334 466 |
| A02A | ANTACIDS | 4 537 | 4 691 | 4 772 | 4 442 | 4 719 | 43 | 116 | 995 | 1 644 | 1 964 | 6 238 |
| A02AA | Magnesium compounds | 0 | 0 | 0 | <5 | 12 | 58 | 0 | 0 | 8 | <5 | 3 |
| A02AA04 | magnesium hydroxide | 0 | 0 | 0 | <5 | 12 | 58 | 0 | 0 | 8 | <5 | 3 |
| A02AC | Calcium compounds | 1 293 | 1 229 | 1 085 | 1 009 | 928 | 36 | 16 | 144 | 327 | 441 | 627 |
| A02AC01 | calcium carbonate ¹⁾ | 1 293 | 1 229 | 1 085 | 1 009 | 928 | 36 | 16 | 144 | 327 | 441 | 627 |
| A02AD | Combinations and complexes of aluminium, calcium and magnesium compounds | 1 495 | 1 485 | 1 526 | 1 039 | 1 179 | 60 | 26 | 576 | 373 | 204 | 169 |
| A02AD01 | ordinary salt combinations ¹⁾ | 1 495 | 1 485 | 1 526 | 1 039 | 1 179 | 60 | 26 | 576 | 373 | 204 | 169 |
| A02AH | Antacids with sodium bicarbonate | 2 187 | 2 341 | 2 471 | 2 684 | 2 837 | 36 | 41 | 292 | 1 037 | 1 467 | 5 146 |
| A02B | DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) | 314 287 | 336 339 | 364 176 | 391 644 | 415 383 | 55 | 7 566 | 91 979 | 199 537 | 116 301 | 328 228 |

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|--|-----------------------|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|---------------|----------------|----------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| A02BA H₂-receptor antagonists | 58 630 | 57 804 | 57 052 | 55 116 | 53 694 | 59 | 1 310 | 14 602 | 24 818 | 12 964 | 16 190 |
| A02BA01 cimetidine | 56 | 46 | 34 | 28 | 23 | 74 | 0 | <5 | 17 | <5 | 27 |
| A02BA02 ranitidine ¹⁾ | 55 484 | 54 984 | 54 650 | 53 485 | 52 431 | 59 | 1 303 | 14 438 | 24 223 | 12 467 | 15 021 |
| A02BA03 famotidine ¹⁾ | 2 878 | 2 547 | 2 313 | 1 618 | 1 312 | 56 | 9 | 174 | 612 | 517 | 1 142 |
| A02BA53 famotidine, combinations ¹⁾ | 378 | 367 | 221 | 127 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| A02BB Prostaglandins | 248 | 259 | 255 | 360 | 346 | 86 | <5 | 228 | 70 | 46 | 188 |
| A02BB01 misoprostol | 248 | 259 | 255 | 360 | 346 | 86 | <5 | 228 | 70 | 46 | 188 |
| A02BC Proton pump inhibitors | 269 754 | 292 835 | 321 967 | 352 025 | 377 400 | 54 | 6 407 | 81 487 | 182 681 | 106 825 | 311 191 |
| A02BC01 omeprazole | 46 873 | 47 082 | 48 114 | 47 472 | 45 183 | 55 | 3 293 | 9 061 | 19 890 | 12 939 | 46 827 |
| A02BC02 pantoprazole ¹⁾ | 85 176 | 102 237 | 125 091 | 148 733 | 171 451 | 54 | 672 | 39 791 | 81 449 | 49 539 | 63 305 |
| A02BC03 lansoprazole | 50 018 | 48 809 | 47 348 | 46 359 | 43 483 | 51 | 419 | 7 545 | 22 279 | 13 240 | 30 872 |
| A02BC05 esomeprazole | 111 446 | 117 963 | 125 642 | 135 124 | 142 299 | 55 | 2 466 | 31 792 | 71 031 | 37 010 | 170 187 |
| A02BX Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) | 1 807 | 1 909 | 2 143 | 2 375 | 2 724 | 62 | 263 | 945 | 930 | 586 | 659 |
| A02BX02 sucralfate | 403 | 366 | 419 | 440 | 470 | 62 | <5 | 132 | 191 | 143 | 239 |
| A02BX13 alginic acid | 1 414 | 1 549 | 1 739 | 1 945 | 2 239 | 62 | 259 | 803 | 733 | 444 | 401 |
| A03 DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS | 60 485 | 62 554 | 65 509 | 69 717 | 72 136 | 71 | 1 484 | 25 258 | 27 484 | 17 910 | 15 329 |
| A03A DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS | 3 471 | 3 623 | 3 150 | 3 568 | 4 373 | 56 | 229 | 1 025 | 1 510 | 1 609 | 1 786 |
| A03AA Synthetic anticholinergics, esters with tertiary amino group | 28 | 29 | 26 | 27 | 30 | 63 | 0 | 14 | 13 | <5 | 34 |
| A03AA04 mebeverine | 27 | 29 | 26 | 27 | 30 | 63 | 0 | 14 | 13 | <5 | 34 |
| A03AA07 dicycloverine | <5 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| A03AB Synthetic anticholinergics, quaternary ammonium compounds | 112 | 132 | 160 | 214 | 497 | 49 | <5 | 34 | 182 | 279 | 275 |
| A03AB02 glycopyrronium bromide | 105 | 128 | 155 | 206 | 491 | 50 | <5 | 32 | 178 | 279 | 270 |
| A03AB05 propantheline | 7 | <5 | 5 | 8 | 6 | 0 | 0 | <5 | <5 | 0 | 5 |
| A03AD Papaverine and derivatives | 37 | 59 | 47 | 62 | 39 | 18 | <5 | 6 | 22 | 9 | 56 |
| A03AD01 papaverine | 37 | 59 | 47 | 62 | 39 | 18 | <5 | 6 | 22 | 9 | 56 |
| A03AX Other drugs for functional gastrointestinal disorders | 3 302 | 3 405 | 2 924 | 3 271 | 3 815 | 57 | 225 | 972 | 1 296 | 1 322 | 1 422 |
| A03AX13 silicones | 3 302 | 3 405 | 2 924 | 3 271 | 3 815 | 57 | 225 | 972 | 1 296 | 1 322 | 1 422 |
| A03B BELLADONNA AND DERIVATIVES, PLAIN | 1 382 | 1 617 | 1 910 | 2 134 | 2 390 | 59 | 19 | 995 | 988 | 388 | 924 |
| A03BA Belladonna alkaloids, tertiary amines | 1 098 | 1 297 | 1 510 | 1 670 | 1 825 | 58 | 14 | 778 | 720 | 313 | 619 |

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group A

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|---------------|---------------|---------------|---------------|--------------------|-------------------------------------|---------------|---------------|---------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| A03BA01 atropine | 26 | 22 | 23 | 29 | 38 | 61 | 0 | 18 | 13 | 7 | 27 |
| A03BA03 hyoscyamine | 1 072 | 1 276 | 1 487 | 1 641 | 1 787 | 58 | 14 | 760 | 707 | 306 | 592 |
| A03BB Belladonna alkaloids, semisynthetic, quaternary ammonium compounds | 285 | 321 | 406 | 471 | 578 | 60 | 5 | 223 | 274 | 76 | 305 |
| A03BB01 butylscopolamine | 267 | 300 | 386 | 458 | 564 | 60 | <5 | 218 | 269 | 73 | 302 |
| A03BB03 methylscopolamine | 18 | 23 | 21 | 13 | 14 | 64 | <5 | 5 | 5 | <5 | 3 |
| A03C ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS | 18 | 19 | 20 | 16 | 14 | 50 | 0 | 0 | 10 | <5 | 32 |
| A03CA Synthetic anticholinergic agents in combination with psycholeptics | 18 | 19 | 20 | 16 | 14 | 50 | 0 | 0 | 10 | <5 | 32 |
| A03CA02 clidinium and psycholeptics | 18 | 19 | 20 | 16 | 14 | 50 | 0 | 0 | 10 | <5 | 32 |
| A03F PROPULSIVES | 56 321 | 58 104 | 61 221 | 64 906 | 66 521 | 72 | 1 246 | 23 493 | 25 467 | 16 315 | 12 587 |
| A03FA Propulsives | 56 321 | 58 104 | 61 221 | 64 906 | 66 521 | 72 | 1 246 | 23 493 | 25 467 | 16 315 | 12 587 |
| A03FA01 metoclopramide | 56 214 | 57 999 | 61 099 | 64 774 | 66 391 | 72 | 1 231 | 23 459 | 25 412 | 16 289 | 12 054 |
| A03FA02 cisapride | 93 | 83 | 79 | 83 | 59 | 63 | 7 | 13 | 29 | 10 | 394 |
| A03FA03 domperidone | 44 | 55 | 71 | 62 | 80 | 68 | 8 | 24 | 27 | 21 | 125 |
| A03FA05 alizapride | 0 | 0 | 0 | 11 | 9 | 56 | 0 | 5 | <5 | 0 | 15 |
| A04 ANTIEMETICS AND ANTINAUSEANTS | 13 055 | 13 797 | 14 669 | 15 274 | 16 026 | 59 | 331 | 2 893 | 8 628 | 4 174 | 32 758 |
| A04A ANTIEMETICS AND ANTINAUSEANTS | 13 055 | 13 797 | 14 669 | 15 274 | 16 026 | 59 | 331 | 2 893 | 8 628 | 4 174 | 32 758 |
| A04AA Serotonin (5HT₃) antagonists | 10 867 | 11 434 | 11 986 | 12 407 | 12 856 | 58 | 250 | 1 839 | 7 072 | 3 695 | 23 811 |
| A04AA01 ondansetron | 10 437 | 11 150 | 11 784 | 12 278 | 12 840 | 58 | 249 | 1 837 | 7 063 | 3 691 | 23 557 |
| A04AA02 granisetron | <5 | 0 | <5 | <5 | <5 | 25 | <5 | <5 | 0 | 0 | 148 |
| A04AA03 tropisetron | 613 | 440 | 324 | 210 | 26 | 65 | <5 | 6 | 13 | 6 | 60 |
| A04AA05 palonosetron | <5 | 5 | <5 | 7 | 16 | 75 | 0 | 5 | 11 | 0 | 46 |
| A04AD Other antiemetics | 3 194 | 3 887 | 4 658 | 5 185 | 5 735 | 68 | 82 | 1 472 | 3 367 | 814 | 8 947 |
| A04AD01 scopolamine | 2 112 | 2 135 | 2 400 | 2 318 | 2 424 | 58 | 80 | 914 | 1 035 | 395 | 893 |
| A04AD10 dronabinol | 5 | <5 | 5 | 5 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| A04AD12 aprepitant | 1 078 | 1 761 | 2 269 | 2 873 | 3 323 | 76 | <5 | 559 | 2 342 | 420 | 8 054 |
| A05 BILE AND LIVER THERAPY | 1 909 | 2 015 | 2 303 | 2 600 | 2 728 | 74 | 95 | 910 | 1 258 | 465 | 9 873 |
| A05A BILE THERAPY | 1 909 | 2 015 | 2 303 | 2 600 | 2 728 | 74 | 95 | 910 | 1 258 | 465 | 9 873 |
| A05AA Bile acid preparations | 1 909 | 2 015 | 2 303 | 2 600 | 2 728 | 74 | 95 | 910 | 1 258 | 465 | 9 873 |
| A05AA02 ursodeoxycholic acid | 1 909 | 2 015 | 2 303 | 2 600 | 2 728 | 74 | 95 | 910 | 1 258 | 465 | 9 873 |
| A06 DRUGS FOR CONSTIPATION | 31 408 | 44 230 | 50 571 | 49 919 | 55 321 | 56 | 7 281 | 8 512 | 18 809 | 20 719 | 32 451 |
| A06A DRUGS FOR CONSTIPATION | 31 408 | 44 230 | 50 571 | 49 919 | 55 321 | 56 | 7 281 | 8 512 | 18 809 | 20 719 | 32 451 |
| A06AA Softeners, emollients | 105 | 112 | 208 | 368 | 743 | 52 | 100 | 94 | 237 | 312 | 452 |

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|---------------|---------------|---------------|---------------|--------------------|-------------------------------------|---------------|---------------|---------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| A06AA01 liquid paraffin ¹⁾ | 105 | 112 | 194 | 354 | 699 | 53 | 84 | 90 | 230 | 295 | 271 |
| A06AB Contact laxatives | 13 383 | 15 058 | 21 757 | 22 562 | 24 463 | 57 | 345 | 2 844 | 10 211 | 11 063 | 7 368 |
| A06AB02 bisacodyl ¹⁾ | 3 858 | 4 056 | 6 514 | 6 040 | 5 666 | 61 | 63 | 766 | 1 869 | 2 968 | 1 884 |
| A06AB06 senna glycosides ¹⁾ | 2 020 | 2 120 | 4 322 | 2 820 | 2 216 | 56 | 7 | 139 | 665 | 1 405 | 1 099 |
| A06AB08 sodium picosulfate ¹⁾ | 8 584 | 10 082 | 10 948 | 11 687 | 12 659 | 54 | 275 | 1 497 | 4 899 | 5 988 | 2 713 |
| A06AB20 contact laxatives in combination ¹⁾ | <5 | 6 | 8 | <5 | <5 | 100 | 0 | 0 | <5 | <5 | 2 |
| A06AB53 dantron, combinations | <5 | <5 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| A06AB56 senna glycosides, combinations ¹⁾ | 17 | 10 | 12 | 11 | 8 | 75 | 0 | <5 | 5 | <5 | 1 |
| A06AB58 sodium picosulfate, combinations ¹⁾ | 0 | 31 | 1 581 | 3 535 | 5 410 | 59 | 6 | 572 | 3 335 | 1 497 | 1 669 |
| A06AC Bulk-forming laxatives | 1 772 | 1 996 | 2 054 | 2 084 | 2 266 | 59 | 46 | 645 | 857 | 718 | 629 |
| A06AC01 ispaghula (psylla seeds) ¹⁾ | 1 772 | 1 996 | 2 054 | 2 084 | 2 266 | 59 | 46 | 645 | 857 | 718 | 629 |
| A06AD Osmotically acting laxatives | 18 687 | 30 442 | 30 643 | 29 326 | 32 340 | 54 | 6 764 | 4 774 | 9 617 | 11 185 | 14 265 |
| A06AD11 lactulose ¹⁾ | 13 507 | 14 464 | 14 513 | 14 603 | 14 837 | 51 | 770 | 1 979 | 5 483 | 6 605 | 4 022 |
| A06AD12 lactitol | 78 | 59 | 58 | 51 | 39 | 49 | 27 | 8 | <5 | <5 | 49 |
| A06AD15 macrogol | 0 | 45 | 79 | 135 | 221 | 57 | 209 | 11 | <5 | 0 | 207 |
| A06AD17 sodium phosphate ¹⁾ | 847 | 9 665 | 7 334 | 2 813 | 2 015 | 56 | <5 | 363 | 1 102 | 548 | 412 |
| A06AD65 macrogol, combinations ¹⁾ | 4 947 | 7 273 | 9 943 | 12 962 | 16 618 | 56 | 5 921 | 2 545 | 3 564 | 4 588 | 9 575 |
| A06AG Enemas | 4 649 | 4 892 | 5 458 | 5 325 | 5 466 | 48 | 541 | 1 308 | 1 838 | 1 779 | 7 994 |
| A06AG02 bisacodyl ¹⁾ | 1 475 | 1 410 | 1 680 | 1 676 | 1 699 | 45 | 43 | 474 | 703 | 479 | 754 |
| A06AG04 glycerol ¹⁾ | 772 | 827 | 905 | 861 | 763 | 47 | 164 | 222 | 199 | 178 | 3 875 |
| A06AG10 docusate sodium, incl. combinations ¹⁾ | 1 217 | 1 394 | 1 484 | 1 369 | 1 412 | 49 | 72 | 333 | 486 | 521 | 1 724 |
| A06AG11 laurilsulfate, incl. combinations ¹⁾ | 1 567 | 1 647 | 1 826 | 1 786 | 1 920 | 50 | 269 | 347 | 580 | 724 | 1 641 |
| A06AH Peripheral opioid receptor antagonists | 164 | 197 | 195 | 181 | 177 | 51 | 0 | 18 | 93 | 66 | 979 |
| A06AH01 methylnaltrexone bromide | 164 | 197 | 195 | 181 | 177 | 51 | 0 | 18 | 93 | 66 | 979 |
| A06AX Other drugs for constipation | 0 | 0 | 0 | 9 | 474 | 82 | <5 | 198 | 196 | 79 | 764 |
| A06AX04 linaclotide | 0 | 0 | 0 | 0 | 216 | 71 | <5 | 97 | 80 | 38 | 201 |
| A06AX05 prucalopride | 0 | 0 | 0 | 9 | 271 | 91 | 0 | 108 | 122 | 41 | 562 |
| A07 ANTIDIARRHEALS, INTESTINAL ANTI-INFLAMMATORY/ANTI-INFECTIVE AGENTS | 62 586 | 69 807 | 72 492 | 73 982 | 76 993 | 58 | 7 302 | 20 917 | 31 642 | 17 132 | 130 269 |
| A07A INTESTINAL ANTIINFECTIVES | 25 618 | 31 199 | 32 204 | 32 358 | 33 905 | 64 | 6 772 | 8 404 | 11 592 | 7 137 | 13 574 |
| A07AA Antibiotics | 25 618 | 31 199 | 32 204 | 32 358 | 33 905 | 64 | 6 772 | 8 404 | 11 592 | 7 137 | 13 574 |

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group A

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|---------------|---------------|---------------|---------------|--------------------|-------------------------------------|--------------|---------------|--------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| A07AA01 neomycin | 0 | 0 | 0 | 0 | 37 | 73 | 0 | 21 | 14 | <5 | 18 |
| A07AA02 nystatin | 25 376 | 30 730 | 31 544 | 31 731 | 33 307 | 64 | 6 747 | 8 172 | 11 360 | 7 028 | 11 626 |
| A07AA06 paromomycin | 81 | 154 | 316 | 257 | 322 | 68 | 21 | 165 | 127 | 9 | 274 |
| A07AA09 vancomycin | 177 | 182 | 200 | 234 | 238 | 60 | <5 | 39 | 90 | 106 | 792 |
| A07AA11 rifaximin | <5 | 184 | 211 | 189 | 230 | 66 | 6 | 114 | 103 | 7 | 759 |
| A07AA12 fidaxomicin | 0 | 0 | 0 | <5 | 7 | 57 | 0 | <5 | <5 | <5 | 104 |
| A07B INTESTINAL ADSORBENTS | 95 | 80 | 84 | 102 | 103 | 40 | 21 | 44 | 23 | 15 | 22 |
| A07BA Charcoal preparations | 95 | 80 | 84 | 96 | 88 | 40 | 21 | 37 | 17 | 13 | 12 |
| A07BA01 medicinal charcoal ¹⁾ | 95 | 80 | 84 | 96 | 88 | 40 | 21 | 37 | 17 | 13 | 12 |
| A07BB Bismuth preparations | 0 | 0 | 0 | 6 | 15 | 40 | 0 | 7 | 6 | <5 | 10 |
| A07C ELECTROLYTES WITH CARBOHYDRATES | 182 | 259 | 279 | 364 | 449 | 47 | 175 | 142 | 87 | 45 | 1 130 |
| A07CA Oral rehydration salt formulations¹⁾ | 182 | 259 | 279 | 364 | 442 | 48 | 168 | 142 | 87 | 45 | 188 |
| A07D ANTIPROPULSIVES | 16 106 | 16 710 | 17 200 | 18 029 | 18 647 | 56 | 108 | 3 598 | 8 482 | 6 459 | 8 167 |
| A07DA Antipropulsives | 16 106 | 16 710 | 17 200 | 18 029 | 18 647 | 56 | 108 | 3 598 | 8 482 | 6 459 | 8 167 |
| A07DA01 diphenoxylate | <5 | <5 | <5 | <5 | <5 | - | 0 | 0 | <5 | 0 | 13 |
| A07DA02 opium | 56 | 79 | 86 | 80 | 143 | 65 | 0 | 14 | 84 | 45 | 389 |
| A07DA03 loperamide ¹⁾ | 15 829 | 16 464 | 16 933 | 17 714 | 18 322 | 56 | 107 | 3 501 | 8 337 | 6 377 | 7 623 |
| A07DA53 loperamide, combinations ¹⁾ | 326 | 294 | 283 | 359 | 361 | 53 | <5 | 105 | 159 | 96 | 142 |
| A07E INTESTINAL ANTI-INFLAMMATORY AGENTS | 21 914 | 22 753 | 23 690 | 24 490 | 25 601 | 52 | 230 | 8 879 | 12 408 | 4 084 | 105 133 |
| A07EA Corticosteroids acting locally | 5 014 | 5 212 | 5 155 | 5 208 | 5 537 | 61 | 65 | 1 803 | 2 605 | 1 064 | 15 510 |
| A07EA01 prednisolone | 1 011 | 1 175 | 1 292 | 1 222 | 1 163 | 50 | 8 | 452 | 554 | 149 | 1 175 |
| A07EA02 hydrocortisone | 1 233 | 1 154 | 408 | 356 | 327 | 69 | <5 | 95 | 179 | 52 | 549 |
| A07EA06 budesonide | 2 972 | 3 190 | 3 583 | 3 766 | 4 153 | 63 | 58 | 1 298 | 1 923 | 874 | 13 786 |
| A07EB Antiallergic agents, excl. corticosteroids | 54 | 53 | 64 | 50 | 35 | 86 | 5 | 8 | 20 | <5 | 494 |
| A07EB01 cromoglicic acid | 54 | 53 | 64 | 50 | 35 | 86 | 5 | 8 | 20 | <5 | 494 |
| A07EC Aminosalicylic acid and similar agents | 19 275 | 19 918 | 20 669 | 21 351 | 22 091 | 50 | 186 | 7 916 | 10 748 | 3 241 | 89 128 |
| A07EC01 sulfasalazine | 6 194 | 6 104 | 5 966 | 5 803 | 5 666 | 55 | <5 | 1 335 | 3 228 | 1 099 | 6 665 |
| A07EC02 mesalazine | 12 549 | 13 330 | 14 229 | 15 091 | 16 050 | 48 | 181 | 6 462 | 7 322 | 2 085 | 78 923 |
| A07EC03 olsalazine | 488 | 494 | 452 | 406 | 381 | 47 | <5 | 97 | 215 | 68 | 1 360 |
| A07EC04 balsalazide | 809 | 750 | 687 | 613 | 589 | 44 | 0 | 198 | 310 | 81 | 2 179 |
| A07F ANTIDIARRHEAL MICROORGANISMS | 694 | 1 252 | 1 507 | 1 244 | 1 228 | 67 | 40 | 605 | 472 | 111 | 2 081 |
| A07FA Antidiarrheal microorganisms | 694 | 1 252 | 1 507 | 1 244 | 1 228 | 67 | 40 | 605 | 472 | 111 | 2 081 |

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group A

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 | |
|--------------|--|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|--------------|---------------|---------------|-------------------|----------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK | |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | | |
| A07FA01 | lactic acid producing organisms | 581 | 918 | 912 | 768 | 806 | 70 | 15 | 427 | 335 | 29 | 1 618 |
| A07FA02 | saccharomyces boulardii | 116 | 283 | 381 | 431 | 505 | 63 | 29 | 220 | 170 | 86 | 348 |
| A07FA51 | lactic acid producing organisms, combinations | 0 | 0 | 0 | 16 | 14 | 57 | <5 | 11 | <5 | 0 | 35 |
| A07X | OTHER ANTIDIARRHEALS | 139 | 99 | 117 | 64 | 43 | 77 | <5 | 21 | 18 | <5 | 35 |
| A07XA | Other antidiarrheals | 139 | 99 | 117 | 64 | 43 | 77 | <5 | 21 | 18 | <5 | 35 |
| A08 | ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS | 38 343 | 19 168 | 10 373 | 7 674 | 7 245 | 77 | <5 | 2 709 | 3 958 | 575 | 12 126 |
| A08A | ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS | 38 343 | 19 168 | 10 373 | 7 674 | 7 245 | 77 | <5 | 2 709 | 3 958 | 575 | 12 126 |
| A08AA | Centrally acting antiobesity products | 25 710 | 5 782 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| A08AA10 | sibutramine | 25 710 | 5 782 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| A08AB | Peripherally acting antiobesity products | 14 540 | 14 575 | 10 373 | 7 674 | 7 245 | 77 | <5 | 2 709 | 3 958 | 575 | 12 126 |
| A08AB01 | orlistat | 14 540 | 14 575 | 10 373 | 7 674 | 7 245 | 77 | <5 | 2 709 | 3 958 | 575 | 12 126 |
| A08AX | Other antiobesity drugs | <5 | <5 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| A08AX01 | rimonabant | <5 | <5 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| A09 | DIGESTIVES, INCL. ENZYMES | 5 126 | 5 479 | 5 758 | 5 740 | 5 720 | 57 | 121 | 876 | 2 755 | 1 968 | 15 474 |
| A09A | DIGESTIVES, INCL. ENZYMES | 5 126 | 5 479 | 5 758 | 5 740 | 5 720 | 57 | 121 | 876 | 2 755 | 1 968 | 15 474 |
| A09AA | Enzyme preparations | 5 070 | 5 441 | 5 699 | 5 692 | 5 637 | 57 | 121 | 852 | 2 722 | 1 942 | 15 402 |
| A09AA02 | multienzymes (lipase, protease etc.) | 5 070 | 5 441 | 5 699 | 5 687 | 5 628 | 57 | 121 | 848 | 2 718 | 1 941 | 15 382 |
| A09AB | Acid preparations | 65 | 50 | 61 | 52 | 63 | 79 | 0 | 10 | 24 | 29 | 26 |
| A09AB01 | glutamic acid hydrochloride ¹⁾ | 52 | 44 | 54 | 39 | 45 | 76 | 0 | <5 | 17 | 25 | 17 |
| A09AB02 | betaine hydrochloride | 0 | 0 | <5 | <5 | 10 | 90 | 0 | 6 | <5 | <5 | 8 |
| A09AB03 | hydrochloric acid ¹⁾ | <5 | 6 | 6 | 10 | 8 | 88 | 0 | <5 | 5 | <5 | 1 |
| A09AB04 | citric acid | 10 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| A09AC | Enzyme and acid preparations, combinations | 0 | 15 | 17 | 9 | 33 | 70 | 0 | 19 | 14 | 0 | 45 |
| A09AC02 | multienzymes and acid preparations | 0 | 15 | 17 | 9 | 33 | 70 | 0 | 19 | 14 | 0 | 45 |
| A10 | DRUGS USED IN DIABETES | 145 677 | 152 065 | 156 542 | 161 132 | 165 315 | 44 | 1 839 | 23 380 | 85 385 | 54 711 | 582 040 |
| A10A | INSULINS AND ANALOGUES | 52 603 | 54 014 | 54 994 | 56 508 | 58 187 | 43 | 1 811 | 14 207 | 26 328 | 15 841 | 329 145 |
| A10AB | Insulins and analogues for injection, fast-acting | 33 562 | 34 874 | 35 659 | 36 959 | 38 386 | 43 | 1 804 | 12 961 | 16 707 | 6 914 | 121 146 |
| A10AB01 | insulin (human) | 1 823 | 1 604 | 1 403 | 1 294 | 1 144 | 40 | 12 | 185 | 627 | 320 | 2 332 |

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group A

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|---------------|---------------|---------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| A10AB04 insulin lispro | 8 615 | 8 835 | 9 021 | 9 118 | 9 462 | 42 | 194 | 3 930 | 4 200 | 1 138 | 32 647 |
| A10AB05 insulin aspart | 23 900 | 25 159 | 25 860 | 27 075 | 28 325 | 43 | 1 664 | 9 100 | 12 058 | 5 503 | 84 956 |
| A10AB06 insulin glulisine | 270 | 375 | 404 | 379 | 408 | 47 | <5 | 143 | 218 | 45 | 1 211 |
| A10AC Insulins and analogues for injection, intermediate-acting | 33 129 | 32 520 | 31 916 | 32 046 | 32 559 | 42 | 582 | 5 201 | 15 605 | 11 171 | 97 083 |
| A10AC01 insulin (human) | 33 129 | 32 520 | 31 916 | 32 046 | 32 559 | 42 | 582 | 5 201 | 15 605 | 11 171 | 97 083 |
| A10AD Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting | 9 736 | 9 112 | 8 304 | 7 706 | 7 154 | 43 | <5 | 458 | 3 270 | 3 423 | 30 446 |
| A10AD01 insulin (human) | 17 | <5 | <5 | <5 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| A10AD03 insulin (pork) | 0 | 0 | <5 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| A10AD04 insulin lispro | 672 | 647 | 643 | 609 | 645 | 44 | <5 | 117 | 322 | 205 | 2 584 |
| A10AD05 insulin aspart | 9 075 | 8 476 | 7 672 | 7 111 | 6 522 | 43 | <5 | 341 | 2 957 | 3 222 | 27 862 |
| A10AE Insulins and analogues for injection, long-acting | 11 310 | 13 695 | 15 222 | 16 426 | 17 686 | 45 | 793 | 6 980 | 7 730 | 2 183 | 80 470 |
| A10AE02 insulin (beef) | <5 | <5 | <5 | <5 | <5 | - | 0 | 0 | <5 | 0 | 12 |
| A10AE04 insulin glargine | 6 958 | 8 433 | 9 559 | 10 629 | 11 727 | 45 | 244 | 4 672 | 5 289 | 1 522 | 49 534 |
| A10AE05 insulin detemir | 4 493 | 5 526 | 5 927 | 6 023 | 6 207 | 46 | 569 | 2 418 | 2 534 | 686 | 30 923 |
| A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS | 111 436 | 117 293 | 121 207 | 125 155 | 128 629 | 44 | 30 | 10 776 | 71 489 | 46 334 | 252 895 |
| A10BA Biguanides | 95 537 | 101 637 | 103 523 | 105 196 | 106 357 | 44 | 22 | 9 537 | 60 248 | 36 550 | 47 497 |
| A10BA02 metformin | 95 537 | 101 637 | 103 523 | 105 196 | 106 357 | 44 | 22 | 9 537 | 60 248 | 36 550 | 47 497 |
| A10BB Sulfonamides, urea derivatives | 47 349 | 46 112 | 43 116 | 40 676 | 38 381 | 40 | 10 | 1 691 | 19 842 | 16 838 | 16 755 |
| A10BB01 glibenclamide | 1 738 | 1 539 | 1 343 | 1 190 | 1 098 | 42 | 7 | 45 | 481 | 565 | 562 |
| A10BB02 chlorpropamide | <5 | <5 | <5 | <5 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| A10BB07 glipizide | 5 229 | 4 807 | 4 281 | 3 860 | 3 413 | 41 | 0 | 96 | 1 431 | 1 886 | 1 955 |
| A10BB12 glimepiride | 40 684 | 40 028 | 37 733 | 35 800 | 34 007 | 40 | <5 | 1 557 | 18 001 | 14 445 | 14 238 |
| A10BD Combinations of oral blood glucose lowering drugs | 3 852 | 8 219 | 10 974 | 13 316 | 15 765 | 36 | 0 | 1 106 | 10 401 | 4 258 | 61 014 |
| A10BD03 metformin and rosiglitazone | 2 575 | 2 284 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| A10BD04 glimepiride and rosiglitazone | <5 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| A10BD05 metformin and pioglitazone | 27 | 32 | 35 | 26 | 30 | 43 | 0 | <5 | 21 | 5 | 113 |
| A10BD07 metformin and sitagliptin | 318 | 2 187 | 4 053 | 5 228 | 6 295 | 36 | 0 | 443 | 4 130 | 1 722 | 24 095 |
| A10BD08 metformin and vildagliptin | 1 068 | 4 791 | 7 030 | 8 175 | 9 360 | 37 | 0 | 648 | 6 192 | 2 520 | 36 271 |
| A10BD10 metformin and saxagliptin | 0 | 0 | 0 | 0 | 43 | 23 | 0 | 6 | 29 | 8 | 114 |
| A10BD11 metformin and linagliptin | 0 | 0 | 0 | 0 | 166 | 35 | 0 | 16 | 115 | 35 | 421 |
| A10BF Alpha glucosidase inhibitors | 922 | 813 | 701 | 640 | 597 | 43 | 0 | 40 | 295 | 262 | 871 |

ATC group A

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|---------------|----------------|----------------|----------------|--------------------|-------------------------------------|---------------|---------------|---------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| A10BF01 acarbose | 922 | 813 | 701 | 640 | 597 | 43 | 0 | 40 | 295 | 262 | 871 |
| A10BG Thiazolidinediones | 5 401 | 4 672 | 1 912 | 1 642 | 1 579 | 40 | 0 | 77 | 1 017 | 485 | 4 101 |
| A10BG02 rosiglitazone | 3 798 | 3 104 | 20 | <5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| A10BG03 pioglitazone | 1 641 | 1 779 | 1 894 | 1 641 | 1 579 | 40 | 0 | 77 | 1 017 | 485 | 4 101 |
| A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors | 1 752 | 6 478 | 9 436 | 11 112 | 13 439 | 41 | 0 | 754 | 7 732 | 4 953 | 49 488 |
| A10BH01 sitagliptin | 1 491 | 4 799 | 6 711 | 7 209 | 7 621 | 41 | 0 | 439 | 4 597 | 2 585 | 29 693 |
| A10BH02 vildagliptin | 288 | 935 | 1 274 | 1 755 | 2 289 | 45 | 0 | 135 | 1 216 | 938 | 6 632 |
| A10BH03 saxagliptin | 0 | 854 | 1 616 | 1 767 | 1 684 | 39 | 0 | 109 | 1 049 | 526 | 6 590 |
| A10BH05 linagliptin | 0 | 0 | 0 | 609 | 2 145 | 39 | 0 | 83 | 1 013 | 1 049 | 6 573 |
| A10BX Other blood glucose lowering drugs, excl. insulins | 847 | 1 335 | 3 523 | 5 430 | 7 805 | 45 | 0 | 973 | 5 700 | 1 132 | 73 168 |
| A10BX02 repaglinide | 330 | 283 | 252 | 237 | 213 | 34 | 0 | 5 | 117 | 91 | 407 |
| A10BX03 nateglinide | 13 | 11 | 9 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| A10BX04 exenatide | 491 | 554 | 795 | 874 | 972 | 46 | 0 | 132 | 720 | 120 | 7 866 |
| A10BX07 liraglutide | 19 | 535 | 2 605 | 4 433 | 5 666 | 46 | 0 | 734 | 4 186 | 746 | 62 351 |
| A10BX09 dapagliflozin | 0 | 0 | 0 | 0 | 1 311 | 41 | 0 | 141 | 961 | 209 | 2 329 |
| A10BX10 lixisenatide | 0 | 0 | 0 | 0 | 73 | 49 | 0 | 11 | 49 | 13 | 215 |
| A11 VITAMINS | 91 052 | 93 046 | 102 139 | 119 090 | 128 838 | 60 | 1 249 | 33 473 | 49 263 | 44 853 | 71 879 |
| A11A MULTIVITAMINS, COMBINATIONS | 0 | 0 | 28 | 96 | 138 | 47 | 68 | 65 | 5 | 0 | 465 |
| A11AA Multivitamins with minerals | 0 | 0 | 28 | 96 | 138 | 47 | 68 | 65 | 5 | 0 | 465 |
| A11AA03 multivitamins and other minerals, incl. combinations | 0 | 0 | 28 | 96 | 138 | 47 | 68 | 65 | 5 | 0 | 465 |
| A11B MULTIVITAMINS, PLAIN | 78 | 100 | 74 | 69 | 44 | 64 | 25 | 19 | 0 | 0 | 48 |
| A11BA Multivitamins, plain | 78 | 100 | 74 | 69 | 44 | 64 | 25 | 19 | 0 | 0 | 48 |
| A11C VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO | 9 836 | 11 360 | 17 026 | 25 182 | 34 758 | 60 | 699 | 13 897 | 13 136 | 7 026 | 19 136 |
| A11CA Vitamin A, plain | 29 | 30 | 42 | 58 | 51 | 59 | 5 | 19 | 25 | <5 | 146 |
| A11CA01 retinol (vit A) | 13 | 14 | 20 | 37 | 35 | 57 | <5 | 13 | 18 | <5 | 51 |
| A11CA02 betacarotene | 16 | 16 | 22 | 21 | 16 | 63 | <5 | 6 | 7 | 0 | 95 |
| A11CC Vitamin D and analogues | 9 815 | 11 337 | 16 992 | 25 144 | 34 722 | 60 | 695 | 13 884 | 13 118 | 7 025 | 18 991 |
| A11CC01 ergocalciferol | 3 096 | 4 250 | 8 654 | 13 289 | 49 | 67 | 0 | 24 | 20 | 5 | 18 |
| A11CC03 alfacalcidol | 3 790 | 3 884 | 4 123 | 4 861 | 4 730 | 47 | 140 | 747 | 1 854 | 1 989 | 6 713 |
| A11CC04 calcitriol | 2 297 | 2 396 | 2 632 | 2 947 | 3 068 | 46 | 8 | 561 | 1 277 | 1 222 | 3 545 |
| A11CC05 colecalciferol | 753 | 939 | 1 733 | 4 421 | 27 121 | 63 | 552 | 12 633 | 10 079 | 3 857 | 8 715 |

ATC group A

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|---------------|---------------|---------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| A11D VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12¹⁾ | 762 | 790 | 749 | 800 | 784 | 38 | 10 | 127 | 457 | 190 | 691 |
| A11DA Vitamin B1, plain | 745 | 782 | 739 | 788 | 774 | 37 | 10 | 125 | 453 | 186 | 685 |
| A11DA01 thiamine (vit B1) ¹⁾ | 745 | 782 | 739 | 788 | 774 | 37 | 10 | 125 | 453 | 186 | 685 |
| A11DB Vitamin B1 in combination with vitamin B6 and/or vitamin B12 | 17 | 8 | 10 | 12 | 10 | 70 | 0 | <5 | <5 | <5 | 7 |
| A11E VITAMIN B-COMPLEX, INCL. COMBINATIONS | 78 387 | 78 352 | 82 349 | 92 535 | 93 711 | 60 | 315 | 19 496 | 36 573 | 37 327 | 48 503 |
| A11EA Vitamin B-complex, plain¹⁾ | 77 313 | 77 144 | 80 810 | 91 094 | 92 410 | 60 | 270 | 19 244 | 36 097 | 36 799 | 47 144 |
| A11EB Vitamin B-complex with vitamin C | 114 | 92 | 155 | 231 | 270 | 54 | <5 | 101 | 113 | 53 | 71 |
| A11EX Vitamin B-complex, other combinations | 1 008 | 1 155 | 1 443 | 1 278 | 1 083 | 39 | 42 | 157 | 389 | 495 | 1 288 |
| A11G ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS | 3 507 | 3 677 | 3 759 | 3 674 | 3 502 | 68 | 16 | 390 | 771 | 2 325 | 1 112 |
| A11GA Ascorbic acid (vitamin C), plain | 3 507 | 3 677 | 3 759 | 3 674 | 3 502 | 68 | 16 | 390 | 771 | 2 325 | 1 112 |
| A11GA01 ascorbic acid (vit C) ¹⁾ | 3 507 | 3 677 | 3 759 | 3 674 | 3 502 | 68 | 16 | 390 | 771 | 2 325 | 1 112 |
| A11H OTHER PLAIN VITAMIN PREPARATIONS | 1 462 | 1 604 | 1 730 | 1 589 | 1 757 | 63 | 189 | 966 | 452 | 150 | 1 385 |
| A11HA Other plain vitamin preparations | 1 462 | 1 604 | 1 730 | 1 589 | 1 757 | 63 | 189 | 966 | 452 | 150 | 1 385 |
| A11HA01 nicotinamide | 5 | 13 | 11 | 19 | 11 | 45 | <5 | <5 | <5 | <5 | 9 |
| A11HA02 pyridoxine (vit B6) ¹⁾ | 871 | 1 072 | 1 134 | 1 109 | 1 374 | 64 | 111 | 836 | 330 | 97 | 574 |
| A11HA03 tocopherol (vit E) ¹⁾ | 572 | 442 | 412 | 320 | 289 | 53 | 69 | 87 | 89 | 44 | 644 |
| A11HA04 riboflavin (vit B2) | 16 | 12 | 11 | 9 | 21 | 86 | <5 | 5 | 12 | <5 | 9 |
| A11HA05 biotin | 0 | 0 | 0 | 0 | <5 | 50 | <5 | <5 | 0 | 0 | 70 |
| A11HA06 pyridoxal phosphate | 0 | 66 | 161 | 131 | 56 | 79 | <5 | 32 | 18 | <5 | 29 |
| A11HA08 tocofersolan | 0 | 0 | <5 | <5 | <5 | 67 | <5 | 0 | 0 | 0 | 51 |
| A11J OTHER VITAMIN PRODUCTS, COMBINATIONS | 59 | 61 | 91 | 94 | 79 | 59 | 53 | 16 | 10 | 0 | 236 |
| A11JA Combinations of vitamins | 59 | 48 | 53 | 55 | 62 | 52 | 53 | 9 | 0 | 0 | 226 |
| A11JB Vitamins with minerals | 0 | 13 | 38 | 39 | 17 | 88 | 0 | 7 | 10 | 0 | 10 |
| A12 MINERAL SUPPLEMENTS | 91 581 | 100 943 | 111 514 | 125 551 | 134 766 | 78 | 444 | 11 959 | 55 174 | 67 189 | 90 176 |
| A12A CALCIUM | 70 986 | 80 569 | 91 211 | 104 462 | 113 047 | 81 | 249 | 10 509 | 47 669 | 54 620 | 71 788 |
| A12AA Calcium | 1 467 | 1 417 | 1 137 | 1 071 | 1 005 | 69 | 58 | 184 | 399 | 364 | 1 042 |
| A12AA02 calcium glubionate | 8 | 7 | <5 | 6 | <5 | 0 | <5 | 0 | 0 | 0 | 9 |
| A12AA04 calcium carbonate ¹⁾ | 371 | 412 | 188 | <5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| A12AA06 calcium lactate gluconate ¹⁾ | 1 090 | 984 | 928 | 1 034 | 984 | 69 | 56 | 181 | 392 | 355 | 1 018 |

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|--|-----------------------|---------------|---------------|----------------|----------------|--------------------|-------------------------------------|---------------|---------------|---------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| A12AA12 calcium acetate anhydrous | 12 | 28 | 24 | 32 | 18 | 50 | <5 | <5 | 6 | 9 | 13 |
| A12AX Calcium, combinations with vitamin D and/or other drugs | 69 722 | 79 351 | 90 245 | 103 588 | 112 275 | 82 | 196 | 10 364 | 47 356 | 54 359 | 70 746 |
| A12B POTASSIUM | 20 533 | 20 544 | 20 029 | 20 998 | 21 980 | 64 | 82 | 1 172 | 7 271 | 13 455 | 13 969 |
| A12BA Potassium | 20 533 | 20 544 | 20 029 | 20 998 | 21 980 | 64 | 82 | 1 172 | 7 271 | 13 455 | 13 969 |
| A12BA01 potassium chloride | 18 968 | 18 800 | 18 295 | 19 060 | 19 870 | 64 | 16 | 979 | 6 582 | 12 293 | 10 701 |
| A12BA02 potassium citrate | 1 828 | 2 055 | 2 034 | 2 268 | 2 446 | 63 | 71 | 240 | 802 | 1 333 | 3 236 |
| A12BA30 combinations | <5 | <5 | <5 | <5 | 5 | 40 | 0 | <5 | <5 | <5 | 31 |
| A12C OTHER MINERAL SUPPLEMENTS | 3 773 | 4 004 | 4 809 | 5 401 | 5 736 | 60 | 124 | 608 | 2 095 | 2 909 | 4 177 |
| A12CA Sodium | 622 | 715 | 878 | 983 | 1 182 | 67 | 8 | 53 | 361 | 760 | 724 |
| A12CA01 sodium chloride ¹⁾ | 622 | 715 | 878 | 983 | 1 182 | 67 | 8 | 53 | 361 | 760 | 724 |
| A12CB Zinc | 865 | 767 | 697 | 769 | 714 | 68 | 50 | 154 | 222 | 288 | 355 |
| A12CB01 zinc sulfate | 865 | 767 | 697 | 769 | 714 | 68 | 50 | 154 | 222 | 288 | 355 |
| A12CC Magnesium | 2 338 | 2 591 | 3 300 | 3 717 | 3 941 | 56 | 67 | 406 | 1 559 | 1 909 | 3 075 |
| A12CC04 magnesium citrate | <5 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| A12CC10 magnesium oxide | 13 | 18 | 103 | 174 | 164 | 57 | <5 | 16 | 61 | 85 | 140 |
| A12CC30 magnesium (different salts in combination) ¹⁾ | 2 328 | 2 573 | 3 212 | 3 563 | 3 792 | 56 | 50 | 392 | 1 507 | 1 843 | 2 568 |
| A12CX Other mineral products | 0 | 0 | 0 | 0 | <5 | 50 | <5 | 0 | 0 | <5 | 24 |
| A14 ANABOLIC AGENTS FOR SYSTEMIC USE | 728 | 847 | 866 | 885 | 1 008 | 84 | <5 | 288 | 627 | 92 | 742 |
| A14A ANABOLIC STEROIDS | 728 | 847 | 866 | 885 | 1 008 | 84 | <5 | 288 | 627 | 92 | 742 |
| A14AA Androstan derivatives | 645 | 827 | 841 | 847 | 963 | 86 | <5 | 267 | 606 | 89 | 533 |
| A14AA07 prasterone | 644 | 827 | 841 | 847 | 963 | 86 | <5 | 267 | 606 | 89 | 533 |
| A14AA08 oxandrolone | <5 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| A14AB Estren derivatives | 84 | 21 | 25 | 24 | 26 | 12 | 0 | 12 | 12 | <5 | 104 |
| A14AB01 nandrolone | 84 | 21 | 25 | 24 | 26 | 12 | 0 | 12 | 12 | <5 | 104 |
| A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS | 293 | 548 | 663 | 604 | 507 | 60 | 106 | 227 | 153 | 21 | 171 809 |
| A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS | 293 | 317 | 335 | 379 | 396 | 55 | 103 | 162 | 114 | 17 | 171 698 |
| A16AA Amino acids and derivatives | 107 | 123 | 131 | 157 | 164 | 54 | 80 | 56 | 24 | <5 | 3 484 |
| A16AA01 levocarnitine | 73 | 87 | 79 | 86 | 99 | 43 | 72 | 20 | <5 | <5 | 1 701 |
| A16AA03 glutamine | 17 | 12 | 19 | 11 | 17 | 82 | 0 | 14 | <5 | 0 | 24 |
| A16AA04 mercaptamine | 7 | 10 | 8 | 8 | 8 | 38 | <5 | <5 | 0 | 0 | 741 |
| A16AA06 betaine | 11 | 16 | 20 | 22 | 23 | 48 | 6 | 13 | <5 | 0 | 1 006 |

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group A

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|------------|------------|------------|------------|--------------------|-------------------------------------|-----------|-----------|----------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| A16AB Enzymes | 51 | 50 | 56 | 59 | 65 | 38 | <5 | 29 | 27 | 5 | 135 770 |
| A16AB02 imiglucerase | 10 | 7 | 7 | <5 | 7 | 57 | 0 | <5 | <5 | <5 | 13 904 |
| A16AB03 agalsidase alfa | 16 | 32 | 33 | 34 | 24 | 38 | 0 | 11 | 9 | <5 | 40 967 |
| A16AB04 agalsidase beta | 23 | 18 | 7 | 14 | 23 | 35 | 0 | 13 | 10 | 0 | 33 830 |
| A16AB05 laronidase | 0 | <5 | <5 | 0 | <5 | 100 | 0 | <5 | 0 | 0 | 255 |
| A16AB07 alglucosidase alfa | <5 | <5 | <5 | <5 | <5 | 0 | 0 | 0 | <5 | 0 | 12 592 |
| A16AB08 galsulfase | 0 | 0 | 0 | <5 | <5 | 100 | <5 | 0 | 0 | 0 | 13 672 |
| A16AB09 idursulfase | <5 | <5 | <5 | <5 | <5 | 0 | <5 | <5 | 0 | 0 | 8 202 |
| A16AB10 velaglucerase alfa | 0 | 0 | 6 | 5 | 5 | 20 | 0 | <5 | <5 | 0 | 12 349 |
| A16AX Various alimentary tract and metabolism products | 139 | 149 | 151 | 166 | 170 | 62 | 20 | 78 | 63 | 9 | 32 443 |
| A16AX01 thioctic acid | 122 | 121 | 109 | 113 | 118 | 67 | 0 | 48 | 61 | 9 | 141 |
| A16AX03 sodium phenylbutyrate | <5 | <5 | <5 | <5 | <5 | 0 | <5 | 0 | 0 | 0 | 42 |
| A16AX04 nitisinone | 12 | 13 | 14 | 14 | 16 | 31 | 12 | <5 | 0 | 0 | 13 420 |
| A16AX05 zinc acetate | <5 | 7 | 8 | 11 | 11 | 55 | <5 | 9 | <5 | 0 | 128 |
| A16AX06 miglustat | 0 | <5 | <5 | <5 | <5 | 50 | <5 | <5 | 0 | 0 | 2 370 |
| A16AX07 sapropterin | 0 | 5 | 15 | 22 | 20 | 70 | <5 | 16 | <5 | 0 | 16 344 |

2.6 ATC group B – Blood and bloodforming organs

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|--|-----------------------|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|---------------|----------------|----------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15–44 | 45–69 | ≥70 | | | | | | | |
| B BLOOD AND BLOOD FORMING ORGANS | 562 344 | 581 349 | 597 921 | 617 386 | 629 097 | 49 | 3 070 | 61 114 | 272 750 | 292 163 | 1 045 480 |
| B01 ANTITHROMBOTIC AGENTS | 472 410 | 485 783 | 497 174 | 509 369 | 519 085 | 44 | 434 | 23 024 | 225 701 | 269 926 | 568 727 |
| B01A ANTITHROMBOTIC AGENTS | 472 410 | 485 783 | 497 174 | 509 369 | 519 085 | 44 | 434 | 23 024 | 225 701 | 269 926 | 568 727 |
| B01AA Vitamin K antagonists | 86 427 | 88 730 | 92 222 | 94 810 | 88 089 | 40 | 56 | 3 016 | 26 086 | 58 931 | 69 966 |
| B01AA01 dicoumarol | 93 | 90 | 93 | 81 | 70 | 53 | 0 | 9 | 23 | 38 | 350 |
| B01AA02 phenindione | 27 | 24 | 15 | <5 | <5 | 67 | 0 | 0 | <5 | <5 | 62 |
| B01AA03 warfarin | 86 322 | 88 631 | 92 133 | 94 729 | 88 017 | 40 | 56 | 3 007 | 26 061 | 58 893 | 69 554 |
| B01AB Heparin group | 32 041 | 36 949 | 42 027 | 46 978 | 49 253 | 58 | 207 | 10 898 | 22 420 | 15 728 | 109 761 |
| B01AB01 heparin | 826 | 926 | 943 | 1 056 | 1 141 | 55 | 125 | 196 | 538 | 282 | 2 317 |
| B01AB02 antithrombin III | <5 | <5 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| B01AB04 dalteparin | 15 917 | 21 249 | 25 588 | 28 632 | 28 495 | 59 | 49 | 6 129 | 13 463 | 8 854 | 63 234 |
| B01AB05 enoxaparin | 15 744 | 15 363 | 16 078 | 17 952 | 20 454 | 56 | 37 | 4 716 | 8 867 | 6 834 | 44 175 |
| B01AB10 tinzaparin | 0 | 0 | 6 | 7 | 10 | 80 | 0 | 5 | <5 | <5 | 35 |
| B01AC Platelet aggregation inhibitors excl. heparin | 380 882 | 390 081 | 394 911 | 399 674 | 400 083 | 43 | 183 | 10 233 | 183 793 | 205 874 | 235 616 |
| B01AC04 clopidogrel | 26 429 | 28 372 | 29 470 | 28 352 | 25 620 | 37 | <5 | 616 | 11 985 | 13 017 | 28 974 |
| B01AC05 ticlopidine | 420 | 327 | 273 | 229 | 187 | 48 | 0 | <5 | 71 | 115 | 546 |
| B01AC06 acetylsalicylic acid | 370 132 | 376 011 | 377 738 | 379 980 | 378 066 | 43 | 182 | 9 778 | 174 501 | 193 605 | 98 822 |
| B01AC07 dipyridamole | 18 755 | 19 310 | 19 501 | 19 782 | 19 830 | 44 | 0 | 302 | 7 562 | 11 966 | 22 433 |
| B01AC09 epoprostenol | 7 | <5 | <5 | <5 | <5 | 50 | 0 | 0 | <5 | 0 | 1 635 |
| B01AC11 iloprost | <5 | <5 | 6 | 10 | 9 | 78 | 0 | <5 | <5 | <5 | 2 145 |
| B01AC21 treprostinil | 9 | 9 | 8 | 9 | 15 | 60 | <5 | 10 | <5 | 0 | 21 292 |
| B01AC22 prasugrel | 31 | 214 | 487 | 1 130 | 1 711 | 19 | 0 | 110 | 1 323 | 278 | 7 633 |
| B01AC24 ticagrelor | 0 | 0 | 26 | 2 341 | 6 773 | 26 | 0 | 321 | 4 305 | 2 147 | 35 264 |
| B01AC30 combinations | 5 557 | 8 788 | 11 324 | 13 223 | 14 622 | 43 | 0 | 282 | 6 201 | 8 139 | 16 610 |
| B01AC56 acetylsalicylic acid and esomeprazole | 0 | 0 | 0 | 80 | 312 | 46 | 0 | 5 | 148 | 159 | 262 |
| B01AD Enzymes | <5 | <5 | <5 | <5 | <5 | 100 | <5 | 0 | <5 | 0 | 570 |
| B01AD02 alteplase | <5 | <5 | <5 | <5 | <5 | 100 | <5 | 0 | <5 | 0 | 570 |
| B01AE Direct thrombin inhibitors | 9 | 187 | 1 168 | 4 102 | 13 879 | 40 | 0 | 189 | 4 853 | 8 837 | 81 235 |
| B01AE07 dabigatran etexilate | 9 | 187 | 1 168 | 4 102 | 13 879 | 40 | 0 | 189 | 4 853 | 8 837 | 81 235 |
| B01AF Direct factor Xa inhibitors | 45 | 191 | 899 | 1 666 | 15 590 | 47 | 0 | 753 | 5 629 | 9 208 | 71 534 |
| B01AF01 rivaroxaban | 45 | 191 | 899 | 1 332 | 13 426 | 45 | 0 | 703 | 4 659 | 8 064 | 68 150 |
| B01AF02 apixaban | 0 | 0 | 0 | 335 | 2 261 | 54 | 0 | 51 | 994 | 1 216 | 3 384 |
| B01AX Other antithrombotic agents | 16 | 17 | 8 | 5 | 6 | 100 | 0 | <5 | <5 | <5 | 46 |
| B01AX05 fondaparinux | 16 | 17 | 8 | 5 | 6 | 100 | 0 | <5 | <5 | <5 | 46 |
| B02 ANTIHEMORRHAGICS | 12 439 | 12 210 | 12 954 | 13 337 | 13 981 | 92 | 308 | 6 869 | 6 171 | 633 | 291 429 |

ATC group B

| ATC level | | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|--------------|--|-----------------------|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|---------------|---------------|---------------|-------------------|
| | | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | | | | | | | | <15 | 15-44 | 45-69 | ≥70 | |
| B02A | ANTIFIBRINOLYTICS | 12 034 | 11 846 | 12 577 | 12 908 | 13 492 | 94 | 198 | 6 702 | 6 061 | 531 | 7 304 |
| B02AA | Amino acids | 12 033 | 11 845 | 12 575 | 12 906 | 13 490 | 94 | 198 | 6 700 | 6 061 | 531 | 5 052 |
| B02AA02 | tranexamic acid | 12 033 | 11 845 | 12 575 | 12 906 | 13 490 | 94 | 198 | 6 700 | 6 061 | 531 | 5 052 |
| B02AB | Proteinase inhibitors | <5 | <5 | <5 | <5 | <5 | 50 | 0 | <5 | 0 | 0 | 2 252 |
| B02AB02 | alfa1 antitrypsin | <5 | <5 | <5 | <5 | <5 | 50 | 0 | <5 | 0 | 0 | 2 252 |
| B02B | VITAMIN K AND OTHER HEMOSTATICS | 468 | 419 | 427 | 507 | 564 | 35 | 132 | 189 | 133 | 110 | 284 125 |
| B02BA | Vitamin K | 275 | 212 | 208 | 224 | 246 | 59 | 50 | 65 | 46 | 85 | 131 |
| B02BA01 | phytomenadione | 275 | 212 | 208 | 224 | 246 | 59 | 50 | 65 | 46 | 85 | 131 |
| B02BB | Fibrinogen | 0 | 0 | <5 | <5 | <5 | 100 | 0 | 0 | <5 | 0 | 95 |
| B02BB01 | fibrinogen, human | 0 | 0 | <5 | <5 | <5 | 100 | 0 | 0 | <5 | 0 | 95 |
| B02BD | Blood coagulation factors | 187 | 189 | 190 | 241 | 258 | 6 | 82 | 113 | 56 | 7 | 271 368 |
| B02BD01 | coagulation factor IX, II, VII and X in combination | <5 | <5 | <5 | <5 | <5 | 100 | 0 | <5 | 0 | 0 | 554 |
| B02BD02 | coagulation factor VIII | 129 | 134 | 132 | 169 | 176 | 1 | 58 | 77 | 39 | <5 | 221 029 |
| B02BD03 | factor VIII inhibitor bypassing activity | 6 | 6 | 7 | 6 | 9 | 0 | <5 | <5 | <5 | <5 | 13 052 |
| B02BD04 | coagulation factor IX | 30 | 28 | 30 | 37 | 42 | 0 | 16 | 17 | 7 | <5 | 18 399 |
| B02BD06 | von Willebrand factor and coagulation factor VIII in combination | 15 | 12 | 9 | 14 | 15 | 47 | <5 | 7 | <5 | <5 | 3 528 |
| B02BD07 | coagulation factor XIII | 0 | 0 | 0 | <5 | <5 | 100 | 0 | 0 | <5 | 0 | 116 |
| B02BD08 | eptacog alfa (activated) | 7 | 7 | 7 | 10 | 12 | 33 | 6 | <5 | <5 | 0 | 5 905 |
| B02BD09 | nonacog alfa | 0 | <5 | <5 | <5 | <5 | 0 | 0 | <5 | <5 | 0 | 1 766 |
| B02BD10 | von Willebrand factor | 0 | <5 | <5 | <5 | <5 | 67 | <5 | <5 | 0 | 0 | 7 018 |
| B02BX | Other systemic hemostatics | 6 | 18 | 28 | 41 | 59 | 58 | 0 | 11 | 30 | 18 | 12 532 |
| B02BX04 | romiplostim | 6 | 14 | 15 | 17 | 20 | 45 | 0 | <5 | 11 | 5 | 6 453 |
| B02BX05 | eltrombopag | 0 | <5 | 15 | 25 | 39 | 64 | 0 | 7 | 19 | 13 | 6 078 |
| B03 | ANTIANEMIC PREPARATIONS | 120 950 | 129 328 | 135 640 | 144 891 | 146 457 | 65 | 2 171 | 33 801 | 55 493 | 54 992 | 117 709 |
| B03A | IRON PREPARATIONS | 22 178 | 24 019 | 25 072 | 25 887 | 27 377 | 69 | 1 290 | 8 306 | 5 986 | 11 795 | 9 405 |
| B03AA | Iron bivalent, oral preparations | 20 801 | 22 588 | 23 597 | 24 308 | 25 635 | 68 | 1 286 | 7 351 | 5 467 | 11 531 | 7 305 |
| B03AA01 | ferrous glycine sulfate ¹⁾ | 2 892 | 3 574 | 4 189 | 4 998 | 6 968 | 72 | 104 | 2 504 | 1 689 | 2 671 | 3 437 |
| B03AA02 | ferrous fumarate ¹⁾ | 1 333 | 1 320 | 1 324 | 1 361 | 1 466 | 49 | 992 | 256 | 79 | 139 | 237 |
| B03AA03 | ferrous gluconate | 112 | 101 | 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| B03AA07 | ferrous sulfate ¹⁾ | 16 693 | 17 767 | 18 255 | 18 290 | 17 470 | 68 | 194 | 4 654 | 3 744 | 8 878 | 3 631 |
| B03AC | Iron, parenteral preparations | 1 461 | 1 524 | 1 577 | 1 699 | 1 869 | 87 | 5 | 1 010 | 551 | 303 | 2 100 |

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group B

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|---------------|---------------|---------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| B03B VITAMIN B12 AND FOLIC ACID | 100 602 | 107 727 | 113 339 | 122 260 | 122 663 | 65 | 953 | 27 040 | 50 141 | 44 529 | 34 781 |
| B03BA Vitamin B12 (cyanocobalamin and analogues) | 69 156 | 76 095 | 79 008 | 85 534 | 83 417 | 67 | 210 | 19 132 | 31 842 | 32 233 | 18 958 |
| B03BA01 cyanocobalamin | 6 558 | 7 389 | 7 469 | 8 514 | 8 210 | 69 | 25 | 2 644 | 3 186 | 2 355 | 1 687 |
| B03BA02 cyanocobalamin tannin complex | 36 404 | 39 772 | 40 827 | 44 239 | 43 570 | 67 | 68 | 10 098 | 16 498 | 16 906 | 9 573 |
| B03BA03 hydroxocobalamin | 28 055 | 31 131 | 32 969 | 35 304 | 33 807 | 67 | 112 | 7 037 | 12 992 | 13 666 | 7 425 |
| B03BA05 mecobalamin | 16 | 38 | 91 | 125 | 211 | 66 | 6 | 103 | 84 | 18 | 271 |
| B03BB Folic acid and derivatives | 36 595 | 36 321 | 39 074 | 41 739 | 44 258 | 60 | 754 | 8 663 | 20 009 | 14 832 | 15 822 |
| B03BB01 folic acid ¹⁾ | 36 595 | 36 321 | 39 074 | 41 739 | 44 258 | 60 | 754 | 8 663 | 20 009 | 14 832 | 15 822 |
| B03X OTHER ANTIANEMIC PREPARATIONS | 3 639 | 3 485 | 3 456 | 3 440 | 3 287 | 40 | 26 | 304 | 1 112 | 1 845 | 73 523 |
| B03XA Other antianemic preparations | 3 639 | 3 485 | 3 456 | 3 440 | 3 287 | 40 | 26 | 304 | 1 112 | 1 845 | 73 523 |
| B03XA01 erythropoietin | 470 | 334 | 279 | 280 | 255 | 47 | <5 | 25 | 89 | 140 | 5 253 |
| B03XA02 darbepoetin alfa | 2 785 | 2 714 | 2 704 | 2 871 | 2 778 | 40 | 26 | 256 | 939 | 1 557 | 61 438 |
| B03XA03 methoxy polyethylene glycol-epoetin beta | 452 | 475 | 516 | 446 | 291 | 36 | 0 | 27 | 98 | 166 | 6 832 |
| B06 OTHER HEMATOLOGICAL AGENTS | 49 | 54 | 52 | 81 | 84 | 62 | <5 | 47 | 30 | <5 | 42 199 |
| B06A OTHER HEMATOLOGICAL AGENTS | 49 | 54 | 52 | 81 | 84 | 62 | <5 | 47 | 30 | <5 | 42 199 |
| B06AA Enzymes | 8 | 7 | 5 | <5 | <5 | 100 | 0 | <5 | <5 | 0 | 4 |
| B06AA03 hyaluronidase | 5 | <5 | <5 | <5 | <5 | 100 | 0 | <5 | <5 | 0 | 4 |
| B06AA55 streptokinase, combinations | <5 | 5 | <5 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| B06AB Other hem products | 0 | 0 | <5 | <5 | <5 | 100 | 0 | 0 | <5 | 0 | 269 |
| B06AC Drugs used in hereditary angioedema | 41 | 47 | 46 | 76 | 80 | 60 | <5 | 46 | 27 | <5 | 41 926 |
| B06AC01 c1-inhibitor, plasma derived | 39 | 37 | 29 | 44 | 55 | 64 | <5 | 33 | 16 | <5 | 27 019 |
| B06AC02 icatibant | 6 | 14 | 23 | 53 | 57 | 60 | <5 | 30 | 23 | <5 | 14 881 |
| B06AC04 conestat alfa | 0 | 0 | 0 | <5 | <5 | 100 | 0 | 0 | <5 | 0 | 26 |

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

2.7 ATC group C – Cardiovascular system

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|--|-----------------------|----------------|----------------|------------------|------------------|--------------------|-------------------------------------|---------------|----------------|----------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15–44 | 45–69 | ≥70 | | | | | | | |
| C CARDIOVASCULAR SYSTEM | 945 886 | 975 141 | 998 461 | 1 019 237 | 1 040 279 | 51 | 6 903 | 99 153 | 542 497 | 391 726 | 1 571 794 |
| C01 CARDIAC THERAPY | 124 930 | 122 995 | 120 544 | 119 110 | 113 974 | 48 | 4 966 | 8 673 | 38 900 | 61 435 | 82 567 |
| C01A CARDIAC GLYCOSIDES | 25 820 | 24 749 | 23 214 | 20 106 | 16 077 | 49 | 40 | 111 | 2 991 | 12 935 | 4 615 |
| C01AA Digitalis glycosides | 25 820 | 24 749 | 23 214 | 20 106 | 16 077 | 49 | 40 | 111 | 2 991 | 12 935 | 4 615 |
| C01AA04 digitoxin | 24 736 | 23 709 | 22 197 | 14 057 | 3 070 | 53 | 0 | 16 | 385 | 2 669 | 624 |
| C01AA05 digoxin | 1 123 | 1 068 | 1 084 | 10 662 | 14 333 | 48 | 40 | 102 | 2 776 | 11 415 | 3 991 |
| C01B ANTIARRHYTHMICS, CLASS I AND III | 10 321 | 11 688 | 12 400 | 13 122 | 13 951 | 36 | 89 | 588 | 7 335 | 5 939 | 28 187 |
| C01BA Antiarrhythmics, class Ia | 173 | 159 | 131 | 121 | 114 | 53 | 0 | 5 | 47 | 62 | 275 |
| C01BA01 quinidine | <5 | <5 | 5 | <5 | <5 | 100 | 0 | 0 | 0 | <5 | 6 |
| C01BA03 disopyramide | 170 | 156 | 126 | 117 | 112 | 52 | 0 | 5 | 47 | 60 | 269 |
| C01BB Antiarrhythmics, class Ib | 23 | 17 | 17 | 18 | 17 | 35 | 0 | 5 | 9 | <5 | 156 |
| C01BB01 lidocaine | 0 | 0 | 0 | <5 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| C01BB02 mexiletine | 23 | 17 | 17 | 17 | 17 | 35 | 0 | 5 | 9 | <5 | 156 |
| C01BC Antiarrhythmics, class Ic | 5 783 | 6 393 | 6 735 | 7 036 | 7 373 | 40 | 82 | 438 | 4 521 | 2 332 | 14 613 |
| C01BC03 propafenone | <5 | <5 | 5 | <5 | <5 | 100 | 0 | 0 | <5 | <5 | 5 |
| C01BC04 flecainide | 5 780 | 6 390 | 6 730 | 7 033 | 7 371 | 40 | 82 | 438 | 4 520 | 2 331 | 14 607 |
| C01BD Antiarrhythmics, class III | 4 475 | 5 432 | 5 809 | 6 269 | 6 750 | 31 | 7 | 157 | 2 952 | 3 634 | 13 143 |
| C01BD01 amiodarone | 4 475 | 4 853 | 4 912 | 5 236 | 5 593 | 30 | 7 | 119 | 2 296 | 3 171 | 3 899 |
| C01BD07 dronedarone | 0 | 767 | 1 034 | 1 166 | 1 269 | 36 | 0 | 41 | 729 | 499 | 9 244 |
| C01C CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES | 12 217 | 14 121 | 15 618 | 18 389 | 19 662 | 59 | 4 839 | 6 913 | 6 531 | 1 379 | 13 112 |
| C01CA Adrenergic and dopaminergic agents | 12 217 | 14 121 | 15 618 | 18 389 | 19 662 | 59 | 4 839 | 6 913 | 6 531 | 1 379 | 13 112 |
| C01CA01 etilefrine | 114 | 95 | 112 | 110 | 100 | 63 | <5 | 26 | 40 | 33 | 223 |
| C01CA02 isoprenaline | 0 | 0 | 0 | <5 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| C01CA06 phenylephrine | 0 | 0 | 0 | 0 | <5 | - | 0 | <5 | 0 | 0 | 1 |
| C01CA17 midodrine | 14 | 16 | 20 | 20 | 28 | 57 | 0 | 16 | 7 | 5 | 217 |
| C01CA24 epinephrine | 12 082 | 14 006 | 15 480 | 18 251 | 19 530 | 59 | 4 838 | 6 869 | 6 482 | 1 341 | 12 662 |
| C01CA26 ephedrine | 7 | 6 | 8 | 8 | 6 | 0 | 0 | <5 | <5 | 0 | 10 |
| C01D VASODILATORS USED IN CARDIAC DISEASES | 83 930 | 79 479 | 75 844 | 73 279 | 69 136 | 47 | 0 | 1 095 | 23 221 | 44 820 | 36 507 |
| C01DA Organic nitrates | 83 930 | 79 479 | 75 844 | 73 279 | 69 136 | 47 | 0 | 1 095 | 23 221 | 44 820 | 36 507 |
| C01DA02 glyceryl trinitrate | 65 061 | 60 717 | 58 282 | 56 629 | 53 076 | 46 | 0 | 1 031 | 20 175 | 31 870 | 12 272 |
| C01DA08 isosorbide dinitrate | 2 787 | 2 311 | 1 950 | 1 705 | 1 377 | 52 | 0 | 8 | 177 | 1 192 | 1 078 |
| C01DA14 isosorbide mononitrate | 35 905 | 34 145 | 31 873 | 30 300 | 28 711 | 50 | 0 | 129 | 5 959 | 22 623 | 23 156 |
| C01E OTHER CARDIAC PREPARATIONS | 138 | 138 | 67 | 11 | 29 | 52 | 0 | 6 | 14 | 9 | 146 |
| C01EB Other cardiac preparations | 138 | 138 | 67 | 11 | 29 | 52 | 0 | 6 | 14 | 9 | 146 |

ATC group C

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 | |
|--------------|---|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|--------------|--------------|---------------|-------------------|---------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK | |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | | |
| C01EB09 | ubidecarenone | 129 | 126 | 59 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| C01EB15 | trimetazidine | 9 | 10 | 6 | 7 | 8 | 63 | 0 | <5 | 6 | <5 | 8 |
| C01EB17 | ivabradine | 0 | 0 | 0 | <5 | 15 | 67 | 0 | 5 | 5 | 5 | 111 |
| C01EB18 | ranolazine | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | <5 | <5 | 27 |
| C02 | ANTIHYPERTENSIVES | 17 689 | 17 442 | 17 597 | 17 548 | 17 267 | 27 | 20 | 711 | 8 063 | 8 473 | 68 778 |
| C02A | ANTIADRENERGIC AGENTS, CENTRALLY ACTING | 6 702 | 6 469 | 6 521 | 6 520 | 6 532 | 40 | <5 | 320 | 3 549 | 2 661 | 6 102 |
| C02AB | Methyldopa | 410 | 141 | 107 | 88 | 65 | 69 | 0 | 26 | 24 | 15 | 143 |
| C02AB01 | methyldopa (levorotatory) | 410 | 141 | 107 | 88 | 65 | 69 | 0 | 26 | 24 | 15 | 143 |
| C02AC | Imidazoline receptor agonists | 6 347 | 6 340 | 6 427 | 6 440 | 6 476 | 40 | <5 | 295 | 3 532 | 2 647 | 5 959 |
| C02AC01 | clonidine | 78 | 64 | 85 | 80 | 92 | 57 | <5 | 34 | 49 | 7 | 132 |
| C02AC05 | moxonidine | 6 269 | 6 276 | 6 342 | 6 361 | 6 385 | 39 | 0 | 261 | 3 484 | 2 640 | 5 827 |
| C02C | ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING | 11 234 | 11 221 | 11 285 | 11 263 | 10 952 | 19 | 0 | 366 | 4 705 | 5 881 | 13 851 |
| C02CA | Alpha-adrenoreceptor antagonists | 11 233 | 11 221 | 11 285 | 11 263 | 10 952 | 19 | 0 | 366 | 4 705 | 5 881 | 13 851 |
| C02CA01 | prazosin | 0 | 0 | 0 | 0 | 35 | 69 | 0 | 25 | 9 | <5 | 54 |
| C02CA04 | doxazosin | 11 233 | 11 221 | 11 285 | 11 263 | 10 920 | 19 | 0 | 344 | 4 696 | 5 880 | 13 797 |
| C02CC | Guanidine derivatives | <5 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| C02CC02 | guanethidine | <5 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| C02D | ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON | 319 | 301 | 317 | 318 | 335 | 32 | <5 | 12 | 139 | 182 | 351 |
| C02DB | Hydrazinophthalazine derivatives | 285 | 270 | 288 | 294 | 316 | 32 | <5 | 7 | 127 | 180 | 222 |
| C02DB02 | hydralazine | 285 | 270 | 288 | 294 | 316 | 32 | <5 | 7 | 127 | 180 | 222 |
| C02DC | Pyrimidine derivatives | 34 | 32 | 29 | 23 | 20 | 40 | 0 | 5 | 13 | <5 | 129 |
| C02DC01 | minoxidil | 34 | 32 | 29 | 23 | 20 | 40 | 0 | 5 | 13 | <5 | 129 |
| C02DD | Nitroferricyanide derivatives | 0 | 0 | 0 | <5 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| C02DD01 | nitroprusside | 0 | 0 | 0 | <5 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| C02K | OTHER ANTIHYPERTENSIVES | 119 | 142 | 161 | 178 | 193 | 69 | 16 | 56 | 86 | 35 | 48 474 |
| C02KD | Serotonin antagonists | 18 | 19 | 20 | 14 | 13 | 92 | 0 | <5 | 8 | <5 | 456 |
| C02KD01 | ketanserin | 18 | 19 | 20 | 14 | 13 | 92 | 0 | <5 | 8 | <5 | 456 |
| C02KX | Other antihypertensives | 102 | 124 | 142 | 166 | 182 | 68 | 16 | 55 | 79 | 32 | 48 018 |
| C02KX01 | bosentan | 91 | 103 | 114 | 124 | 132 | 67 | 16 | 44 | 50 | 22 | 32 073 |
| C02KX02 | ambrisentan | 12 | 19 | 33 | 46 | 50 | 72 | 0 | 11 | 29 | 10 | 15 945 |
| C02KX03 | sitaxentan | 0 | <5 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| C03 | DIURETICS | 235 555 | 223 842 | 208 905 | 201 895 | 194 790 | 60 | 208 | 8 149 | 73 483 | 112 950 | 87 211 |

ATC group C

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|--------------|---------------|---------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| C03A LOW-CEILING DIURETICS, THIAZIDES | 74 216 | 66 001 | 53 889 | 49 049 | 44 778 | 61 | 10 | 1 804 | 22 594 | 20 370 | 20 026 |
| C03AA Thiazides, plain | 45 271 | 36 364 | 16 033 | 14 935 | 14 014 | 58 | 8 | 649 | 7 128 | 6 229 | 4 026 |
| C03AA01 bendroflumethiazide | 31 710 | 22 807 | <5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| C03AA03 hydrochlorothiazide | 13 625 | 16 731 | 16 032 | 14 935 | 14 014 | 58 | 8 | 649 | 7 128 | 6 229 | 4 026 |
| C03AB Thiazides and potassium in combination | 30 363 | 41 642 | 38 130 | 34 269 | 30 853 | 63 | <5 | 1 165 | 15 500 | 14 186 | 16 000 |
| C03AB01 bendroflumethiazide and potassium | 30 363 | 41 642 | 38 130 | 34 269 | 30 853 | 63 | <5 | 1 165 | 15 500 | 14 186 | 16 000 |
| C03B LOW-CEILING DIURETICS, EXCL. THIAZIDES | 6 | 5 | 6 | 8 | 9 | 56 | 0 | <5 | <5 | <5 | 25 |
| C03BA Sulfonamides, plain | 6 | 5 | 6 | 8 | 9 | 56 | 0 | <5 | <5 | <5 | 25 |
| C03BA04 chlortalidone | 6 | 5 | 6 | 6 | 7 | 43 | 0 | <5 | <5 | <5 | 17 |
| C03BA08 metolazone | 0 | 0 | 0 | <5 | <5 | 100 | 0 | 0 | <5 | <5 | 8 |
| C03C HIGH-CEILING DIURETICS | 127 997 | 127 391 | 125 517 | 125 342 | 124 184 | 60 | 187 | 5 150 | 38 239 | 80 608 | 46 447 |
| C03CA Sulfonamides, plain | 127 997 | 127 391 | 125 517 | 125 342 | 124 184 | 60 | 187 | 5 150 | 38 239 | 80 608 | 46 447 |
| C03CA01 furosemide | 101 621 | 99 010 | 95 661 | 93 558 | 90 249 | 62 | 183 | 4 315 | 29 420 | 56 331 | 19 620 |
| C03CA02 bumetanide | 31 193 | 33 444 | 34 790 | 36 795 | 38 766 | 53 | <5 | 948 | 9 906 | 27 908 | 26 823 |
| C03CA04 torasemide | <5 | <5 | <5 | <5 | <5 | 100 | 0 | 0 | 0 | <5 | 4 |
| C03D POTASSIUM-SPARING AGENTS | 17 602 | 17 636 | 17 868 | 18 231 | 19 007 | 47 | 31 | 987 | 7 481 | 10 508 | 13 353 |
| C03DA Aldosterone antagonists | 17 589 | 17 623 | 17 851 | 18 216 | 18 990 | 47 | 30 | 984 | 7 475 | 10 501 | 13 216 |
| C03DA01 spironolactone | 17 028 | 17 038 | 17 160 | 17 438 | 18 084 | 49 | 30 | 935 | 6 929 | 10 190 | 7 248 |
| C03DA02 potassium canrenoate | 0 | <5 | <5 | 0 | <5 | 0 | 0 | 0 | <5 | 0 | 1 |
| C03DA04 eplerenone | 658 | 678 | 798 | 912 | 1 030 | 14 | 0 | 54 | 614 | 362 | 5 967 |
| C03DB Other potassium-sparing agents | 18 | 18 | 22 | 16 | 19 | 37 | <5 | <5 | 8 | 7 | 136 |
| C03DB01 amiloride | 18 | 18 | 22 | 16 | 19 | 37 | <5 | <5 | 8 | 7 | 136 |
| C03E DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION | 34 026 | 31 692 | 28 452 | 25 731 | 23 234 | 66 | 10 | 585 | 10 485 | 12 154 | 4 130 |
| C03EA Low-ceiling diuretics and potassium-sparing agents | 34 026 | 31 692 | 28 452 | 25 731 | 23 234 | 66 | 10 | 585 | 10 485 | 12 154 | 4 130 |
| C03EA01 hydrochlorothiazide and potassium-sparing agents | 34 026 | 31 692 | 28 452 | 25 731 | 23 234 | 66 | 10 | 585 | 10 485 | 12 154 | 4 130 |
| C03X OTHER DIURETICS | 0 | <5 | <5 | 17 | 35 | 63 | 0 | <5 | 20 | 13 | 3 230 |
| C03XA Vasopressin antagonists | 0 | <5 | <5 | 17 | 35 | 63 | 0 | <5 | 20 | 13 | 3 230 |
| C03XA01 tolvaptan | 0 | <5 | <5 | 17 | 35 | 63 | 0 | <5 | 20 | 13 | 3 230 |
| C04 PERIPHERAL VASODILATORS | 1 340 | 1 165 | 1 019 | 928 | 810 | 46 | <5 | 21 | 223 | 565 | 837 |
| C04A PERIPHERAL VASODILATORS | 1 340 | 1 165 | 1 019 | 928 | 810 | 46 | <5 | 21 | 223 | 565 | 837 |

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|--|-----------------------|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|---------------|----------------|----------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| C04AB Imidazoline derivatives | 0 | 0 | 0 | 0 | <5 | - | 0 | 0 | <5 | <5 | 1 |
| C04AB01 phentolamine | 0 | 0 | 0 | 0 | <5 | - | 0 | 0 | <5 | <5 | 1 |
| C04AD Purine derivatives | 1 334 | 1 160 | 1 018 | 927 | 808 | 46 | <5 | 21 | 222 | 564 | 836 |
| C04AD03 pentoxifylline | 1 334 | 1 160 | 1 018 | 927 | 808 | 46 | <5 | 21 | 222 | 564 | 836 |
| C04AX Other peripheral vasodilators | 6 | 5 | <5 | <5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| C04AX02 phenoxybenzamine | 6 | 5 | <5 | <5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| C05 VASOPROTECTIVES | 56 622 | 59 372 | 62 337 | 61 786 | 66 461 | 57 | 849 | 27 702 | 26 615 | 11 295 | 12 323 |
| C05A AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE | 51 350 | 54 315 | 56 902 | 56 316 | 60 385 | 56 | 808 | 26 588 | 24 023 | 8 966 | 10 092 |
| C05AA Corticosteroids | 49 667 | 52 387 | 54 740 | 53 845 | 57 822 | 56 | 761 | 25 315 | 23 065 | 8 681 | 7 208 |
| C05AA01 hydrocortisone ¹⁾ | 9 649 | 9 749 | 9 666 | 11 151 | 6 121 | 54 | 106 | 2 301 | 2 641 | 1 073 | 1 218 |
| C05AA04 prednisolone ¹⁾ | 41 682 | 44 303 | 46 731 | 45 327 | 53 098 | 56 | 666 | 23 517 | 21 054 | 7 861 | 5 990 |
| C05AE Muscle relaxants | 2 137 | 2 732 | 2 893 | 3 174 | 3 568 | 53 | 39 | 1 805 | 1 428 | 296 | 2 669 |
| C05AE01 glyceryl trinitrate | 2 137 | 2 732 | 2 893 | 3 174 | 3 568 | 53 | 39 | 1 805 | 1 428 | 296 | 2 669 |
| C05AX Other agents for treatment of hemorrhoids and anal fissures for topical use | 901 | 826 | 852 | 1 139 | 841 | 54 | 22 | 392 | 279 | 148 | 215 |
| C05AX03 other preparations, combinations | 885 | 807 | 832 | 1 117 | 819 | 54 | 22 | 380 | 270 | 147 | 147 |
| C05B ANTIVARICOSE THERAPY | 5 490 | 5 250 | 5 664 | 5 663 | 6 294 | 67 | 41 | 1 174 | 2 682 | 2 397 | 2 211 |
| C05BA Heparins or heparinoids for topical use | 5 486 | 5 245 | 5 654 | 5 658 | 6 288 | 67 | 41 | 1 174 | 2 676 | 2 397 | 2 204 |
| C05BA01 organo-heparinoid ¹⁾ | 5 462 | 5 211 | 5 627 | 5 627 | 6 249 | 67 | 41 | 1 169 | 2 655 | 2 384 | 830 |
| C05BA04 pentosan polysulfate sodium | 25 | 34 | 27 | 31 | 40 | 88 | 0 | 6 | 21 | 13 | 1 374 |
| C05BB Sclerosing agents for local injection | <5 | 5 | 10 | 5 | 6 | 33 | 0 | 0 | 6 | 0 | 7 |
| C05BB02 polidocanol | <5 | 5 | 10 | 5 | 6 | 33 | 0 | 0 | 6 | 0 | 7 |
| C05C CAPILLARY STABILIZING AGENTS | 0 | 0 | 0 | 19 | 8 | 88 | 0 | 0 | <5 | 6 | 10 |
| C05CA Bioflavonoids | 0 | 0 | 0 | <5 | 8 | 88 | 0 | 0 | <5 | 6 | 10 |
| C05CA01 rutoside | 0 | 0 | 0 | <5 | 8 | 88 | 0 | 0 | <5 | 6 | 10 |
| C05CX Other capillary stabilizing agents | 0 | 0 | 0 | 16 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| C05CX03 Hippocastani semen | 0 | 0 | 0 | 16 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| C07 BETA BLOCKING AGENTS | 356 313 | 361 077 | 364 247 | 368 506 | 371 823 | 49 | 482 | 20 906 | 165 839 | 184 596 | 180 367 |
| C07A BETA BLOCKING AGENTS | 350 748 | 355 652 | 359 141 | 363 938 | 367 435 | 49 | 482 | 20 712 | 163 140 | 183 101 | 177 451 |
| C07AA Beta blocking agents, non-selective | 25 833 | 24 967 | 24 720 | 24 341 | 24 423 | 59 | 198 | 5 208 | 10 605 | 8 412 | 11 300 |
| C07AA03 pindolol | 28 | 28 | 26 | 20 | 12 | 67 | 0 | <5 | 8 | <5 | 12 |

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group C

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|---------------|----------------|----------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| C07AA05 propranolol | 16 540 | 16 856 | 17 413 | 17 656 | 18 262 | 63 | 179 | 4 992 | 8 391 | 4 700 | 7 110 |
| C07AA06 timolol | 636 | 13 | 9 | 10 | 7 | 86 | 0 | <5 | <5 | <5 | 32 |
| C07AA07 sotalol | 8 818 | 8 082 | 7 269 | 6 706 | 6 098 | 46 | 7 | 169 | 2 199 | 3 723 | 3 724 |
| C07AA12 nadolol | 13 | 17 | 29 | 39 | 88 | 63 | 13 | 52 | 23 | 0 | 422 |
| C07AB Beta blocking agents, selective | 305 475 | 311 151 | 315 104 | 320 868 | 324 369 | 48 | 279 | 13 556 | 143 819 | 166 715 | 149 838 |
| C07AB02 metoprolol | 250 953 | 256 754 | 261 252 | 266 875 | 270 550 | 47 | 256 | 11 357 | 120 827 | 138 110 | 127 946 |
| C07AB03 atenolol | 39 561 | 36 754 | 33 974 | 31 827 | 29 679 | 59 | 22 | 1 337 | 12 347 | 15 973 | 7 485 |
| C07AB07 bisoprolol | 18 388 | 21 004 | 23 115 | 25 416 | 27 355 | 46 | <5 | 1 029 | 11 969 | 14 355 | 14 405 |
| C07AB12 nebivolol | 0 | 0 | 0 | 0 | 9 | 67 | 0 | <5 | <5 | <5 | 2 |
| C07AG Alpha and beta blocking agents | 24 389 | 23 887 | 23 378 | 22 899 | 22 479 | 45 | 15 | 2 290 | 10 462 | 9 712 | 16 313 |
| C07AG01 labetalol | 2 324 | 2 392 | 2 447 | 2 475 | 2 442 | 82 | <5 | 1 563 | 553 | 324 | 2 167 |
| C07AG02 carvedilol | 22 092 | 21 525 | 20 958 | 20 442 | 20 062 | 41 | 13 | 735 | 9 918 | 9 396 | 14 146 |
| C07B BETA BLOCKING AGENTS AND THIAZIDES | 6 057 | 5 815 | 5 485 | 5 214 | 4 816 | 55 | 0 | 208 | 2 923 | 1 685 | 2 916 |
| C07BB Beta blocking agents, selective, and thiazides | 6 057 | 5 815 | 5 485 | 5 214 | 4 816 | 55 | 0 | 208 | 2 923 | 1 685 | 2 916 |
| C07BB07 bisoprolol and thiazides | 6 057 | 5 815 | 5 485 | 5 214 | 4 816 | 55 | 0 | 208 | 2 923 | 1 685 | 2 916 |
| C07BB12 nebivolol and thiazides | 0 | 0 | 0 | 0 | <5 | 100 | 0 | <5 | 0 | 0 | 0 |
| C08 CALCIUM CHANNEL BLOCKERS | 214 671 | 221 256 | 224 233 | 230 084 | 235 380 | 48 | 86 | 9 508 | 112 350 | 113 436 | 144 543 |
| C08C SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS | 192 742 | 200 625 | 205 165 | 212 139 | 218 463 | 48 | 83 | 8 721 | 106 011 | 103 648 | 127 861 |
| C08CA Dihydropyridine derivatives | 192 742 | 200 625 | 205 165 | 212 139 | 218 463 | 48 | 83 | 8 721 | 106 011 | 103 648 | 127 861 |
| C08CA01 amlodipine | 115 250 | 119 283 | 121 607 | 125 897 | 129 021 | 46 | 62 | 4 430 | 62 625 | 61 904 | 54 859 |
| C08CA02 felodipine | 16 692 | 16 309 | 16 008 | 15 423 | 14 850 | 50 | 0 | 340 | 6 396 | 8 114 | 10 823 |
| C08CA03 isradipine | 664 | 620 | 568 | 518 | 493 | 55 | <5 | 8 | 198 | 286 | 888 |
| C08CA05 nifedipine | 29 940 | 31 649 | 32 708 | 34 567 | 36 991 | 49 | 21 | 2 781 | 17 924 | 16 265 | 40 689 |
| C08CA06 nimodipine | 32 | 44 | 51 | 56 | 39 | 59 | 0 | 11 | 26 | <5 | 39 |
| C08CA13 lercanidipine | 33 491 | 36 038 | 37 460 | 39 048 | 40 491 | 50 | 0 | 1 332 | 20 462 | 18 697 | 20 562 |
| C08D SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS | 23 260 | 21 851 | 20 196 | 19 116 | 18 080 | 56 | <5 | 806 | 6 799 | 10 472 | 16 682 |
| C08DA Phenylalkylamine derivatives | 17 237 | 16 444 | 15 365 | 14 679 | 13 847 | 56 | <5 | 717 | 5 255 | 7 872 | 8 934 |
| C08DA01 verapamil | 17 237 | 16 444 | 15 365 | 14 679 | 13 847 | 56 | <5 | 717 | 5 255 | 7 872 | 8 934 |
| C08DB Benzothiazepine derivatives | 6 091 | 5 473 | 4 875 | 4 472 | 4 281 | 55 | 0 | 92 | 1 567 | 2 622 | 7 748 |
| C08DB01 diltiazem | 6 091 | 5 473 | 4 875 | 4 472 | 4 281 | 55 | 0 | 92 | 1 567 | 2 622 | 7 748 |

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|--|-----------------------|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|---------------|----------------|----------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | | | | | | | <15 | 15-44 | 45-69 | ≥70 | |
| C09 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM | 473 388 | 498 501 | 517 053 | 535 479 | 552 012 | 48 | 434 | 29 254 | 300 073 | 222 251 | 533 396 |
| C09A ACE INHIBITORS, PLAIN | 125 439 | 130 265 | 132 249 | 134 815 | 135 072 | 41 | 376 | 7 246 | 63 735 | 63 715 | 57 995 |
| C09AA ACE inhibitors, plain | 125 439 | 130 265 | 132 249 | 134 815 | 135 072 | 41 | 376 | 7 246 | 63 735 | 63 715 | 57 995 |
| C09AA01 captopril | 3 233 | 2 858 | 2 509 | 2 221 | 1 962 | 45 | 178 | 84 | 644 | 1 056 | 3 893 |
| C09AA02 enalapril | 43 095 | 45 453 | 45 871 | 46 498 | 46 508 | 46 | 196 | 3 066 | 22 721 | 20 525 | 18 461 |
| C09AA03 lisinopril | 27 084 | 26 749 | 26 060 | 25 506 | 24 380 | 46 | <5 | 1 397 | 11 903 | 11 078 | 10 653 |
| C09AA05 ramipril | 52 684 | 55 804 | 58 431 | 61 192 | 62 787 | 35 | 6 | 2 725 | 28 703 | 31 353 | 24 825 |
| C09AA10 trandolapril | 111 | 92 | 85 | 83 | 77 | 22 | 0 | 6 | 37 | 34 | 162 |
| C09B ACE INHIBITORS, COMBINATIONS | 35 260 | 35 985 | 35 727 | 35 224 | 34 166 | 48 | 0 | 1 128 | 17 383 | 15 655 | 25 843 |
| C09BA ACE inhibitors and diuretics | 35 023 | 35 193 | 34 459 | 33 721 | 32 644 | 48 | 0 | 1 047 | 16 470 | 15 127 | 23 915 |
| C09BA02 enalapril and diuretics | 20 154 | 20 520 | 20 244 | 20 047 | 19 540 | 48 | 0 | 677 | 10 079 | 8 784 | 15 018 |
| C09BA03 lisinopril and diuretics | 14 889 | 14 697 | 14 237 | 13 715 | 13 133 | 49 | 0 | 373 | 6 403 | 6 357 | 8 897 |
| C09BB ACE inhibitors and calcium channel blockers | 259 | 820 | 1 307 | 1 536 | 1 546 | 43 | 0 | 83 | 922 | 541 | 1 928 |
| C09BB02 enalapril and lercanidipine | 259 | 820 | 1 307 | 1 536 | 1 546 | 43 | 0 | 83 | 922 | 541 | 1 928 |
| C09C ANGIOTENSIN II ANTAGONISTS, PLAIN | 168 742 | 180 140 | 187 470 | 197 324 | 206 884 | 51 | 84 | 14 729 | 116 705 | 75 366 | 174 588 |
| C09CA Angiotensin II antagonists, plain | 168 742 | 180 140 | 187 470 | 197 324 | 206 884 | 51 | 84 | 14 729 | 116 705 | 75 366 | 174 588 |
| C09CA01 losartan | 42 955 | 51 872 | 57 364 | 61 615 | 63 676 | 51 | 42 | 3 801 | 35 328 | 24 505 | 38 633 |
| C09CA02 eprosartan | 2 322 | 2 063 | 1 785 | 1 601 | 1 443 | 52 | 0 | 43 | 659 | 741 | 2 830 |
| C09CA03 valsartan | 20 380 | 20 748 | 22 462 | 25 171 | 28 100 | 47 | 0 | 1 838 | 16 359 | 9 903 | 27 546 |
| C09CA04 irbesartan | 22 328 | 21 419 | 20 347 | 19 745 | 19 088 | 49 | 0 | 796 | 10 652 | 7 640 | 25 910 |
| C09CA06 candesartan | 74 704 | 78 234 | 79 742 | 83 562 | 88 885 | 52 | 40 | 7 960 | 50 382 | 30 503 | 64 142 |
| C09CA07 telmisartan | 5 866 | 5 988 | 5 977 | 5 838 | 5 822 | 44 | <5 | 312 | 3 323 | 2 186 | 12 242 |
| C09CA08 olmesartan medoxomil | 1 751 | 1 680 | 1 642 | 1 642 | 1 639 | 50 | <5 | 132 | 993 | 513 | 3 285 |
| C09D ANGIOTENSIN II ANTAGONISTS, COMBINATIONS | 184 232 | 195 551 | 202 970 | 210 395 | 217 369 | 49 | 0 | 8 479 | 125 318 | 83 572 | 274 794 |
| C09DA Angiotensin II antagonists and diuretics | 174 848 | 179 893 | 180 857 | 181 947 | 182 682 | 51 | 0 | 6 301 | 103 430 | 72 951 | 189 040 |
| C09DA01 losartan and diuretics | 63 952 | 66 088 | 66 981 | 67 519 | 67 346 | 52 | 0 | 2 225 | 36 785 | 28 336 | 46 754 |
| C09DA02 eprosartan and diuretics | 2 042 | 1 924 | 1 774 | 1 661 | 1 552 | 48 | 0 | 47 | 827 | 678 | 3 277 |
| C09DA03 valsartan and diuretics | 25 424 | 25 643 | 25 522 | 25 941 | 26 635 | 49 | 0 | 971 | 15 382 | 10 282 | 36 076 |
| C09DA04 irbesartan and diuretics | 31 418 | 30 818 | 29 807 | 28 634 | 27 373 | 50 | 0 | 676 | 15 090 | 11 607 | 41 885 |
| C09DA06 candesartan and diuretics | 48 685 | 51 649 | 52 876 | 54 286 | 55 802 | 50 | 0 | 2 249 | 32 933 | 20 620 | 49 094 |
| C09DA07 telmisartan and diuretics | 3 724 | 3 991 | 3 940 | 3 818 | 3 785 | 41 | 0 | 128 | 2 268 | 1 389 | 9 737 |
| C09DA08 olmesartan medoxomil and diuretics | 1 144 | 1 124 | 1 146 | 1 117 | 1 087 | 50 | 0 | 44 | 655 | 388 | 2 219 |

ATC group C

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|--|-----------------------|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|---------------|----------------|----------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| C09DB Angiotensin II antagonists and calcium channel blockers | 11 764 | 16 484 | 18 665 | 21 178 | 23 699 | 40 | 0 | 1 529 | 14 849 | 7 321 | 45 870 |
| C09DB01 valsartan and amlodipine | 11 764 | 16 483 | 18 494 | 20 903 | 23 407 | 40 | 0 | 1 503 | 14 659 | 7 245 | 45 174 |
| C09DB02 olmesartan medoxomil and amlodipine | 0 | <5 | 185 | 280 | 297 | 37 | 0 | 26 | 193 | 78 | 695 |
| C09DX Angiotensin II antagonists, other combinations | 0 | 4 017 | 8 368 | 12 249 | 16 435 | 37 | 0 | 987 | 10 399 | 5 049 | 39 884 |
| C09DX01 valsartan, amlodipine and hydrochlorothiazide | 0 | 4 017 | 8 368 | 12 249 | 16 435 | 37 | 0 | 987 | 10 399 | 5 049 | 39 884 |
| C09X OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM | 93 | 93 | 84 | 80 | 69 | 41 | <5 | <5 | 40 | 23 | 177 |
| C09XA Renin-inhibitors | 93 | 93 | 84 | 80 | 69 | 41 | <5 | <5 | 40 | 23 | 177 |
| C09XA02 aliskiren | 93 | 92 | 84 | 80 | 69 | 41 | <5 | <5 | 40 | 23 | 177 |
| C09XA52 aliskiren and hydrochlorothiazide | 0 | <5 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| C10 LIPID MODIFYING AGENTS | 452 790 | 478 362 | 495 451 | 504 104 | 509 945 | 46 | 147 | 20 352 | 278 359 | 211 087 | 461 771 |
| C10A LIPID MODIFYING AGENTS, PLAIN | 452 090 | 477 639 | 494 337 | 501 719 | 506 662 | 46 | 147 | 20 223 | 276 226 | 210 066 | 447 592 |
| C10AA HMG CoA reductase inhibitors | 447 810 | 472 860 | 488 704 | 495 110 | 499 107 | 46 | 133 | 19 452 | 271 913 | 207 609 | 339 655 |
| C10AA01 simvastatin | 356 768 | 349 782 | 336 480 | 314 351 | 290 634 | 47 | 21 | 8 994 | 146 138 | 135 481 | 119 305 |
| C10AA02 lovastatin | 1 424 | 1 260 | 1 134 | 1 050 | 930 | 57 | 0 | 7 | 347 | 576 | 1 437 |
| C10AA03 pravastatin | 22 329 | 21 340 | 20 827 | 20 330 | 19 842 | 49 | 11 | 465 | 9 393 | 9 973 | 20 039 |
| C10AA04 fluvastatin | 7 465 | 7 510 | 7 474 | 7 445 | 7 372 | 47 | <5 | 508 | 4 259 | 2 604 | 12 182 |
| C10AA05 atorvastatin | 79 686 | 112 783 | 140 852 | 166 650 | 189 401 | 44 | 78 | 9 406 | 116 854 | 63 063 | 160 886 |
| C10AA07 rosuvastatin | 571 | 2 115 | 4 420 | 6 722 | 9 506 | 45 | 26 | 950 | 6 406 | 2 124 | 25 748 |
| C10AA08 pitavastatin | 0 | 0 | 0 | 0 | 6 | 33 | 0 | 0 | 5 | <5 | 57 |
| C10AB Fibrates | 317 | 331 | 317 | 314 | 314 | 30 | <5 | 56 | 215 | 39 | 1 715 |
| C10AB02 bezafibrate | 64 | 58 | 49 | 50 | 47 | 36 | <5 | <5 | 34 | 8 | 180 |
| C10AB04 gemfibrozil | 101 | 104 | 103 | 93 | 85 | 31 | 0 | 12 | 58 | 15 | 796 |
| C10AB05 fenofibrate | 154 | 170 | 167 | 173 | 184 | 28 | <5 | 41 | 124 | 16 | 739 |
| C10AC Bile acid sequestrants | 2 090 | 2 238 | 2 413 | 2 439 | 2 530 | 54 | 8 | 468 | 1 413 | 641 | 8 479 |
| C10AC01 colestyramine | 1 566 | 1 686 | 1 817 | 1 795 | 1 864 | 59 | 7 | 401 | 991 | 465 | 2 244 |
| C10AC02 colestipol | 308 | 292 | 273 | 280 | 287 | 42 | <5 | 20 | 149 | 117 | 817 |
| C10AC04 colesevelam | 237 | 280 | 351 | 407 | 444 | 37 | 0 | 64 | 317 | 63 | 5 417 |
| C10AD Nicotinic acid and derivatives | 285 | 396 | 391 | 351 | 58 | 24 | 0 | 10 | 38 | 10 | 614 |
| C10AD02 nicotinic acid | 218 | 153 | 107 | 30 | 29 | 28 | 0 | 6 | 16 | 7 | 534 |
| C10AD06 acipimox | 11 | 12 | 9 | 9 | 6 | 50 | 0 | 0 | <5 | <5 | 46 |
| C10AD52 nicotinic acid, combinations | 69 | 249 | 301 | 315 | 27 | 15 | 0 | 5 | 21 | <5 | 34 |

ATC group C

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|--|-----------------------|---------------|---------------|---------------|---------------|--------------------|-------------------------------------|--------------|---------------|--------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| C10AX Other lipid modifying agents | 14 589 | 16 505 | 19 315 | 22 165 | 24 366 | 43 | 6 | 1 765 | 16 130 | 6 465 | 97 129 |
| C10AX06 omega-3-triglycerides incl. other esters and acids | 2 754 | 3 038 | 3 591 | 3 992 | 4 199 | 30 | <5 | 602 | 3 011 | 584 | 26 631 |
| C10AX09 ezetimibe | 12 126 | 13 819 | 16 166 | 18 711 | 20 751 | 45 | <5 | 1 209 | 13 574 | 5 964 | 70 498 |
| C10B LIPID MODIFYING AGENTS, COMBINATIONS | 0 | 81 | 1 370 | 2 661 | 3 215 | 40 | 0 | 160 | 2 121 | 934 | 11 555 |
| C10BA HMG CoA reductase inhibitors in combination with other lipid modifying agents | 0 | 81 | 1 370 | 2 661 | 3 215 | 40 | 0 | 160 | 2 121 | 934 | 11 555 |
| C10BA02 simvastatin and ezetimibe | 0 | 81 | 1 370 | 2 661 | 3 215 | 40 | 0 | 160 | 2 121 | 934 | 11 555 |

2.8 ATC group D – Dermatologicals

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|----------------|----------------|----------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15–44 | 45–69 | ≥70 | | | | | | | |
| D DERMATOLOGICALS | 587 812 | 611 440 | 624 493 | 632 680 | 645 684 | 54 | 79 769 | 246 820 | 216 869 | 102 226 | 245 500 |
| D01 ANTIFUNGALS FOR DERMATOLOGICAL USE | 111 682 | 116 703 | 120 515 | 121 196 | 128 325 | 47 | 12 588 | 48 465 | 46 581 | 20 691 | 34 037 |
| D01A ANTIFUNGALS FOR TOPICAL USE | 96 750 | 101 082 | 105 109 | 105 050 | 111 180 | 48 | 12 335 | 41 833 | 38 231 | 18 781 | 17 247 |
| D01AA Antibiotics | 219 | 54 | 52 | 36 | 41 | 88 | 5 | 28 | 6 | <5 | 10 |
| D01AA01 nystatin | 219 | 54 | 52 | 36 | 41 | 88 | 5 | 28 | 6 | <5 | 10 |
| D01AC Imidazole and triazole derivatives | 74 998 | 79 238 | 83 294 | 83 177 | 87 831 | 48 | 10 095 | 32 361 | 29 741 | 15 634 | 11 120 |
| D01AC01 clotrimazole ¹⁾ | 8 811 | 9 516 | 8 746 | 8 018 | 8 572 | 52 | 1 201 | 3 272 | 2 203 | 1 896 | 1 261 |
| D01AC02 miconazole ¹⁾ | 1 880 | 2 121 | 2 193 | 1 928 | 2 157 | 44 | 321 | 782 | 687 | 367 | 371 |
| D01AC03 econazole ¹⁾ | 2 177 | 1 119 | 588 | 694 | 732 | 56 | 44 | 172 | 258 | 258 | 93 |
| D01AC08 ketoconazole ¹⁾ | 14 992 | 15 121 | 16 258 | 16 243 | 16 928 | 41 | 1 136 | 7 922 | 5 861 | 2 009 | 2 918 |
| D01AC20 combinations ¹⁾ | 50 909 | 55 208 | 59 481 | 59 953 | 63 529 | 49 | 7 826 | 21 824 | 22 029 | 11 850 | 6 478 |
| D01AE Other antifungals for topical use | 24 330 | 24 671 | 24 755 | 24 872 | 26 681 | 46 | 2 563 | 10 780 | 9 626 | 3 712 | 6 116 |
| D01AE02 methylrosaniline ¹⁾ | 696 | 694 | 751 | 698 | 736 | 55 | 227 | 155 | 196 | 158 | 79 |
| D01AE14 ciclopirox ¹⁾ | <5 | <5 | 13 | 48 | 841 | 53 | 36 | 277 | 414 | 114 | 305 |
| D01AE15 terbinafine ¹⁾ | 16 909 | 17 514 | 17 812 | 18 224 | 19 247 | 42 | 2 062 | 8 500 | 6 163 | 2 522 | 3 232 |
| D01AE16 amorolfine | 7 081 | 6 829 | 6 520 | 6 232 | 6 333 | 54 | 275 | 2 002 | 3 074 | 982 | 2 500 |
| D01B ANTIFUNGALS FOR SYSTEMIC USE | 18 300 | 19 232 | 19 020 | 19 762 | 21 092 | 40 | 433 | 8 382 | 9 965 | 2 312 | 16 791 |
| D01BA Antifungals for systemic use | 18 300 | 19 232 | 19 020 | 19 762 | 21 092 | 40 | 433 | 8 382 | 9 965 | 2 312 | 16 791 |
| D01BA01 griseofulvin | 19 | 15 | 19 | 21 | 38 | 42 | 32 | 5 | <5 | 0 | 21 |
| D01BA02 terbinafine | 18 285 | 19 222 | 19 009 | 19 744 | 21 060 | 40 | 407 | 8 377 | 9 964 | 2 312 | 16 769 |
| D02 EMOLLIENTS AND PROTECTIVES | 1 841 | 2 223 | 2 338 | 2 528 | 2 548 | 54 | 430 | 793 | 866 | 459 | 989 |
| D02A EMOLLIENTS AND PROTECTIVES | 1 841 | 2 223 | 2 338 | 2 528 | 2 548 | 54 | 430 | 793 | 866 | 459 | 989 |
| D02AB Zinc products¹⁾ | 6 | 10 | 15 | 6 | 9 | 67 | <5 | <5 | <5 | <5 | 2 |
| D02AE Carbamide products | 670 | 859 | 971 | 1 178 | 1 153 | 55 | 159 | 398 | 346 | 250 | 652 |
| D02AE01 carbamide ¹⁾ | 670 | 859 | 971 | 1 178 | 1 153 | 55 | 159 | 398 | 346 | 250 | 652 |
| D02AF Salicylic acid preparations | 1 048 | 1 229 | 1 206 | 1 167 | 1 179 | 54 | 170 | 341 | 486 | 182 | 206 |
| D02AX Other emollients and protectives | 125 | 148 | 168 | 228 | 244 | 53 | 112 | 65 | 39 | 28 | 128 |
| D03 PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS | 91 | 60 | 68 | 80 | 85 | 44 | 0 | <5 | 48 | 34 | 29 |
| D03A CICATRIZANTS | 91 | 60 | 68 | 80 | 85 | 44 | 0 | <5 | 48 | 34 | 29 |
| D03AA Cod-liver oil ointments | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group D

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|---------------|---------------|---------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| D03AX Other cicatrizants | 84 | 60 | 68 | 80 | 85 | 44 | 0 | <5 | 48 | 34 | 29 |
| D03AX03 dexpanthenol | 84 | 60 | 68 | 80 | 85 | 44 | 0 | <5 | 48 | 34 | 29 |
| D04 ANTI PRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. | 3 676 | 3 871 | 4 259 | 4 334 | 6 703 | 66 | 820 | 2 744 | 1 793 | 1 346 | 1 086 |
| D04A ANTI PRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. | 3 676 | 3 871 | 4 259 | 4 334 | 6 703 | 66 | 820 | 2 744 | 1 793 | 1 346 | 1 086 |
| D04AA Antihistamines for topical use | <5 | 0 | <5 | 8 | 8 | 75 | <5 | <5 | 5 | 0 | 13 |
| D04AA13 dimetindene | <5 | 0 | <5 | 8 | 8 | 75 | <5 | <5 | 5 | 0 | 13 |
| D04AB Anesthetics for topical use | 2 637 | 2 798 | 3 097 | 3 675 | 5 410 | 68 | 562 | 2 418 | 1 475 | 955 | 928 |
| D04AB01 lidocaine ¹⁾ | 2 637 | 2 798 | 3 097 | 3 675 | 5 410 | 68 | 562 | 2 418 | 1 475 | 955 | 928 |
| D04AX Other antipruritics | 1 052 | 1 093 | 1 169 | 674 | 1 307 | 57 | 261 | 328 | 319 | 399 | 145 |
| D05 ANTIPSORIATICS | 27 497 | 29 930 | 31 269 | 31 759 | 30 335 | 45 | 513 | 9 091 | 15 659 | 5 072 | 45 746 |
| D05A ANTIPSORIATICS FOR TOPICAL USE | 26 165 | 28 654 | 29 921 | 30 308 | 28 872 | 45 | 508 | 8 802 | 14 726 | 4 836 | 37 380 |
| D05AA Tars¹⁾ | 980 | 1 044 | 1 017 | 905 | 960 | 59 | 114 | 290 | 345 | 211 | 227 |
| D05AC Anthracen derivatives | 11 | 9 | 7 | <5 | 10 | 60 | <5 | <5 | 5 | <5 | 2 |
| D05AC01 dithranol | 11 | 9 | 7 | <5 | 10 | 60 | <5 | <5 | 5 | <5 | 2 |
| D05AD Psoralens for topical use | 6 | <5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D05AD01 trioxysalen | 6 | <5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D05AX Other antipsoriatics for topical use | 25 359 | 27 804 | 29 076 | 29 573 | 28 055 | 44 | 398 | 8 569 | 14 445 | 4 643 | 37 147 |
| D05AX02 calcipotriol | 8 744 | 8 029 | 5 640 | 2 226 | 1 559 | 41 | 12 | 364 | 845 | 338 | 808 |
| D05AX03 calcitriol | 1 084 | 1 127 | 1 092 | 1 174 | 1 170 | 49 | 38 | 348 | 596 | 188 | 785 |
| D05AX52 calcipotriol, combinations | 19 312 | 22 343 | 25 237 | 27 797 | 26 578 | 44 | 364 | 8 206 | 13 654 | 4 354 | 35 555 |
| D05B ANTIPSORIATICS FOR SYSTEMIC USE | 1 886 | 1 880 | 1 943 | 2 106 | 2 106 | 43 | 6 | 463 | 1 315 | 322 | 8 366 |
| D05BA Psoralens for systemic use | 34 | 40 | 32 | 26 | 20 | 50 | 0 | <5 | 10 | 6 | 15 |
| D05BA02 methoxsalen | 33 | 35 | 29 | 26 | 20 | 50 | 0 | <5 | 10 | 6 | 15 |
| D05BA03 bergapten | <5 | 5 | <5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D05BB Retinoids for treatment of psoriasis | 1 819 | 1 808 | 1 866 | 2 019 | 2 026 | 43 | 6 | 440 | 1 271 | 309 | 5 647 |
| D05BB02 acitretin | 1 819 | 1 808 | 1 866 | 2 019 | 2 026 | 43 | 6 | 440 | 1 271 | 309 | 5 647 |
| D05BX Other antipsoriatics for systemic use | 41 | 42 | 50 | 71 | 63 | 35 | 0 | 19 | 37 | 7 | 2 704 |
| D05BX51 fumaric acid derivatives, combinations | 41 | 42 | 50 | 71 | 63 | 35 | 0 | 19 | 37 | 7 | 2 704 |
| D06 ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE | 105 182 | 111 213 | 113 829 | 110 679 | 110 706 | 58 | 13 150 | 44 988 | 35 328 | 17 240 | 22 970 |

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group D

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|--|-----------------------|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|----------------|----------------|---------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| D06A ANTIBIOTICS FOR TOPICAL USE | 54 026 | 58 829 | 61 008 | 58 567 | 57 381 | 55 | 11 064 | 18 261 | 17 904 | 10 152 | 5 132 |
| D06AA Tetracycline and derivatives | 2 682 | 2 729 | 2 878 | 2 922 | 3 260 | 54 | 392 | 891 | 1 279 | 698 | 414 |
| D06AA02 chlortetracycline | 23 | 19 | 28 | 27 | 27 | 52 | 0 | 6 | 14 | 7 | 9 |
| D06AA03 oxytetracycline | 2 659 | 2 710 | 2 850 | 2 897 | 3 234 | 54 | 392 | 885 | 1 266 | 691 | 405 |
| D06AX Other antibiotics for topical use | 51 499 | 56 239 | 58 299 | 55 806 | 54 292 | 55 | 10 703 | 17 409 | 16 676 | 9 504 | 4 719 |
| D06AX01 fusidic acid | 49 106 | 53 684 | 55 137 | 53 101 | 51 166 | 55 | 9 616 | 16 441 | 16 045 | 9 064 | 4 283 |
| D06AX05 bacitracin | 1 802 | 1 739 | 2 378 | 1 986 | 2 231 | 50 | 698 | 699 | 466 | 368 | 248 |
| D06AX09 mupirocin | 17 | 14 | 31 | 41 | 90 | 48 | 11 | 41 | 30 | 8 | 20 |
| D06AX13 retapamulin | 746 | 1 008 | 1 005 | 875 | 1 046 | 56 | 458 | 299 | 178 | 111 | 168 |
| D06B CHEMOTHERAPEUTICS FOR TOPICAL USE | 53 024 | 54 414 | 54 942 | 54 044 | 55 283 | 61 | 2 216 | 27 463 | 18 106 | 7 498 | 17 837 |
| D06BA Sulfonamides | 3 202 | 3 373 | 3 410 | 3 569 | 3 482 | 54 | 562 | 1 212 | 1 067 | 641 | 522 |
| D06BA01 silver sulfadiazine | 3 202 | 3 373 | 3 410 | 3 569 | 3 482 | 54 | 562 | 1 212 | 1 067 | 641 | 522 |
| D06BB Antivirals | 41 307 | 41 885 | 40 813 | 39 042 | 38 980 | 59 | 1 470 | 21 524 | 11 094 | 4 892 | 15 119 |
| D06BB03 aciclovir ¹⁾ | 20 098 | 19 696 | 18 274 | 16 784 | 16 801 | 71 | 1 015 | 7 723 | 6 410 | 1 653 | 2 796 |
| D06BB04 podophyllotoxin | 13 402 | 13 567 | 13 738 | 12 944 | 13 095 | 45 | 138 | 11 550 | 1 333 | 74 | 2 854 |
| D06BB06 penciclovir ¹⁾ | 4 000 | 3 349 | 2 738 | 1 886 | 1 560 | 71 | 50 | 628 | 673 | 209 | 303 |
| D06BB10 imiquimod | 4 705 | 6 196 | 7 040 | 8 413 | 8 386 | 53 | 274 | 2 330 | 2 797 | 2 985 | 9 166 |
| D06BB11 docosanol | <5 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| D06BX Other chemotherapeutics | 8 721 | 9 426 | 11 017 | 11 737 | 13 197 | 67 | 190 | 4 863 | 6 102 | 2 042 | 2 197 |
| D06BX01 metronidazole | 8 721 | 9 426 | 11 017 | 11 737 | 12 942 | 68 | 190 | 4 862 | 5 974 | 1 916 | 1 913 |
| D06BX02 ingenol mebutate | 0 | 0 | 0 | 0 | 259 | 48 | 0 | <5 | 129 | 129 | 284 |
| D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS | 347 215 | 359 113 | 361 203 | 366 001 | 368 248 | 54 | 51 799 | 113 605 | 133 896 | 68 948 | 80 627 |
| D07A CORTICOSTEROIDS, PLAIN | 286 433 | 299 004 | 300 645 | 311 219 | 314 150 | 55 | 46 435 | 96 713 | 112 503 | 58 499 | 62 340 |
| D07AA Corticosteroids, weak (group I) | 26 763 | 28 352 | 28 849 | 30 901 | 29 941 | 55 | 13 608 | 8 031 | 5 179 | 3 123 | 3 441 |
| D07AA02 hydrocortisone ¹⁾ | 26 763 | 28 352 | 28 849 | 30 901 | 29 931 | 55 | 13 606 | 8 028 | 5 176 | 3 121 | 3 434 |
| D07AB Corticosteroids, moderately potent (group II) | 96 512 | 102 087 | 102 552 | 102 396 | 105 292 | 55 | 24 482 | 31 854 | 31 264 | 17 692 | 14 202 |
| D07AB02 hydrocortisone butyrate | 64 889 | 67 907 | 70 580 | 97 892 | 85 367 | 55 | 20 746 | 26 143 | 24 385 | 14 093 | 11 492 |
| D07AB08 desonide | 33 079 | 35 702 | 33 950 | 5 881 | 21 365 | 54 | 4 146 | 6 083 | 7 306 | 3 830 | 2 710 |
| D07AC Corticosteroids, potent (group III) | 153 609 | 158 099 | 157 096 | 164 821 | 163 406 | 54 | 16 526 | 52 939 | 61 300 | 32 641 | 32 499 |
| D07AC01 betamethasone | 50 086 | 52 441 | 54 076 | 58 253 | 58 313 | 54 | 3 696 | 18 866 | 23 367 | 12 384 | 7 375 |
| D07AC03 desoximetasone | 13 853 | 13 701 | 12 998 | 12 664 | 11 671 | 54 | 479 | 3 144 | 5 217 | 2 831 | 4 561 |

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group D

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 | |
|----------------|--|---------------|---------------|---------------|---------------|--------------------|-------------------------------------|--------------|---------------|---------------|-------------------|---------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK | |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | | |
| D07AC04 | fluocinolone acetonide | 6 572 | 6 500 | 6 008 | 5 854 | 5 421 | 53 | 181 | 1 019 | 2 574 | 1 647 | 963 |
| D07AC08 | fluocinonide | 792 | 724 | 670 | 602 | 541 | 51 | 6 | 94 | 282 | 159 | 92 |
| D07AC13 | mometasone | 74 342 | 78 920 | 78 528 | 82 943 | 83 267 | 54 | 10 904 | 28 207 | 28 901 | 15 255 | 16 652 |
| D07AC17 | fluticasone | 15 468 | 13 078 | 11 896 | 12 072 | 11 613 | 55 | 1 896 | 3 963 | 3 685 | 2 069 | 2 856 |
| D07AD | Corticosteroids, very potent (group IV) | 49 945 | 52 825 | 54 584 | 57 408 | 60 150 | 56 | 1 826 | 18 115 | 28 439 | 11 770 | 12 198 |
| D07AD01 | clobetazol | 49 945 | 52 825 | 54 584 | 57 408 | 60 150 | 56 | 1 826 | 18 115 | 28 439 | 11 770 | 12 198 |
| D07B | CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS | 37 064 | 36 056 | 37 823 | 29 417 | 29 528 | 49 | 3 310 | 8 798 | 11 328 | 6 092 | 3 044 |
| D07BB | Corticosteroids, moderately potent, combinations with antiseptics | 17 785 | 15 445 | 15 218 | 194 | 1 955 | 46 | 273 | 464 | 810 | 408 | 262 |
| D07BB02 | desonide and antiseptics | 17 619 | 15 445 | 15 217 | 194 | 1 955 | 46 | 273 | 464 | 810 | 408 | 262 |
| D07BB03 | triamcinolone and antiseptics | 0 | 0 | <5 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| D07BB04 | hydrocortisone butyrate and antiseptics | 193 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| D07BC | Corticosteroids, potent, combinations with antiseptics | 20 114 | 21 373 | 23 508 | 29 251 | 27 796 | 49 | 3 073 | 8 389 | 10 609 | 5 725 | 2 782 |
| D07BC01 | betamethasone and antiseptics | 17 301 | 18 864 | 21 243 | 26 888 | 25 387 | 49 | 2 889 | 7 733 | 9 533 | 5 232 | 2 552 |
| D07BC02 | fluocinolone acetonide and antiseptics | 2 918 | 2 601 | 2 358 | 2 471 | 2 540 | 50 | 196 | 690 | 1 125 | 529 | 229 |
| D07C | CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS | 26 357 | 26 769 | 26 158 | 26 354 | 25 078 | 54 | 4 889 | 7 315 | 8 374 | 4 500 | 3 100 |
| D07CA | Corticosteroids, weak, combinations with antibiotics | 26 351 | 26 768 | 26 158 | 26 350 | 25 072 | 54 | 4 889 | 7 310 | 8 373 | 4 500 | 3 098 |
| D07CA01 | hydrocortisone and antibiotics | 26 351 | 26 768 | 26 158 | 26 350 | 25 072 | 54 | 4 889 | 7 310 | 8 373 | 4 500 | 3 098 |
| D07CB | Corticosteroids, moderately potent, combinations with antibiotics | 0 | 0 | 0 | 0 | <5 | 67 | 0 | <5 | 0 | 0 | 1 |
| D07CB01 | triamcinolone and antibiotics | 0 | 0 | 0 | 0 | <5 | 67 | 0 | <5 | 0 | 0 | 1 |
| D07CC | Corticosteroids, potent, combinations with antibiotics | 6 | <5 | 0 | 5 | <5 | 67 | 0 | <5 | <5 | 0 | 2 |
| D07CC01 | betamethasone and antibiotics | 6 | <5 | 0 | <5 | <5 | 50 | 0 | <5 | <5 | 0 | 1 |
| D07CC05 | fluocinonide and antibiotics | 0 | 0 | 0 | <5 | <5 | 100 | 0 | <5 | 0 | 0 | 1 |
| D07X | CORTICOSTEROIDS, OTHER COMBINATIONS | 26 626 | 26 439 | 25 912 | 26 280 | 26 715 | 50 | 881 | 9 022 | 11 768 | 5 044 | 12 143 |

ATC group D

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|--|-----------------------|---------------|---------------|---------------|---------------|--------------------|-------------------------------------|---------------|---------------|--------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| D07XC Corticosteroids, potent, other combinations | 26 626 | 26 439 | 25 912 | 26 280 | 26 715 | 50 | 881 | 9 022 | 11 768 | 5 044 | 12 143 |
| D07XC01 betamethasone | 26 626 | 26 439 | 25 912 | 26 280 | 26 715 | 50 | 881 | 9 022 | 11 768 | 5 044 | 12 143 |
| D08 ANTISEPTICS AND DISINFECTANTS | 18 621 | 19 280 | 19 088 | 19 212 | 20 441 | 58 | 3 330 | 8 336 | 6 476 | 2 299 | 3 002 |
| D08A ANTISEPTICS AND DISINFECTANTS¹⁾ | 18 621 | 19 280 | 19 088 | 19 212 | 20 441 | 58 | 3 330 | 8 336 | 6 476 | 2 299 | 3 002 |
| D08AB Aluminium agents | 285 | 278 | 338 | 416 | 429 | 54 | 151 | 119 | 101 | 58 | 76 |
| D08AC Biguanides and amidines | 15 171 | 15 910 | 15 689 | 15 791 | 17 326 | 59 | 2 479 | 7 391 | 5 657 | 1 799 | 2 466 |
| D08AC01 dibrompropamide ¹⁾ | 5 115 | 5 282 | 3 802 | 4 729 | 5 561 | 50 | 1 908 | 1 763 | 1 088 | 802 | 726 |
| D08AC02 chlorhexidine ¹⁾ | 10 315 | 10 883 | 12 095 | 11 282 | 12 076 | 63 | 681 | 5 742 | 4 631 | 1 022 | 1 740 |
| D08AG Iodine products | 54 | 74 | 62 | 85 | 79 | 48 | 9 | 18 | 28 | 24 | 21 |
| D08AG01 iodine/octylphenoxypolyglycoether ¹⁾ | 5 | <5 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| D08AG02 povidone-iodine | 20 | 31 | 26 | 56 | 50 | 54 | <5 | 12 | 21 | 15 | 12 |
| D08AG03 iodine ¹⁾ | 29 | 42 | 36 | 29 | 29 | 38 | 7 | 6 | 7 | 9 | 9 |
| D08AJ Quaternary ammonium compounds | 135 | 151 | 173 | 134 | 124 | 55 | 19 | 29 | 34 | 42 | 53 |
| D08AJ03 cetylpyridinium ¹⁾ | 135 | 151 | 173 | 134 | 124 | 55 | 19 | 29 | 34 | 42 | 53 |
| D08AL Silver compounds | 0 | <5 | <5 | <5 | 10 | 20 | <5 | 5 | <5 | <5 | 6 |
| D08AL01 silver nitrate | 0 | <5 | <5 | <5 | 10 | 20 | <5 | 5 | <5 | <5 | 6 |
| D08AX Other antiseptics and disinfectants | 3 131 | 3 022 | 2 970 | 2 922 | 2 618 | 49 | 717 | 819 | 684 | 398 | 379 |
| D08AX01 hydrogen peroxide ¹⁾ | 2 059 | 1 829 | 1 740 | 1 669 | 1 526 | 52 | 434 | 480 | 393 | 219 | 170 |
| D08AX06 potassium permanganate ¹⁾ | 1 095 | 1 207 | 1 240 | 1 264 | 1 103 | 45 | 288 | 341 | 295 | 179 | 209 |
| D09 MEDICATED DRESSINGS | 1 937 | 1 913 | 1 848 | 1 767 | 1 718 | 57 | 124 | 354 | 574 | 666 | 522 |
| D09A MEDICATED DRESSINGS | 1 937 | 1 913 | 1 848 | 1 767 | 1 718 | 57 | 124 | 354 | 574 | 666 | 522 |
| D09AA Medicated dressings with antiinfectives | 1 937 | 1 913 | 1 848 | 1 684 | 1 607 | 57 | 119 | 348 | 528 | 612 | 216 |
| D09AA02 fusidic acid | 1 937 | 1 913 | 1 848 | 1 684 | 1 607 | 57 | 119 | 348 | 528 | 612 | 216 |
| D09AB Zinc bandages | 0 | 0 | 0 | 84 | 112 | 60 | 5 | 6 | 46 | 55 | 305 |
| D09AB01 zinc bandage without supplements | 0 | 0 | 0 | 84 | 112 | 60 | 5 | 6 | 46 | 55 | 305 |
| D10 ANTI-ACNE PREPARATIONS | 51 472 | 54 317 | 60 886 | 66 816 | 70 355 | 65 | 4 489 | 53 369 | 10 148 | 2 349 | 38 718 |
| D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE | 47 904 | 50 390 | 56 374 | 61 689 | 64 217 | 67 | 4 377 | 47 668 | 9 841 | 2 331 | 20 689 |
| D10AD Retinoids for topical use in acne | 24 388 | 27 056 | 32 174 | 36 043 | 37 161 | 66 | 2 966 | 29 779 | 3 360 | 1 056 | 13 506 |
| D10AD01 tretinoin | 9 888 | 10 547 | 10 221 | 10 977 | 6 861 | 79 | 195 | 3 679 | 2 196 | 791 | 849 |
| D10AD02 retinol | 117 | 170 | 176 | 185 | 63 | 59 | 7 | 16 | 30 | 10 | 16 |
| D10AD03 adapalene | 8 449 | 7 113 | 6 598 | 5 960 | 6 750 | 67 | 607 | 5 265 | 641 | 237 | 1 407 |

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group D

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|---------------|---------------|---------------|---------------|--------------------|-------------------------------------|---------------|--------------|--------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | <15 | | 15-44 | 45-69 | ≥70 | | |
| D10AD51 tretinoin, combinations | 0 | 0 | 0 | 0 | <5 | 100 | 0 | <5 | 0 | <5 | 2 |
| D10AD53 adapalene, combinations | 7 081 | 10 280 | 16 392 | 20 141 | 24 781 | 63 | 2 270 | 21 880 | 598 | 33 | 11 232 |
| D10AE Peroxides | 2 245 | 2 267 | 2 354 | 2 633 | 2 995 | 58 | 353 | 2 495 | 133 | 14 | 566 |
| D10AE01 benzoyl peroxide ¹⁾ | 2 245 | 2 267 | 2 354 | 2 633 | 2 995 | 58 | 353 | 2 495 | 133 | 14 | 566 |
| D10AF Antiinfectives for treatment of acne | 16 046 | 16 076 | 16 714 | 17 068 | 17 498 | 65 | 1 269 | 13 120 | 2 697 | 412 | 3 447 |
| D10AF01 clindamycin | 16 009 | 16 054 | 16 677 | 17 029 | 17 450 | 65 | 1 265 | 13 087 | 2 686 | 412 | 3 424 |
| D10AF02 erythromycin | 41 | 24 | 38 | 41 | 50 | 72 | <5 | 34 | 12 | 0 | 22 |
| D10AX Other anti-acne preparations for topical use | 13 292 | 13 285 | 13 815 | 14 942 | 15 685 | 71 | 710 | 10 017 | 4 072 | 886 | 3 170 |
| D10AX03 azelaic acid | 13 286 | 13 276 | 13 810 | 14 935 | 15 673 | 71 | 710 | 10 011 | 4 071 | 881 | 3 169 |
| D10AX30 various combinations | 7 | 11 | 5 | 7 | 12 | 75 | 0 | 6 | <5 | 5 | 2 |
| D10B ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE | 5 153 | 5 748 | 6 609 | 7 853 | 9 255 | 49 | 236 | 8 594 | 403 | 22 | 18 029 |
| D10BA Retinoids for treatment of acne | 5 153 | 5 748 | 6 609 | 7 853 | 9 255 | 49 | 236 | 8 594 | 403 | 22 | 18 029 |
| D10BA01 isotretinoin | 5 153 | 5 748 | 6 609 | 7 853 | 9 255 | 49 | 236 | 8 594 | 403 | 22 | 18 029 |
| D11 OTHER DERMATOLOGICAL PREPARATIONS | 15 690 | 16 780 | 18 059 | 18 430 | 19 627 | 57 | 2 997 | 9 216 | 5 757 | 1 657 | 17 674 |
| D11A OTHER DERMATOLOGICAL PREPARATIONS | 15 690 | 16 780 | 18 059 | 18 430 | 19 627 | 57 | 2 997 | 9 216 | 5 757 | 1 657 | 17 674 |
| D11AC Medicated shampoos | 974 | 1 059 | 1 205 | 1 220 | 1 449 | 50 | 132 | 933 | 275 | 109 | 198 |
| D11AC03 selenium compounds ¹⁾ | 974 | 1 059 | 1 205 | 1 220 | 1 449 | 50 | 132 | 933 | 275 | 109 | 198 |
| D11AF Wart and anti-corn preparations¹⁾ | 1 498 | 1 926 | 2 068 | 1 972 | 2 333 | 52 | 1 030 | 886 | 315 | 102 | 414 |
| D11AH Agents for dermatitis, excluding corticosteroids | 10 323 | 10 818 | 12 174 | 12 661 | 13 169 | 57 | 1 825 | 5 964 | 4 344 | 1 036 | 12 875 |
| D11AH01 tacrolimus | 6 804 | 7 498 | 8 318 | 8 696 | 8 887 | 57 | 1 202 | 4 067 | 2 919 | 699 | 4 128 |
| D11AH02 pimecrolimus | 3 712 | 3 534 | 3 996 | 3 952 | 4 224 | 59 | 655 | 1 917 | 1 315 | 337 | 1 980 |
| D11AH04 alitretinoin | 0 | 0 | 80 | 221 | 317 | 53 | 0 | 105 | 200 | 12 | 6 767 |
| D11AX Other dermatologicals | 2 940 | 3 036 | 2 677 | 2 634 | 2 757 | 64 | 14 | 1 479 | 847 | 417 | 4 187 |
| D11AX01 minoxidil | 175 | 202 | 161 | 199 | 292 | 71 | <5 | 174 | 85 | 29 | 159 |
| D11AX10 finasteride | 797 | 742 | 673 | 625 | 583 | 1 | 0 | 447 | 132 | <5 | 2 876 |
| D11AX16 eflornithine | 0 | <5 | 126 | 295 | 380 | 99 | 6 | 228 | 122 | 24 | 276 |
| D11AX18 diclofenac | 1 702 | 1 604 | 1 132 | 709 | 465 | 49 | 0 | 5 | 161 | 299 | 504 |

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

2.9 ATC group G – Genito urinary system and sex hormones

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|----------------|----------------|----------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| G GENITO URINARY SYSTEM AND SEX HORMONES | 703 423 | 721 846 | 745 367 | 761 600 | 785 598 | 80 | 3 475 | 431 263 | 242 798 | 108 062 | 897 948 |
| G01 GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS | 30 699 | 32 068 | 33 034 | 33 653 | 35 989 | 99 | 105 | 25 894 | 8 335 | 1 655 | 7 770 |
| G01A ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS | 30 699 | 32 068 | 33 034 | 33 653 | 35 989 | 99 | 105 | 25 894 | 8 335 | 1 655 | 7 770 |
| G01AA Antibiotics | 15 244 | 20 707 | 20 475 | 20 926 | 22 040 | 100 | 48 | 15 896 | 5 326 | 770 | 5 117 |
| G01AA10 clindamycin | 15 244 | 20 707 | 20 475 | 20 926 | 22 040 | 100 | 48 | 15 896 | 5 326 | 770 | 5 117 |
| G01AD Organic acids | 0 | 0 | 0 | <5 | 7 | 57 | <5 | 0 | <5 | <5 | 6 |
| G01AD02 acetic acid | 0 | 0 | 0 | <5 | 7 | 57 | <5 | 0 | <5 | <5 | 6 |
| G01AF Imidazole derivatives | 16 777 | 12 788 | 13 896 | 14 039 | 15 467 | 99 | 57 | 11 142 | 3 322 | 946 | 2 632 |
| G01AF01 metronidazole | 9 685 | 5 467 | 6 546 | 7 327 | 7 569 | 99 | 8 | 5 486 | 1 821 | 254 | 1 049 |
| G01AF02 clotrimazole ¹⁾ | 5 326 | 5 614 | 5 949 | 5 667 | 6 873 | 99 | 44 | 4 954 | 1 279 | 596 | 1 336 |
| G01AF04 miconazole ¹⁾ | 768 | 634 | 64 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| G01AF05 econazole ¹⁾ | 1 324 | 1 335 | 1 621 | 1 328 | 1 322 | 97 | 7 | 939 | 266 | 110 | 247 |
| G01AX Other antiinfectives and antiseptics | 6 | <5 | 5 | 8 | 9 | 67 | 0 | <5 | 7 | 0 | 11 |
| G01AX03 policresulen | 6 | <5 | 5 | 8 | 9 | 67 | 0 | <5 | 7 | 0 | 11 |
| G02 OTHER GYNECOLOGICALS | 44 047 | 45 250 | 46 752 | 47 284 | 47 703 | 99 | 7 | 41 722 | 5 794 | 180 | 49 757 |
| G02A UTEROTONICS | 12 | 15 | 11 | 7 | 6 | 100 | 0 | <5 | <5 | 0 | 1 |
| G02AB Ergot alkaloids | 12 | 15 | 11 | 7 | 5 | 100 | 0 | <5 | <5 | 0 | 1 |
| G02AB01 methylergometrine | 12 | 15 | 11 | 7 | 5 | 100 | 0 | <5 | <5 | 0 | 1 |
| G02AD Prostaglandins | 0 | 0 | 0 | 0 | <5 | 100 | 0 | 0 | <5 | 0 | 0 |
| G02AD02 dinoprostone | 0 | 0 | 0 | 0 | <5 | 100 | 0 | 0 | <5 | 0 | 0 |
| G02B CONTRACEPTIVES FOR TOPICAL USE | 41 674 | 42 960 | 44 425 | 45 106 | 45 532 | 100 | <5 | 40 437 | 5 089 | <5 | 46 800 |
| G02BA Intrauterine contraceptives | 24 803 | 24 858 | 25 084 | 25 507 | 25 540 | 100 | <5 | 20 992 | 4 544 | <5 | 29 497 |
| G02BA03 plastic IUD with progestogen | 24 803 | 24 858 | 25 084 | 25 507 | 25 540 | 100 | <5 | 20 992 | 4 544 | <5 | 29 497 |
| G02BB Intravaginal contraceptives | 17 064 | 18 263 | 19 552 | 19 825 | 20 195 | 100 | <5 | 19 635 | 558 | <5 | 17 303 |
| G02BB01 vaginal ring with progestogen and estrogen | 17 064 | 18 263 | 19 552 | 19 825 | 20 195 | 100 | <5 | 19 635 | 558 | <5 | 17 303 |
| G02C OTHER GYNECOLOGICALS | 2 458 | 2 367 | 2 414 | 2 267 | 2 270 | 75 | <5 | 1 383 | 706 | 177 | 2 955 |
| G02CB Prolactine inhibitors | 2 458 | 2 367 | 2 414 | 2 267 | 2 270 | 75 | <5 | 1 383 | 706 | 177 | 2 955 |
| G02CB01 bromocriptine | 1 312 | 1 226 | 1 248 | 1 057 | 998 | 90 | <5 | 753 | 196 | 48 | 656 |
| G02CB03 cabergoline | 943 | 921 | 948 | 1 004 | 1 104 | 63 | <5 | 573 | 417 | 111 | 1 475 |
| G02CB04 quinagolide | 302 | 284 | 260 | 245 | 224 | 71 | 0 | 101 | 103 | 20 | 825 |

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group G

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|--|-----------------------|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|----------------|----------------|---------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM | 515 229 | 525 683 | 538 164 | 545 211 | 558 156 | 98 | 2 687 | 370 176 | 145 086 | 40 207 | 417 475 |
| G03A HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE | 307 262 | 315 379 | 321 843 | 326 979 | 336 365 | 100 | 1 123 | 321 156 | 14 074 | 12 | 180 806 |
| G03AA Progestogens and estrogens, fixed combinations | 214 962 | 221 431 | 225 448 | 228 299 | 233 755 | 100 | 929 | 227 829 | 4 992 | 5 | 129 658 |
| G03AA07 levonorgestrel and ethinylestradiol | 87 148 | 90 257 | 97 290 | 113 359 | 125 595 | 100 | 662 | 122 774 | 2 157 | <5 | 57 242 |
| G03AA09 desogestrel and ethinylestradiol | 55 278 | 61 035 | 63 104 | 56 448 | 51 914 | 100 | 163 | 50 599 | 1 151 | <5 | 19 075 |
| G03AA12 drospirenone and ethinylestradiol | 74 740 | 72 600 | 68 101 | 59 748 | 56 408 | 100 | 136 | 54 834 | 1 437 | <5 | 45 837 |
| G03AA13 norelgestromin and ethinylestradiol | 8 924 | 8 982 | 9 054 | 8 962 | 8 904 | 100 | 11 | 8 646 | 246 | <5 | 6 514 |
| G03AA14 nomegestrol and estradiol | 0 | 0 | 0 | 972 | 1 194 | 100 | <5 | 1 148 | 42 | 0 | 990 |
| G03AB Progestogens and estrogens, sequential preparations | 18 862 | 17 640 | 16 199 | 14 793 | 13 478 | 100 | 24 | 12 695 | 758 | <5 | 5 457 |
| G03AB03 levonorgestrel and ethinylestradiol | <5 | 0 | <5 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| G03AB04 norethisterone and ethinylestradiol | 18 546 | 16 059 | 14 345 | 12 782 | 11 584 | 100 | 19 | 10 919 | 645 | <5 | 3 569 |
| G03AB08 dienogest and estradiol | 326 | 1 624 | 1 895 | 2 050 | 1 921 | 100 | 5 | 1 801 | 115 | 0 | 1 888 |
| G03AC Progestogens | 89 490 | 92 562 | 96 460 | 100 424 | 105 909 | 100 | 223 | 97 142 | 8 538 | 6 | 45 632 |
| G03AC01 norethisterone | 8 182 | 7 402 | 6 657 | 6 120 | 5 776 | 100 | <5 | 4 906 | 865 | <5 | 1 314 |
| G03AC03 levonorgestrel | 141 | 115 | <5 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| G03AC06 medroxyprogesterone | 19 971 | 19 607 | 19 338 | 18 871 | 18 870 | 100 | 41 | 15 208 | 3 618 | <5 | 4 465 |
| G03AC08 etonogestrel | 2 807 | 3 298 | 4 147 | 5 381 | 6 642 | 100 | 19 | 6 456 | 167 | 0 | 7 620 |
| G03AC09 desogestrel | 60 277 | 64 136 | 68 331 | 72 227 | 77 052 | 100 | 167 | 72 932 | 3 951 | <5 | 32 233 |
| G03AD Emergency contraceptives | 100 | 159 | 165 | 134 | 241 | 98 | <5 | 230 | 10 | 0 | 59 |
| G03AD01 levonorgestrel ¹⁾ | 99 | 79 | 87 | 82 | 113 | 96 | <5 | 106 | 6 | 0 | 23 |
| G03AD02 ulipristal | <5 | 80 | 78 | 53 | 129 | 99 | 0 | 124 | 5 | 0 | 36 |
| G03B ANDROGENS | 5 234 | 5 552 | 6 300 | 7 262 | 8 752 | 10 | 64 | 2 248 | 5 233 | 1 207 | 27 346 |
| G03BA 3-oxoandrosten (4) derivatives | 5 231 | 5 550 | 6 282 | 7 254 | 8 741 | 10 | 64 | 2 239 | 5 231 | 1 207 | 27 337 |
| G03BA03 testosterone | 5 231 | 5 550 | 6 282 | 7 254 | 8 741 | 10 | 64 | 2 239 | 5 231 | 1 207 | 27 337 |
| G03BB 5-androstanon (3) derivatives | <5 | <5 | 22 | 8 | 11 | 0 | 0 | 9 | <5 | 0 | 9 |
| G03BB01 mesterolone | <5 | <5 | 22 | 8 | 11 | 0 | 0 | 9 | <5 | 0 | 9 |
| G03C ESTROGENS | 112 831 | 116 574 | 121 775 | 123 293 | 126 359 | 100 | 171 | 5 313 | 85 519 | 35 356 | 81 297 |

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group G

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|--|-----------------------|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|---------------|---------------|---------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| G03CA Natural and semisynthetic estrogens, plain | 104 463 | 108 549 | 114 351 | 116 345 | 119 654 | 100 | 171 | 5 112 | 79 746 | 34 625 | 71 751 |
| G03CA01 ethinylestradiol | 140 | 127 | 112 | 71 | 48 | 94 | 21 | 18 | 7 | <5 | 343 |
| G03CA03 estradiol | 89 792 | 95 212 | 102 308 | 105 497 | 109 820 | 100 | 41 | 4 824 | 76 993 | 27 962 | 66 623 |
| G03CA04 estriol ¹⁾ | 16 213 | 14 807 | 13 574 | 12 313 | 11 302 | 100 | 109 | 303 | 3 465 | 7 425 | 4 783 |
| G03CA53 estradiol, combinations | <5 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| G03CA57 conjugated estrogens | <5 | <5 | <5 | <5 | <5 | 100 | 0 | 0 | <5 | <5 | 1 |
| G03CX Other estrogens | 9 183 | 8 841 | 8 224 | 7 705 | 7 534 | 100 | 0 | 239 | 6 500 | 795 | 9 545 |
| G03CX01 tibolone | 9 183 | 8 841 | 8 224 | 7 705 | 7 534 | 100 | 0 | 239 | 6 500 | 795 | 9 545 |
| G03D PROGESTOGENS | 37 790 | 38 788 | 39 101 | 40 073 | 41 850 | 100 | 1 336 | 30 428 | 9 883 | 203 | 19 566 |
| G03DA Pregnen (4) derivatives | 13 106 | 12 990 | 13 134 | 13 808 | 14 386 | 100 | 40 | 10 401 | 3 757 | 188 | 16 775 |
| G03DA02 medroxyprogesterone | 7 215 | 6 869 | 6 816 | 6 651 | 6 590 | 100 | 40 | 3 620 | 2 818 | 112 | 1 206 |
| G03DA04 progesterone | 5 987 | 6 240 | 6 465 | 7 294 | 7 929 | 100 | 0 | 6 898 | 954 | 77 | 15 569 |
| G03DB Pregnen derivatives | 0 | 0 | 12 | 127 | 159 | 100 | 0 | 142 | 17 | 0 | 422 |
| G03DB08 dienogest | 0 | 0 | 12 | 127 | 159 | 100 | 0 | 142 | 17 | 0 | 422 |
| G03DC Estren derivatives | 25 413 | 26 536 | 26 716 | 26 901 | 28 086 | 100 | 1 296 | 20 514 | 6 261 | 15 | 2 370 |
| G03DC02 norethisterone | 25 413 | 26 536 | 26 716 | 26 901 | 28 086 | 100 | 1 296 | 20 514 | 6 261 | 15 | 2 370 |
| G03F PROGESTOGENS AND ESTROGENS IN COMBINATION | 45 758 | 44 082 | 43 373 | 41 804 | 41 341 | 100 | <5 | 2 671 | 35 273 | 3 395 | 31 095 |
| G03FA Progestogens and estrogens, fixed combinations | 36 195 | 35 051 | 34 460 | 33 190 | 32 658 | 100 | 0 | 815 | 28 609 | 3 234 | 25 342 |
| G03FA01 norethisterone and estrogen | 35 628 | 34 521 | 33 827 | 32 517 | 31 956 | 100 | 0 | 777 | 27 983 | 3 196 | 24 516 |
| G03FA12 medroxyprogesterone and estrogen | 527 | 715 | 764 | 795 | 801 | 100 | 0 | 47 | 713 | 41 | 826 |
| G03FA15 dienogest and estrogen | 233 | <5 | <5 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| G03FB Progestogens and estrogens, sequential preparations | 10 851 | 10 322 | 10 082 | 9 652 | 9 671 | 100 | <5 | 1 940 | 7 560 | 169 | 5 753 |
| G03FB05 norethisterone and estrogen | 10 851 | 10 322 | 10 082 | 9 652 | 9 671 | 100 | <5 | 1 940 | 7 560 | 169 | 5 753 |
| G03G GONADOTROPINS AND OTHER OVULATION STIMULANTS | 11 093 | 10 343 | 10 634 | 10 473 | 10 334 | 94 | <5 | 10 051 | 277 | <5 | 67 928 |
| G03GA Gonadotropins | 6 013 | 6 137 | 6 273 | 6 248 | 6 317 | 97 | <5 | 6 177 | 136 | <5 | 66 334 |
| G03GA01 chorionic gonadotrophin | 1 277 | 1 476 | 1 660 | 1 317 | 1 143 | 83 | <5 | 1 057 | 82 | <5 | 469 |
| G03GA02 human menopausal gonadotrophin | 1 601 | 1 540 | 1 842 | 2 064 | 2 101 | 100 | 0 | 2 074 | 27 | 0 | 19 752 |
| G03GA04 urofollitropin | 0 | 85 | 154 | 200 | 268 | 100 | 0 | 261 | 7 | 0 | 2 094 |
| G03GA05 follitropin alfa | 1 770 | 1 743 | 1 799 | 1 941 | 1 926 | 99 | 0 | 1 904 | 22 | 0 | 19 183 |
| G03GA06 follitropin beta | 2 916 | 3 016 | 2 824 | 2 408 | 2 335 | 100 | 0 | 2 312 | 23 | 0 | 18 952 |

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group G

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|---------------|---------------|---------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| G03GA07 lutropin alfa | 65 | 26 | 21 | 17 | 9 | 100 | 0 | 8 | <5 | 0 | 46 |
| G03GA08 choriogonadotropin alfa | 4 556 | 4 538 | 4 600 | 4 820 | 5 007 | 100 | 0 | 4 951 | 56 | 0 | 3 114 |
| G03GA09 corifollitropin alfa | 0 | 132 | 316 | 283 | 323 | 100 | 0 | 316 | 7 | 0 | 2 556 |
| G03GA30 combinations | 8 | <5 | <5 | 16 | 8 | 100 | 0 | 8 | 0 | 0 | 168 |
| G03GB Ovulation stimulants, synthetic | 6 483 | 5 387 | 5 646 | 5 315 | 5 048 | 90 | 0 | 4 870 | 176 | <5 | 1 594 |
| G03GB02 clomifene | 6 483 | 5 387 | 5 646 | 5 315 | 5 048 | 90 | 0 | 4 870 | 176 | <5 | 1 594 |
| G03H ANTIANDROGENS | 16 171 | 16 764 | 17 326 | 18 067 | 17 481 | 99 | 93 | 16 912 | 390 | 86 | 7 182 |
| G03HA Antiandrogens, plain | 181 | 205 | 199 | 178 | 175 | 7 | 0 | 38 | 53 | 84 | 530 |
| G03HA01 cyproterone | 181 | 205 | 199 | 178 | 175 | 7 | 0 | 38 | 53 | 84 | 530 |
| G03HB Antiandrogens and estrogens | 15 999 | 16 565 | 17 130 | 17 895 | 17 309 | 100 | 93 | 16 877 | 337 | <5 | 6 652 |
| G03HB01 cyproterone and estrogen | 15 999 | 16 565 | 17 130 | 17 895 | 17 309 | 100 | 93 | 16 877 | 337 | <5 | 6 652 |
| G03X OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM | 1 298 | 1 142 | 979 | 867 | 767 | 95 | <5 | 29 | 252 | 485 | 2 256 |
| G03XA Antigonadotropins and similar agents | 50 | 49 | 50 | 51 | 53 | 26 | <5 | 18 | 26 | 8 | 168 |
| G03XA01 danazol | 50 | 49 | 50 | 51 | 53 | 26 | <5 | 18 | 26 | 8 | 168 |
| G03XB Progesterone receptor modulators | 0 | <5 | <5 | 6 | 15 | 100 | 0 | 8 | 7 | 0 | 59 |
| G03XB01 mifepristone | 0 | <5 | <5 | 6 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| G03XB02 ulipristal | 0 | 0 | 0 | 0 | 15 | 100 | 0 | 8 | 7 | 0 | 59 |
| G03XC Selective estrogen receptor modulators | 1 248 | 1 092 | 927 | 810 | 699 | 100 | 0 | <5 | 219 | 477 | 2 029 |
| G03XC01 raloxifene | 1 248 | 1 092 | 927 | 810 | 699 | 100 | 0 | <5 | 219 | 477 | 2 029 |
| G04 UROLOGICALS | 148 765 | 156 067 | 166 514 | 175 080 | 185 259 | 20 | 690 | 17 601 | 94 869 | 72 099 | 422 946 |
| G04B UROLOGICALS | 109 819 | 113 502 | 119 124 | 123 051 | 128 784 | 28 | 690 | 15 300 | 72 960 | 39 834 | 345 788 |
| G04BA Acidifiers | <5 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| G04BA01 ammonium chloride | <5 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| G04BD Drugs for urinary frequency and incontinence | 44 578 | 46 177 | 49 166 | 50 206 | 52 117 | 68 | 647 | 4 099 | 22 145 | 25 226 | 158 270 |
| G04BD04 oxybutynin | 1 480 | 1 504 | 1 516 | 1 525 | 1 468 | 64 | 174 | 429 | 481 | 384 | 8 980 |
| G04BD07 tolterodine | 18 355 | 15 679 | 14 238 | 12 763 | 11 304 | 72 | 389 | 589 | 4 145 | 6 181 | 33 309 |
| G04BD08 solifenacin | 17 349 | 19 877 | 21 934 | 22 341 | 20 910 | 69 | 93 | 1 638 | 9 117 | 10 062 | 62 000 |
| G04BD10 darifenacin | 5 630 | 5 126 | 4 566 | 4 059 | 3 475 | 74 | 0 | 190 | 1 421 | 1 864 | 10 134 |
| G04BD11 fesoterodine | 5 380 | 7 639 | 10 610 | 12 962 | 13 441 | 67 | 16 | 1 067 | 6 028 | 6 330 | 34 631 |
| G04BD12 mirabegron | 0 | 0 | 0 | 0 | 6 735 | 65 | <5 | 606 | 3 193 | 2 933 | 9 216 |
| G04BE Drugs used in erectile dysfunction | 66 640 | 68 779 | 71 519 | 74 530 | 78 488 | 0 | 40 | 11 309 | 51 895 | 15 244 | 187 480 |

ATC group G

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|--|-----------------------|---------------|---------------|---------------|---------------|--------------------|-------------------------------------|--------------|---------------|---------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| G04BE01 alprostadil | 2 180 | 2 543 | 2 525 | 2 809 | 2 893 | 0 | 0 | 122 | 1 879 | 892 | 4 868 |
| G04BE03 sildenafil | 34 734 | 34 385 | 34 578 | 34 385 | 35 222 | 1 | 38 | 4 864 | 22 723 | 7 597 | 79 654 |
| G04BE04 yohimbine | 19 | 15 | 10 | 7 | 11 | 18 | 0 | <5 | 5 | <5 | 7 |
| G04BE08 tadalafil | 26 821 | 29 887 | 32 997 | 36 673 | 40 063 | 0 | <5 | 6 325 | 27 201 | 6 535 | 87 605 |
| G04BE09 vardenafil | 10 376 | 9 934 | 9 427 | 9 073 | 8 785 | 0 | 0 | 1 095 | 5 978 | 1 712 | 14 664 |
| G04BE30 combinations | 616 | 495 | 539 | 347 | 293 | 0 | 0 | 14 | 205 | 74 | 683 |
| G04BX Other urologicals | 10 | 11 | 11 | 13 | 19 | 47 | <5 | 6 | 6 | <5 | 38 |
| G04BX01 magnesium hydroxide | 10 | 11 | 11 | 13 | 19 | 47 | <5 | 6 | 6 | <5 | 38 |
| G04C DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY | 45 440 | 49 918 | 55 531 | 61 004 | 66 317 | 1 | 0 | 2 511 | 26 618 | 37 188 | 77 157 |
| G04CA Alpha-adrenoreceptor antagonists | 34 945 | 38 363 | 43 210 | 48 624 | 53 898 | 1 | 0 | 1 429 | 23 388 | 29 081 | 56 742 |
| G04CA01 alfuzosin | 536 | 498 | 451 | 398 | 48 | 2 | 0 | <5 | 13 | 33 | 23 |
| G04CA02 tamsulosin | 33 877 | 37 383 | 41 362 | 43 587 | 45 144 | 2 | 0 | 1 323 | 19 745 | 24 076 | 37 853 |
| G04CA03 terazosin | 744 | 649 | 598 | 599 | 601 | 2 | 0 | 99 | 242 | 260 | 495 |
| G04CA52 tamsulosin and dutasteride | 0 | <5 | 1 628 | 6 169 | 10 799 | 0 | 0 | 15 | 4 566 | 6 218 | 18 370 |
| G04CB Testosterone-5-alpha reductase inhibitors | 14 939 | 16 984 | 18 676 | 18 628 | 18 209 | 0 | 0 | 1 094 | 5 109 | 12 006 | 20 415 |
| G04CB01 finasteride | 12 852 | 15 194 | 17 122 | 17 271 | 17 016 | 0 | 0 | 1 065 | 4 827 | 11 124 | 17 056 |
| G04CB02 dutasteride | 2 331 | 1 939 | 1 661 | 1 421 | 1 258 | 0 | 0 | 37 | 303 | 918 | 3 360 |

2.10 ATC group H – Systemic hormonal preparations, excl. sex hormones and insulins

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|----------------|----------------|----------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15–44 | 45–69 | ≥70 | | | | | | | |
| H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS | 375 465 | 387 821 | 402 923 | 414 206 | 422 537 | 67 | 16 419 | 109 977 | 183 711 | 112 430 | 444 841 |
| H01 PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES | 24 490 | 24 833 | 24 910 | 24 985 | 25 586 | 66 | 9 288 | 13 214 | 1 949 | 1 135 | 293 310 |
| H01A ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES | 1 577 | 1 658 | 1 767 | 1 866 | 1 975 | 44 | 1 068 | 534 | 335 | 38 | 156 436 |
| H01AA ACTH | <5 | <5 | <5 | 0 | <5 | 100 | 0 | 0 | <5 | 0 | 0 |
| H01AA02 tetracosactide | <5 | <5 | <5 | 0 | <5 | 100 | 0 | 0 | <5 | 0 | 0 |
| H01AB Thyrotropin | 0 | <5 | 7 | 10 | 16 | 81 | 0 | <5 | 11 | <5 | 148 |
| H01AB01 thyrotropin alfa | 0 | <5 | 7 | 10 | 16 | 81 | 0 | <5 | 11 | <5 | 148 |
| H01AC Somatropin and somatropin agonists | 1 555 | 1 631 | 1 735 | 1 825 | 1 928 | 43 | 1 068 | 520 | 305 | 35 | 147 177 |
| H01AC01 somatropin | 1 555 | 1 631 | 1 735 | 1 825 | 1 928 | 43 | 1 068 | 520 | 305 | 35 | 147 177 |
| H01AX Other anterior pituitary lobe hormones and analogues | 21 | 24 | 24 | 31 | 30 | 40 | 0 | 11 | 18 | <5 | 9 110 |
| H01AX01 pegvisomant | 21 | 24 | 24 | 31 | 30 | 40 | 0 | 11 | 18 | <5 | 9 110 |
| H01B POSTERIOR PITUITARY LOBE HORMONES | 18 807 | 18 982 | 19 167 | 18 728 | 19 133 | 62 | 8 249 | 8 817 | 1 235 | 832 | 36 738 |
| H01BA Vasopressin and analogues | 11 288 | 11 248 | 11 388 | 11 209 | 11 257 | 36 | 8 213 | 1 065 | 1 156 | 823 | 35 184 |
| H01BA02 desmopressin | 11 288 | 11 248 | 11 387 | 11 209 | 11 257 | 36 | 8 213 | 1 065 | 1 156 | 823 | 35 184 |
| H01BA04 terlipressin | 0 | 0 | <5 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| H01BB Oxytocin and analogues | 7 522 | 7 736 | 7 781 | 7 522 | 7 878 | 99 | 36 | 7 754 | 79 | 9 | 1 554 |
| H01BB02 oxytocin | 7 522 | 7 736 | 7 781 | 7 522 | 7 878 | 99 | 36 | 7 754 | 79 | 9 | 1 554 |
| H01C HYPOTHALAMIC HORMONES | 4 315 | 4 430 | 4 218 | 4 643 | 4 737 | 92 | 7 | 4 002 | 455 | 273 | 100 135 |
| H01CA Gonadotropin-releasing hormones | 2 829 | 2 314 | 2 076 | 2 362 | 2 337 | 100 | 0 | 2 307 | 30 | 0 | 5 670 |
| H01CA02 nafarelin | 2 829 | 2 314 | 2 076 | 2 362 | 2 337 | 100 | 0 | 2 307 | 30 | 0 | 5 670 |
| H01CB Somatostatin and analogues | 498 | 593 | 630 | 726 | 751 | 47 | 7 | 74 | 397 | 273 | 89 088 |
| H01CB02 octreotide | 398 | 472 | 497 | 569 | 569 | 47 | <5 | 57 | 306 | 203 | 63 079 |
| H01CB03 lanreotide | 118 | 137 | 148 | 184 | 204 | 46 | <5 | 19 | 101 | 80 | 25 691 |
| H01CB05 pasireotide | 0 | 0 | 0 | 0 | <5 | 50 | 0 | <5 | <5 | <5 | 318 |
| H01CC Anti-gonadotropin-releasing hormones | 1 246 | 1 887 | 1 774 | 1 814 | 1 934 | 100 | 0 | 1 902 | 32 | 0 | 5 378 |
| H01CC01 ganirelix | 975 | 1 513 | 1 397 | 1 429 | 1 504 | 100 | 0 | 1 475 | 29 | 0 | 4 153 |
| H01CC02 cetorelix | 298 | 481 | 413 | 406 | 451 | 100 | 0 | 447 | <5 | 0 | 1 225 |
| H02 CORTICOSTEROIDS FOR SYSTEMIC USE | 190 388 | 197 259 | 208 089 | 214 495 | 216 737 | 56 | 4 963 | 60 959 | 91 689 | 59 126 | 54 764 |

ATC group H

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|---------------|---------------|---------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN | 190 244 | 197 075 | 207 853 | 214 275 | 216 497 | 56 | 4 962 | 60 912 | 91 547 | 59 076 | 54 704 |
| H02AA Mineralocorticoids | 1 178 | 1 223 | 1 267 | 1 323 | 1 367 | 56 | 89 | 429 | 614 | 235 | 369 |
| H02AA02 fludrocortisone | 1 178 | 1 223 | 1 267 | 1 323 | 1 367 | 56 | 89 | 429 | 614 | 235 | 369 |
| H02AB Glucocorticoids | 190 110 | 196 940 | 207 710 | 214 119 | 216 331 | 56 | 4 958 | 60 871 | 91 484 | 59 018 | 54 335 |
| H02AB01 betamethasone | 1 700 | 1 637 | 1 528 | 1 495 | 1 988 | 42 | 1 156 | 296 | 443 | 93 | 638 |
| H02AB02 dexamethasone | 2 118 | 2 552 | 2 786 | 3 208 | 3 485 | 45 | 100 | 346 | 1 830 | 1 209 | 4 152 |
| H02AB04 methylprednisolone | 10 745 | 10 812 | 11 020 | 11 094 | 11 015 | 54 | 41 | 2 524 | 5 779 | 2 671 | 4 003 |
| H02AB06 prednisolone | 143 524 | 152 240 | 159 525 | 167 804 | 168 968 | 58 | 3 118 | 38 314 | 73 245 | 54 291 | 30 480 |
| H02AB07 prednisone | <5 | 82 | 246 | 267 | 347 | 70 | 0 | 55 | 173 | 119 | 858 |
| H02AB08 triamcinolone | 34 538 | 32 179 | 35 711 | 33 528 | 34 019 | 49 | 450 | 20 047 | 11 698 | 1 824 | 4 774 |
| H02AB09 hydrocortisone | 437 | 481 | 549 | 597 | 637 | 68 | 67 | 244 | 290 | 36 | 3 085 |
| H02AB10 cortisone | 2 593 | 2 662 | 2 750 | 2 817 | 2 820 | 51 | 135 | 741 | 1 361 | 583 | 6 241 |
| H02AB13 deflazacort | 18 | 17 | 25 | 25 | 26 | 42 | 10 | 7 | 7 | <5 | 105 |
| H02B CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS | 332 | 372 | 415 | 409 | 386 | 63 | <5 | 65 | 219 | 101 | 60 |
| H02BX Corticosteroids for systemic use, combinations | 332 | 372 | 415 | 409 | 386 | 63 | <5 | 65 | 219 | 101 | 60 |
| H02BX01 methylprednisolone, combinations | 332 | 372 | 415 | 409 | 386 | 63 | <5 | 65 | 219 | 101 | 60 |
| H03 THYROID THERAPY | 174 354 | 180 847 | 185 868 | 192 035 | 197 795 | 82 | 1 370 | 37 312 | 98 828 | 60 285 | 62 729 |
| H03A THYROID PREPARATIONS | 170 772 | 177 261 | 182 151 | 187 897 | 193 254 | 82 | 1 349 | 35 988 | 96 813 | 59 104 | 59 438 |
| H03AA Thyroid hormones | 170 772 | 177 261 | 182 151 | 187 897 | 193 254 | 82 | 1 349 | 35 988 | 96 813 | 59 104 | 59 438 |
| H03AA01 levothyroxine sodium | 170 484 | 176 910 | 181 641 | 187 229 | 192 528 | 82 | 1 343 | 35 746 | 96 396 | 59 043 | 54 495 |
| H03AA02 liothyronine sodium | 4 095 | 4 142 | 4 538 | 4 698 | 4 750 | 90 | 15 | 1 402 | 2 890 | 443 | 3 244 |
| H03AA03 combinations of levothyroxine and liothyronine | 429 | 328 | 549 | 701 | 872 | 92 | <5 | 350 | 483 | 38 | 1 025 |
| H03AA05 thyroid gland preparations | 0 | 182 | 187 | 265 | 353 | 90 | 0 | 139 | 203 | 11 | 675 |
| H03B ANTITHYROID PREPARATIONS | 5 019 | 5 125 | 5 432 | 5 927 | 6 398 | 80 | 35 | 2 055 | 2 922 | 1 386 | 3 289 |
| H03BA Thiouracils | 552 | 521 | 651 | 582 | 581 | 90 | 0 | 325 | 207 | 49 | 553 |
| H03BA02 propylthiouracil | 552 | 521 | 651 | 582 | 581 | 90 | 0 | 325 | 207 | 49 | 553 |
| H03BB Sulfur-containing imidazole derivatives | 4 590 | 4 727 | 5 042 | 5 510 | 6 039 | 79 | 35 | 1 856 | 2 797 | 1 351 | 2 736 |
| H03BB01 carbimazole | 4 590 | 4 727 | 5 042 | 5 510 | 6 039 | 79 | 35 | 1 856 | 2 797 | 1 351 | 2 736 |
| H03C IODINE THERAPY | 0 | 0 | 0 | 0 | <5 | 50 | 0 | <5 | <5 | 0 | 2 |
| H03CA Iodine therapy | 0 | 0 | 0 | 0 | <5 | 50 | 0 | <5 | <5 | 0 | 2 |
| H04 PANCREATIC HORMONES | 5 336 | 5 490 | 5 591 | 5 586 | 5 688 | 47 | 1 115 | 2 730 | 1 489 | 354 | 2 328 |
| H04A GLYCOGENOLYTIC HORMONES | 5 336 | 5 490 | 5 591 | 5 586 | 5 688 | 47 | 1 115 | 2 730 | 1 489 | 354 | 2 328 |

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|--------------|--------------|--------------|--------------|--------------------|-------------------------------------|--------------|--------------|------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| H04AA Glycogenolytic hormones | 5 336 | 5 490 | 5 591 | 5 586 | 5 688 | 47 | 1 115 | 2 730 | 1 489 | 354 | 2 328 |
| H04AA01 glucagon | 5 336 | 5 490 | 5 591 | 5 586 | 5 688 | 47 | 1 115 | 2 730 | 1 489 | 354 | 2 328 |
| H05 CALCIUM HOMEOSTASIS | 748 | 803 | 916 | 1 090 | 1 224 | 59 | <5 | 138 | 611 | 474 | 31 710 |
| H05A PARATHYROID HORMONES AND ANALOGUES | 237 | 263 | 294 | 377 | 468 | 82 | 0 | 52 | 264 | 152 | 13 519 |
| H05AA Parathyroid hormones and analogues | 237 | 263 | 294 | 377 | 468 | 82 | 0 | 52 | 264 | 152 | 13 519 |
| H05AA02 teriparatide | 213 | 253 | 281 | 367 | 467 | 82 | 0 | 52 | 263 | 152 | 13 507 |
| H05AA03 parathyroid hormone | 25 | 12 | 13 | 11 | <5 | 100 | 0 | 0 | <5 | 0 | 12 |
| H05B ANTI-PARATHYROID AGENTS | 511 | 541 | 623 | 713 | 756 | 46 | <5 | 86 | 347 | 322 | 18 191 |
| H05BA Calcitonin preparations | 86 | 80 | 83 | 69 | 21 | 76 | 0 | <5 | <5 | 16 | 61 |
| H05BA01 calcitonin (salmon synthetic) | 86 | 80 | 83 | 69 | 21 | 76 | 0 | <5 | <5 | 16 | 61 |
| H05BX Other anti-parathyroid agents | 425 | 461 | 540 | 644 | 735 | 45 | <5 | 84 | 344 | 306 | 18 130 |
| H05BX01 cinacalcet | 391 | 418 | 474 | 501 | 525 | 49 | <5 | 52 | 233 | 239 | 13 406 |
| H05BX02 paricalcitol | 44 | 59 | 87 | 188 | 284 | 36 | <5 | 47 | 144 | 92 | 4 724 |

2.11 ATC group J – Antiinfectives for systemic use

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|------------------|------------------|------------------|------------------|--------------------|-------------------------------------|----------------|----------------|----------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15–44 | 45–69 | ≥70 | | | | | | | |
| J ANTIINFECTIVES FOR SYSTEMIC USE | 1 394 508 | 1 252 392 | 1 326 405 | 1 336 787 | 1 288 914 | 59 | 148 972 | 513 276 | 429 761 | 196 905 | 816 142 |
| J01 ANTIBACTERIALS FOR SYSTEMIC USE | 1 138 247 | 1 180 410 | 1 250 480 | 1 261 271 | 1 195 320 | 59 | 142 487 | 468 553 | 397 925 | 186 355 | 300 301 |
| J01A TETRACYCLINES | 161 073 | 167 058 | 188 189 | 206 426 | 187 918 | 57 | 2 071 | 84 508 | 72 040 | 29 299 | 35 708 |
| J01AA Tetracyclines | 161 073 | 167 058 | 188 189 | 206 426 | 187 918 | 57 | 2 071 | 84 508 | 72 040 | 29 299 | 35 708 |
| J01AA02 doxycycline | 124 472 | 129 848 | 148 596 | 164 753 | 145 943 | 56 | 800 | 54 640 | 62 924 | 27 579 | 19 837 |
| J01AA04 lymecycline | 13 528 | 14 771 | 19 412 | 22 520 | 23 686 | 58 | 713 | 17 012 | 5 044 | 917 | 10 646 |
| J01AA06 oxytetracycline | 5 244 | 5 164 | 2 625 | <5 | 10 | 60 | 0 | <5 | 5 | <5 | 2 |
| J01AA07 tetracycline | 20 086 | 19 710 | 21 378 | 22 166 | 20 959 | 58 | 615 | 14 643 | 4 724 | 977 | 4 946 |
| J01AA08 minocycline | 16 | 58 | 85 | 145 | 240 | 53 | <5 | 110 | 121 | 8 | 267 |
| J01AA12 tigecycline | <5 | <5 | <5 | <5 | <5 | 100 | 0 | 0 | <5 | 0 | 10 |
| J01B AMPHENICOLS | 0 | <5 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| J01BA Amphenicols | 0 | <5 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| J01BA01 chloramphenicol | 0 | <5 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| J01C BETA-LACTAM ANTIBACTERIALS, PENICILLINS | 744 434 | 776 398 | 797 519 | 801 997 | 774 820 | 61 | 106 267 | 295 965 | 247 707 | 124 881 | 128 672 |
| J01CA Penicillins with extended spectrum | 283 578 | 301 349 | 309 246 | 318 249 | 321 225 | 74 | 34 035 | 103 410 | 107 225 | 76 555 | 55 332 |
| J01CA01 ampicillin | 19 | 39 | 24 | 56 | 57 | 44 | <5 | 5 | 15 | 36 | 44 |
| J01CA02 pivampicillin | 0 | 0 | <5 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| J01CA04 amoxicillin | 118 112 | 127 541 | 131 915 | 137 759 | 134 844 | 55 | 29 472 | 32 013 | 45 798 | 27 561 | 18 331 |
| J01CA08 pivmecillinam | 176 709 | 186 059 | 189 598 | 193 934 | 200 464 | 87 | 4 911 | 74 806 | 66 281 | 54 466 | 36 946 |
| J01CA11 mecillinam | <5 | <5 | <5 | 10 | 8 | 88 | <5 | <5 | <5 | <5 | 10 |
| J01CE Beta-lactamase sensitive penicillins | 444 689 | 458 149 | 466 195 | 458 225 | 438 658 | 54 | 75 654 | 180 708 | 133 405 | 48 891 | 41 726 |
| J01CE01 benzylpenicillin | 58 | 52 | 64 | 85 | 103 | 45 | <5 | 13 | 30 | 56 | 136 |
| J01CE02 phenoxymethylpenicillin | 444 622 | 458 036 | 466 096 | 458 104 | 438 508 | 54 | 75 651 | 180 645 | 133 360 | 48 852 | 41 081 |
| J01CE08 benzathine benzylpenicillin | 40 | 99 | 83 | 81 | 112 | 26 | <5 | 65 | 39 | 7 | 509 |
| J01CF Beta-lactamase resistant penicillins | 85 870 | 92 702 | 100 307 | 104 992 | 87 628 | 49 | 4 556 | 37 435 | 30 816 | 14 821 | 30 941 |
| J01CF01 dicloxacillin | 84 083 | 91 099 | 98 912 | 103 764 | 81 161 | 49 | 4 269 | 34 689 | 28 506 | 13 697 | 27 501 |
| J01CF02 cloxacillin | 2 153 | 1 929 | 1 714 | 1 520 | 8 105 | 47 | 296 | 3 286 | 2 982 | 1 541 | 3 388 |
| J01CF05 flucloxacillin | 32 | 22 | 17 | 21 | 28 | 36 | 20 | <5 | <5 | <5 | 51 |
| J01CR Combinations of penicillins, incl. beta-lactamase inhibitors | 120 | 135 | 114 | 188 | 434 | 57 | 212 | 57 | 85 | 80 | 674 |
| J01CR02 amoxicillin and enzyme inhibitor | 101 | 118 | 94 | 151 | 381 | 60 | 211 | 50 | 60 | 60 | 370 |
| J01CR05 piperacillin and enzyme inhibitor | 19 | 17 | 20 | 37 | 53 | 36 | <5 | 7 | 25 | 20 | 303 |

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|----------------|----------------|---------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| J01D OTHER BETA-LACTAM ANTIBACTERIALS | 24 378 | 23 566 | 23 142 | 21 542 | 22 070 | 58 | 2 780 | 7 850 | 7 488 | 3 952 | 11 360 |
| J01DB First-generation cephalosporins | 23 974 | 23 116 | 22 707 | 20 726 | 20 949 | 59 | 2 716 | 7 477 | 7 116 | 3 640 | 3 084 |
| J01DB01 cefalexin | 23 952 | 23 099 | 22 698 | 20 707 | 20 940 | 59 | 2 716 | 7 477 | 7 113 | 3 634 | 3 070 |
| J01DB03 cefalotin | 23 | 17 | 9 | 20 | 9 | 11 | 0 | 0 | <5 | 6 | 14 |
| J01DC Second-generation cephalosporins | 63 | 71 | 72 | 103 | 98 | 52 | <5 | 6 | 26 | 64 | 81 |
| J01DC02 cefuroxime | 63 | 71 | 72 | 103 | 98 | 52 | <5 | 6 | 26 | 64 | 81 |
| J01DD Third-generation cephalosporins | 346 | 388 | 362 | 705 | 1 010 | 46 | 68 | 363 | 332 | 247 | 6 278 |
| J01DD01 cefotaxime | 122 | 120 | 134 | 447 | 703 | 48 | 5 | 237 | 262 | 199 | 4 422 |
| J01DD02 ceftazidime | 71 | 80 | 57 | 68 | 73 | 47 | 13 | 36 | 14 | 10 | 1 193 |
| J01DD04 ceftriaxone | 155 | 190 | 177 | 195 | 238 | 39 | 51 | 91 | 57 | 39 | 663 |
| J01DF Monobactams | 11 | 13 | 8 | 9 | 10 | 50 | 0 | 9 | 0 | <5 | 450 |
| J01DF01 aztreonam | 11 | 13 | 8 | 9 | 10 | 50 | 0 | 9 | 0 | <5 | 450 |
| J01DH Carbapenems | 56 | 43 | 53 | 69 | 85 | 54 | 8 | 27 | 28 | 22 | 1 466 |
| J01DH02 meropenem | 46 | 39 | 40 | 58 | 62 | 53 | 7 | 23 | 19 | 13 | 993 |
| J01DH03 ertapenem | 8 | <5 | 13 | 10 | 17 | 65 | 0 | <5 | 8 | 6 | 403 |
| J01DH04 doripenem | 0 | 0 | 0 | <5 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| J01DH51 imipenem and enzyme inhibitor | <5 | <5 | <5 | <5 | 7 | 43 | <5 | <5 | <5 | <5 | 71 |
| J01E SULFONAMIDES AND TRIMETHOPRIM | 118 489 | 117 088 | 116 661 | 114 940 | 116 722 | 75 | 13 833 | 30 594 | 38 511 | 33 784 | 11 262 |
| J01EA Trimethoprim and derivatives | 88 503 | 86 108 | 84 347 | 80 744 | 78 689 | 85 | 8 074 | 21 487 | 25 244 | 23 884 | 6 469 |
| J01EA01 trimethoprim | 88 503 | 86 108 | 84 347 | 80 744 | 78 689 | 85 | 8 074 | 21 487 | 25 244 | 23 884 | 6 469 |
| J01EE Combinations of sulfonamides and trimethoprim, incl. derivatives | 34 027 | 34 976 | 36 389 | 38 556 | 42 790 | 57 | 6 310 | 9 987 | 14 728 | 11 765 | 4 793 |
| J01EE01 sulfamethoxazole and trimethoprim | 34 027 | 34 976 | 36 389 | 38 556 | 42 790 | 57 | 6 310 | 9 987 | 14 728 | 11 765 | 4 793 |
| J01F MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS | 283 337 | 301 083 | 349 643 | 343 543 | 296 521 | 57 | 36 035 | 130 094 | 101 074 | 29 318 | 49 680 |
| J01FA Macrolides | 244 678 | 257 943 | 304 755 | 295 755 | 238 975 | 58 | 31 273 | 106 756 | 79 931 | 21 015 | 37 320 |
| J01FA01 erythromycin | 123 140 | 129 188 | 170 347 | 152 858 | 120 963 | 59 | 24 475 | 46 177 | 38 818 | 11 493 | 16 287 |
| J01FA02 spiramycin | 3 033 | 2 794 | 2 744 | 2 645 | 2 018 | 62 | 20 | 684 | 1 036 | 278 | 331 |
| J01FA06 roxithromycin | 0 | 0 | 0 | 0 | <5 | 50 | 0 | 0 | <5 | 0 | 1 |
| J01FA09 clarithromycin | 36 958 | 37 830 | 43 161 | 48 582 | 34 941 | 58 | 3 047 | 13 182 | 14 153 | 4 559 | 6 087 |
| J01FA10 azithromycin | 90 850 | 98 413 | 101 180 | 105 207 | 90 289 | 59 | 4 514 | 50 957 | 29 387 | 5 431 | 14 581 |
| J01FA15 telithromycin | 0 | 0 | 0 | <5 | 6 | 83 | 0 | 5 | <5 | 0 | 32 |

ATC group J

| ATC level | | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|--------------|--------------------------------------|-----------------------|---------------|---------------|---------------|---------------|--------------------|-------------------------------------|---------------|---------------|---------------|-------------------|
| | | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | | | | | | | | <15 | 15-44 | 45-69 | ≥70 | |
| J01FF | Lincosamides | 45 847 | 51 154 | 53 678 | 56 641 | 66 378 | 53 | 5 559 | 27 379 | 24 193 | 9 247 | 12 360 |
| J01FF01 | clindamycin | 45 847 | 51 154 | 53 678 | 56 641 | 66 378 | 53 | 5 559 | 27 379 | 24 193 | 9 247 | 12 360 |
| J01G | AMINOGLYCOSIDE ANTIBACTERIALS | 289 | 273 | 252 | 255 | 242 | 48 | 49 | 115 | 55 | 23 | 10 408 |
| J01GA | Streptomycins | 0 | 0 | 0 | 0 | <5 | 0 | 0 | 0 | 0 | <5 | 15 |
| J01GA01 | streptomycin | 0 | 0 | 0 | 0 | <5 | 0 | 0 | 0 | 0 | <5 | 15 |
| J01GB | Other aminoglycosides | 289 | 273 | 252 | 255 | 241 | 49 | 49 | 115 | 55 | 22 | 10 393 |
| J01GB01 | tobramycin | 258 | 250 | 219 | 229 | 211 | 49 | 46 | 104 | 44 | 17 | 9 413 |
| J01GB03 | gentamicin | 26 | 16 | 19 | 14 | 21 | 33 | <5 | <5 | 10 | <5 | 305 |
| J01GB06 | amikacin | 5 | 10 | 14 | 12 | 9 | 78 | 0 | 7 | <5 | <5 | 675 |
| J01M | QUINOLONE ANTIBACTERIALS | 60 651 | 64 703 | 67 271 | 69 685 | 68 203 | 49 | 608 | 16 510 | 29 583 | 21 502 | 15 682 |
| J01MA | Fluoroquinolones | 60 651 | 64 703 | 67 271 | 69 685 | 68 203 | 49 | 608 | 16 510 | 29 583 | 21 502 | 15 682 |
| J01MA01 | ofloxacin | 2 717 | 2 516 | 2 242 | 2 057 | 1 647 | 41 | <5 | 488 | 688 | 468 | 571 |
| J01MA02 | ciprofloxacin | 58 298 | 62 445 | 65 193 | 67 734 | 66 556 | 49 | 606 | 15 803 | 29 009 | 21 138 | 14 268 |
| J01MA12 | levofloxacin | 15 | 21 | 31 | 20 | 18 | 61 | 0 | <5 | 12 | <5 | 78 |
| J01MA14 | moxifloxacin | 71 | 142 | 205 | 263 | 290 | 56 | 0 | 271 | 16 | <5 | 764 |
| J01X | OTHER ANTIBACTERIALS | 51 069 | 54 632 | 58 484 | 59 562 | 61 581 | 85 | 1 421 | 12 317 | 21 417 | 26 426 | 37 530 |
| J01XA | Glycopeptide antibacterials | 27 | 23 | 27 | 35 | 29 | 72 | 6 | 6 | 7 | 10 | 316 |
| J01XA01 | vancomycin | 26 | 21 | 24 | 35 | 28 | 75 | 6 | 6 | 7 | 9 | 288 |
| J01XA02 | teicoplanin | <5 | <5 | <5 | 0 | <5 | 0 | 0 | 0 | 0 | <5 | 28 |
| J01XB | Polymyxins | 64 | 55 | 63 | 72 | 79 | 62 | 18 | 35 | 19 | 7 | 2 845 |
| J01XB01 | colistin | 64 | 55 | 63 | 72 | 79 | 62 | 18 | 35 | 19 | 7 | 2 845 |
| J01XC | Steroid antibacterials | 711 | 757 | 663 | 592 | 646 | 57 | 16 | 234 | 217 | 179 | 408 |
| J01XC01 | fusidic acid | 711 | 757 | 663 | 592 | 646 | 57 | 16 | 234 | 217 | 179 | 408 |
| J01XD | Imidazole derivatives | 23 | 24 | 26 | 25 | 28 | 39 | 0 | <5 | 18 | 7 | 71 |
| J01XD01 | metronidazole | 23 | 24 | 26 | 25 | 28 | 39 | 0 | <5 | 18 | 7 | 71 |
| J01XE | Nitrofurantoin derivatives | 31 296 | 33 594 | 36 784 | 36 250 | 36 821 | 86 | 1 308 | 9 330 | 12 824 | 13 359 | 3 922 |
| J01XE01 | nitrofurantoin | 31 296 | 33 594 | 36 784 | 36 250 | 36 821 | 86 | 1 308 | 9 330 | 12 824 | 13 359 | 3 922 |
| J01XX | Other antibacterials | 23 185 | 24 887 | 25 921 | 28 098 | 29 569 | 84 | 113 | 3 461 | 10 306 | 15 689 | 29 967 |
| J01XX01 | fosfomicin | 0 | 0 | 0 | <5 | 6 | 83 | 0 | <5 | <5 | <5 | 12 |
| J01XX05 | methenamine | 22 969 | 24 644 | 25 647 | 27 852 | 29 300 | 84 | 111 | 3 412 | 10 190 | 15 587 | 21 579 |
| J01XX08 | linezolid | 223 | 252 | 279 | 252 | 273 | 47 | <5 | 48 | 119 | 104 | 8 368 |
| J01XX09 | daptomycin | 0 | 0 | 0 | <5 | <5 | 100 | 0 | 0 | <5 | 0 | 9 |
| J02 | ANTIMYCOTICS FOR SYSTEMIC USE | 42 646 | 45 330 | 46 501 | 47 777 | 48 187 | 86 | 452 | 30 539 | 13 792 | 3 404 | 32 205 |
| J02A | ANTIMYCOTICS FOR SYSTEMIC USE | 42 646 | 45 330 | 46 501 | 47 777 | 48 187 | 86 | 452 | 30 539 | 13 792 | 3 404 | 32 205 |
| J02AA | Antibiotics | <5 | 0 | <5 | <5 | <5 | 0 | 0 | <5 | <5 | 0 | 66 |

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|--|-----------------------|---------------|---------------|---------------|---------------|--------------------|-------------------------------------|---------------|---------------|--------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| J02AA01 amphotericin B | <5 | 0 | <5 | <5 | <5 | 0 | 0 | <5 | <5 | 0 | 66 |
| J02AB Imidazole derivatives | 2 262 | 2 163 | 2 227 | 2 264 | 1 716 | 45 | 17 | 1 137 | 493 | 69 | 502 |
| J02AB02 ketoconazole | 2 262 | 2 163 | 2 227 | 2 264 | 1 716 | 45 | 17 | 1 137 | 493 | 69 | 502 |
| J02AC Triazole derivatives | 40 488 | 43 283 | 44 379 | 45 621 | 46 571 | 88 | 437 | 29 463 | 13 328 | 3 343 | 26 822 |
| J02AC01 fluconazole | 40 227 | 42 967 | 43 936 | 45 311 | 46 203 | 88 | 425 | 29 298 | 13 170 | 3 310 | 15 279 |
| J02AC02 itraconazole | 526 | 471 | 635 | 608 | 576 | 76 | 7 | 344 | 199 | 26 | 953 |
| J02AC03 voriconazole | 65 | 80 | 80 | 88 | 87 | 37 | <5 | 19 | 48 | 16 | 7 265 |
| J02AC04 posaconazole | 9 | 22 | 40 | 55 | 63 | 30 | <5 | 18 | 38 | <5 | 3 324 |
| J02AX Other antimycotics for systemic use | <5 | <5 | 5 | 6 | 7 | 71 | <5 | <5 | <5 | <5 | 4 815 |
| J02AX04 caspofungin | <5 | <5 | <5 | <5 | <5 | 75 | 0 | <5 | <5 | <5 | 1 456 |
| J02AX05 micafungin | 0 | 0 | <5 | <5 | <5 | 67 | <5 | <5 | <5 | 0 | 3 359 |
| J02AX06 anidulafungin | <5 | 0 | <5 | <5 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| J04 ANTIMYCOBACTERIALS | 1 336 | 1 573 | 1 645 | 1 877 | 1 980 | 50 | 144 | 923 | 556 | 357 | 6 043 |
| J04A DRUGS FOR TREATMENT OF TUBERCULOSIS | 931 | 1 126 | 1 194 | 1 454 | 1 524 | 53 | 138 | 814 | 354 | 218 | 5 676 |
| J04AB Antibiotics | 401 | 444 | 474 | 621 | 563 | 49 | 72 | 132 | 184 | 175 | 1 507 |
| J04AB02 rifampicin | 377 | 422 | 458 | 608 | 555 | 48 | 72 | 128 | 182 | 173 | 1 357 |
| J04AB04 rifabutin | 25 | 24 | 17 | 14 | 9 | 56 | 0 | 5 | <5 | <5 | 150 |
| J04AB30 capreomycin | 0 | 0 | 0 | <5 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| J04AC Hydrazides | 64 | 75 | 88 | 78 | 95 | 59 | 18 | 40 | 29 | 8 | 99 |
| J04AC01 isoniazid | 64 | 75 | 88 | 78 | 95 | 59 | 18 | 40 | 29 | 8 | 99 |
| J04AD Thiocarbamide derivatives | <5 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| J04AD01 protionamide | <5 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| J04AK Other drugs for treatment of tuberculosis | 126 | 203 | 207 | 283 | 318 | 53 | <5 | 189 | 88 | 37 | 1 141 |
| J04AK01 pyrazinamide | 20 | 28 | 37 | 50 | 68 | 65 | <5 | 48 | 13 | <5 | 150 |
| J04AK02 ethambutol | 115 | 198 | 200 | 268 | 304 | 52 | <5 | 180 | 86 | 35 | 991 |
| J04AM Combinations of drugs for treatment of tuberculosis | 493 | 645 | 684 | 808 | 917 | 55 | 67 | 668 | 146 | 36 | 2 928 |
| J04AM02 rifampicin and isoniazid | 433 | 578 | 619 | 752 | 856 | 55 | 67 | 624 | 130 | 35 | 2 360 |
| J04AM05 rifampicin, pyrazinamide and isoniazid | 76 | 138 | 111 | 180 | 225 | 52 | 0 | 157 | 53 | 15 | 536 |
| J04AM06 rifampicin, pyrazinamide, ethambutol and isoniazid | 58 | 47 | 47 | 0 | 14 | 71 | 0 | 9 | 5 | 0 | 32 |
| J04B DRUGS FOR TREATMENT OF LEPRO | 405 | 449 | 454 | 423 | 457 | 42 | 6 | 109 | 203 | 139 | 368 |
| J04BA Drugs for treatment of lepra | 405 | 449 | 454 | 423 | 457 | 42 | 6 | 109 | 203 | 139 | 368 |
| J04BA02 dapsone | 405 | 449 | 454 | 423 | 457 | 42 | 6 | 109 | 203 | 139 | 368 |

ATC group J

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|---------------|---------------|---------------|---------------|--------------------|-------------------------------------|---------------|---------------|--------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| J05 ANTIVIRALS FOR SYSTEMIC USE | 304 693 | 31 034 | 32 722 | 34 845 | 39 342 | 61 | 996 | 19 303 | 14 471 | 4 572 | 398 145 |
| J05A DIRECT ACTING ANTIVIRALS | 304 693 | 31 034 | 32 722 | 34 845 | 39 342 | 61 | 996 | 19 303 | 14 471 | 4 572 | 398 145 |
| J05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors | 23 038 | 24 889 | 27 463 | 30 034 | 32 041 | 65 | 608 | 15 781 | 11 516 | 4 136 | 52 486 |
| J05AB01 aciclovir | 10 264 | 11 316 | 12 172 | 12 655 | 12 598 | 69 | 399 | 6 603 | 4 099 | 1 497 | 4 951 |
| J05AB04 ribavirin | 770 | 705 | 760 | 900 | 785 | 35 | <5 | 389 | 389 | <5 | 14 945 |
| J05AB06 ganciclovir | 0 | <5 | <5 | 0 | <5 | 0 | <5 | 0 | 0 | 0 | 1 |
| J05AB09 famciclovir | 0 | 0 | 0 | <5 | <5 | 0 | <5 | <5 | 0 | 0 | 8 |
| J05AB11 valaciclovir | 12 244 | 13 096 | 14 811 | 16 807 | 18 985 | 64 | 205 | 9 121 | 7 007 | 2 652 | 16 750 |
| J05AB14 valganciclovir | 246 | 283 | 319 | 347 | 365 | 39 | 8 | 96 | 224 | 37 | 15 831 |
| J05AD Phosphonic acid derivatives | 0 | 0 | 0 | <5 | <5 | 100 | 0 | 0 | <5 | 0 | 46 |
| J05AD01 foscarnet | 0 | 0 | 0 | <5 | <5 | 100 | 0 | 0 | <5 | 0 | 46 |
| J05AE Protease inhibitors | 728 | 860 | 1 105 | 1 557 | 1 551 | 38 | <5 | 793 | 730 | 25 | 93 830 |
| J05AE01 saquinavir | 11 | 9 | 7 | 7 | 7 | 29 | 0 | <5 | <5 | <5 | 322 |
| J05AE02 indinavir | 6 | <5 | <5 | <5 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| J05AE03 ritonavir | 499 | 604 | 720 | 864 | 963 | 42 | <5 | 563 | 382 | 15 | 3 664 |
| J05AE07 fosamprenavir | <5 | <5 | <5 | <5 | <5 | 0 | 0 | 0 | <5 | 0 | 41 |
| J05AE08 atazanavir | 660 | 780 | 920 | 1 080 | 1 140 | 40 | <5 | 634 | 483 | 21 | 42 501 |
| J05AE09 tipranavir | <5 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| J05AE10 darunavir | 55 | 70 | 91 | 132 | 177 | 33 | <5 | 67 | 106 | <5 | 9 266 |
| J05AE11 telaprevir | 0 | 0 | 16 | 94 | 85 | 29 | 0 | 35 | 50 | 0 | 17 484 |
| J05AE12 boceprevir | 0 | 0 | 76 | 256 | 161 | 39 | 0 | 63 | 98 | 0 | 20 550 |
| J05AF Nucleoside and nucleotide reverse transcriptase inhibitors | 388 | 399 | 420 | 489 | 587 | 39 | 21 | 275 | 279 | 12 | 21 110 |
| J05AF01 zidovudine | 41 | 34 | 35 | 30 | 36 | 39 | <5 | 17 | 14 | <5 | 299 |
| J05AF02 didanosine | 53 | 37 | 22 | 17 | 15 | 47 | 0 | 5 | 9 | <5 | 247 |
| J05AF04 stavudine | 13 | 13 | <5 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| J05AF05 lamivudine | 117 | 100 | 93 | 92 | 100 | 43 | 18 | 28 | 50 | <5 | 1 027 |
| J05AF06 abacavir | 48 | 51 | 54 | 60 | 66 | 52 | 15 | 25 | 25 | <5 | 1 326 |
| J05AF07 tenofovir disoproxil | 158 | 163 | 191 | 228 | 297 | 41 | <5 | 163 | 130 | <5 | 10 006 |
| J05AF08 adefovir dipivoxil | 33 | 22 | 15 | 11 | 10 | 30 | 0 | <5 | 8 | 0 | 633 |
| J05AF09 emtricitabine | 11 | 11 | 9 | 6 | 8 | 25 | 0 | <5 | 6 | 0 | 155 |
| J05AF10 entecavir | 87 | 106 | 126 | 160 | 175 | 36 | 0 | 83 | 89 | <5 | 7 385 |
| J05AF11 telbivudine | 8 | 5 | <5 | 0 | <5 | 0 | 0 | <5 | <5 | 0 | 32 |

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|--|-----------------------|--------------|--------------|--------------|--------------|--------------------|-------------------------------------|--------------|--------------|------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| J05AG Non-nucleoside reverse transcriptase inhibitors | 573 | 529 | 467 | 425 | 398 | 38 | 10 | 155 | 218 | 15 | 10 670 |
| J05AG01 nevirapine | 186 | 191 | 184 | 176 | 164 | 38 | <5 | 61 | 96 | 5 | 4 538 |
| J05AG03 efavirenz | 382 | 321 | 258 | 221 | 192 | 40 | 7 | 79 | 97 | 9 | 4 641 |
| J05AG04 etravirine | 12 | 23 | 28 | 28 | 35 | 37 | <5 | 11 | 22 | <5 | 1 197 |
| J05AG05 rilpivirine | 0 | 0 | 0 | <5 | 12 | 25 | 0 | 7 | 5 | 0 | 294 |
| J05AH Neuraminidase inhibitors | 282 095 | 3 860 | 2 646 | 1 808 | 3 993 | 53 | 365 | 1 820 | 1 432 | 376 | 982 |
| J05AH01 zanamivir | 2 542 | 35 | 36 | 34 | 85 | 62 | <5 | 47 | 29 | 6 | 22 |
| J05AH02 oseltamivir | 279 946 | 3 829 | 2 612 | 1 776 | 3 911 | 53 | 362 | 1 774 | 1 404 | 371 | 960 |
| J05AR Antivirals for treatment of HIV infections, combinations | 1 927 | 2 184 | 2 445 | 2 775 | 3 043 | 36 | 15 | 1 555 | 1 414 | 59 | 197 516 |
| J05AR01 zidovudine and lamivudine | 606 | 514 | 421 | 350 | 249 | 44 | <5 | 113 | 122 | 13 | 6 870 |
| J05AR02 lamivudine and abacavir | 258 | 279 | 290 | 335 | 376 | 31 | <5 | 154 | 209 | 11 | 14 805 |
| J05AR03 tenofovir disoproxil and emtricitabine | 890 | 1 065 | 1 230 | 1 433 | 1 526 | 41 | <5 | 838 | 661 | 25 | 73 746 |
| J05AR04 zidovudine, lamivudine and abacavir | 36 | 35 | 31 | 23 | 17 | 53 | 0 | 5 | 11 | <5 | 725 |
| J05AR06 emtricitabine, tenofovir disoproxil and efavirenz | 362 | 514 | 650 | 767 | 792 | 29 | <5 | 383 | 395 | 11 | 62 687 |
| J05AR08 emtricitabine, tenofovir disoproxil and rilpivirine | 0 | 0 | 0 | 143 | 339 | 29 | 0 | 195 | 142 | <5 | 26 130 |
| J05AR09 emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat | 0 | 0 | 0 | 0 | 33 | 33 | 0 | 17 | 16 | 0 | 1 238 |
| J05AR10 lopinavir and ritonavir | 583 | 551 | 510 | 480 | 401 | 49 | 10 | 235 | 151 | 5 | 11 316 |
| J05AX Other antivirals | 97 | 179 | 271 | 325 | 379 | 40 | 7 | 156 | 211 | 5 | 21 506 |
| J05AX05 inosine pranobex | <5 | 31 | 81 | 61 | 45 | 76 | <5 | 27 | 15 | 0 | 188 |
| J05AX07 enfuvirtide | <5 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| J05AX08 raltegravir | 96 | 148 | 190 | 264 | 333 | 35 | <5 | 128 | 196 | 5 | 20 761 |
| J05AX09 maraviroc | 5 | 7 | 7 | 7 | 8 | 25 | 0 | <5 | 6 | 0 | 556 |

2.12 ATC group L – Antineoplastic and immunomodulating agents

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|---------------|---------------|---------------|---------------|--------------------|-------------------------------------|---------------|---------------|---------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | 72 795 | 76 656 | 81 612 | 86 336 | 90 729 | 54 | 1 264 | 19 959 | 43 089 | 26 417 | 2 668 185 |
| L02 ENDOCRINE THERAPY | 24 457 | 24 886 | 25 999 | 26 144 | 26 900 | 52 | 147 | 3 181 | 9 392 | 14 180 | 320 416 |
| L02A HORMONES AND RELATED AGENTS | 10 788 | 11 009 | 11 761 | 11 175 | 11 171 | 22 | 145 | 1 965 | 1 991 | 7 070 | 90 600 |
| L02AA Estrogens | 25 | 17 | 7 | <5 | <5 | 0 | 0 | <5 | 0 | 0 | 0 |
| L02AA02 polyestradiol phosphate | 25 | 17 | 7 | <5 | <5 | 0 | 0 | <5 | 0 | 0 | 0 |
| L02AB Progestogens | 188 | 178 | 202 | 166 | 154 | 81 | 0 | 8 | 66 | 80 | 337 |
| L02AB01 megestrol | 178 | 178 | 202 | 166 | 154 | 81 | 0 | 8 | 66 | 80 | 337 |
| L02AB02 medroxyprogesterone | 12 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| L02AE Gonadotropin releasing hormone analogues | 10 590 | 10 827 | 11 558 | 11 011 | 11 019 | 21 | 145 | 1 957 | 1 927 | 6 990 | 90 262 |
| L02AE01 buserelin | 1 282 | 1 474 | 1 898 | 1 313 | 1 355 | 100 | 0 | 1 338 | 17 | 0 | 2 230 |
| L02AE02 leuprorelin | 3 887 | 3 891 | 4 012 | 3 957 | 3 736 | 16 | 144 | 411 | 491 | 2 690 | 33 032 |
| L02AE03 goserelin | 5 601 | 5 619 | 5 783 | 5 861 | 6 028 | 7 | <5 | 239 | 1 437 | 4 351 | 54 724 |
| L02AE04 triptorelin | 8 | <5 | 12 | 13 | 13 | 100 | 0 | 10 | <5 | 0 | 46 |
| L02AE05 histrelin | 0 | 0 | 12 | 20 | 20 | 0 | 0 | 0 | <5 | 17 | 230 |
| L02B HORMONE ANTAGONISTS AND RELATED AGENTS | 16 800 | 17 127 | 17 878 | 18 866 | 19 816 | 59 | <5 | 1 267 | 8 511 | 10 036 | 229 817 |
| L02BA Anti-estrogens | 4 959 | 4 109 | 3 861 | 3 999 | 4 250 | 96 | <5 | 695 | 2 604 | 949 | 12 251 |
| L02BA01 tamoxifen | 4 716 | 3 893 | 3 597 | 3 766 | 4 036 | 96 | <5 | 692 | 2 488 | 854 | 3 847 |
| L02BA03 fulvestrant | 267 | 242 | 296 | 267 | 246 | 98 | 0 | 5 | 129 | 112 | 8 405 |
| L02BB Anti-androgens | 6 380 | 6 641 | 7 008 | 6 983 | 6 964 | 0 | 0 | <5 | 1 517 | 5 445 | 44 433 |
| L02BB01 flutamide | 352 | 305 | 253 | 248 | 202 | 1 | 0 | <5 | 18 | 182 | 914 |
| L02BB03 bicalutamide | 6 058 | 6 362 | 6 775 | 6 765 | 6 720 | 0 | 0 | 0 | 1 479 | 5 241 | 38 357 |
| L02BB04 enzalutamide | 0 | 0 | 0 | 0 | 85 | 0 | 0 | 0 | 29 | 56 | 5 162 |
| L02BG Aromatase inhibitors | 6 601 | 7 219 | 7 378 | 7 777 | 8 322 | 98 | 0 | 586 | 4 499 | 3 237 | 34 712 |
| L02BG03 anastrozole | 3 276 | 2 901 | 2 331 | 1 857 | 1 537 | 93 | 0 | 68 | 810 | 659 | 6 608 |
| L02BG04 letrozole | 2 360 | 3 478 | 4 365 | 5 300 | 6 155 | 100 | 0 | 506 | 3 316 | 2 333 | 24 363 |
| L02BG06 exemestane | 1 200 | 1 108 | 929 | 809 | 901 | 99 | 0 | 18 | 544 | 339 | 3 741 |
| L02BX Other hormone antagonists and related agents | 0 | 89 | 377 | 836 | 1 182 | 0 | 0 | 0 | 337 | 845 | 138 420 |
| L02BX02 degarelix | 0 | 89 | 271 | 380 | 487 | 0 | 0 | 0 | 164 | 323 | 5 075 |
| L02BX03 abiraterone | 0 | 0 | 107 | 484 | 762 | 0 | 0 | 0 | 209 | 553 | 133 345 |
| L03 IMMUNOSTIMULANTS | 5 663 | 5 883 | 6 294 | 6 765 | 6 747 | 60 | 54 | 2 351 | 3 715 | 627 | 325 389 |
| L03A IMMUNOSTIMULANTS | 5 663 | 5 883 | 6 294 | 6 765 | 6 747 | 60 | 54 | 2 351 | 3 715 | 627 | 325 389 |
| L03AA Colony stimulating factors | 2 085 | 2 222 | 2 426 | 2 691 | 2 831 | 59 | 38 | 481 | 1 732 | 580 | 91 238 |
| L03AA02 filgrastim | 362 | 415 | 587 | 599 | 623 | 49 | 32 | 119 | 367 | 105 | 10 058 |

ATC group L

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|--|-----------------------|---------------|---------------|---------------|---------------|--------------------|-------------------------------------|---------------|---------------|--------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| L03AA13 pegfilgrastim | 1 815 | 1 919 | 1 958 | 2 218 | 2 353 | 61 | 6 | 398 | 1 458 | 491 | 81 180 |
| L03AB Interferons | 2 666 | 2 649 | 2 756 | 2 891 | 2 722 | 57 | 16 | 1 316 | 1 354 | 36 | 152 565 |
| L03AB01 interferon alfa natural | 5 | 11 | 20 | 20 | 14 | 64 | 0 | 8 | 6 | 0 | 1 500 |
| L03AB03 interferon gamma | 9 | 9 | 9 | 10 | 10 | 60 | <5 | 7 | <5 | 0 | 937 |
| L03AB04 interferon alfa-2a | 14 | 19 | 19 | 23 | 25 | 48 | 0 | <5 | 14 | 7 | 934 |
| L03AB05 interferon alfa-2b | 62 | 74 | 63 | 49 | 40 | 38 | 0 | 9 | 27 | <5 | 1 365 |
| L03AB07 interferon beta-1a | 1 348 | 1 217 | 1 183 | 1 178 | 1 159 | 70 | 10 | 559 | 585 | 5 | 89 662 |
| L03AB08 interferon beta-1b | 372 | 533 | 637 | 652 | 611 | 65 | 0 | 327 | 280 | <5 | 27 199 |
| L03AB10 peginterferon alfa-2b | 416 | 310 | 273 | 337 | 260 | 42 | <5 | 117 | 131 | 8 | 9 150 |
| L03AB11 peginterferon alfa-2a | 468 | 503 | 594 | 687 | 651 | 34 | 0 | 316 | 327 | 8 | 21 817 |
| L03AC Interleukins | 0 | 0 | <5 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| L03AC01 aldesleukin | 0 | 0 | <5 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| L03AX Other immunostimulants | 1 023 | 1 148 | 1 266 | 1 358 | 1 322 | 72 | <5 | 624 | 685 | 11 | 81 586 |
| L03AX03 BCG vaccine | 7 | 13 | 12 | 10 | 12 | 17 | 0 | <5 | <5 | 7 | 73 |
| L03AX13 glatiramer acetate | 1 016 | 1 135 | 1 254 | 1 348 | 1 310 | 72 | <5 | 623 | 681 | <5 | 81 513 |
| L04 IMMUNOSUPPRESSANTS | 37 221 | 39 932 | 42 913 | 46 379 | 49 521 | 55 | 926 | 13 743 | 25 996 | 8 856 | 1 592 934 |
| L04A IMMUNOSUPPRESSANTS | 37 221 | 39 932 | 42 913 | 46 379 | 49 521 | 55 | 926 | 13 743 | 25 996 | 8 856 | 1 592 934 |
| L04AA Selective immunosuppressants | 4 619 | 4 910 | 5 466 | 6 255 | 7 280 | 51 | 89 | 1 892 | 4 149 | 1 150 | 248 941 |
| L04AA06 mycophenolic acid | 2 965 | 3 266 | 3 591 | 3 926 | 4 207 | 37 | 78 | 993 | 2 485 | 651 | 38 945 |
| L04AA10 sirolimus | 70 | 101 | 130 | 150 | 189 | 35 | 5 | 23 | 142 | 19 | 5 688 |
| L04AA13 leflunomide | 1 362 | 1 458 | 1 539 | 1 662 | 1 785 | 69 | 0 | 221 | 1 113 | 451 | 10 094 |
| L04AA18 everolimus | 263 | 294 | 336 | 402 | 449 | 29 | 7 | 59 | 283 | 100 | 26 820 |
| L04AA21 efalizumab | 118 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| L04AA23 natalizumab | 58 | 49 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| L04AA24 abatacept | <5 | <5 | 0 | 0 | 72 | 75 | 0 | 11 | 42 | 19 | 3 598 |
| L04AA25 eculizumab | <5 | <5 | 5 | 8 | 10 | 60 | <5 | 6 | <5 | <5 | 30 993 |
| L04AA27 fingolimod | 0 | 0 | 186 | 487 | 896 | 74 | <5 | 562 | 333 | 0 | 129 879 |
| L04AA31 teriflunomide | 0 | 0 | 0 | 0 | 140 | 77 | 0 | 83 | 56 | <5 | 2 925 |
| L04AB Tumor necrosis factor alpha (TNF-) inhibitors | 8 409 | 9 649 | 11 057 | 12 629 | 13 980 | 53 | 184 | 5 185 | 7 409 | 1 202 | 1 097 987 |
| L04AB01 etanercept | 5 162 | 5 078 | 6 122 | 6 948 | 6 521 | 54 | 110 | 2 053 | 3 679 | 679 | 448 004 |
| L04AB02 infliximab | 83 | <5 | 0 | 0 | <5 | 0 | 0 | 0 | <5 | 0 | 5 |
| L04AB04 adalimumab | 3 519 | 3 993 | 4 121 | 4 589 | 4 962 | 50 | 79 | 2 259 | 2 325 | 299 | 457 394 |
| L04AB05 certolizumab pegol | 0 | 135 | 314 | 606 | 1 232 | 72 | <5 | 310 | 742 | 179 | 54 835 |
| L04AB06 golimumab | 0 | 1 038 | 1 208 | 1 219 | 2 145 | 50 | <5 | 915 | 1 140 | 89 | 137 748 |
| L04AC Interleukin inhibitors | 69 | 127 | 180 | 293 | 436 | 42 | 16 | 185 | 206 | 29 | 41 098 |

ATC group L

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---------------------------------------|-----------------------|---------------|---------------|---------------|---------------|--------------------|-------------------------------------|--------------|---------------|--------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| L04AC03 anakinra | 68 | 75 | 85 | 121 | 125 | 48 | 12 | 46 | 54 | 13 | 7 955 |
| L04AC05 ustekinumab | <5 | 50 | 92 | 166 | 304 | 40 | <5 | 136 | 151 | 16 | 27 440 |
| L04AC07 tocilizumab | 0 | 0 | 0 | 0 | <5 | 33 | 0 | <5 | <5 | 0 | 52 |
| L04AC08 canakinumab | 0 | <5 | 6 | 7 | 6 | 17 | <5 | <5 | 0 | 0 | 5 651 |
| L04AD Calcineurin inhibitors | 4 578 | 4 799 | 5 027 | 5 288 | 5 524 | 39 | 166 | 1 458 | 3 114 | 786 | 113 734 |
| L04AD01 ciclosporin | 3 289 | 3 307 | 3 332 | 3 274 | 3 199 | 38 | 71 | 707 | 1 818 | 603 | 58 604 |
| L04AD02 tacrolimus | 1 349 | 1 570 | 1 770 | 2 092 | 2 381 | 39 | 96 | 770 | 1 328 | 187 | 55 130 |
| L04AX Other immunosuppressants | 26 860 | 28 382 | 29 767 | 31 228 | 32 173 | 58 | 635 | 7 756 | 16 835 | 6 947 | 91 174 |
| L04AX01 azathioprine | 6 197 | 6 390 | 6 714 | 7 087 | 7 362 | 52 | 219 | 3 400 | 3 037 | 706 | 6 543 |
| L04AX02 thalidomide | 330 | 348 | 320 | 330 | 295 | 47 | <5 | 5 | 100 | 187 | 9 208 |
| L04AX03 methotrexate | 20 347 | 21 622 | 22 692 | 23 702 | 24 355 | 61 | 416 | 4 385 | 13 597 | 5 957 | 10 973 |
| L04AX04 lenalidomide | 106 | 157 | 171 | 236 | 257 | 46 | 0 | <5 | 140 | 116 | 54 740 |
| L04AX05 pirfenidone | 0 | 0 | 0 | 21 | 50 | 30 | 0 | 0 | 37 | 13 | 9 709 |

2.13 ATC group M – Musculo-skeletal system

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|--|-----------------------|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|----------------|----------------|----------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| M MUSCULO-SKELETAL SYSTEM | 891 127 | 901 910 | 927 355 | 937 937 | 925 319 | 57 | 14 318 | 327 053 | 427 476 | 156 472 | 331 706 |
| M01 ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS | 815 420 | 824 208 | 833 848 | 838 542 | 821 122 | 57 | 12 426 | 317 311 | 389 001 | 102 384 | 207 077 |
| M01A ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS | 815 299 | 824 121 | 833 776 | 838 491 | 821 087 | 57 | 12 426 | 317 303 | 388 989 | 102 369 | 206 330 |
| M01AB Acetic acid derivatives and related substances | 491 574 | 505 424 | 508 808 | 485 786 | 439 563 | 55 | 6 513 | 184 377 | 205 498 | 43 175 | 52 567 |
| M01AB01 indometacin | 11 675 | 2 710 | 1 116 | 1 153 | 1 129 | 61 | 17 | 410 | 560 | 142 | 925 |
| M01AB02 sulindac | 386 | 16 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| M01AB05 diclofenac ¹⁾ | 464 462 | 481 108 | 483 169 | 461 621 | 417 775 | 54 | 6 473 | 179 796 | 193 678 | 37 828 | 41 400 |
| M01AB15 ketorolac | 11 | 27 | 23 | 9 | 12 | 67 | 0 | 6 | 5 | <5 | 3 |
| M01AB55 diclofenac, combinations | 23 266 | 29 244 | 31 576 | 29 001 | 25 182 | 63 | 31 | 5 475 | 13 812 | 5 864 | 10 238 |
| M01AC Oxicams | 81 319 | 76 309 | 69 293 | 59 451 | 52 902 | 54 | 228 | 17 095 | 28 296 | 7 283 | 13 486 |
| M01AC01 piroxicam | 55 461 | 51 627 | 47 991 | 43 612 | 39 641 | 52 | 202 | 14 318 | 21 151 | 3 970 | 9 900 |
| M01AC06 meloxicam | 26 731 | 25 438 | 21 952 | 16 207 | 13 527 | 61 | 27 | 2 862 | 7 288 | 3 350 | 3 586 |
| M01AE Propionic acid derivatives | 273 810 | 276 001 | 294 401 | 332 774 | 343 199 | 61 | 5 879 | 131 480 | 162 628 | 43 212 | 84 727 |
| M01AE01 ibuprofen ¹⁾ | 211 641 | 215 745 | 226 838 | 225 258 | 217 264 | 61 | 4 957 | 91 560 | 98 875 | 21 872 | 30 058 |
| M01AE02 naproxen ¹⁾ | 59 487 | 58 354 | 62 549 | 65 207 | 72 012 | 57 | 901 | 26 134 | 33 945 | 11 032 | 21 188 |
| M01AE03 ketoprofen | 7 912 | 7 478 | 7 396 | 6 735 | 5 438 | 60 | 15 | 1 109 | 3 139 | 1 175 | 2 623 |
| M01AE14 dexibuprofen | 1 417 | 1 025 | 881 | 707 | 637 | 62 | <5 | 270 | 279 | 86 | 153 |
| M01AE17 dexketoprofen | 0 | 0 | 0 | 0 | <5 | 67 | 0 | <5 | <5 | 0 | 0 |
| M01AE52 naproxen and esomeprazole | 0 | 0 | 5 217 | 50 859 | 64 416 | 63 | 57 | 18 326 | 34 985 | 11 048 | 30 705 |
| M01AG Fenamates | 669 | 106 | 304 | 309 | 337 | 82 | <5 | 196 | 131 | 7 | 293 |
| M01AG02 tolfenamic acid | 669 | 106 | 304 | 309 | 337 | 82 | <5 | 196 | 131 | 7 | 293 |
| M01AH Coxibs | 35 851 | 35 999 | 36 515 | 43 619 | 72 688 | 56 | 95 | 22 510 | 38 463 | 11 620 | 38 045 |
| M01AH01 celecoxib | 8 030 | 7 851 | 7 720 | 9 983 | 16 437 | 62 | 32 | 4 650 | 8 643 | 3 112 | 10 706 |
| M01AH04 parecoxib | <5 | 0 | 0 | <5 | <5 | 100 | 0 | 0 | <5 | 0 | 29 |
| M01AH05 etoricoxib | 28 047 | 28 365 | 29 013 | 34 034 | 57 270 | 55 | 63 | 18 140 | 30 396 | 8 671 | 27 310 |
| M01AX Other antiinflammatory and antirheumatic agents, non-steroids | 51 313 | 48 137 | 41 749 | 37 374 | 34 782 | 66 | 5 | 2 372 | 19 684 | 12 721 | 17 212 |
| M01AX01 nabumetone | 9 107 | 7 343 | 6 378 | 4 799 | 3 773 | 67 | <5 | 709 | 2 143 | 920 | 1 880 |
| M01AX05 glucosamine ¹⁾ | 41 918 | 40 410 | 34 884 | 31 959 | 30 393 | 66 | <5 | 1 598 | 17 213 | 11 579 | 13 933 |
| M01C SPECIFIC ANTIRHEUMATIC AGENTS | 285 | 242 | 208 | 133 | 99 | 73 | 0 | 14 | 53 | 32 | 747 |
| M01CB Gold preparations | 241 | 199 | 171 | 100 | 71 | 82 | 0 | 8 | 40 | 23 | 243 |
| M01CB01 sodium aurothiomalate | 74 | 36 | 30 | 26 | 19 | 63 | 0 | <5 | 6 | 10 | 58 |

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group M

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|--|-----------------------|---------------|---------------|---------------|---------------|--------------------|-------------------------------------|---------------|---------------|---------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| M01CB03 auranofin | 167 | 163 | 141 | 74 | 52 | 88 | 0 | 5 | 34 | 13 | 185 |
| M01CC Penicillamine and similar agents | 12 | 14 | 13 | 12 | 12 | 33 | 0 | <5 | 7 | <5 | 74 |
| M01CC01 penicillamine | 12 | 14 | 13 | 12 | 12 | 33 | 0 | <5 | 7 | <5 | 74 |
| M01CX Other specific antirheumatic agents | 32 | 30 | 24 | 21 | 16 | 63 | 0 | <5 | 6 | 8 | 430 |
| M02 TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN | 27 101 | 24 394 | 53 477 | 59 206 | 60 159 | 60 | 2 258 | 18 757 | 24 818 | 14 326 | 5 738 |
| M02A TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN | 27 101 | 24 394 | 53 477 | 59 206 | 60 157 | 60 | 2 258 | 18 756 | 24 817 | 14 326 | 5 738 |
| M02AA Antiinflammatory preparations, non-steroids for topical use | 27 032 | 24 200 | 53 269 | 59 087 | 60 050 | 60 | 2 256 | 18 707 | 24 792 | 14 295 | 5 725 |
| M02AA10 ketoprofen ¹⁾ | 23 095 | 20 122 | 47 409 | 51 291 | 51 649 | 60 | 1 871 | 16 056 | 21 638 | 12 084 | 4 175 |
| M02AA13 ibuprofen ¹⁾ | 3 853 | 3 998 | 4 923 | 5 837 | 5 818 | 60 | 294 | 1 806 | 2 142 | 1 576 | 982 |
| M02AA15 diclofenac | 160 | 167 | 1 322 | 2 402 | 2 890 | 58 | 98 | 918 | 1 117 | 757 | 568 |
| M02AB Capsaicin and similar agents | 5 | 6 | 6 | 8 | 5 | 60 | 0 | 0 | <5 | <5 | 1 |
| M02AB01 capsaicin | 5 | 6 | 6 | 8 | 5 | 60 | 0 | 0 | <5 | <5 | 1 |
| M02AC Preparations with salicylic acid derivatives | 69 | 189 | 207 | 124 | 119 | 49 | <5 | 60 | 32 | 25 | 11 |
| M02AX Other topical products for joint and muscular pain | 11 | 13 | 9 | 5 | 8 | 100 | 0 | 0 | 0 | 8 | 2 |
| M02AX10 various | 11 | 13 | 9 | 5 | 8 | 100 | 0 | 0 | 0 | 8 | 2 |
| M03 MUSCLE RELAXANTS | 5 592 | 5 918 | 6 009 | 5 939 | 6 104 | 57 | 100 | 1 642 | 3 525 | 837 | 12 862 |
| M03B MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS | 5 388 | 5 657 | 5 654 | 5 586 | 5 630 | 55 | 99 | 1 373 | 3 333 | 825 | 9 377 |
| M03BA Carbamic acid esters | 1 087 | 1 097 | 1 030 | 911 | 745 | 68 | 0 | 165 | 525 | 55 | 2 000 |
| M03BA02 carisoprodol | 1 087 | 1 097 | 1 030 | 911 | 745 | 68 | 0 | 165 | 525 | 55 | 2 000 |
| M03BA52 carisoprodol, combinations excl. psycholeptics | <5 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| M03BB Oxazol, thiazine, and triazine derivatives | 0 | 0 | <5 | 0 | <5 | 33 | 0 | <5 | <5 | 0 | 7 |
| M03BB03 chlorzoxazone | 0 | 0 | <5 | 0 | <5 | 33 | 0 | <5 | <5 | 0 | 7 |
| M03BC Ethers, chemically close to antihistamines | <5 | <5 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| M03BC51 orphenadrine, combinations | <5 | <5 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| M03BX Other centrally acting agents | 4 318 | 4 583 | 4 652 | 4 696 | 4 901 | 53 | 99 | 1 212 | 2 818 | 772 | 7 370 |
| M03BX01 baclofen | 4 277 | 4 544 | 4 608 | 4 650 | 4 850 | 53 | 99 | 1 201 | 2 783 | 767 | 6 965 |
| M03BX02 tizanidine | 59 | 59 | 71 | 75 | 78 | 37 | 0 | 19 | 54 | 5 | 406 |

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|--|-----------------------|--------|--------|--------|--------|--------------------|-------------------------------------|-------|--------|--------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| M03C MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS | 0 | 0 | <5 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| M03CA Dantrolene and derivatives | 0 | 0 | <5 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| M03CA01 dantrolene | 0 | 0 | <5 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| M04 ANTIGOUT PREPARATIONS | 39 433 | 40 882 | 43 057 | 45 482 | 47 763 | 28 | 20 | 2 942 | 20 661 | 24 140 | 22 086 |
| M04A ANTIGOUT PREPARATIONS | 39 433 | 40 882 | 43 057 | 45 482 | 47 763 | 28 | 20 | 2 942 | 20 661 | 24 140 | 22 086 |
| M04AA Preparations inhibiting uric acid production | 36 397 | 37 670 | 39 470 | 41 688 | 43 558 | 28 | 6 | 2 505 | 18 839 | 22 208 | 17 641 |
| M04AA01 allopurinol | 36 397 | 37 661 | 39 441 | 41 625 | 43 473 | 28 | 6 | 2 492 | 18 798 | 22 177 | 14 747 |
| M04AA03 febuxostat | 0 | 9 | 33 | 75 | 105 | 24 | 0 | 15 | 49 | 41 | 2 894 |
| M04AB Preparations increasing uric acid excretion | 2 123 | 2 062 | 2 072 | 2 041 | 1 970 | 31 | <5 | 117 | 880 | 972 | 2 267 |
| M04AB01 probenecid | 2 123 | 2 062 | 2 072 | 2 041 | 1 970 | 31 | <5 | 117 | 880 | 972 | 2 267 |
| M04AC Preparations with no effect on uric acid metabolism | 2 597 | 3 070 | 3 688 | 4 213 | 5 085 | 23 | 13 | 576 | 2 318 | 2 178 | 2 178 |
| M04AC01 colchicine | 2 597 | 3 070 | 3 688 | 4 213 | 5 085 | 23 | 13 | 576 | 2 318 | 2 178 | 2 178 |
| M05 DRUGS FOR TREATMENT OF BONE DISEASES | 56 744 | 57 597 | 58 371 | 59 962 | 61 037 | 88 | <5 | 686 | 22 624 | 37 725 | 83 135 |
| M05B DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION | 56 744 | 57 597 | 58 371 | 59 962 | 61 037 | 88 | <5 | 686 | 22 624 | 37 725 | 83 135 |
| M05BA Bisphosphonates | 54 669 | 55 785 | 56 550 | 57 193 | 58 056 | 88 | <5 | 635 | 21 747 | 35 672 | 52 164 |
| M05BA01 etidronic acid | 297 | 240 | 205 | 151 | 22 | 82 | 0 | 0 | 6 | 16 | 13 |
| M05BA02 clodronic acid | 44 | 48 | 48 | 41 | 34 | 59 | 0 | 0 | 12 | 22 | 418 |
| M05BA03 pamidronic acid | 13 | 21 | 19 | 16 | 18 | 56 | 0 | 0 | 12 | 6 | 85 |
| M05BA04 alendronic acid | 52 053 | 52 702 | 52 893 | 53 133 | 53 858 | 88 | <5 | 544 | 19 770 | 33 542 | 37 102 |
| M05BA06 ibandronic acid | 704 | 696 | 668 | 653 | 664 | 93 | 0 | <5 | 271 | 391 | 2 034 |
| M05BA07 risedronic acid | 1 214 | 1 097 | 948 | 832 | 639 | 94 | 0 | <5 | 227 | 408 | 1 538 |
| M05BA08 zoledronic acid | 835 | 1 584 | 2 329 | 2 908 | 3 378 | 89 | 0 | 91 | 1 745 | 1 542 | 10 974 |
| M05BB Bisphosphonates, combinations | 2 267 | 1 950 | 1 659 | 1 434 | 668 | 94 | 0 | <5 | 132 | 535 | 533 |
| M05BB01 etidronic acid and calcium, sequential | 2 267 | 1 950 | 1 659 | 1 434 | 668 | 94 | 0 | <5 | 132 | 535 | 533 |
| M05BX Other drugs affecting bone structure and mineralization | 0 | 27 | 398 | 1 851 | 3 212 | 79 | 0 | 55 | 941 | 2 216 | 30 437 |
| M05BX04 denosumab | 0 | 27 | 398 | 1 851 | 3 212 | 79 | 0 | 55 | 941 | 2 216 | 30 437 |
| M09 OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM | <5 | 0 | 0 | 31 | 76 | 24 | 0 | <5 | 55 | 19 | 809 |

ATC group M

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|------|------|------|------|--------------------|-------------------------------------|-------|-------|-----|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | | | | | | | <15 | 15-44 | 45-69 | ≥70 | |
| M09A OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM | <5 | 0 | 0 | 31 | 76 | 24 | 0 | <5 | 55 | 19 | 809 |
| M09AB Enzymes | 0 | 0 | 0 | 31 | 76 | 24 | 0 | <5 | 55 | 19 | 809 |
| M09AB02 collagenase clostridium histolyticum | 0 | 0 | 0 | 31 | 76 | 24 | 0 | <5 | 55 | 19 | 809 |
| M09AX Other drugs for disorders of the musculo-skeletal system | <5 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| M09AX01 hyaluronic acid | <5 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |

2.14 ATC group N – Nervous system

| ATC level | | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|--------------|--|-----------------------|------------------|------------------|------------------|------------------|--------------------|-------------------------------------|----------------|----------------|----------------|-------------------|
| | | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | | | | | | | | <15 | 15–44 | 45–69 | ≥70 | |
| N | NERVOUS SYSTEM | 1 230 918 | 1 248 505 | 1 279 676 | 1 304 344 | 1 327 510 | 59 | 30 708 | 421 950 | 580 132 | 294 720 | 2 600 528 |
| N02 | ANALGESICS | 693 686 | 710 536 | 739 147 | 766 791 | 790 759 | 61 | 9 388 | 253 955 | 353 797 | 173 619 | 657 256 |
| N02A | OPIOIDS | 487 517 | 491 941 | 500 644 | 514 434 | 528 298 | 56 | 4 736 | 174 143 | 236 612 | 112 807 | 384 344 |
| N02AA | Natural opium alkaloids | 405 617 | 401 941 | 403 516 | 404 550 | 404 507 | 56 | 4 513 | 139 206 | 180 704 | 80 084 | 236 283 |
| N02AA01 | morphine | 7 048 | 7 000 | 6 790 | 6 820 | 6 852 | 49 | 13 | 931 | 3 262 | 2 646 | 13 709 |
| N02AA03 | hydromorphone | 41 | 40 | 48 | 68 | 95 | 48 | <5 | 17 | 60 | 17 | 4 094 |
| N02AA05 | oxycodone | 16 910 | 19 067 | 20 444 | 22 975 | 26 884 | 54 | 19 | 4 560 | 12 252 | 10 053 | 62 873 |
| N02AA08 | dihydrocodeine | 49 | 47 | 52 | 47 | 53 | 81 | 0 | 12 | 37 | <5 | 323 |
| N02AA55 | oxycodone, combinations | 228 | 1 001 | 1 831 | 2 874 | 4 069 | 56 | 0 | 405 | 1 701 | 1 963 | 11 978 |
| N02AA59 | codeine, combinations excl. psycholeptics | 392 734 | 387 507 | 387 930 | 387 038 | 383 925 | 56 | 4 494 | 136 369 | 171 522 | 71 540 | 143 306 |
| N02AB | Phenylpiperidine derivatives | 10 453 | 11 167 | 11 306 | 11 506 | 12 148 | 59 | 7 | 2 085 | 5 181 | 4 875 | 44 304 |
| N02AB01 | ketobemidone | 3 731 | 3 994 | 3 972 | 3 993 | 4 143 | 55 | <5 | 1 204 | 2 076 | 861 | 5 505 |
| N02AB02 | pethidine | 1 340 | 1 343 | 1 243 | 1 201 | 1 281 | 60 | 0 | 380 | 715 | 186 | 1 868 |
| N02AB03 | fentanyl | 5 857 | 6 331 | 6 583 | 6 785 | 7 173 | 62 | 5 | 583 | 2 649 | 3 936 | 36 930 |
| N02AC | Diphenylpropylamine derivatives | 7 442 | 4 700 | 30 | 15 | 12 | 75 | 0 | <5 | 6 | <5 | 68 |
| N02AC04 | dextropropoxyphene | 0 | 0 | 9 | 15 | 12 | 75 | 0 | <5 | 6 | <5 | 68 |
| N02AC54 | dextropropoxyphene, combinations excl. psycholeptics | 7 442 | 4 700 | 22 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| N02AD | Benzomorphan derivatives | 45 | 41 | 35 | 30 | 24 | 42 | 0 | <5 | 14 | 8 | 367 |
| N02AD01 | pentazocine | 45 | 41 | 35 | 30 | 24 | 42 | 0 | <5 | 14 | 8 | 367 |
| N02AE | Oripavine derivatives | 12 080 | 13 189 | 14 009 | 15 272 | 15 863 | 71 | 6 | 1 270 | 4 215 | 10 372 | 47 087 |
| N02AE01 | buprenorphine | 12 080 | 13 189 | 14 009 | 15 272 | 15 863 | 71 | 6 | 1 270 | 4 215 | 10 372 | 47 087 |
| N02AG | Opioids in combination with antispasmodics | 1 729 | 1 840 | 1 776 | 1 959 | 1 895 | 57 | <5 | 484 | 936 | 474 | 1 653 |
| N02AG01 | morphine and antispasmodics | 218 | 263 | 310 | 384 | 314 | 50 | 0 | 10 | 79 | 225 | 58 |
| N02AG02 | ketobemidone and antispasmodics | 1 515 | 1 584 | 1 470 | 1 577 | 1 586 | 58 | <5 | 474 | 858 | 253 | 1 595 |
| N02AX | Other opioids | 114 947 | 127 986 | 138 495 | 155 617 | 172 547 | 58 | 268 | 50 812 | 80 230 | 41 237 | 54 583 |
| N02AX02 | tramadol | 114 947 | 127 986 | 138 478 | 155 326 | 172 161 | 58 | 267 | 50 718 | 80 035 | 41 141 | 52 057 |
| N02AX06 | tapentadol | 0 | 0 | 31 | 495 | 615 | 57 | <5 | 161 | 315 | 138 | 2 526 |
| N02B | OTHER ANALGESICS AND ANTIPYRETICS | 281 468 | 305 897 | 337 952 | 363 609 | 386 155 | 64 | 3 328 | 90 709 | 174 676 | 117 442 | 79 050 |
| N02BA | Salicylic acid and derivatives | 806 | 840 | 883 | 797 | 938 | 60 | 242 | 301 | 249 | 146 | 323 |
| N02BA01 | acetylsalicylic acid | 802 | 836 | 879 | 791 | 931 | 60 | 242 | 298 | 245 | 146 | 294 |
| N02BA11 | diflunisal | <5 | <5 | <5 | <5 | <5 | 100 | 0 | 0 | <5 | 0 | 12 |

ATC group N

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|---------------|----------------|----------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| N02BA51 acetylsalicylic acid, combinations excl. psycholeptics | <5 | <5 | <5 | <5 | <5 | 100 | 0 | <5 | <5 | 0 | 16 |
| N02BB Pyrazolones | 885 | 887 | 891 | 970 | 1 051 | 68 | 5 | 501 | 361 | 184 | 283 |
| N02BB02 metamizole sodium | 22 | 12 | 5 | 13 | 18 | 44 | <5 | <5 | 8 | 7 | 9 |
| N02BB51 phenazone, combinations excl. psycholeptics | 863 | 875 | 886 | 957 | 1 033 | 69 | <5 | 499 | 353 | 177 | 274 |
| N02BE Anilides | 280 253 | 304 673 | 336 641 | 362 291 | 384 456 | 64 | 3 085 | 90 049 | 174 082 | 117 240 | 71 669 |
| N02BE01 paracetamol ¹⁾ | 280 253 | 304 673 | 336 641 | 362 291 | 384 388 | 64 | 3 084 | 90 012 | 174 064 | 117 228 | 71 647 |
| N02BE51 paracetamol, combinations excl. psycholeptics ¹⁾ | 0 | 0 | 0 | 0 | 134 | 63 | <5 | 52 | 48 | 33 | 21 |
| N02BG Other analgesics and antipyretics | <5 | 0 | <5 | 68 | 404 | 48 | 0 | 94 | 284 | 26 | 6 775 |
| N02BG07 flupirtine | <5 | 0 | 0 | <5 | <5 | 50 | 0 | <5 | <5 | 0 | 2 |
| N02BG08 ziconotide | 0 | 0 | <5 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| N02BG10 cannabinoids | 0 | 0 | <5 | 67 | 402 | 48 | 0 | 93 | 283 | 26 | 6 774 |
| N02C ANTIMIGRAINE PREPARATIONS | 87 608 | 88 921 | 91 693 | 94 417 | 97 251 | 80 | 1 991 | 46 229 | 45 158 | 3 873 | 193 862 |
| N02CA Ergot alkaloids | 3 477 | 3 072 | 2 918 | 2 496 | 877 | 83 | <5 | 95 | 536 | 245 | 519 |
| N02CA04 methysergide | 6 | 6 | 9 | 7 | <5 | 25 | 0 | <5 | <5 | <5 | 6 |
| N02CA52 ergotamine, combinations excl. psycholeptics | 13 | 15 | 15 | 12 | 21 | 76 | 0 | <5 | 10 | 8 | 24 |
| N02CA72 ergotamine, combinations with psycholeptics | 3 458 | 3 053 | 2 895 | 2 477 | 856 | 83 | <5 | 92 | 527 | 236 | 488 |
| N02CC Selective serotonin (5HT₁) agonists | 81 971 | 83 476 | 85 970 | 89 144 | 93 214 | 80 | 1 911 | 45 329 | 42 539 | 3 435 | 190 971 |
| N02CC01 sumatriptan | 40 472 | 41 843 | 43 349 | 45 284 | 47 946 | 78 | 1 681 | 25 466 | 19 104 | 1 695 | 85 021 |
| N02CC02 naratriptan | 1 497 | 1 501 | 1 581 | 1 651 | 1 707 | 87 | 8 | 738 | 882 | 79 | 5 052 |
| N02CC03 zolmitriptan | 14 223 | 14 230 | 14 481 | 14 789 | 15 150 | 82 | 129 | 6 757 | 7 651 | 613 | 27 801 |
| N02CC04 rizatriptan | 22 306 | 22 398 | 23 373 | 24 259 | 25 269 | 82 | 219 | 12 792 | 11 405 | 853 | 31 718 |
| N02CC05 almotriptan | 3 286 | 3 053 | 2 936 | 2 939 | 2 988 | 83 | 9 | 1 488 | 1 403 | 88 | 6 050 |
| N02CC06 eletriptan | 11 192 | 11 289 | 11 403 | 11 471 | 11 735 | 83 | 38 | 5 180 | 6 198 | 319 | 35 308 |
| N02CC07 frovatriptan | 19 | 6 | 5 | 7 | 8 | 88 | 0 | 5 | <5 | 0 | 21 |
| N02CX Other antimigraine preparations | 3 163 | 3 418 | 3 920 | 3 949 | 4 271 | 79 | 89 | 1 109 | 2 779 | 294 | 2 372 |
| N02CX01 pizotifen | 53 | 61 | 60 | 78 | 72 | 85 | <5 | 29 | 35 | 7 | 234 |
| N02CX02 clonidine | 3 111 | 3 357 | 3 861 | 3 874 | 4 199 | 79 | 88 | 1 080 | 2 744 | 287 | 2 138 |
| N03 ANTIEPILEPTICS | 100 382 | 103 954 | 108 555 | 113 451 | 116 903 | 56 | 3 557 | 36 383 | 54 679 | 22 284 | 375 234 |
| N03A ANTIEPILEPTICS | 100 382 | 103 954 | 108 555 | 113 451 | 116 903 | 56 | 3 557 | 36 383 | 54 679 | 22 284 | 375 234 |
| N03AA Barbiturates and derivatives | 2 844 | 2 700 | 2 544 | 2 430 | 2 361 | 52 | 29 | 242 | 1 262 | 828 | 1 856 |

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group N

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|---------------|---------------|---------------|---------------|--------------------|-------------------------------------|---------------|---------------|---------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| N03AA02 phenobarbital | 2 574 | 2 426 | 2 270 | 2 149 | 2 064 | 52 | 28 | 206 | 1 124 | 706 | 1 325 |
| N03AA03 primidone | 284 | 288 | 287 | 293 | 309 | 48 | <5 | 36 | 142 | 130 | 531 |
| N03AB Hydantoin derivatives | 2 218 | 2 051 | 1 938 | 1 798 | 1 704 | 43 | 18 | 187 | 952 | 547 | 800 |
| N03AB02 phenytoin | 2 217 | 2 051 | 1 937 | 1 798 | 1 704 | 43 | 18 | 187 | 952 | 547 | 800 |
| N03AB05 fosphenytoin | <5 | 0 | <5 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| N03AD Succinimide derivatives | 139 | 149 | 173 | 183 | 206 | 64 | 99 | 83 | 21 | <5 | 1 852 |
| N03AD01 ethosuximide | 139 | 149 | 173 | 183 | 206 | 64 | 99 | 83 | 21 | <5 | 1 852 |
| N03AE Benzodiazepine derivatives | 13 713 | 13 528 | 13 006 | 12 558 | 11 748 | 54 | 136 | 3 104 | 6 134 | 2 374 | 5 720 |
| N03AE01 clonazepam | 13 713 | 13 528 | 13 006 | 12 558 | 11 748 | 54 | 136 | 3 104 | 6 134 | 2 374 | 5 720 |
| N03AF Carboxamide derivatives | 20 004 | 19 238 | 18 449 | 17 652 | 16 961 | 47 | 761 | 4 549 | 8 474 | 3 177 | 31 839 |
| N03AF01 carbamazepine | 17 750 | 16 830 | 15 931 | 15 023 | 14 205 | 47 | 290 | 3 513 | 7 539 | 2 863 | 13 337 |
| N03AF02 oxcarbazepine | 2 236 | 2 298 | 2 375 | 2 426 | 2 526 | 45 | 468 | 894 | 857 | 307 | 9 962 |
| N03AF03 rufinamide | 96 | 96 | 97 | 99 | 100 | 36 | 24 | 67 | 8 | <5 | 2 118 |
| N03AF04 eslicarbazepine | <5 | 205 | 213 | 233 | 294 | 50 | <5 | 150 | 121 | 21 | 6 421 |
| N03AG Fatty acid derivatives | 13 867 | 14 184 | 14 347 | 14 693 | 15 127 | 45 | 1 643 | 5 986 | 6 165 | 1 333 | 33 653 |
| N03AG01 valproic acid | 13 786 | 14 111 | 14 279 | 14 623 | 15 047 | 45 | 1 621 | 5 958 | 6 138 | 1 330 | 32 749 |
| N03AG03 aminobutyric acid | 0 | 0 | 0 | 7 | 16 | 88 | 0 | 11 | <5 | <5 | 10 |
| N03AG04 vigabatrin | 114 | 100 | 88 | 90 | 94 | 56 | 45 | 24 | 21 | <5 | 615 |
| N03AG06 tiagabine | 12 | 11 | 13 | 10 | 10 | 50 | 0 | <5 | 7 | 0 | 280 |
| N03AX Other antiepileptics | 61 469 | 66 054 | 71 880 | 77 827 | 82 517 | 59 | 1 914 | 27 105 | 37 846 | 15 652 | 299 514 |
| N03AX03 sultiame | 64 | 98 | 130 | 161 | 206 | 45 | 172 | 32 | <5 | 0 | 1 274 |
| N03AX09 lamotrigine | 22 368 | 23 711 | 24 878 | 26 197 | 27 013 | 60 | 1 000 | 13 283 | 10 379 | 2 351 | 80 475 |
| N03AX10 felbamate | 25 | 23 | 21 | 21 | 20 | 30 | 0 | 17 | <5 | 0 | 441 |
| N03AX11 topiramate | 3 039 | 3 060 | 3 047 | 3 127 | 3 230 | 71 | 232 | 1 772 | 1 120 | 106 | 10 188 |
| N03AX12 gabapentin | 20 412 | 24 447 | 26 611 | 28 936 | 30 998 | 60 | 58 | 6 664 | 16 168 | 8 108 | 47 147 |
| N03AX14 levetiracetam | 4 977 | 5 539 | 6 101 | 6 784 | 7 307 | 48 | 614 | 2 735 | 2 666 | 1 292 | 43 313 |
| N03AX15 zonisamide | 444 | 457 | 473 | 520 | 611 | 54 | 86 | 324 | 171 | 30 | 7 922 |
| N03AX16 pregabalin | 17 120 | 15 264 | 16 892 | 18 332 | 19 654 | 59 | 12 | 4 670 | 10 230 | 4 742 | 99 469 |
| N03AX17 stiripentol | 19 | 33 | 30 | 24 | 21 | 33 | 14 | 7 | 0 | 0 | 1 291 |
| N03AX18 lacosamide | 122 | 262 | 341 | 411 | 445 | 52 | 13 | 247 | 161 | 24 | 5 529 |
| N03AX21 retigabine | 0 | 0 | 18 | 138 | 103 | 59 | <5 | 70 | 29 | <5 | 846 |
| N03AX22 perampanel | 0 | 0 | 0 | 0 | 149 | 48 | <5 | 97 | 47 | <5 | 1 620 |
| N04 ANTI-PARKINSON DRUGS | 17 238 | 17 787 | 18 178 | 18 653 | 19 088 | 51 | 19 | 1 581 | 8 209 | 9 279 | 129 739 |
| N04A ANTICHOLINERGIC AGENTS | 3 034 | 2 915 | 2 808 | 2 667 | 2 481 | 50 | 6 | 519 | 1 548 | 408 | 1 521 |
| N04AA Tertiary amines | 2 991 | 2 880 | 2 773 | 2 635 | 2 448 | 50 | 6 | 517 | 1 526 | 399 | 1 443 |
| N04AA01 trihexyphenidyl | 15 | 22 | 23 | 20 | 27 | 56 | 5 | 9 | 11 | <5 | 196 |
| N04AA02 biperiden | 2 971 | 2 854 | 2 747 | 2 611 | 2 418 | 50 | <5 | 508 | 1 514 | 395 | 1 239 |

ATC group N

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|--|-----------------------|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|----------------|----------------|----------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| N04AA04 procyclidine | 5 | <5 | <5 | <5 | <5 | 33 | 0 | 0 | <5 | <5 | 8 |
| N04AB Ethers chemically close to antihistamines | 48 | 40 | 38 | 37 | 34 | 65 | 0 | <5 | 23 | 9 | 77 |
| N04AB02 orphenadrine (chloride) | 48 | 40 | 38 | 37 | 34 | 65 | 0 | <5 | 23 | 9 | 77 |
| N04B DOPAMINERGIC AGENTS | 14 267 | 14 940 | 15 436 | 16 047 | 16 673 | 51 | 13 | 1 071 | 6 698 | 8 891 | 128 218 |
| N04BA Dopa and dopa derivatives | 7 716 | 7 906 | 8 015 | 8 279 | 8 579 | 43 | 12 | 149 | 2 575 | 5 843 | 70 223 |
| N04BA02 levodopa and decarboxylase inhibitor | 7 051 | 7 180 | 7 277 | 7 562 | 7 860 | 44 | 12 | 143 | 2 279 | 5 426 | 52 617 |
| N04BA03 levodopa, decarboxylase inhibitor and COMT inhibitor | 1 358 | 1 448 | 1 395 | 1 415 | 1 399 | 37 | 0 | 15 | 596 | 788 | 17 606 |
| N04BB Adamantane derivatives | 114 | 114 | 123 | 142 | 161 | 58 | <5 | 53 | 85 | 22 | 500 |
| N04BB01 amantadine | 114 | 114 | 123 | 142 | 161 | 58 | <5 | 53 | 85 | 22 | 500 |
| N04BC Dopamine agonists | 8 784 | 9 442 | 9 976 | 10 381 | 10 874 | 54 | 0 | 904 | 5 438 | 4 532 | 38 000 |
| N04BC01 bromocriptine | <5 | <5 | <5 | <5 | <5 | 0 | 0 | 0 | <5 | 0 | 12 |
| N04BC04 ropinirole | 2 316 | 2 665 | 2 667 | 2 676 | 2 729 | 45 | 0 | 157 | 1 481 | 1 091 | 14 194 |
| N04BC05 pramipexole | 6 258 | 6 501 | 6 946 | 7 350 | 7 750 | 57 | 0 | 747 | 3 793 | 3 210 | 15 971 |
| N04BC06 cabergoline | 322 | 209 | 177 | 142 | 121 | 50 | 0 | 8 | 36 | 77 | 410 |
| N04BC07 apomorphine | 19 | 18 | 21 | 19 | 18 | 56 | 0 | 0 | 10 | 8 | 1 036 |
| N04BC09 rotigotine | 427 | 517 | 541 | 528 | 573 | 45 | 0 | 23 | 279 | 271 | 6 379 |
| N04BD Monoamine oxidase B inhibitors | 2 862 | 3 184 | 3 339 | 3 519 | 3 652 | 37 | 0 | 48 | 1 789 | 1 815 | 18 432 |
| N04BD01 selegiline | 2 116 | 2 126 | 2 087 | 2 138 | 2 183 | 37 | 0 | 29 | 1 080 | 1 074 | 3 028 |
| N04BD02 rasagiline | 864 | 1 183 | 1 329 | 1 460 | 1 530 | 37 | 0 | 21 | 748 | 761 | 15 404 |
| N04BX Other dopaminergic agents | 230 | 192 | 152 | 160 | 119 | 50 | 0 | 0 | 52 | 67 | 1 062 |
| N04BX01 tolcapone | 13 | 11 | 11 | 9 | 8 | 38 | 0 | 0 | 5 | <5 | 60 |
| N04BX02 entacapone | 218 | 181 | 141 | 151 | 111 | 50 | 0 | 0 | 47 | 64 | 1 001 |
| N05 PSYCHOLEPTICS | 616 964 | 614 376 | 618 313 | 616 277 | 619 567 | 63 | 9 295 | 141 729 | 281 090 | 187 453 | 584 464 |
| N05A ANTIPSYCHOTICS | 104 082 | 104 077 | 104 361 | 106 114 | 106 651 | 55 | 902 | 37 444 | 48 021 | 20 284 | 299 592 |
| N05AA Phenothiazines with aliphatic side-chain | 25 877 | 24 617 | 23 180 | 21 794 | 20 118 | 57 | 21 | 5 236 | 10 692 | 4 169 | 7 788 |
| N05AA01 chlorpromazine | 492 | 439 | 389 | 280 | 222 | 59 | 0 | 92 | 96 | 34 | 789 |
| N05AA02 levomepromazine | 25 435 | 24 212 | 22 826 | 21 541 | 19 912 | 57 | 21 | 5 150 | 10 605 | 4 136 | 6 999 |
| N05AB Phenothiazines with piperazine structure | 19 829 | 18 276 | 17 128 | 15 768 | 13 470 | 68 | 18 | 2 733 | 5 861 | 4 858 | 5 995 |
| N05AB01 dixyrazine | 54 | 32 | <5 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| N05AB02 fluphenazine | 27 | 22 | 20 | 15 | 14 | 50 | 0 | 0 | 6 | 8 | 30 |
| N05AB03 perphenazine | 5 736 | 5 423 | 5 084 | 4 728 | 3 506 | 59 | 0 | 581 | 2 167 | 758 | 4 023 |
| N05AB04 prochlorperazine | 14 075 | 12 860 | 12 078 | 11 063 | 10 061 | 71 | 18 | 2 162 | 3 757 | 4 124 | 1 937 |
| N05AB06 trifluoperazine | <5 | <5 | <5 | <5 | <5 | 0 | 0 | 0 | 0 | <5 | 5 |

ATC group N

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|---------------|----------------|---------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| N05AC Phenothiazines with piperidine structure | 70 | 62 | 61 | 50 | 54 | 57 | 0 | <5 | 31 | 21 | 186 |
| N05AC01 periciazine | <5 | <5 | <5 | <5 | <5 | 100 | 0 | 0 | <5 | 0 | 3 |
| N05AC02 thioridazine | 66 | 58 | 57 | 47 | 49 | 55 | 0 | <5 | 29 | 18 | 144 |
| N05AC04 pipotiazine | <5 | <5 | <5 | <5 | <5 | 75 | 0 | 0 | <5 | <5 | 38 |
| N05AD Butyrophenone derivatives | 4 473 | 4 277 | 4 089 | 4 023 | 3 966 | 54 | <5 | 390 | 1 526 | 2 048 | 1 322 |
| N05AD01 haloperidol | 4 466 | 4 270 | 4 082 | 4 014 | 3 959 | 54 | <5 | 388 | 1 523 | 2 046 | 1 314 |
| N05AD03 melperone | 7 | 6 | 6 | 6 | 7 | 43 | 0 | <5 | <5 | <5 | 7 |
| N05AD08 droperidol | 0 | <5 | <5 | <5 | <5 | 0 | 0 | 0 | <5 | 0 | 0 |
| N05AE Indole derivatives | 1 302 | 1 164 | 1 033 | 957 | 902 | 61 | <5 | 419 | 447 | 34 | 11 472 |
| N05AE03 sertindole | 186 | 161 | 138 | 127 | 125 | 58 | 0 | 75 | 46 | <5 | 1 336 |
| N05AE04 ziprasidone | 1 118 | 1 006 | 897 | 831 | 778 | 61 | <5 | 345 | 401 | 30 | 10 136 |
| N05AF Thioxanthene derivatives | 24 245 | 23 752 | 22 935 | 22 560 | 22 303 | 55 | 30 | 7 546 | 11 231 | 3 496 | 12 153 |
| N05AF01 flupentixol | 5 006 | 4 918 | 4 621 | 4 478 | 4 351 | 66 | <5 | 1 118 | 2 230 | 1 002 | 2 420 |
| N05AF03 chlorprothixene | 17 012 | 16 658 | 16 269 | 16 097 | 15 541 | 53 | 28 | 5 903 | 7 581 | 2 029 | 6 682 |
| N05AF05 zuclopentixol | 2 908 | 2 822 | 2 661 | 2 581 | 3 044 | 51 | <5 | 766 | 1 752 | 525 | 3 051 |
| N05AG Diphenylbutylpiperidine derivatives | 142 | 135 | 139 | 128 | 117 | 36 | <5 | 65 | 38 | 10 | 286 |
| N05AG02 pimozide | 116 | 118 | 117 | 111 | 115 | 37 | <5 | 64 | 37 | 10 | 284 |
| N05AG03 penfluridol | 27 | 17 | 22 | 17 | <5 | 0 | 0 | <5 | <5 | 0 | 2 |
| N05AH Diazepines, oxazepines, thiazepines and oxepines | 28 510 | 31 688 | 35 237 | 39 939 | 44 837 | 52 | 110 | 20 833 | 19 247 | 4 647 | 131 169 |
| N05AH02 clozapine | 2 299 | 2 362 | 2 398 | 2 459 | 2 533 | 37 | 0 | 1 196 | 1 264 | 73 | 9 636 |
| N05AH03 olanzapine | 16 068 | 15 799 | 15 754 | 16 072 | 16 385 | 47 | 29 | 6 503 | 7 660 | 2 193 | 55 961 |
| N05AH04 quetiapine | 11 509 | 15 094 | 18 864 | 23 376 | 28 125 | 56 | 85 | 14 330 | 11 202 | 2 508 | 64 599 |
| N05AH05 asenapine | 0 | 0 | 0 | 117 | 87 | 62 | 0 | 42 | 44 | <5 | 973 |
| N05AL Benzamides | 580 | 548 | 527 | 566 | 569 | 46 | <5 | 281 | 262 | 25 | 3 709 |
| N05AL03 tiapride | 5 | 7 | 7 | 7 | 5 | 60 | <5 | <5 | <5 | 0 | 44 |
| N05AL05 amisulpride | 575 | 541 | 520 | 559 | 564 | 46 | 0 | 278 | 261 | 25 | 3 665 |
| N05AN Lithium | 7 995 | 7 877 | 7 727 | 7 792 | 7 682 | 57 | <5 | 2 242 | 4 295 | 1 143 | 13 520 |
| N05AN01 lithium | 7 995 | 7 877 | 7 727 | 7 792 | 7 682 | 57 | <5 | 2 242 | 4 295 | 1 143 | 13 520 |
| N05AX Other antipsychotics | 11 446 | 12 299 | 12 804 | 13 193 | 13 752 | 49 | 762 | 6 122 | 4 799 | 2 069 | 111 993 |
| N05AX07 prothipendyl | 0 | 0 | <5 | <5 | <5 | 100 | 0 | <5 | <5 | 0 | 1 |
| N05AX08 risperidone | 8 150 | 8 255 | 8 366 | 8 303 | 8 392 | 47 | 651 | 2 956 | 2 915 | 1 870 | 34 957 |
| N05AX12 aripiprazole | 3 625 | 4 379 | 4 744 | 4 916 | 5 143 | 52 | 150 | 3 040 | 1 749 | 204 | 55 928 |
| N05AX13 paliperidone | 0 | 0 | 37 | 512 | 782 | 43 | 0 | 461 | 302 | 19 | 21 106 |
| N05B ANXIOLYTICS | 282 070 | 277 880 | 273 985 | 273 911 | 270 647 | 64 | 3 336 | 62 510 | 127 039 | 77 762 | 103 939 |
| N05BA Benzodiazepine derivatives | 261 074 | 255 446 | 250 055 | 249 597 | 245 061 | 65 | 2 923 | 52 738 | 117 007 | 72 393 | 90 020 |

ATC group N

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|--|-----------------------|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|---------------|----------------|----------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| N05BA01 diazepam | 138 282 | 132 588 | 128 283 | 125 831 | 120 562 | 63 | 2 716 | 25 624 | 57 908 | 34 314 | 43 108 |
| N05BA02 chlordiazepoxide | <5 | <5 | <5 | <5 | <5 | 0 | 0 | 0 | <5 | 0 | 3 |
| N05BA04 oxazepam | 134 703 | 133 963 | 131 939 | 134 353 | 134 612 | 67 | 70 | 29 659 | 63 754 | 41 129 | 39 881 |
| N05BA06 lorazepam | 20 | 21 | 30 | 31 | 48 | 58 | <5 | 16 | 17 | 12 | 71 |
| N05BA08 bromazepam | 7 | 5 | 6 | 7 | 8 | 75 | 0 | 0 | <5 | <5 | 28 |
| N05BA09 clobazam | 558 | 615 | 645 | 706 | 710 | 52 | 236 | 340 | 126 | 8 | 1 996 |
| N05BA12 alprazolam | 4 521 | 4 340 | 4 024 | 4 133 | 3 851 | 47 | 0 | 1 556 | 1 885 | 410 | 4 934 |
| N05BB Diphenylmethane derivatives | 28 280 | 30 163 | 31 960 | 32 347 | 33 868 | 62 | 417 | 12 239 | 13 920 | 7 292 | 9 533 |
| N05BB01 hydroxyzine | 28 280 | 30 163 | 31 960 | 32 347 | 33 868 | 62 | 417 | 12 239 | 13 920 | 7 292 | 9 533 |
| N05BC Carbamates | 10 | 6 | 7 | 6 | <5 | 75 | 0 | 0 | 0 | <5 | 4 |
| N05BC01 meprobamate | 10 | 6 | 7 | 6 | <5 | 75 | 0 | 0 | 0 | <5 | 4 |
| N05BE Azaspirodecanedione derivatives | 2 394 | 2 345 | 2 371 | 2 580 | 2 403 | 59 | <5 | 880 | 1 184 | 335 | 4 381 |
| N05BE01 buspirone | 2 394 | 2 345 | 2 371 | 2 580 | 2 403 | 59 | <5 | 880 | 1 184 | 335 | 4 381 |
| N05C HYPNOTICS AND SEDATIVES | 405 810 | 406 162 | 411 062 | 407 120 | 410 808 | 65 | 6 023 | 79 044 | 185 450 | 140 291 | 180 934 |
| N05CA Barbiturates, plain | <5 | <5 | <5 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| N05CA04 barbital | <5 | <5 | <5 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| N05CC Aldehydes and derivatives | 0 | 0 | 0 | 0 | 5 | 40 | <5 | <5 | 0 | 0 | 9 |
| N05CC01 chloral hydrate | 0 | 0 | 0 | 0 | 5 | 40 | <5 | <5 | 0 | 0 | 9 |
| N05CD Benzodiazepine derivatives | 44 520 | 41 807 | 39 255 | 34 101 | 28 367 | 58 | 1 192 | 5 465 | 11 539 | 10 171 | 18 439 |
| N05CD01 flurazepam | 20 | 17 | 16 | 16 | 16 | 50 | 0 | 0 | 7 | 9 | 53 |
| N05CD02 nitrazepam | 35 856 | 33 406 | 31 315 | 27 880 | 24 446 | 60 | 316 | 4 332 | 10 394 | 9 404 | 8 317 |
| N05CD03 flunitrazepam | 8 479 | 7 690 | 6 971 | 5 780 | 1 185 | 49 | 0 | 241 | 635 | 309 | 2 631 |
| N05CD04 estazolam | <5 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| N05CD05 triazolam | 105 | 115 | 98 | 107 | 91 | 56 | 0 | 27 | 36 | 28 | 90 |
| N05CD08 midazolam | 1 071 | 1 493 | 1 759 | 2 255 | 3 117 | 47 | 995 | 1 016 | 625 | 481 | 7 348 |
| N05CF Benzodiazepine related drugs | 351 044 | 349 542 | 352 287 | 355 331 | 355 049 | 66 | 63 | 58 651 | 166 861 | 129 474 | 124 617 |
| N05CF01 zopiclone | 308 363 | 305 048 | 306 107 | 306 438 | 303 992 | 66 | 49 | 46 150 | 141 911 | 115 882 | 105 568 |
| N05CF02 zolpidem | 53 835 | 55 244 | 56 956 | 61 114 | 62 261 | 66 | 14 | 15 397 | 29 902 | 16 948 | 19 049 |
| N05CF03 zaleplon | 7 | <5 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| N05CH Melatonin receptor agonists | 38 868 | 42 795 | 48 436 | 53 571 | 56 177 | 60 | 5 015 | 22 745 | 20 937 | 7 480 | 35 515 |
| N05CH01 melatonin | 38 868 | 42 795 | 48 436 | 53 571 | 56 177 | 60 | 5 015 | 22 745 | 20 937 | 7 480 | 35 515 |
| N05CM Other hypnotics and sedatives | 1 944 | 2 109 | 2 131 | 2 141 | 2 087 | 47 | 0 | 161 | 550 | 1 376 | 2 354 |
| N05CM02 clomethiazole | 1 870 | 2 048 | 2 057 | 2 007 | 1 986 | 47 | 0 | 140 | 509 | 1 337 | 2 198 |
| N05CM05 scopolamine | 77 | 65 | 75 | 89 | 65 | 54 | 0 | <5 | 23 | 40 | 105 |

ATC group N

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|--|-----------------------|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|----------------|----------------|---------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| N05CM06 propiomazine | 0 | 0 | 0 | 15 | 38 | 53 | 0 | 18 | 19 | <5 | 51 |
| N05CM09 Valerianae radix | 0 | 0 | 0 | 33 | <5 | 0 | 0 | <5 | 0 | 0 | 0 |
| N05CM11 bromides | 0 | 0 | <5 | <5 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| N06 PSYCHOANALEPTICS | 325 942 | 333 134 | 341 017 | 349 413 | 353 980 | 63 | 11 105 | 119 649 | 147 825 | 75 401 | 558 153 |
| N06A ANTIDEPRESSANTS | 292 396 | 297 124 | 303 747 | 310 242 | 313 336 | 66 | 644 | 102 509 | 144 598 | 65 585 | 288 610 |
| N06AA Non-selective monoamine reuptake inhibitors | 60 237 | 61 908 | 63 098 | 64 758 | 65 888 | 72 | 87 | 16 665 | 35 298 | 13 838 | 27 129 |
| N06AA02 imipramine | 34 | 26 | 22 | 19 | 21 | 62 | <5 | <5 | 8 | 9 | 58 |
| N06AA04 clomipramine | 3 276 | 3 080 | 2 907 | 2 714 | 2 602 | 70 | 12 | 414 | 1 504 | 672 | 2 080 |
| N06AA05 opipramol | 5 | 6 | 6 | 9 | 5 | 40 | 0 | 0 | <5 | <5 | 11 |
| N06AA06 trimipramine | 11 930 | 11 431 | 10 943 | 10 553 | 9 890 | 70 | <5 | 1 923 | 5 056 | 2 907 | 6 306 |
| N06AA07 lofepramine | 15 | 13 | 12 | 11 | 9 | 56 | 0 | <5 | 5 | <5 | 51 |
| N06AA09 amitriptyline | 40 585 | 43 086 | 45 318 | 47 831 | 49 857 | 73 | 67 | 13 811 | 27 248 | 8 731 | 16 347 |
| N06AA10 nortriptyline | 1 837 | 2 104 | 1 983 | 1 980 | 1 996 | 68 | <5 | 589 | 938 | 468 | 690 |
| N06AA12 doxepin | 3 348 | 3 017 | 2 749 | 2 496 | 2 280 | 69 | 0 | 161 | 935 | 1 184 | 1 585 |
| N06AA21 maprotiline | <5 | <5 | <5 | <5 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| N06AB Selective serotonin reuptake inhibitors | 178 930 | 180 612 | 184 013 | 186 449 | 185 672 | 66 | 534 | 66 420 | 81 396 | 37 322 | 150 351 |
| N06AB03 fluoxetine | 9 010 | 9 289 | 9 634 | 10 578 | 10 750 | 76 | 175 | 6 295 | 3 593 | 687 | 15 485 |
| N06AB04 citalopram | 32 885 | 30 680 | 29 143 | 27 158 | 25 200 | 69 | 6 | 5 753 | 12 505 | 6 936 | 16 582 |
| N06AB05 paroxetine | 17 508 | 16 895 | 16 172 | 15 536 | 14 828 | 69 | <5 | 3 073 | 8 090 | 3 663 | 14 268 |
| N06AB06 sertraline | 26 427 | 26 384 | 27 181 | 28 814 | 29 740 | 66 | 348 | 12 044 | 12 171 | 5 177 | 29 506 |
| N06AB08 fluvoxamine | 620 | 603 | 586 | 552 | 559 | 55 | 0 | 222 | 265 | 72 | 1 011 |
| N06AB10 escitalopram | 98 493 | 102 626 | 107 172 | 109 487 | 109 896 | 65 | 26 | 41 455 | 46 709 | 21 706 | 73 500 |
| N06AF Monoamine oxidase inhibitors, non-selective | 111 | 111 | 102 | 95 | 97 | 62 | 0 | 27 | 51 | 19 | 1 099 |
| N06AF03 phenelzine | 102 | 102 | 94 | 88 | 91 | 60 | 0 | 25 | 48 | 18 | 574 |
| N06AF04 tranlycypromine | 9 | 9 | 9 | 7 | 6 | 83 | 0 | <5 | <5 | <5 | 525 |
| N06AG Monoamine oxidase A inhibitors | 965 | 880 | 853 | 758 | 738 | 64 | <5 | 171 | 412 | 154 | 1 649 |
| N06AG02 moclobemide | 965 | 880 | 853 | 758 | 738 | 64 | <5 | 171 | 412 | 154 | 1 649 |
| N06AX Other antidepressants | 90 568 | 92 850 | 95 460 | 98 898 | 101 299 | 60 | 38 | 31 666 | 46 252 | 23 343 | 108 382 |
| N06AX01 oxitriptan | 244 | 261 | 308 | 293 | 276 | 79 | 7 | 160 | 98 | 11 | 325 |
| N06AX02 tryptophan | 5 | <5 | <5 | 6 | 8 | 75 | 0 | <5 | <5 | <5 | 12 |
| N06AX03 mianserin | 31 289 | 30 307 | 29 477 | 28 143 | 27 133 | 61 | 11 | 6 127 | 13 004 | 7 991 | 10 305 |
| N06AX05 trazodone | <5 | <5 | <5 | <5 | 12 | 75 | 0 | <5 | 11 | 0 | 12 |
| N06AX06 nefazodone | 43 | 42 | 36 | 36 | 30 | 47 | 0 | <5 | 27 | <5 | 293 |
| N06AX11 mirtazapine | 30 394 | 31 458 | 33 331 | 35 820 | 36 953 | 57 | 8 | 10 228 | 15 424 | 11 293 | 29 086 |
| N06AX12 bupropion | 5 978 | 7 641 | 8 808 | 10 205 | 11 330 | 59 | <5 | 5 616 | 4 863 | 850 | 21 402 |

ATC group N

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|---------------|---------------|---------------|---------------|--------------------|-------------------------------------|---------------|--------------|---------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| N06AX14 tianeptine | <5 | <5 | <5 | <5 | <5 | 33 | 0 | <5 | 0 | 0 | 69 |
| N06AX16 venlafaxine | 28 734 | 28 791 | 29 240 | 30 295 | 31 108 | 62 | 11 | 11 414 | 15 108 | 4 575 | 34 549 |
| N06AX18 reboxetine | 530 | 512 | 424 | 413 | 383 | 66 | 0 | 168 | 182 | 33 | 792 |
| N06AX21 duloxetine | 2 419 | 2 804 | 3 021 | 3 203 | 3 503 | 67 | 0 | 1 064 | 1 913 | 526 | 11 361 |
| N06AX22 agomelatine | 0 | 28 | 22 | 15 | 18 | 61 | 0 | <5 | 14 | <5 | 175 |
| N06AX25 Hyperici herba | 0 | 0 | 0 | <5 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| N06B PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS | 27 837 | 30 080 | 31 221 | 33 009 | 34 763 | 38 | 10 621 | 20 661 | 3 321 | 160 | 200 254 |
| N06BA Centrally acting sympathomimetics | 27 490 | 29 711 | 30 821 | 32 609 | 34 369 | 38 | 10 616 | 20 453 | 3 186 | 114 | 199 614 |
| N06BA01 amfetamine | 269 | 303 | 336 | 383 | 402 | 44 | 28 | 260 | 99 | 15 | 7 336 |
| N06BA02 dexamfetamine | 1 024 | 1 167 | 1 285 | 1 473 | 1 691 | 45 | 61 | 1 150 | 456 | 24 | 22 248 |
| N06BA04 methylphenidate | 24 240 | 26 471 | 27 302 | 28 993 | 30 397 | 38 | 9 953 | 17 893 | 2 492 | 59 | 136 353 |
| N06BA07 modafinil | 291 | 329 | 349 | 366 | 436 | 60 | 22 | 268 | 127 | 19 | 4 882 |
| N06BA09 atomoxetine | 3 213 | 3 055 | 3 108 | 3 036 | 3 282 | 35 | 1 199 | 1 909 | 172 | <5 | 28 578 |
| N06BA12 lisdexamfetamine | 0 | 0 | 0 | <5 | 26 | 54 | <5 | 18 | <5 | 0 | 217 |
| N06BC Xanthine derivatives | 281 | 285 | 326 | 322 | 309 | 51 | <5 | 171 | 103 | 34 | 168 |
| N06BC01 caffeine | 281 | 285 | 326 | 322 | 309 | 51 | <5 | 171 | 103 | 34 | 168 |
| N06BX Other psychostimulants and nootropics | 75 | 102 | 86 | 88 | 95 | 45 | <5 | 44 | 35 | 12 | 472 |
| N06BX03 piracetam | 65 | 77 | 70 | 77 | 84 | 44 | <5 | 35 | 35 | 12 | 284 |
| N06BX13 idebenone | 10 | 8 | 10 | 11 | 11 | 55 | <5 | 9 | 0 | 0 | 188 |
| N06BX17 adrafinil | 0 | 18 | 6 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| N06C PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION | 0 | 0 | 0 | <5 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| N06CA Antidepressants in combination with psycholeptics | 0 | 0 | 0 | <5 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| N06CA02 melitracen and psycholeptics | 0 | 0 | 0 | <5 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| N06D ANTI-DEMENTIA DRUGS | 13 344 | 14 174 | 14 759 | 15 519 | 15 483 | 62 | <5 | 32 | 1 505 | 13 944 | 69 290 |
| N06DA Anticholinesterases | 12 372 | 12 920 | 12 850 | 13 047 | 12 995 | 62 | 0 | 6 | 1 297 | 11 692 | 50 614 |
| N06DA02 donepezil | 9 243 | 8 920 | 8 530 | 8 320 | 7 960 | 64 | 0 | 5 | 762 | 7 193 | 22 334 |
| N06DA03 rivastigmine | 2 975 | 3 935 | 4 303 | 4 776 | 5 146 | 60 | 0 | <5 | 556 | 4 589 | 25 873 |
| N06DA04 galantamine | 558 | 502 | 395 | 347 | 301 | 56 | 0 | 0 | 37 | 264 | 2 407 |
| N06DX Other anti-dementia drugs | 1 538 | 1 969 | 3 030 | 3 598 | 3 682 | 60 | <5 | 26 | 422 | 3 232 | 18 676 |
| N06DX01 memantine | 1 538 | 1 816 | 2 837 | 3 467 | 3 645 | 60 | 0 | <5 | 411 | 3 231 | 18 664 |
| N06DX02 Ginkgo folium | 0 | 153 | 193 | 131 | 37 | 76 | <5 | 23 | 11 | <5 | 12 |

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|---------------|---------------|---------------|---------------|--------------------|-------------------------------------|---------------|---------------|--------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| N07 OTHER NERVOUS SYSTEM DRUGS | 46 042 | 47 182 | 48 455 | 45 131 | 50 686 | 52 | 55 | 17 204 | 29 951 | 3 476 | 283 947 |
| N07A PARASYMPATHOMIMETICS | 721 | 660 | 684 | 733 | 747 | 65 | <5 | 117 | 359 | 267 | 2 553 |
| N07AA Anticholinesterases | 493 | 509 | 523 | 568 | 591 | 60 | <5 | 104 | 256 | 227 | 1 245 |
| N07AA01 neostigmine | 0 | 0 | 0 | 0 | <5 | 0 | <5 | 0 | 0 | 0 | 15 |
| N07AA02 pyridostigmine | 492 | 505 | 519 | 566 | 588 | 60 | <5 | 103 | 255 | 227 | 1 226 |
| N07AA30 ambenonium | <5 | <5 | <5 | <5 | <5 | 100 | 0 | <5 | <5 | <5 | 5 |
| N07AA51 neostigmine, combinations | 0 | <5 | <5 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| N07AB Choline esters | 112 | 22 | 33 | 30 | 29 | 66 | 0 | <5 | 19 | 8 | 38 |
| N07AB01 carbachol | 112 | 22 | 33 | 30 | 29 | 66 | 0 | <5 | 19 | 8 | 38 |
| N07AX Other parasympathomimetics | 123 | 130 | 131 | 138 | 131 | 91 | 0 | 11 | 88 | 32 | 1 269 |
| N07AX01 pilocarpine | 123 | 130 | 131 | 138 | 131 | 91 | 0 | 11 | 88 | 32 | 1 269 |
| N07B DRUGS USED IN ADDICTIVE DISORDERS | 44 554 | 45 745 | 46 701 | 41 867 | 47 793 | 52 | 38 | 16 748 | 28 141 | 2 866 | 207 996 |
| N07BA Drugs used in nicotine dependence | 34 174 | 34 822 | 35 032 | 29 885 | 23 082 | 55 | <5 | 7 219 | 14 431 | 1 431 | 34 441 |
| N07BA01 nicotine ¹⁾ | 769 | 906 | 1 000 | 916 | 928 | 49 | 0 | 111 | 552 | 265 | 572 |
| N07BA03 varenicline | 33 475 | 34 002 | 34 123 | 29 045 | 22 201 | 55 | <5 | 7 113 | 13 916 | 1 171 | 33 869 |
| N07BB Drugs used in alcohol dependence | 4 984 | 4 866 | 4 953 | 4 948 | 17 479 | 58 | 35 | 5 397 | 10 654 | 1 393 | 13 034 |
| N07BB01 disulfiram | 4 533 | 4 450 | 4 541 | 4 523 | 4 315 | 29 | 0 | 1 384 | 2 678 | 253 | 2 966 |
| N07BB03 acamprosate | 550 | 526 | 543 | 588 | 580 | 32 | 0 | 170 | 378 | 32 | 862 |
| N07BB04 naltrexone | 26 | 19 | 17 | 14 | 11 314 | 73 | 35 | 3 535 | 6 711 | 1 033 | 7 797 |
| N07BB05 nalmefene | 0 | 0 | 0 | 0 | 1 722 | 30 | <5 | 458 | 1 170 | 93 | 1 410 |
| N07BC Drugs used in opioid dependence | 5 704 | 6 368 | 7 048 | 7 353 | 7 736 | 31 | <5 | 4 311 | 3 367 | 56 | 160 521 |
| N07BC01 buprenorphine ²⁾ | 1 981 | 2 133 | 2 270 | 2 465 | 2 650 | 30 | 0 | 1 632 | 1 015 | <5 | 48 680 |
| N07BC02 methadone ²⁾ | 3 140 | 3 337 | 3 636 | 3 631 | 3 718 | 34 | <5 | 1 710 | 1 954 | 52 | 83 032 |
| N07BC51 buprenorphine, combinations ²⁾ | 1 194 | 1 562 | 1 759 | 1 925 | 2 012 | 25 | 0 | 1 419 | 592 | <5 | 28 809 |
| N07C ANTIVERTIGO PREPARATIONS | 421 | 424 | 454 | 531 | 555 | 66 | <5 | 110 | 305 | 138 | 1 325 |
| N07CA Antivertigo preparations | 421 | 424 | 454 | 531 | 555 | 66 | <5 | 110 | 305 | 138 | 1 325 |
| N07CA01 betahistine | 410 | 413 | 438 | 512 | 535 | 66 | <5 | 100 | 296 | 138 | 1 298 |
| N07CA03 flunarizine | 11 | 11 | 16 | 19 | 20 | 70 | <5 | 10 | 9 | 0 | 27 |
| N07X OTHER NERVOUS SYSTEM DRUGS | 361 | 366 | 644 | 2 061 | 2 114 | 60 | 12 | 300 | 1 556 | 246 | 72 072 |
| N07XX Other nervous system drugs | 361 | 366 | 644 | 2 061 | 2 114 | 60 | 12 | 300 | 1 556 | 246 | 72 072 |

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

²⁾The figures only include methadone dispensed according to prescription from the pharmacies. Patients may also receive this drug dispensed according to special arrangements in the health regions.

ATC group N

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---------------------------|-----------------------|------|------|-------|-------|--------------------|-------------------------------------|-------|-------|-----|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | | | | | | | <15 | 15-44 | 45-69 | ≥70 | |
| N07XX02 riluzole | 286 | 278 | 294 | 297 | 285 | 37 | 0 | 17 | 161 | 107 | 4 141 |
| N07XX04 sodium oxybate | 33 | 49 | 58 | 63 | 84 | 57 | 10 | 54 | 17 | <5 | 6 387 |
| N07XX05 amifampridine | 0 | 0 | 0 | <5 | <5 | 33 | 0 | <5 | <5 | 0 | 2 766 |
| N07XX06 tetrabenazine | 42 | 37 | 35 | 41 | 43 | 49 | <5 | 11 | 24 | 7 | 791 |
| N07XX07 fampridine | 0 | <5 | 257 | 1 659 | 1 692 | 64 | <5 | 211 | 1 351 | 129 | 57 313 |
| N07XX09 dimethyl fumarate | 0 | 0 | 0 | 0 | 8 | 63 | 0 | 7 | <5 | 0 | 674 |

2.15 ATC group P – Antiparasitic products, insecticides and repellents

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|---------------|---------------|---------------|---------------|--------------------|-------------------------------------|---------------|---------------|---------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15–44 | 45–69 | ≥70 | | | | | | | |
| P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS | 86 714 | 88 743 | 92 296 | 95 141 | 96 547 | 62 | 3 632 | 43 659 | 38 204 | 11 052 | 36 412 |
| P01 ANTIPROTOZOALS | 83 638 | 85 626 | 88 926 | 91 618 | 92 720 | 63 | 2 396 | 41 873 | 37 582 | 10 869 | 34 292 |
| P01A AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES | 54 583 | 55 588 | 57 290 | 58 106 | 58 337 | 65 | 676 | 24 828 | 24 363 | 8 470 | 6 694 |
| P01AB Nitroimidazole derivatives | 54 576 | 55 587 | 57 289 | 58 103 | 58 335 | 65 | 675 | 24 827 | 24 363 | 8 470 | 6 673 |
| P01AB01 metronidazole | 54 571 | 55 540 | 57 236 | 58 039 | 58 227 | 65 | 670 | 24 770 | 24 317 | 8 470 | 6 218 |
| P01AB02 tinidazole | 7 | 6 | 9 | 124 | 149 | 68 | 6 | 79 | 62 | <5 | 452 |
| P01AB03 ornidazole | 0 | 46 | 73 | 9 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| P01AB06 nimorazole | 0 | 0 | 0 | <5 | <5 | 0 | 0 | 0 | <5 | 0 | 2 |
| P01AC Dichloroacetamide derivatives | 13 | <5 | 11 | 12 | 9 | 56 | <5 | 5 | <5 | 0 | 21 |
| P01AC01 diloxanide | 13 | <5 | 11 | 12 | 9 | 56 | <5 | 5 | <5 | 0 | 21 |
| P01AX Other agents against amoebiasis and other protozoal diseases | <5 | <5 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| P01AX11 nitazoxanide | <5 | <5 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| P01B ANTIMALARIALS | 29 645 | 30 716 | 32 446 | 34 304 | 35 069 | 59 | 1 727 | 17 369 | 13 530 | 2 443 | 27 595 |
| P01BA Aminoquinolines | 5 421 | 5 684 | 5 912 | 6 128 | 6 131 | 82 | 37 | 1 619 | 3 411 | 1 064 | 3 583 |
| P01BA01 chloroquine | 40 | 21 | 17 | 22 | 14 | 79 | 0 | <5 | 8 | <5 | 15 |
| P01BA02 hydroxychloroquine | 5 371 | 5 661 | 5 897 | 6 107 | 6 112 | 82 | 37 | 1 612 | 3 402 | 1 061 | 3 553 |
| P01BA03 primaquine | 12 | <5 | 0 | 0 | 6 | 67 | 0 | <5 | <5 | <5 | 14 |
| P01BB Biguanides | 19 494 | 20 468 | 21 918 | 23 899 | 24 803 | 54 | 1 196 | 13 559 | 9 002 | 1 046 | 22 150 |
| P01BB01 proguanil | 22 | 11 | 7 | <5 | <5 | 100 | 0 | <5 | <5 | 0 | 2 |
| P01BB51 proguanil, combinations | 19 476 | 20 459 | 21 913 | 23 898 | 24 799 | 54 | 1 196 | 13 557 | 9 000 | 1 046 | 22 148 |
| P01BC Methanolquinolines | 5 044 | 4 802 | 4 841 | 4 473 | 4 312 | 58 | 498 | 2 296 | 1 178 | 340 | 1 857 |
| P01BC01 quinine | 629 | 569 | 473 | 439 | 396 | 65 | 0 | 14 | 161 | 221 | 264 |
| P01BC02 mefloquine | 4 415 | 4 235 | 4 368 | 4 035 | 3 917 | 57 | 498 | 2 282 | 1 017 | 120 | 1 594 |
| P01BD Diaminopyrimidines | 5 | <5 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| P01BD01 pyrimethamine | 5 | <5 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| P01BE Artemisinin and derivatives, plain | 0 | 0 | 0 | <5 | <5 | 0 | 0 | <5 | 0 | 0 | 2 |
| P01BE03 artesunate | 0 | 0 | 0 | <5 | <5 | 0 | 0 | <5 | 0 | 0 | 2 |
| P01BF Artemisinin and derivatives, combinations | 0 | <5 | <5 | <5 | <5 | 0 | 0 | <5 | 0 | 0 | 3 |
| P01BF01 artemether and lumefantrine | 0 | <5 | <5 | <5 | <5 | 0 | 0 | <5 | 0 | 0 | 3 |
| P01C AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS | <5 | <5 | 0 | <5 | <5 | 100 | 0 | 0 | <5 | 0 | 3 |

ATC group P

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|--------------|--------------|--------------|--------------|--------------------|-------------------------------------|--------------|--------------|--------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| P01CX Other agents against leishmaniasis and trypanosomiasis | <5 | <5 | 0 | <5 | <5 | 100 | 0 | 0 | <5 | 0 | 3 |
| P01CX01 pentamidine isethionate | <5 | <5 | 0 | <5 | <5 | 100 | 0 | 0 | <5 | 0 | 3 |
| P02 ANTHELMINTICS | 2 047 | 2 107 | 2 224 | 2 315 | 2 388 | 57 | 1 057 | 857 | 378 | 96 | 1 235 |
| P02B ANTITREMATODALS | 19 | 26 | 41 | 50 | 55 | 51 | <5 | 39 | 13 | <5 | 161 |
| P02BA Quinoline derivatives and related substances | 19 | 26 | 41 | 50 | 55 | 51 | <5 | 39 | 13 | <5 | 161 |
| P02BA01 praziquantel | 19 | 26 | 41 | 50 | 55 | 51 | <5 | 39 | 13 | <5 | 161 |
| P02C ANTINEMATODAL AGENTS | 2 016 | 2 068 | 2 171 | 2 262 | 2 330 | 57 | 1 054 | 814 | 367 | 95 | 1 060 |
| P02CA Benzimidazole derivatives | 1 870 | 1 900 | 2 004 | 2 070 | 2 127 | 56 | 1 000 | 704 | 341 | 82 | 952 |
| P02CA01 mebendazole | 1 847 | 1 877 | 1 960 | 2 006 | 1 993 | 55 | 978 | 638 | 299 | 78 | 386 |
| P02CA03 albendazole | 24 | 23 | 45 | 70 | 140 | 68 | 25 | 68 | 43 | <5 | 566 |
| P02CF Avermectines | 47 | 62 | 58 | 80 | 86 | 60 | 7 | 56 | 18 | 5 | 90 |
| P02CF01 ivermectin | 47 | 62 | 58 | 80 | 86 | 60 | 7 | 56 | 18 | 5 | 90 |
| P02CX Other antinematodals | 114 | 120 | 119 | 128 | 139 | 71 | 56 | 63 | 10 | 10 | 19 |
| P02CX01 pyrvinium | 114 | 120 | 119 | 128 | 139 | 71 | 56 | 63 | 10 | 10 | 19 |
| P02D ANTICESTODALS | 18 | 18 | 26 | 13 | 16 | 44 | <5 | 12 | <5 | 0 | 14 |
| P02DA Salicylic acid derivatives | 18 | 18 | 26 | 13 | 16 | 44 | <5 | 12 | <5 | 0 | 14 |
| P02DA01 niclosamide | 18 | 18 | 26 | 13 | 16 | 44 | <5 | 12 | <5 | 0 | 14 |
| P03 ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS | 1 157 | 1 176 | 1 297 | 1 374 | 1 688 | 50 | 205 | 1 062 | 322 | 99 | 885 |
| P03A ECTOPARASITICIDES, INCL. SCABICIDES | 1 157 | 1 176 | 1 297 | 1 374 | 1 688 | 50 | 205 | 1 062 | 322 | 99 | 885 |
| P03AC Pyrethrines, incl. synthetic compounds | 1 085 | 1 093 | 1 222 | 1 298 | 1 618 | 49 | 192 | 1 029 | 300 | 97 | 861 |
| P03AC04 permethrin ¹⁾ | 1 085 | 1 093 | 1 222 | 1 298 | 1 618 | 49 | 192 | 1 029 | 300 | 97 | 861 |
| P03AX Other ectoparasiticides, incl. scabicides | 77 | 86 | 82 | 84 | 80 | 59 | 14 | 41 | 23 | <5 | 24 |
| P03AX01 benzyl benzoate ¹⁾ | 18 | 24 | 28 | 21 | 34 | 59 | 6 | 21 | 6 | <5 | 11 |
| P03AX03 malathion ¹⁾ | 59 | 62 | 54 | 63 | 47 | 60 | 9 | 20 | 17 | <5 | 13 |

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

2.16 ATC group R – Respiratory system

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 | |
|--------------|---|------------------|------------------|------------------|------------------|--------------------|-------------------------------------|----------------|----------------|----------------|-------------------|------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK | |
| | <15 | 15–44 | 45–69 | ≥70 | | | | | | | | |
| R | RESPIRATORY SYSTEM | 1 183 767 | 1 183 735 | 1 223 490 | 1 239 078 | 1 220 116 | 56 | 159 501 | 441 102 | 449 667 | 169 846 | 1 363 495 |
| R01 | NASAL PREPARATIONS | 348 415 | 353 908 | 364 669 | 376 523 | 376 766 | 57 | 30 790 | 174 044 | 139 735 | 32 197 | 105 797 |
| R01A | DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE | 294 861 | 297 143 | 307 141 | 316 067 | 316 889 | 56 | 29 575 | 141 622 | 116 543 | 29 149 | 99 550 |
| R01AA | Sympathomimetics, plain | 3 803 | 4 017 | 3 672 | 3 650 | 3 520 | 52 | 1 127 | 1 181 | 865 | 347 | 266 |
| R01AA05 | oxymetazoline ¹⁾ | 1 550 | 1 802 | 1 781 | 1 847 | 1 824 | 54 | 854 | 539 | 307 | 124 | 121 |
| R01AA07 | xylometazoline ¹⁾ | 2 264 | 2 233 | 1 899 | 1 812 | 1 700 | 51 | 273 | 643 | 561 | 223 | 146 |
| R01AB | Sympathomimetics, combinations excl. corticosteroids | 514 | 602 | 603 | 468 | 387 | 57 | 8 | 142 | 153 | 84 | 68 |
| R01AB06 | xylometazoline ¹⁾ | 514 | 602 | 603 | 468 | 387 | 57 | 8 | 142 | 153 | 84 | 68 |
| R01AC | Antiallergic agents, excl. corticosteroids | 44 853 | 39 407 | 40 956 | 39 433 | 38 277 | 56 | 9 782 | 18 085 | 8 870 | 1 540 | 10 213 |
| R01AC01 | cromoglicic acid ¹⁾ | 10 197 | 8 772 | 8 705 | 7 943 | 7 646 | 59 | 1 674 | 3 489 | 2 121 | 362 | 2 014 |
| R01AC02 | levocabastine ¹⁾ | 34 686 | 30 659 | 32 377 | 31 556 | 30 702 | 55 | 8 165 | 14 614 | 6 751 | 1 172 | 8 164 |
| R01AC03 | azelastine ¹⁾ | 227 | 198 | 127 | 151 | 132 | 58 | 15 | 67 | 39 | 11 | 36 |
| R01AD | Corticosteroids | 252 559 | 259 097 | 267 954 | 278 421 | 279 941 | 56 | 19 624 | 124 856 | 108 195 | 27 266 | 88 406 |
| R01AD01 | beclometasone | 1 943 | 11 | <5 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| R01AD04 | flunisolide | 2 634 | 11 | 9 | 10 | 10 | 60 | 0 | 0 | 6 | <5 | 18 |
| R01AD05 | budesonide | 39 753 | 34 996 | 32 644 | 31 215 | 28 699 | 57 | 1 459 | 10 673 | 13 064 | 3 503 | 10 406 |
| R01AD08 | fluticasone | 27 939 | 24 352 | 22 518 | 21 931 | 21 129 | 55 | 919 | 7 645 | 9 829 | 2 736 | 9 386 |
| R01AD09 | mometasone | 143 465 | 141 114 | 144 414 | 151 022 | 152 995 | 56 | 9 341 | 67 572 | 60 361 | 15 721 | 47 677 |
| R01AD11 | triamcinolone | 11 025 | 9 687 | 8 713 | 7 889 | 6 924 | 57 | 293 | 2 747 | 3 072 | 812 | 2 821 |
| R01AD12 | fluticasone furoate | 38 322 | 60 417 | 70 241 | 77 348 | 79 316 | 56 | 8 001 | 40 135 | 25 800 | 5 380 | 17 569 |
| R01AD58 | fluticasone, combinations | 0 | 0 | 0 | 0 | 1 551 | 54 | 75 | 822 | 517 | 137 | 527 |
| R01AX | Other nasal preparations | 572 | 630 | 728 | 836 | 1 000 | 52 | 64 | 283 | 311 | 342 | 597 |
| R01AX03 | ipratropium bromide | 302 | 355 | 422 | 469 | 534 | 51 | <5 | 55 | 185 | 293 | 440 |
| R01AX06 | mupirocin | 270 | 276 | 306 | 367 | 466 | 53 | 63 | 228 | 126 | 49 | 157 |
| R01B | NASAL DECONGESTANTS FOR SYSTEMIC USE | 75 490 | 81 771 | 83 161 | 88 700 | 89 209 | 67 | 1 640 | 48 028 | 34 998 | 4 543 | 6 246 |
| R01BA | Sympathomimetics | 75 490 | 81 771 | 83 161 | 88 700 | 89 209 | 67 | 1 640 | 48 028 | 34 998 | 4 543 | 6 246 |
| R01BA01 | phenylpropanolamine | 75 490 | 81 771 | 83 161 | 88 700 | 89 207 | 67 | 1 640 | 48 028 | 34 996 | 4 543 | 6 235 |
| R01BA52 | pseudoephedrine, combinations | 0 | 0 | 0 | 0 | <5 | 50 | 0 | 0 | <5 | 0 | 12 |
| R03 | DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES | 419 368 | 423 205 | 418 109 | 420 887 | 418 306 | 54 | 81 746 | 107 422 | 152 534 | 76 604 | 1 013 119 |
| R03A | ADRENERGICS, INHALANTS | 328 514 | 335 492 | 347 921 | 354 853 | 357 307 | 54 | 57 184 | 97 977 | 136 035 | 66 111 | 680 822 |
| R03AA | Alpha- and beta-adrenoreceptor agonists | 181 | 209 | 246 | 251 | 201 | 35 | 188 | 9 | <5 | 0 | 171 |
| R03AA01 | epinephrine | 181 | 209 | 246 | 251 | 201 | 35 | 188 | 9 | <5 | 0 | 171 |

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group R

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|---------------|---------------|---------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| R03AC Selective beta-2-adrenoreceptor agonists | 244 327 | 249 080 | 258 858 | 265 033 | 266 976 | 54 | 54 565 | 75 258 | 93 661 | 43 492 | 137 211 |
| R03AC02 salbutamol | 190 769 | 198 277 | 208 540 | 216 082 | 219 571 | 54 | 53 185 | 62 233 | 72 287 | 31 866 | 71 249 |
| R03AC03 terbutaline | 38 318 | 35 556 | 34 151 | 32 149 | 29 979 | 57 | 1 323 | 11 197 | 12 701 | 4 758 | 10 860 |
| R03AC04 fenoterol | 17 | 17 | 16 | 12 | 14 | 36 | 0 | <5 | 11 | <5 | 29 |
| R03AC12 salmeterol | 10 555 | 10 563 | 9 699 | 9 202 | 8 885 | 56 | 207 | 1 011 | 4 173 | 3 494 | 15 100 |
| R03AC13 formoterol | 16 879 | 16 627 | 15 456 | 14 434 | 13 601 | 56 | 277 | 2 775 | 6 686 | 3 863 | 17 892 |
| R03AC18 indacaterol | 0 | 713 | 4 814 | 7 450 | 9 343 | 46 | 0 | 195 | 4 938 | 4 210 | 22 081 |
| R03AK Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics | 164 535 | 168 449 | 175 117 | 178 269 | 180 135 | 56 | 9 205 | 47 246 | 81 459 | 42 225 | 543 440 |
| R03AK06 salmeterol and fluticasone | 90 149 | 90 997 | 94 190 | 95 885 | 94 551 | 55 | 7 557 | 22 444 | 40 708 | 23 842 | 306 202 |
| R03AK07 formoterol and budesonide | 76 239 | 79 114 | 82 417 | 83 238 | 83 758 | 56 | 1 605 | 23 847 | 39 846 | 18 460 | 226 346 |
| R03AK08 formoterol and beclometasone | 1 522 | 1 783 | 1 942 | 2 795 | 4 443 | 58 | 35 | 1 496 | 2 194 | 718 | 7 459 |
| R03AK11 formoterol and fluticasone | 0 | 0 | 0 | 0 | 2 239 | 58 | 97 | 741 | 1 051 | 350 | 3 433 |
| R03AL Adrenergics in combination with anticholinergics | <5 | <5 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| R03AL02 salbutamol and ipratropium bromide | <5 | <5 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| R03B OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS | 140 443 | 146 450 | 149 797 | 152 867 | 153 128 | 51 | 41 257 | 21 544 | 51 923 | 38 404 | 257 374 |
| R03BA Glucocorticoids | 88 434 | 91 633 | 92 760 | 94 053 | 91 993 | 51 | 40 963 | 18 515 | 22 691 | 9 824 | 76 144 |
| R03BA01 beclometasone | 4 729 | 4 380 | 4 075 | 4 021 | 3 713 | 55 | 750 | 908 | 1 375 | 680 | 3 091 |
| R03BA02 budesonide | 25 860 | 25 066 | 23 194 | 21 290 | 19 625 | 57 | 2 355 | 5 063 | 8 027 | 4 180 | 24 177 |
| R03BA05 fluticasone | 59 302 | 62 013 | 64 095 | 63 972 | 61 703 | 47 | 38 208 | 9 994 | 9 683 | 3 818 | 39 025 |
| R03BA07 mometasone | <5 | <5 | 0 | 546 | 703 | 53 | 66 | 289 | 273 | 75 | 917 |
| R03BA08 ciclesonide | 0 | 1 874 | 3 476 | 6 104 | 8 080 | 58 | 550 | 2 589 | 3 728 | 1 213 | 8 934 |
| R03BB Anticholinergics | 57 032 | 60 133 | 62 625 | 64 442 | 66 894 | 52 | 689 | 3 722 | 31 806 | 30 677 | 180 997 |
| R03BB01 ipratropium bromide | 39 555 | 38 289 | 35 884 | 32 181 | 28 751 | 57 | 688 | 3 114 | 12 772 | 12 177 | 21 875 |
| R03BB04 tiotropium bromide | 22 767 | 27 429 | 32 809 | 39 704 | 41 458 | 48 | <5 | 622 | 20 363 | 20 470 | 153 377 |
| R03BB05 aclidinium bromide | 0 | 0 | 0 | 0 | 1 518 | 48 | 0 | 41 | 794 | 683 | 2 557 |
| R03BB06 glycopyrronium bromide | 0 | 0 | 0 | 0 | 1 899 | 49 | 0 | 49 | 1 032 | 818 | 3 187 |
| R03BC Antiallergic agents, excl. corticosteroids | 521 | 454 | 430 | 383 | 345 | 66 | 24 | 114 | 168 | 39 | 233 |
| R03BC01 cromoglicic acid | 521 | 454 | 430 | 383 | 345 | 66 | 24 | 114 | 168 | 39 | 233 |
| R03C ADRENERGICS FOR SYSTEMIC USE | 68 733 | 63 272 | 40 582 | 33 966 | 27 069 | 49 | 19 921 | 2 690 | 3 291 | 1 167 | 3 651 |
| R03CA Alpha- and beta-adrenoreceptor agonists | 55 608 | 49 364 | 23 993 | 17 522 | 12 615 | 50 | 8 216 | 1 785 | 2 017 | 597 | 2 064 |
| R03CA02 ephedrine | 55 608 | 49 364 | 23 993 | 17 522 | 12 615 | 50 | 8 216 | 1 785 | 2 017 | 597 | 2 064 |

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|--|-----------------------|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|----------------|----------------|---------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| R03CC Selective beta-2-adrenoreceptor agonists | 16 104 | 16 917 | 17 886 | 17 339 | 14 953 | 48 | 12 177 | 917 | 1 285 | 574 | 1 587 |
| R03CC02 salbutamol | 4 877 | 4 731 | 4 844 | 4 351 | 3 497 | 47 | 2 840 | 236 | 281 | 140 | 262 |
| R03CC03 terbutaline | 11 149 | 12 109 | 12 968 | 12 926 | 11 371 | 48 | 9 449 | 661 | 905 | 356 | 1 097 |
| R03CC12 bambuterol | 238 | 245 | 210 | 219 | 206 | 55 | 0 | 21 | 107 | 78 | 228 |
| R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES | 40 012 | 41 123 | 42 178 | 42 327 | 41 450 | 56 | 8 029 | 10 347 | 16 308 | 6 766 | 71 273 |
| R03DA Xanthines | 5 287 | 4 785 | 4 300 | 3 856 | 3 431 | 60 | 5 | 196 | 1 685 | 1 545 | 2 475 |
| R03DA02 choline theophyllinate | 8 | 10 | 6 | 8 | 7 | 100 | 0 | <5 | 6 | 0 | 31 |
| R03DA04 theophylline | 5 272 | 4 768 | 4 288 | 3 844 | 3 417 | 60 | 5 | 192 | 1 676 | 1 544 | 2 374 |
| R03DA05 aminophylline | 26 | 19 | 19 | 14 | 17 | 65 | 0 | <5 | 11 | <5 | 69 |
| R03DC Leukotriene receptor antagonists | 35 710 | 37 220 | 38 267 | 38 587 | 37 874 | 56 | 8 017 | 10 146 | 14 661 | 5 050 | 40 039 |
| R03DC01 zafirlukast | 25 | 22 | 22 | 21 | 19 | 63 | 0 | <5 | 10 | 8 | 202 |
| R03DC03 montelukast | 35 686 | 37 199 | 38 245 | 38 567 | 37 857 | 56 | 8 017 | 10 145 | 14 652 | 5 043 | 39 837 |
| R03DX Other systemic drugs for obstructive airway diseases | 53 | 145 | 751 | 1 058 | 1 303 | 49 | 18 | 155 | 637 | 493 | 28 758 |
| R03DX05 omalizumab | 53 | 84 | 133 | 175 | 256 | 59 | 18 | 139 | 94 | 5 | 25 264 |
| R03DX07 roflumilast | 0 | 61 | 620 | 885 | 1 049 | 47 | 0 | 16 | 545 | 488 | 3 494 |
| R05 COUGH AND COLD PREPARATIONS | 385 148 | 382 371 | 422 433 | 413 274 | 375 144 | 59 | 25 725 | 119 313 | 158 652 | 71 454 | 67 953 |
| R05C EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS | 133 512 | 135 840 | 147 156 | 135 972 | 113 567 | 57 | 5 525 | 23 052 | 48 326 | 36 664 | 29 677 |
| R05CA Expectorants | 3 334 | 3 671 | 4 351 | 3 935 | 3 977 | 55 | 1 726 | 872 | 864 | 515 | 288 |
| R05CA10 combinations ¹⁾ | 3 334 | 3 671 | 4 351 | 3 935 | 3 977 | 55 | 1 726 | 872 | 864 | 515 | 288 |
| R05CB Mucolytics | 130 752 | 132 821 | 143 557 | 132 685 | 110 178 | 57 | 3 870 | 22 309 | 47 688 | 36 311 | 29 389 |
| R05CB01 acetylcysteine ¹⁾ | 126 968 | 128 953 | 139 329 | 128 839 | 106 696 | 57 | 2 486 | 21 649 | 46 895 | 35 666 | 22 149 |
| R05CB02 bromhexine ¹⁾ | 4 561 | 4 658 | 4 974 | 4 549 | 4 134 | 54 | 1 383 | 760 | 1 059 | 932 | 679 |
| R05CB12 tiopronin | 5 | 5 | <5 | <5 | <5 | 50 | 0 | <5 | <5 | 0 | 25 |
| R05CB13 dornase alfa (desoxyribonuclease) | 109 | 118 | 128 | 130 | 129 | 50 | 41 | 76 | 11 | <5 | 6 537 |
| R05D COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS | 258 842 | 254 586 | 283 928 | 281 002 | 259 319 | 60 | 18 354 | 91 366 | 111 630 | 37 969 | 33 797 |
| R05DA Opium alkaloids and derivatives | 258 842 | 254 586 | 283 928 | 281 002 | 259 319 | 60 | 18 354 | 91 366 | 111 630 | 37 969 | 33 797 |
| R05DA01 ethylmorphine | 249 476 | 245 677 | 274 413 | 271 657 | 250 796 | 60 | 18 005 | 88 676 | 107 603 | 36 512 | 30 954 |
| R05DA03 hydrocodone | 581 | 592 | 592 | 543 | 514 | 62 | <5 | 84 | 281 | 147 | 187 |
| R05DA04 codeine | 7 715 | 7 203 | 7 752 | 7 704 | 6 904 | 64 | 77 | 2 437 | 3 309 | 1 081 | 1 762 |
| R05DA07 noscapine ¹⁾ | 1 763 | 1 880 | 1 952 | 1 664 | 1 636 | 60 | 298 | 476 | 593 | 269 | 152 |

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group R

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|----------------|----------------|---------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| R05DA09 dextromethorphan | <5 | <5 | 0 | <5 | <5 | 0 | 0 | <5 | 0 | 0 | 1 |
| R05DA20 combinations | 3 036 | 2 836 | 2 918 | 2 979 | 2 631 | 62 | 16 | 709 | 1 445 | 461 | 742 |
| R05F COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS | 41 525 | 41 844 | 48 192 | 49 235 | 46 193 | 62 | 2 840 | 16 573 | 19 768 | 7 012 | 4 479 |
| R05FA Opium derivatives and expectorants | 41 525 | 41 844 | 48 192 | 49 235 | 46 193 | 62 | 2 840 | 16 573 | 19 768 | 7 012 | 4 479 |
| R05FA02 opium derivatives and expectorants | 41 525 | 41 844 | 48 192 | 49 235 | 46 193 | 62 | 2 840 | 16 573 | 19 768 | 7 012 | 4 479 |
| R06 ANTIHISTAMINES FOR SYSTEMIC USE | 519 116 | 511 537 | 529 217 | 544 575 | 555 485 | 59 | 72 192 | 228 452 | 198 865 | 55 976 | 161 378 |
| R06A ANTIHISTAMINES FOR SYSTEMIC USE | 519 116 | 511 537 | 529 217 | 544 575 | 555 485 | 59 | 72 192 | 228 452 | 198 865 | 55 976 | 161 378 |
| R06AA Aminoalkyl ethers | 18 | 15 | 14 | 23 | 29 | 66 | <5 | 10 | 9 | 8 | 36 |
| R06AA02 diphenhydramine | <5 | <5 | 0 | 6 | 11 | 55 | 0 | 7 | <5 | <5 | 6 |
| R06AA04 clemastine | 14 | 14 | 14 | 17 | 18 | 72 | <5 | <5 | 7 | 6 | 29 |
| R06AB Substituted alkylamines | 35 818 | 25 263 | 22 719 | 20 363 | 19 417 | 67 | 4 377 | 7 068 | 5 420 | 2 552 | 5 641 |
| R06AB02 dexchlorpheniramine | 35 818 | 25 263 | 22 719 | 20 363 | 19 417 | 67 | 4 377 | 7 068 | 5 420 | 2 552 | 5 641 |
| R06AD Phenothiazine derivatives | 62 798 | 64 453 | 65 875 | 66 127 | 66 678 | 62 | 3 639 | 23 906 | 29 361 | 9 772 | 34 934 |
| R06AD01 alimemazine | 56 465 | 57 913 | 59 728 | 60 223 | 60 961 | 62 | 3 587 | 21 603 | 26 924 | 8 847 | 32 253 |
| R06AD02 promethazine | 6 991 | 7 154 | 6 719 | 6 464 | 6 242 | 68 | 54 | 2 527 | 2 689 | 972 | 2 671 |
| R06AD03 thiethylperazine | <5 | 5 | <5 | 5 | 6 | 83 | 0 | <5 | <5 | <5 | 11 |
| R06AE Piperazine derivatives | 294 720 | 285 404 | 293 955 | 285 833 | 277 991 | 59 | 37 525 | 109 473 | 100 565 | 30 428 | 56 389 |
| R06AE03 cyclizine ¹⁾ | 655 | 737 | 759 | 731 | 774 | 71 | 15 | 219 | 349 | 191 | 389 |
| R06AE05 meclozine ¹⁾ | 1 956 | 2 031 | 2 165 | 2 271 | 2 613 | 88 | 89 | 1 943 | 373 | 208 | 246 |
| R06AE07 cetirizine ¹⁾ | 291 604 | 282 294 | 290 730 | 282 583 | 274 382 | 58 | 37 420 | 107 239 | 99 718 | 30 005 | 55 259 |
| R06AE09 levocetirizine | 844 | 703 | 661 | 611 | 572 | 63 | 12 | 262 | 245 | 53 | 495 |
| R06AX Other antihistamines for systemic use | 164 938 | 169 564 | 178 145 | 206 281 | 223 948 | 59 | 30 493 | 101 709 | 75 409 | 16 337 | 64 378 |
| R06AX02 cyproheptadine | 59 | 40 | 17 | 24 | 31 | 58 | 6 | <5 | 12 | 9 | 20 |
| R06AX13 loratadine ¹⁾ | 92 307 | 83 864 | 82 823 | 71 385 | 61 729 | 61 | 3 188 | 27 904 | 24 245 | 6 392 | 15 676 |
| R06AX17 ketotifen | <5 | 7 | 10 | 9 | 10 | 60 | <5 | <5 | <5 | <5 | 10 |
| R06AX22 ebastine ¹⁾ | 11 035 | 10 315 | 10 432 | 9 816 | 9 205 | 66 | 120 | 3 930 | 4 274 | 881 | 7 189 |
| R06AX26 fexofenadine | 24 496 | 27 017 | 30 412 | 29 345 | 29 771 | 62 | 708 | 15 293 | 11 259 | 2 511 | 10 075 |
| R06AX27 desloratadine | 48 971 | 55 048 | 60 505 | 103 482 | 129 266 | 57 | 26 786 | 57 704 | 37 816 | 6 960 | 31 407 |
| R07 OTHER RESPIRATORY SYSTEM PRODUCTS | 0 | 0 | 0 | <5 | 12 | 50 | <5 | 8 | 0 | 0 | 15 248 |
| R07A OTHER RESPIRATORY SYSTEM PRODUCTS | 0 | 0 | 0 | <5 | 12 | 50 | <5 | 8 | 0 | 0 | 15 248 |
| R07AX Other respiratory system products | 0 | 0 | 0 | <5 | 9 | 33 | <5 | 7 | 0 | 0 | 15 231 |
| R07AX02 ivacaftor | 0 | 0 | 0 | <5 | 9 | 33 | <5 | 7 | 0 | 0 | 15 231 |

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

2.17 ATC group S – Sensory organs

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|--|-----------------------|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|----------------|----------------|----------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15–44 | 45–69 | ≥70 | | | | | | | |
| S SENSORY ORGANS | 596 290 | 609 467 | 617 742 | 618 314 | 612 715 | 57 | 110 059 | 175 648 | 194 853 | 132 155 | 301 674 |
| S01 OPHTHALMOLOGICALS | 526 629 | 538 818 | 549 815 | 547 600 | 540 362 | 58 | 96 802 | 152 891 | 167 700 | 122 969 | 286 482 |
| S01A ANTIINFECTIVES | 250 367 | 269 034 | 266 933 | 262 214 | 249 591 | 55 | 69 067 | 72 654 | 72 004 | 35 866 | 43 884 |
| S01AA Antibiotics | 247 638 | 266 185 | 264 028 | 259 211 | 246 579 | 55 | 68 931 | 71 627 | 70 766 | 35 255 | 42 446 |
| S01AA01 chloramphenicol | 182 292 | 197 212 | 200 731 | 197 307 | 185 720 | 55 | 44 299 | 56 530 | 56 960 | 27 931 | 35 016 |
| S01AA02 chlortetracycline | <5 | <5 | <5 | <5 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| S01AA11 gentamicin | 1 763 | 1 702 | 1 597 | 1 252 | 111 | 53 | 7 | 41 | 37 | 26 | 15 |
| S01AA12 tobramycin | 2 332 | 2 302 | 2 322 | 2 028 | 1 783 | 56 | 212 | 548 | 613 | 410 | 171 |
| S01AA13 fusidic acid | 75 838 | 82 810 | 75 325 | 71 484 | 64 306 | 57 | 27 388 | 15 436 | 13 903 | 7 579 | 5 626 |
| S01AA26 azithromycin | 0 | 0 | 0 | 2 795 | 8 981 | 60 | 2 917 | 2 615 | 2 400 | 1 049 | 949 |
| S01AA30 combinations of different antibiotics | 4 936 | 5 105 | 5 269 | 4 340 | 4 797 | 58 | 271 | 1 065 | 1 855 | 1 606 | 668 |
| S01AD Antivirals | 3 249 | 3 266 | 3 171 | 3 399 | 3 230 | 56 | 120 | 911 | 1 372 | 827 | 810 |
| S01AD01 idoxuridine | <5 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| S01AD03 aciclovir | 3 248 | 3 266 | 3 171 | 3 399 | 3 230 | 56 | 120 | 911 | 1 372 | 827 | 810 |
| S01AE Fluoroquinolones | 1 982 | 2 138 | 2 327 | 2 468 | 2 613 | 55 | 150 | 1 002 | 988 | 473 | 616 |
| S01AE03 ciprofloxacin | 1 982 | 2 138 | 2 327 | 2 468 | 2 613 | 55 | 150 | 1 002 | 988 | 473 | 616 |
| S01AX Other antiinfectives | <5 | <5 | <5 | <5 | <5 | 50 | 0 | <5 | <5 | 0 | 12 |
| S01AX09 chlorhexidine | 0 | 0 | 0 | 0 | <5 | 100 | 0 | 0 | <5 | 0 | 3 |
| S01AX15 propamidine | 0 | 0 | <5 | <5 | <5 | 100 | 0 | 0 | <5 | 0 | 0 |
| S01B ANTIINFLAMMATORY AGENTS | 44 119 | 45 945 | 46 769 | 49 872 | 51 179 | 58 | 1 750 | 9 100 | 18 909 | 21 420 | 15 850 |
| S01BA Corticosteroids, plain | 30 111 | 30 638 | 31 478 | 33 551 | 33 532 | 58 | 1 709 | 8 087 | 13 529 | 10 207 | 10 495 |
| S01BA01 dexamethasone | 18 319 | 18 993 | 20 148 | 20 502 | 20 553 | 55 | 529 | 4 500 | 8 877 | 6 647 | 7 161 |
| S01BA04 prednisolone | 12 418 | 11 840 | 10 925 | 13 613 | 13 742 | 59 | 1 129 | 4 280 | 5 361 | 2 972 | 2 167 |
| S01BA07 fluorometholone | 17 | 16 | 12 | 12 | 7 | 57 | 0 | 0 | 5 | <5 | 10 |
| S01BA09 clobetasone | 18 | 16 | 13 | 16 | 15 | 53 | <5 | <5 | 7 | <5 | 42 |
| S01BA13 rimexolone | 4 177 | 4 351 | 4 414 | 4 285 | 4 162 | 58 | 194 | 1 024 | 1 591 | 1 353 | 1 115 |
| S01BB Corticosteroids and mydriatics in combination | <5 | <5 | <5 | <5 | <5 | 100 | 0 | 0 | 0 | <5 | 0 |
| S01BB03 fluorometholone and mydriatics | <5 | <5 | <5 | <5 | <5 | 100 | 0 | 0 | 0 | <5 | 0 |
| S01BC Antiinflammatory agents, non-steroids | 15 618 | 17 141 | 17 568 | 18 734 | 20 187 | 58 | 47 | 1 441 | 6 325 | 12 374 | 5 354 |
| S01BC03 diclofenac | 15 618 | 15 814 | 11 689 | 7 413 | 6 137 | 56 | 37 | 969 | 2 182 | 2 949 | 1 315 |
| S01BC10 nepafenac | 0 | 1 528 | 6 095 | 10 294 | 9 113 | 58 | 8 | 219 | 2 694 | 6 192 | 2 869 |
| S01BC11 bromfenac | 0 | 0 | 0 | 1 372 | 5 325 | 58 | <5 | 266 | 1 582 | 3 473 | 1 171 |
| S01C ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION | 56 226 | 56 906 | 57 674 | 57 855 | 57 314 | 58 | 1 082 | 8 618 | 20 464 | 27 150 | 10 941 |

ATC group S

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|---------------|---------------|---------------|---------------|--------------------|-------------------------------------|--------------|---------------|---------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| S01CA Corticosteroids and anti-infectives in combination | 56 226 | 56 906 | 57 674 | 57 855 | 57 314 | 58 | 1 082 | 8 618 | 20 464 | 27 150 | 10 941 |
| S01CA01 dexamethasone and anti-infectives | 56 226 | 56 906 | 57 674 | 57 855 | 57 314 | 58 | 1 082 | 8 618 | 20 464 | 27 150 | 10 941 |
| S01E ANTIGLAUCOMA PREPARATIONS AND MIOTICS | 68 940 | 70 039 | 70 786 | 71 402 | 72 192 | 56 | 215 | 2 134 | 21 767 | 48 076 | 129 995 |
| S01EA Sympathomimetics in glaucoma therapy | 3 992 | 4 077 | 4 222 | 4 446 | 4 920 | 53 | 5 | 182 | 1 344 | 3 389 | 4 346 |
| S01EA01 epinephrine | <5 | <5 | <5 | <5 | <5 | 100 | 0 | 0 | <5 | <5 | 2 |
| S01EA02 dipivefrine | 122 | 9 | <5 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| S01EA03 apraclonidine | 97 | 115 | 122 | 145 | 155 | 58 | 0 | 15 | 54 | 86 | 79 |
| S01EA05 brimonidine | 3 838 | 3 983 | 4 122 | 4 351 | 4 805 | 53 | 5 | 170 | 1 303 | 3 327 | 4 265 |
| S01EB Parasympathomimetics | 1 433 | 1 291 | 1 254 | 1 179 | 1 012 | 60 | <5 | 52 | 271 | 686 | 1 031 |
| S01EB01 pilocarpine | 1 431 | 1 289 | 1 253 | 1 178 | 1 012 | 60 | <5 | 52 | 271 | 686 | 1 027 |
| S01EB02 carbachol | <5 | <5 | <5 | <5 | <5 | 100 | 0 | 0 | <5 | 0 | 5 |
| S01EC Carbonic anhydrase inhibitors | 9 634 | 10 040 | 10 322 | 10 647 | 10 892 | 57 | 123 | 698 | 2 823 | 7 248 | 12 683 |
| S01EC01 acetazolamide | 1 531 | 1 699 | 1 828 | 1 926 | 1 840 | 55 | 42 | 542 | 635 | 621 | 1 025 |
| S01EC03 dorzolamide | 2 660 | 2 503 | 2 393 | 2 342 | 2 357 | 58 | 15 | 51 | 571 | 1 720 | 2 853 |
| S01EC04 brinzolamide | 5 811 | 6 195 | 6 452 | 6 759 | 7 109 | 56 | 71 | 120 | 1 743 | 5 175 | 8 805 |
| S01ED Beta blocking agents | 48 377 | 48 841 | 49 028 | 49 468 | 49 878 | 56 | 148 | 1 219 | 15 018 | 33 493 | 63 972 |
| S01ED01 timolol | 22 977 | 22 326 | 21 731 | 21 600 | 21 606 | 57 | 131 | 568 | 7 286 | 13 621 | 22 525 |
| S01ED02 betaxolol | 2 012 | 1 778 | 1 587 | 1 433 | 1 247 | 65 | <5 | 19 | 275 | 950 | 811 |
| S01ED51 timolol, combinations | 25 922 | 27 060 | 27 984 | 28 616 | 29 164 | 55 | 27 | 701 | 8 163 | 20 273 | 40 636 |
| S01EE Prostaglandin analogues | 36 048 | 36 697 | 37 171 | 37 056 | 37 446 | 57 | 26 | 671 | 10 560 | 26 189 | 47 962 |
| S01EE01 latanoprost | 28 946 | 27 890 | 26 156 | 24 231 | 23 338 | 57 | 10 | 355 | 6 112 | 16 861 | 18 837 |
| S01EE03 bimatoprost | 1 807 | 1 867 | 1 871 | 2 061 | 2 247 | 57 | <5 | 59 | 677 | 1 509 | 3 339 |
| S01EE04 travoprost | 4 844 | 5 035 | 6 464 | 7 197 | 7 095 | 55 | <5 | 117 | 2 037 | 4 938 | 11 036 |
| S01EE05 tafluprost | 1 654 | 3 068 | 4 029 | 4 999 | 5 994 | 63 | 13 | 160 | 2 120 | 3 701 | 14 748 |
| S01F MYDRIATICS AND CYCLOPLEGICS | 4 899 | 5 066 | 5 041 | 5 318 | 5 318 | 47 | 405 | 1 251 | 2 383 | 1 279 | 976 |
| S01FA Anticholinergics | 4 891 | 5 062 | 5 038 | 5 312 | 5 311 | 47 | 405 | 1 247 | 2 380 | 1 279 | 971 |
| S01FA01 atropine | 2 670 | 2 549 | 2 323 | 2 323 | 2 185 | 46 | 322 | 464 | 890 | 509 | 436 |
| S01FA04 cyclopentolate | 2 277 | 2 546 | 2 746 | 3 069 | 3 177 | 47 | 78 | 813 | 1 510 | 776 | 500 |
| S01FA06 tropicamide | 157 | 189 | 164 | 140 | 139 | 55 | 8 | 54 | 54 | 23 | 33 |
| S01FA54 cyclopentolate, combinations | 0 | 0 | 0 | 0 | <5 | 50 | 0 | 0 | <5 | 0 | 2 |
| S01FB Sympathomimetics excl. antiglaucoma preparations | 39 | 29 | 35 | 33 | 28 | 46 | 0 | 10 | 17 | <5 | 5 |
| S01FB01 phenylephrine | 39 | 29 | 35 | 33 | 28 | 46 | 0 | 10 | 17 | <5 | 5 |

ATC group S

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|----------------|----------------|----------------|----------------|--------------------|-------------------------------------|---------------|---------------|---------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| S01G DECONGESTANTS AND ANTIALLERGICS | 172 049 | 158 625 | 167 530 | 163 501 | 163 518 | 59 | 28 200 | 72 741 | 50 377 | 12 200 | 46 566 |
| S01GA Sympathomimetics used as decongestants | 23 098 | 20 728 | 21 288 | 20 300 | 19 136 | 61 | 2 106 | 8 630 | 6 728 | 1 672 | 5 673 |
| S01GA51 naphazoline, combinations | 11 | <5 | 6 | <5 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| S01GA52 tetrazyline, combinations | 23 089 | 20 725 | 21 283 | 20 297 | 19 136 | 61 | 2 106 | 8 630 | 6 728 | 1 672 | 5 673 |
| S01GX Other antiallergics | 152 775 | 141 091 | 149 662 | 146 552 | 147 512 | 59 | 26 664 | 65 487 | 44 635 | 10 726 | 40 893 |
| S01GX01 cromoglicic acid ¹⁾ | 25 305 | 22 551 | 23 401 | 22 545 | 21 636 | 62 | 3 067 | 9 114 | 7 612 | 1 843 | 5 350 |
| S01GX02 levocabastine ¹⁾ | 77 301 | 70 567 | 75 499 | 73 827 | 75 061 | 58 | 14 591 | 33 521 | 21 890 | 5 059 | 18 489 |
| S01GX04 nedocromil | 2 018 | 1 777 | 1 702 | 1 442 | 1 395 | 59 | 148 | 712 | 452 | 83 | 288 |
| S01GX05 lodoxamide ¹⁾ | 35 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| S01GX06 emedastine | 490 | 379 | 384 | 376 | 345 | 63 | 58 | 141 | 111 | 35 | 113 |
| S01GX07 azelastine | 691 | 580 | 553 | 531 | 508 | 58 | 62 | 223 | 161 | 62 | 143 |
| S01GX08 ketotifen ¹⁾ | 17 926 | 16 305 | 17 279 | 16 686 | 17 238 | 60 | 2 956 | 7 596 | 5 378 | 1 308 | 6 906 |
| S01GX09 olopatadine | 34 046 | 32 856 | 35 349 | 35 456 | 35 267 | 57 | 6 726 | 15 684 | 10 196 | 2 661 | 9 605 |
| S01X OTHER OPHTHALMOLOGICALS | 18 266 | 26 371 | 34 504 | 40 602 | 45 774 | 76 | 360 | 4 506 | 19 555 | 21 353 | 38 222 |
| S01XA Other ophthalmologicals | 18 266 | 26 371 | 34 504 | 40 602 | 45 774 | 76 | 360 | 4 506 | 19 555 | 21 353 | 38 222 |
| S01XA03 sodium chloride, hypertonic | 20 | 15 | 17 | 10 | 15 | 53 | 0 | 0 | <5 | 11 | 25 |
| S01XA18 ciclosporin | 41 | 70 | 112 | 252 | 474 | 72 | 17 | 107 | 256 | 94 | 6 418 |
| S01XA20 artificial tears and other indifferent preparations ¹⁾ | 18 234 | 26 329 | 34 451 | 40 510 | 45 650 | 76 | 346 | 4 476 | 19 500 | 21 328 | 31 780 |
| S02 OTOLOGICALS | 14 496 | 14 933 | 20 226 | 18 711 | 20 091 | 54 | 3 260 | 5 369 | 8 146 | 3 316 | 3 887 |
| S02A ANTIINFECTIVES | 7 037 | 7 346 | 10 565 | 9 590 | 8 282 | 47 | 2 810 | 2 367 | 2 283 | 822 | 1 469 |
| S02AA Antiinfectives | 7 037 | 7 346 | 10 565 | 9 590 | 8 282 | 47 | 2 810 | 2 367 | 2 283 | 822 | 1 469 |
| S02AA01 chloramphenicol | 123 | 75 | 75 | 17 | 11 | 55 | <5 | <5 | <5 | <5 | 13 |
| S02AA03 boric acid | 0 | 0 | 0 | 0 | 7 | 14 | 0 | <5 | <5 | <5 | 3 |
| S02AA15 ciprofloxacin | 6 937 | 7 290 | 10 501 | 9 576 | 8 264 | 47 | 2 808 | 2 361 | 2 277 | 818 | 1 453 |
| S02B CORTICOSTEROIDS | 7 724 | 7 847 | 10 185 | 9 549 | 10 784 | 60 | 245 | 2 725 | 5 506 | 2 308 | 2 135 |
| S02BA Corticosteroids | 7 724 | 7 847 | 10 185 | 9 549 | 10 784 | 60 | 245 | 2 725 | 5 506 | 2 308 | 2 135 |
| S02BA07 betametasone | 7 724 | 7 847 | 10 185 | 9 549 | 10 784 | 60 | 245 | 2 725 | 5 506 | 2 308 | 2 135 |
| S02C CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION | 70 | 66 | 104 | 91 | 1 764 | 50 | 288 | 520 | 678 | 278 | 283 |
| S02CA Corticosteroids and anti-infectives in combination | 70 | 66 | 104 | 91 | 1 764 | 50 | 288 | 520 | 678 | 278 | 283 |
| S02CA02 flumetasone and antiinfectives | 70 | 66 | 104 | 91 | 64 | 58 | <5 | 19 | 30 | 13 | 10 |
| S02CA05 fluocinolone acetonide and antiinfectives | 0 | 0 | 0 | 0 | 1 702 | 50 | 286 | 501 | 649 | 266 | 272 |

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group S

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|---|-----------------------|---------------|---------------|---------------|---------------|--------------------|-------------------------------------|---------------|---------------|---------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| S03 OPTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS | 75 322 | 77 041 | 68 909 | 73 479 | 73 853 | 54 | 14 028 | 22 537 | 26 694 | 10 594 | 11 304 |
| S03C CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION | 75 322 | 77 041 | 68 909 | 73 479 | 73 853 | 54 | 14 028 | 22 537 | 26 694 | 10 594 | 11 304 |
| S03CA Corticosteroids and anti-infectives in combination | 75 322 | 77 041 | 68 909 | 73 479 | 73 853 | 54 | 14 028 | 22 537 | 26 694 | 10 594 | 11 304 |
| S03CA01 dexamethasone and anti-infectives | 15 356 | 14 416 | 24 937 | 11 256 | 12 789 | 55 | 1 528 | 3 664 | 5 329 | 2 268 | 1 608 |
| S03CA04 hydrocortisone and anti-infectives | 62 503 | 65 038 | 47 812 | 64 616 | 63 093 | 53 | 12 755 | 19 502 | 22 173 | 8 663 | 9 696 |

2.18 ATC group V – Various

| ATC level | 2009 | 2010 | 2011 | 2012 | 2013 | Share of women (%) | 2013 | | | | 2013 |
|--------------------------------|-----------------------|--------------|--------------|--------------|--------------|--------------------|-------------------------------------|--------------|--------------|--------------|-------------------|
| | Number of individuals | | | | | | Number of individuals per age group | | | | Sales in 1000 NOK |
| | <15 | 15-44 | 45-69 | ≥70 | | | | | | | |
| V VARIOUS | 13 317 | 15 898 | 18 601 | 21 869 | 23 890 | 50 | 3 147 | 7 984 | 8 096 | 4 663 | 83 699 |
| V01 ALLERGENS | 6 170 | 7 289 | 8 273 | 8 927 | 9 462 | 47 | 1 701 | 6 078 | 1 646 | 37 | 46 410 |
| V01A ALLERGENS | 6 170 | 7 289 | 8 273 | 8 927 | 9 462 | 47 | 1 701 | 6 078 | 1 646 | 37 | 46 410 |
| V01AA Allergen extracts | 6 170 | 7 289 | 8 273 | 8 927 | 9 462 | 47 | 1 701 | 6 078 | 1 646 | 37 | 46 410 |
| V01AA02 grass pollen | 4 021 | 5 033 | 5 758 | 6 330 | 6 829 | 44 | 1 097 | 4 714 | 1 008 | 10 | 27 195 |
| V01AA03 house dust mites | 301 | 349 | 426 | 488 | 539 | 46 | 114 | 341 | 81 | <5 | 3 126 |
| V01AA05 tree pollen | 3 705 | 4 150 | 4 670 | 4 874 | 4 896 | 50 | 901 | 3 060 | 914 | 21 | 10 980 |
| V01AA07 insects | 185 | 183 | 181 | 156 | 160 | 55 | 17 | 49 | 84 | 10 | 762 |
| V01AA10 flowers | 90 | 108 | 141 | 149 | 149 | 60 | 13 | 85 | 51 | 0 | 736 |
| V01AA11 animals | 217 | 288 | 382 | 425 | 494 | 54 | 100 | 296 | 97 | <5 | 3 610 |

Noen forkortelser og definisjoner / Some abbreviations and definitions

| | | |
|---------|---|--|
| ATC | Anatomisk Terapeutisk Kjemisk (klassifikasjonssystem for legemidler) | Anatomical Therapeutical Chemical (classification system for medicines) |
| DDD | Definert døgndose | Defined Daily Doses |
| EEA | | European Economic Association |
| EØS | Europeisk økonomisk samarbeid | |
| FHI | Folkehelseinstituttet | |
| GP | | General Practitioner |
| ICD -10 | | International Classification of Diseases version 10 |
| ICPC | | International Classification of Primary Care |
| MA | Markedsføringstillatelse | Marketing Authorisation |
| NIPH | | Norwegian Institute of Public Health |
| NMD | Norsk Medisinaldepot | Norwegian Medicinal Depot (wholesaler) |
| NOK | Norske kroner | Norwegian kroner |
| NorPD | Reseptregisteret | Norwegian Prescription Database |
| NSAID | Ikke-steroid antiinflammatorisk legemiddel | Non Steroidal Anti-Inflammatory Drug |
| OTC | Reseptfritt | Over The Counter, non prescription drugs |
| SPC | | Summary of Product Characteristics |
| SSB | Statistisk sentralbyrå | Statistics Norway |
| WHO | Verdens helseorganisasjon | World Health Organization |

Definisjoner

Prevalens

Brukere (individer) defineres som personer som har hentet minst én resept på apotek i perioden. Prevalens er definert som antall brukere per 100 innbyggere (%) i det definerte befolkningsutvalget.

Insidens (nye brukere)

Insidens er antall brukere av et bestemt legemiddel eller en legemiddelgruppe i en definert tidsperiode som ikke var brukere i en tidligere, definert periode. Insidens kan også uttrykkes som andel (%) i forhold til antallet potensielle nye brukere i det definerte befolkningsutvalget.

Definitions

Prevalence

Users (individuals) are defined as persons who had at least one prescription dispensed at pharmacies in the period. Prevalence is defined as the number of users per 100 inhabitants (%) in the defined population sample.

Incidence (new users)

Incidence is the number of users of a particular drug or drug group in a defined time period who were not users in a previous, defined time period. Incidence can be expressed as a percentage relative to the number of potential users in the defined population sample.

Folkemengde i Norge 2009–2013 (per 1. juli)/
Population in Norway 2009–2013 (as of 1st July)

| Year | 2009 | 2010 | 2011 | 2012 | 2013 |
|------------|-----------|-----------|-----------|-----------|-----------|
| Population | 4 829 800 | 4 888 946 | 4 953 217 | 5 018 415 | 5 080 148 |

Folkemengde etter alder i 2013 (per 1. juli)/
Population by age in 2013 (as of 1st July)

| Age groups | <15 | 15–44 | 45–69 | ≥70 |
|------------|---------|-----------|-----------|---------|
| Population | 897 813 | 2 055 878 | 1 571 928 | 554 530 |

Kilde: Statistisk sentralbyrå / Source: Statistics Norway

Liste over publikasjoner basert på data fra Reseptregisteret per mars 2014 / List of publications based on data from the Norwegian Prescription Database (NorPD) as of March 2014

2014:

- Andersen JB, Heldal AT, Engeland A, Gilhus NE. Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries. *Acta Neurol Scand Suppl.* 2014;(198):26-31
- Fredheim OM, Mahic M, Skurtveit S, Dale O, Romundstad P, Borchgrevink PC. Chronic pain and use of opioids: a population based pharmacoepidemiological study from the Norwegian prescription database and the Nord-Trøndelag health study (HUNT). *Pain* 2014 Mar 15. [Epub ahead of print]
- Grytli HH, Fagerland MW, Fosså SD, Taskén KA. Association Between Use of β -Blockers and Prostate Cancer-Specific Survival: A Cohort Study of 3561 Prostate Cancer Patients with High-Risk or Metastatic Disease. *European Urology* 2014;65:635-641.
- Karlstad Ø, Furu K, Skurtveit S, Selmer R. Prescribing of Drugs for Attention-Deficit Hyperactivity Disorder in Opioid Maintenance Treatment Patients in Norway. *Eur Addict Res* 2014;20:59-65.
- Langballe EM, Engdahl B, Nordeng H, Ballard C, Aarsland D, Selbaek G. Short- and Long-Term Mortality Risk Associated with the Use of Antipsychotics Among 26,940 Dementia Outpatients: A Population-Based Study. *Am J Geriatr Psychiatry* 2014;22:321-331.
- Mellbye A, Karlstad O, Skurtveit S, Borchgrevink PC, Fredheim OM. Co-morbidity in persistent opioid users with chronic non-malignant pain in Norway. *Eur J Pain.* 2014 Jan 20. [Epub ahead of print]
- Nordfjærn T, Bjerkeset O, Bratberg G, Moylan S, Berk M, Grawe R. Socio-demographic, lifestyle and psychological predictors of benzodiazepine and z-hypnotic use patterns. *Nord J Psychiatry* 2014;68:107-116.
- Skrivarhaug T, Stene LC, Drivvoll AK, Strom H, Joner G. Incidence of type 1 diabetes in Norway among children aged 0-14 years between 1989 and 2012: has the incidence stopped rising? Results from the Norwegian Childhood Diabetes Registry. *Diabetologia* 2014;57:57-62.
- Svendsen K, Fredheim OM, Romundstad P, Borchgrevink PC, Skurtveit S. Persistent opioid use and socio-economic factors: a population-based study in Norway. *Acta Anaesthesiol Scand.* 2014;58:437-445.

2013:

- Bakken MS, Engeland A, Engesaeter LB, Ranhoff AH, Hunskaar S, Ruths S. Increased risk of hip fracture among older people using antidepressant drugs: data from the Norwegian Prescription Database and the Norwegian Hip Fracture Registry. *Age Ageing* 2013 Jul;42:514-20.
- Berge LI, Riise T, Iversen M. Co-morbidity between diabetes, migraine and depression. *Norsk Epidemiologi* 2013;23:2013.
- Berge LI, Riise T, Fasmer OB, Hundal O, Oedegaard KJ, Midthjell K, et al. Does diabetes have a protective effect on migraine? *Epidemiology* 2013;24:129-34.
- Bjorner T, Tvete IF, Aursnes I, Skomedal T. [Dispensing of benzodiazepines and Z drugs by Norwegian pharmacies 2004–2011]. *Tidsskr Nor Laegeforen* 2013;133:2149-53.
- Brelin S, Loge JH, Skurtveit S, Johannesen TB, Aass N, Ottesen S, et al. Antidepressants to cancer patients during the last year of life—a population-based study. *Psychooncology* 2013;22:506-14.
- Devold HM, Sogaard AJ, Tverdal A, Falch JA, Furu K, Meyer HE. Hip fracture and other predictors of anti-osteoporosis drug use in Norway. *Osteoporos Int* 2013 ;24:1225-33.
- Engeland A, Bjørge T, Daltveit AK, Skurtveit S, Vangen S, Vollset SE, et al. Effects of preconceptional paternal drug exposure on birth outcomes: Cohort study of 340000 pregnancies using Norwegian population-based databases. *British Journal of Clinical Pharmacology* 2013;75:1134-41.
- Fossum GH, Lindbaek M, Gjelstad S, Dalen I, Kvaerner KJ. Are children carrying the burden of broad-spectrum antibiotics in general practice? Prescription pattern for paediatric outpatients with respiratory tract infections in Norway. *BMJ Open* 2013;3:e002285.
- Fredheim OM, Borchgrevink PC, Mahic M, Skurtveit S. A pharmacoepidemiological cohort study of subjects starting strong opioids for nonmalignant pain: a study from the Norwegian Prescription Database. *Pain* 2013 Nov;154:2487-93.
- Holdø I, Handal M, Skurtveit S, Bramness JG. Association between prescribing hypnotics for parents and children in Norway. *Arch Dis Child* 2013 ;98:732-6.

Jonasson C, Tvette IF, Hatlebakk JG. Patterns of proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study. *Scand J Gastroenterol* 2013 ;48:1010-7.

Klovstad H, Natas O, Tverdal A, Aavitsland P. Systematic screening with information and home sampling for genital *Chlamydia trachomatis* infections in young men and women in Norway: a randomized controlled trial. *BMC Infectious Diseases* 2013;13:30.

Kravdal O. The poorer cancer survival among the unmarried in Norway: Is much explained by comorbidities? *Social Science and Medicine* 2013;81:42-52.

Kvaale MK, Grave K, Kristoffersen AB, Norstrom M. The prescription rate of antibacterial agents in dogs in Norway – geographical patterns and trends during the period 2004–2008. *J Vet Pharmacol Ther* 2013 Jun;36:285-91.

Kyrdalen AE, Dahl AA, Hernes E, Smastuen MC, Fossa SD. A national study of adverse effects and global quality of life among candidates for curative treatment for prostate cancer. *BJU Int* 2013 Feb;111:221-32.

Lillefjell M, Haugan T, Martinussen P, Halvorsen T. Treatment outcomes among individuals in a musculoskeletal pain rehabilitation program related to the prevalence and trends in the dispensing of prescribed medications. *Journal of Musculoskeletal Pain* 2013;21:311-319.

Log T, Skurtveit S, Selmer R, Tverdal A, Furu K, Hartz I. The association between prescribed opioid use for mothers and children: a record-linkage study. *Eur J Clin Pharmacol* 2013;69:111-8.

Lund IO, Skurtveit S, Engeland A, Furu K, Ravndal E, Handal M. Prescription drug use among pregnant women in opioid Maintenance Treatment. *Addiction* 2013;108:367-76.

Mauseth SA, Skurtveit S, Spigset O. Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from the Norwegian Prescription Database. *Acta Obstet Gynecol Scand* 2013;92:1208-1215.

Neutel CI, Skurtveit S, Berg C, Sakshaug S. Trends in prescription of strong opioids for 41-80 year old Norwegians, 2005–2010. *Eur J Pain* 2013;18:438-446.

Neutel CI, Skurtveit S, Berg C, Sakshaug S. Multiple prescribers in older frequent opioid users--does it mean abuse? *J Popul Ther Clin Pharmacol* 2013;20:e397-e405.

Nezvalova-Henriksen K, Spigset O, Nordeng H. Triptan safety during pregnancy: a Norwegian population registry study. *Eur J Epidemiol* 2013;28:759-69.

Nordeng H, Lupattelli A, Romøren M, Koren G. Neonatal outcomes after gestational exposure to nitrofurantoin. *Obstetrics and Gynecology* 2013;121:306-13.

Nordfjaern T, Bjerkeset O, Moylan S, Berk M, Grawe RW. Clusters of personality traits and psychological symptoms associated with later benzodiazepine prescriptions in the general population: The HUNT Cohort Study. *Addict Behav* 2013 Oct;38:2575-80.

Nordfjaern T. Prospective associations between benzodiazepine use and later life satisfaction, somatic pain and psychological health among the elderly. *Hum Psychopharmacol* 2013 May;28:248-57.

Persheim MS, Helland A, Spigset O, Slordal L. Potensielt vanedannende legemidler på blåresept ved kroniske sterke smerter. [Potentially addictive drugs on reimbursable prescription for chronic severe pain]. *Tidsskrift for den Norske Laegeforening* 2013;133:150-4. In Norwegian.

Skogar O, Nilsson M, Tornhage CJ, Løkk J. National surveys: a way to manage treatment strategies in Parkinson's disease? Pharmaceutical prescribing patterns and patient experiences of symptom control and their impact on disease. *J Multidiscip Healthc* 2013;6:239-47.

Skollerud LM, Fredheim OM, Svendsen K, Skurtveit S, Borchgrevink PC. Laxative prescriptions to cancer outpatients receiving opioids: A study from the Norwegian prescription database. *Supportive Care in Cancer* 2013;21:67-73.

Skurtveit S, Selmer R, Tverdal A, Furu K, Nystad W, Handal M. Drug exposure: inclusion of dispensed drugs before pregnancy may lead to underestimation of risk associations. *J Clin Epidemiol* 2013 Sep;66:964-72.

Stene LE, Jacobsen GW, Dyb G, Tverdal A, Schei B. Intimate partner violence and cardiovascular risk in women: A population-based cohort study. *Journal of Women's Health* 2013;22:250-8.

Stephansson O, Kieler H, Haglund B, Artama M, Engeland A, Furu K, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. *JAMA* 2013;309:48-54.

Thelle DS, Selmer R, Gjesdal K, Sakshaug S, Jugessur A, Graff-Iversen S, et al. Resting heart rate and physical activity as risk factors for lone atrial fibrillation: a prospective study of 309,540 men and women. *Heart* 2013 Dec;99:1755-60.

Tvete IF, Bjorner T, Aursnes IA, Skomedal T. A 3-year survey quantifying the risk of dose escalation of benzodiazepines and congeners to identify risk factors to aid doctors to more rationale prescribing. *BMJ Open* 2013;3:e003296.

Westin AA, Bramness JG, Chalabianloo F, Rygnestad T, Slordal L. [Pregabalin should be moved to the prescription group B]. *Tidsskr Nor Laegeforen* 2013 Mar 19;133:615-6.

2012:

Berge LI, Riise T, Fasmer OB, Lund A, Oedegaard KJ, Hundal O. Risk of depression in diabetes is highest for young persons using oral anti-diabetic agents. *Diabet Med.* 2012;29:509-14.

Blix HS, Hjellvik V. Økt bruk av antibiotika blant 19-åringar i mai. [Increased use of antibiotics among nineteen-year-olds in May]. *Tidsskr Nor Laegeforen.* 2012 ;132:1084-8. In Norwegian.

Blix HS, Landmark K, Selmer R, Reikvam Å. Forskrivning av antihypertensive legemidler 1975–2010. [Patterns in the prescription of antihypertensive drugs in Norway, 1975 – 2010] *Tidsskr Nor Laegeforen* 2012;132:1224-8. In Norwegian.

Bramness JG, Furu K, Skurtveit S, Engeland A. Effect of withdrawal of carisoprodol on use of other prescribed drugs with abuse potential. *Clin Pharmacol Therap* 2012;91:438-41.

Bramness JG, Skurtveit S, Mørland J, Engeland A. An increased risk of motor vehicle accidents after prescription of methadone. *Addiction.* 2012;107:967-72.

Devold H, Furu K, Skurtveit S, Tverdal A, Falck JA, Søgård AJ. Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway. *Pharmacoepidemiol Drug Saf.* 2012;21:297-304.

Devold HM, Søgård AJ, Tverdal A, Falck JA, Furu K, Meyer HE. Hip fracture and other predictors of anti-osteoporosis drug use in Norway. *Osteoporosis International* 2012;24:1225-33.

Fasmer OB, Riise T, Lund A, Dilsaver SC, Hundal O, Ødegaard KJ. Comorbidity of migraine with ADHD. *J Attend Disord* 2012;16:339-45.

Fredheim OMS, Moksnes K, Borchgrevink PC, Skurtveit S. Opioid switching to methadone: A pharmacoepidemiological study from a national prescription database. *Palliative Medicine* 2012;26:804-12.

Fredheim OM, Moksnes K, Borchgrevink PC, Skurtveit S. Opioid switching to methadone: a pharmacoepidemiological study from a national prescription database. *Palliat Med* 2012;26;804-812.

Gedde-Dahl A, Devold HM, Molden E. Statin medication in patients treated with antiepileptic drugs in Norway. *Pharmacoepidemiology and Drug Safety* 2012;21:881-5.

Gjelsvik B, Heyerdahl F, Hawton K. Prescribed medication availability and deliberate self-poisoning: a longitudinal study. *J Clin Psychiatry.* 2012;73:e548-54.

Handal M, Skurtveit S, Mørland JG. Samtidig bruk av ulike benzodiazepiner. [Co-medication with benzodiazepines]. *Tidsskr Nor Laegeforen.* 2012;132:526-30. In Norwegian.

Hartz I, Furu K, Bratlid T, Handal M, Skurtveit S. Hypnotic drug use among 0-17 year olds during 2004–2011: A nationwide prescription database study. *Scandinavian Journal of Public Health* 2012;40:704-11.

Hjellvik V, Mahic M, Tverdal A. Utdanning og legemiddelbruk. [Education and use of drugs in Norway]. *Tidsskr Nor Laegeforen* 2012;132:2166-70. In Norwegian.

Karlstad O, Nafstad P, Tverdal A, Skurtveit S, Furu K. Comorbidities in an asthma population 8–29 years old: A study from the Norwegian Prescription Database. *Pharmacoepidemiology and Drug Safety* 2012;21:1045-52.

Kieler H, Artama M, Engeland A, Ericsson O, Furu K, Gissler M, Nørgaard M, Nielsen RB, Stephansson O, Valdimarsdottir U, Zoega H, Haglund B. Selective serotonin-reuptake inhibitors during pregnancy and risks of persistent pulmonary hypertension of the newborn: population based cohort study from the five Nordic countries *BMJ.* 2012 Jan 12;344:d8012. doi: 10.1136/bmj.d8012.

Kjome RL, Roraas T, Granas AG, Sandberg S. [Regional differences in sales of glucometer strips and antidiabetics]. *Tidsskr Nor Laegeforen* 2012;132:1453-7.

- Kjosavik SR, Ruths S, Hunskaar S. Use of addictive anxiolytics and hypnotics in a national cohort of incident users in Norway. *Eur J Clin Pharmacol* 2012;68: 311-9.
- Kvaale MK, Grave K, Kristoffersen AB, Norström M. The prescription rate of antibacterial agents in dogs in Norway – geographical patterns and trends during the period 2004–2008. *Journal of Veterinary Pharmacology and Therapeutics* 2012;36:285-291.
- Langhammer A, Krokstad S, Romundstad P, Heggland J, Holmen J. The HUNT study: Participation is associated with survival and depends on socioeconomic status, diseases and symptoms. *BMC Medical Research Methodology* 2012;12:143.
- Lillemoen PKS, Kjosavik SR, Hunskaar S, Ruths S. [Prescriptions for ADHD medication, 2004 – 08]. *Tidsskr Nor Laegeforen* 2012;132:1856-60.
- Mellbye A, Svendsen K, Borchgrevink PC, Skurtveit S, Fredheim OMS. Concomitant medication among persistent opioid users with chronic non-malignant pain. *Acta Anaesthesiologica Scandinavica* 2012;56:1267-76.
- Neutel CI, Skurtveit S, Berg C. What is the point of guidelines? Benzodiazepine and z-hypnotic use by an elderly population. *Sleep Medicine* 2012;13:893-7.
- Neutel I, Skurtveit S, Berg C. Polypharmacy of potentially addictive medication in the older persons – quantifying usage. *Pharmacoepidemiol Drug Saf* 2012;21:199-206
- Neutel CI, Skurtveit S, Berg C. Benzodiazepine and z-hypnotic use in Norwegian elderly, aged 65-79. *Norsk Epidemiologi* 2012;22:203-8.
- Nordbø A, Skurtveit S, Borchgrevink PC, Kaasa S, Fredheim OM. Low-dose transdermal buprenorphine – long-term use and co-medication with other potentially addictive drugs. *Acta Anaesthesiol Scand.* 2012;56:88-94.
- Nordfjærn T. A population-based cohort study of anxiety, depression, sleep and alcohol outcomes among benzodiazepine and z-hypnotic users. *Addictive Behaviors* 2012;37:1151-7.
- Nyborg G, Straand J, Brekke M. Inappropriate prescribing for the elderly – A modern epidemic? *European Journal of Clinical Pharmacology* 2012;68:1085-94.
- Pedersen L, Hansen AB, Svendsen K, Skurtveit S, Borchgrevink PC, Fredheim OMS. [Reimbursement of analgesics for chronic pain]. *Tidsskr Nor Laegeforen* 2012;132:2489-93.
- Romoren M, Lindbaek M, Nordeng H. Pregnancy outcome after gestational exposure to erythromycin – a population-based register study from Norway. *British Journal of Clinical Pharmacology* 2012;74:1053-62.
- Rønning PA, Helseth E, Meling TR, Johannesen TB. A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme. *Neuro-Oncology* 2012;14:1178-84.
- Selmer R, Blix HS, Landmark K, Reikvam Å. Choice of initial antihypertensive drugs and persistence of drug use—a 4-year follow-up of 78,453 incident users. *Eur J Clin Pharmacol* 2012;68:1435-42.
- Skjeldestad FE. [Prescribing contraception for young women]. *Tidsskr Nor Laegeforen.* 2012;132:292-4.
- Steffenak AKM, Wilde-Larsson B, Skurtveit S, Furu K, Nordström G, Hartz I. Mental distress and subsequent use of psychotropic drugs among adolescents – a prospective register linkage study. *J Adolescent Health* 2012;50:578-87
- Steffenak AKM, Wilde-Larsson B, Nordström G, Skurtveit S, Hartz I. Increase in psychotropic drug use between 2006 and 2010 among adolescents in Norway: A nationwide prescription database study. *Clinical Epidemiology* 2012;4:225-31.
- Stene LE, Dyb G, Tverdal A, Jacobsen GW, Schei B. Intimate partner violence and prescription of potentially addictive drugs: prospective cohort study of women in the Oslo Health Study. *BMJ Open.* 2012 Apr 5;2(2):e000614.
- Svendal G, Fasmer OB, Engeland A, Berk M, Lund A. Co-prescription of medication for bipolar disorder and diabetes mellitus: A nationwide population-based study with focus on gender differences. *BMC Medicine* 2012;10:148.
- Svendsen K, Skurtveit S, Romundstad P, Borchgrevink PC, Fredheim OM. Differential patterns of opioid use: defining persistent opioid use in a prescription database. *Eur J Pain* 2012;16:359-69.
- Viktil KK, Engeland A, Furu K. Outcomes after antirheumatic drug use before and during pregnancy – a cohort study among 150 000 pregnant women and expectant fathers. *Scand J Rheum* 2012;41:196-201.
- Von Soest T, Bramness JG, Pedersen W, Wichstrøm L. The relationship between socio-economic status and antidepressant prescription: A longitudinal survey and register study of young adults. *Epidemiology and Psychiatric Sciences* 2012;21:87-95.

Åsvold BO, Vatten LJ, Midthjell K, Bjørø T. Serum TSH within the reference range as a predictor of future hypothyroidism and hyperthyroidism: 11-year follow-up of the HUNT Study in Norway. *J Clin Endocrinol Metab.* 2012;97:93-9.

2011:

Berg C, Sakshaug S, Handal M, Skurtveit S. Z-hypnotika – Sovemidlene som dominerer markedet i Norge. *Norsk Farmaceutisk Tidsskrift* 2011;4:20-23.

Blix H, Hjellvik V, Litlekare I, Rønning M, Tverdal A. Cigarette smoking and risk of subsequent use of antibacterials: a follow-up of 365 117 men and women. *J Antimicrob Chemother* 2011;66:2159-67.

Bramness JG, Sexton JA. The basic pharmacoepidemiology of benzodiazepine use in Norway 2004-9. *Norsk Epidemiologi* 2011; 21: 35-42

Brekke M, Straand J. Does present use of cardiovascular medication reflect elevated cardiovascular risk scores estimated ten years ago? A population based longitudinal observation study. *BMC Public Health.* 2011;11:144.

Dalen DM, Furu K, Locatelli M, Strøm S. Generic substitution: micro evidence from register data in Norway. *Eur J Health Econ* 2011;12:49-59.

Engeland A, Bjørge T, Daltveit AK, Skurtveit S, Vangen S, Vollset SE, Furu K. Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230.000 women in Norway. *Eur J Epidemiol* 2011;26:157-63.

Espnes MG, Bjørge T, Engeland A. Comparison of recorded medication use in the Medical Birth Registry of Norway with prescribed medicines registered in the Norwegian Prescription Database. *Pharmacoepidemiol Drug Saf* 2011;20:243-8.

Fasmer OB, Riise T, Eagan TM, Lund A, Dilsaver SC, Hundal Ø, Ødegaard KJ. Comorbidity of asthma with ADHD. *J Atten Disord* 2011;15:564-71.

Fredheim OM, Borchgrevink P, Nordstrand B, Clausen T, Skurtveit S. Prescription of analgesics to patients in opioid maintenance therapy: A pharmacoepidemiological study. *Drug Alcohol Depend* 2011;116:158-62.

Furu K, Karlstad Ø, Skurtveit S, Håberg SE, Nafstad P, London SJ, Nystad W. High validity of mother-reported use of antiasthmatics among children: a comparison with a population-based prescription database. *J Clin Epidemiol* 2011;64:878-84.

Furu K, Skurtveit S. Legemidler forskrevet til barn og ungdom i alderen 0-17 år i Norge. En studie basert på data fra Reseptregisteret. *Norsk Farmaceutisk Tidsskrift* 2011;119:14-7. In Norwegian.

Ghaderi S, Nordbø SA, Bakken IJ. Chlamydiainfeksjon i Sør-Trøndelag – behandling og oppfølging. [Chlamydia infections in South Trøndelag – treatment and follow-up]. *Tidsskr Nor Laegeforen* 2011;131:461-3. In Norwegian.

Godman B, Sakshaug S, Berg C, Wettermark B, Haycox A. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. *Expert Rev Pharmacoecon Outcomes Res.* 2011;11:121-9.

Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, Garuoliene K, Herholz H, Joppi R, Kalaba M, Laius O, Lonsdale J, Malmström R, Martikainen J, Samaluk V, Sermet C, Schwabe U, Teixeira I, Tilson L, Tulunay F, Vlahovic-Palcevski V, Wendykowska K, Wettermark B, Zara Corinne Gustafsson L. Policies to enhance prescribing efficiency in Europe: findings and future implications. *Frontiers in Pharmacology* 2011

Gjelstad S, Straand J, Dalen I, Fetveit A, Strøm H, Lindbæk M. Do general practitioners' consultation rates influence their prescribing patterns of antibiotics for acute respiratory tract infections? *J Antimicrob Chemother* 2011;66:2425-33.

Hancock D, Håberg SE, Furu K, Whitworth KV, Nafstad P, Nystad W, London SJ. Oral contraceptive pill use before pregnancy and respiratory outcomes in early childhood. *Pediatr Allergy Immunol* 2011;22:528-36.

Handal M, Engeland A, Rønning M, Skurtveit S, Furu K. Use of prescribed opioid analgesics and co-medication with benzodiazepines in women before, during and after pregnancy. A population based cohort study. *Eur J Clin Pharmacol* 2011;67:953-60

Harman C, Reid M, Thomas KV. In situ calibration of a passive sampling device for selected illicit drugs and their metabolites in wastewater, and subsequent year-long assessment of community drug usage. *Environ Sci Technol.* 2011;45:5676-82.

Hartz I, Bramness JG, Skurtveit S. Prescription of antidepressants to patients on opioid maintenance therapy – a pharmacoepidemiological study *Norsk Epidemiologi* 2011;21:77-83.

Hartz I, Tverdal, Aa, Skurtveit S. Langtidsbruk av benzodiazepiner i kombinasjon med opioider og z-hypnotika blant uføretrygdede i Norge. *Norsk Farmaceutisk Tidsskrift* 2011; 119, 24-28

- Hjellvik V, Tverdal A, Strøm H. Boiled coffee intake and subsequent risk for Type 2 Diabetes. *Epidemiology* 2011;22:418-21.
- Hofvind S, Sakshaug S, Ursin G, Graff-Iversen S. Breast cancer incidence trends in Norway –explained by hormone therapy or mammographic screening? *International Journal of Cancer* 2011;95:51-9.
- Karlstad Ø, Tverdal A, Skurtveit S, Nafstad P, Furu K. A prospective study of asthma and subsequent use of hypnotics in young adults. *Pharmacoepidemiol Drug Saf* 2011;20:370-7
- Kjosavik SR, Hunskaar S, Aarsland D, Ruths S. Initial prescription of antipsychotics and antidepressants in general practice and specialist care in Norway. *Acta Psychiatr Scand* 2011;123:459-65.
- Kvaale MK, Grave K, Bangen M, Norström M. Forskrivning av antibakterielle midler til hund og katt i Norge i perioden 2005–2008. *Norsk Veterinærtidsskrift* 2011;123:76-79. In Norwegian.
- Landmark CJ, Fossmark H, Larsson PG, Rytter E, Johannessen SI. Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population. *Epilepsy Res.* 2011;95:51-9.
- Langballe EM, Engdahl B, Selbaek G, Nordeng H. Concomitant use of anti-dementia drugs with psychotropic drugs in Norway—a population-based study. *Pharmacoepidemiol Drug Saf.* 2011;20:1319-26
- Log T, Hartz I, Handal M, Tverdal A, Furu K, Skurtveit S. The association between smoking and subsequent repeated use of prescribed opioids among adolescents and young adults – a population-based cohort study. *Pharmacoepidemiol Drug Saf* 2011;20:90-8.
- Log T, Skurtveit S, Tverdal A, Furu K, Hartz I. Dispensing of prescribed analgesics in Norway among young people with foreign- or Norwegian-born parents. *Scand J Pain* 2011;2:36-44.
- Mahic M, Skurtveit S, Selmer R, Rønning M, Furu K. Prevalence, incidence and persistence of etanercept and adalimumab in Norway 2005–2009. *Pharmacoepidemiol Drug Saf.* 2011;20:457-63.
- Neubert A, Hsia Y, de Jong-van den Berg LT, Janhsen K, Glaeske G, Furu K, Kieler H, Nørgaard M, Clavenna A, Wong IC. Comparison of anti-diabetic drug prescribing in children and adolescents in seven European countries. *Br J Clin Pharmacol.* 2011;72:969-77.
- Skurtveit S, Furu K, Handal M, Borchgrevink P, Fredheim O. To what extent does a cohort of new users of weak opioids develop persistent or probable problematic opioid use? *Pain* 2011;152:1555-61.
- Zoega H, Furu K, Halldórsson M, Thomsen PH, Sourander A, Martikainen JE. Use of ADHD drugs in the Nordic countries: A population-based comparison study. *Acta Psychiatr Scand* 2011;123:360-7.
- Ødegaard KJ, Dilsaver SC, Hundal O, Riise T, Lund A, Akiskal HS, Fasmer OB. Are migraine and bipolar disorders comorbid phenomena?: findings from a pharmacoepidemiological study using the Norwegian Prescription Database. *J Clin Psychopharmacol.* 2011;31:734-9.
- Ødegaard KJ, Riise T, Dilsaver S, Lund A, Akiskal H, Fasmer OB, Hundal Ø. A pharmaco-epidemiological study of migraine and antidepressant medications: Complete one year data from the Norwegian population. *J Affective Disorders* 2011;129:198-204.
- 2010:**
- Amundsen MO, Engdahl B, Berg C, Nordeng H. Cardiovascular co-medication among users of antiobesity drugs: a population-based study. *Pharm World Sci.* 2010;32:752-8.
- Amundsen MO, Engdahl B, Berg C, Nordeng H. Use of psychotropic drugs and analgesics among users of antiobesity drugs—a population based study. *Pharmacoepidemiol Drug Saf* 2010;19:273-9.
- Andersen JB, Engeland A, Owe JF, Gilhus NE. Myasthenia gravis requiring pyridostigmine treatment in a national population cohort. *Eur J Neurol* 2010;17:1445-50.
- Berg A, Furu K, Einen, M, Spigseth O: Bør barn behandles med efedrin mikstur? [Should children be treated with ephedrine mixture?]. *Tidsskr Nor Lægeforen* 2010;24: 2474-5. In Norwegian.
- Berge HM, Gjelstad S, Furu K, Straand J. Glukosaminbruk reduserer ikke behovet for analgetika [Use of glucosamine does not reduce the need for other pain-relieving drugs]. *Tidsskr Nor Laegeforen* 2010;130:1463-6. In Norwegian.
- Bramness JG, Rossow I. Can the total consumption of a medicinal drug be used as an indicator of excessive use? The case of carisoprodol. *Drugs: Education, Prevention, and Policy* 2010;17:168-80

Bramness J, Sandvik P, Engeland A, Skurtveit S. Does pregabalin (Lyrica) help patients reduce their use of benzodiazepines? A comparison with gabapentin using the Norwegian Prescription Database. *Basic Clin Pharmacol Toxicol* 2010;107:883-6

Devold HM, Doung GM, Tverdal A, Furu K, Meyer HE, Falch JA, Sjøgaard AJ. Prescription of anti-osteoporosis drugs during 2004–2007 – a nationwide register study in Norway. *Eur J Clin Pharmacol* 2010;66:299-306.

Fredheim OM, Skurtveit S, Breivik H, Borchgrevink P. Increasing use of opioids from 2004 to 2007 – Pharmacoepidemiological data from a complete national prescription database in Norway. *Eur J Pain* 2010;14:289-294.

Fredheim OM, Log T, Olsen W, Skurtveit S, Sagen Ø, Borchgrevink P. Prescription of opioids to children and adolescents; a study from a national prescription database in Norway. *Pediatric Anesthesia* 2010;20:537-544.

Furu K, Skurtveit S, Strøm H, Rønning M. Reseptregisteret 2004–2009 – en kilde til informasjon. *Norsk Farmaceutisk Tidsskrift* 2010;12:29-31.

Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sørensen HT. The Nordic Countries as a cohort for pharmacoepidemiological research. *Basic Clin Pharmacol Toxicol* 2010;106:86-94.

Gjerden P, Slørdal L, Bramness JG. Prescription persistence and safety of antipsychotic medication: a national registry-based 3-year follow-up. *Eur J Clin Pharmacol* 2010;66:911-7.

Hartz I, Tverdal A, Skille E, Skurtveit S. Disability pension as a predictor of later use of benzodiazepines among benzodiazepines users. *Soc Sci Med* 2010;70:921-5.

Hausken AM, Furu K, Tverdal A, Skurtveit S. Mental distress and subsequent use of anxiolytic drugs – a prospective population-based cohort study of 16 000 individuals. *Scand J Public Health* 2010;38:465-73.

Hjellvik V, Tverdal A, Furu K. Body mass index as predictor for asthma: a cohort study of 118 723 males and females. *Eur Resp J* 2010;35:1235-42.

Hunnskaar S, Welle-Nilsen LK. The market lifecycle of duloxetine for urinary incontinence in Norway. *Acta Obstet Gynecol Scand.* 2010;89:217-22

Kann IC, Biørn E, Lurås H. Competition in general practice: prescriptions to the elderly in a list patient system. *J Health Econ.* 2010;29:751-64

Karlstad Ø, Nafstad P, Tverdal A, Skurtveit S, Furu K. Prevalence, incidence and persistence of anti-asthma medication use in 2- to 29-year-olds: a nationwide prescription study. *Eur J Clin Pharmacol* 2010;66:399-406.

Karouni M, Arulthas S, Larsson PG, Rytter E, Johannessen SI, Landmark CJ. Psychiatric comorbidity in patients with epilepsy: a population-based study. *Eur J Clin Pharmacol* 2010;66:1151-60.

Kjome RL, Granas AG, Nerhus K, Roraas TH, Sandberg S. The prevalence of self-monitoring of blood glucose and costs of glucometer strips in a nationwide cohort. *Diabetes Technol Ther* 2010;12:701-5.

Kornør H, Pedersen W, von Soest T, Rossow I, Bramness JG. Bruk av benzodiazepiner og cannabis blant unge voksne [Use of benzodiazepines and cannabis in young adults]. *Tidsskr Nor Laegeforen* 2010 ;130:928-31. In Norwegian.

Skurtveit S, Furu K, Bramness J, Selmer R, Tverdal A. Benzodiazepines predict use of opioids – a follow-up study of 17 074 men and women. *Pain Med* 2010;11:805-14.

Skurtveit S, Furu K, Selmer R, Handal M, Tverdal A. Nicotine dependence predicts repeated use of prescribed opioids. Prospective population-based cohort study. *Ann Epidemiol* 2010;20:890-7.

Vandraas K, Spigset O, Mahic M, Slørdal S. Non-steroidal anti-inflammatory drugs: use and co-treatment with potentially interacting medications in the elderly. *Eur J Clin Pharmacol* 2010;66:823-9.

2009:

Bachs LC, Engeland A, Mørland JG, Skurtveit S. The risk of motor vehicle accidents involving drivers with prescriptions for codeine or tramadol. *Clin Pharmacol Ther* 2009;85:596-9.

Bramness JG. Bruk av litium i Oslo og i Sogn og Fjordane [Use of lithium in the Norwegian counties Oslo and Sogn og Fjordane]. *Tidsskr Nor Laegeforen* 2009;129:855-7. In Norwegian.

Bramness JG. Ungdom og dagliglivets smerter. [Adolescents and everyday life pains]. *Tidsskr Nor Laegeforen* 2009; 129:1444. In Norwegian.

- Bramness JG, Grøholt B, Engeland A, Furu K. The use of lithium, valproate or lamotrigine for psychiatric conditions in children and adolescents in Norway 2004–2007 – a prescription database study. *J Affect Disord* 2009; 117:208-11.
- Bramness JG, Skurtveit S, Neutel I, Mørland J, Engeland A. An increased risk of road traffic accidents after prescriptions of lithium or valproate? *Pharmacoepidemiol Drug Saf* 2009;18:492-6.
- Bramness JG, Weitoft GR, Hallas J. Use of lithium in the adult populations of Denmark, Norway and Sweden. *J Affect Disord* 2009;118:224-8.
- Devold H, Molden E, Skurtveit S, Furu K. Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy. *Brit J Clin Pharmacol* 2009;67:234-41.
- Engeland A, Bjørge T, Daltveit AK, Vollset SE, Furu K. Validation of disease registration in pregnant women in the Medical Birth Registry of Norway. *Acta Obstet Gynecol Scand* 2009;88:1083-9.
- Fredheim OM, Skurtveit S, Moroz A, Breivik H, Borchgrevink P. Prescription pattern of codeine for non-malignant pain in Norway- a pharmacoepidemiological study from The Norwegian Prescription Database. *Acta Anaesthesiol Scand* 2009;53:627-33.
- Gjerden P, Bramness JG, Slørdal L. The use and potential abuse of anticholinergic antiparkinson drugs in Norway: a pharmacoepidemiological study. *Br J Clin Pharmacol* 2009;67:228-33.
- Gjerden P, Slørdal L, Bramness JG. Association between the use of anticholinergic antiparkinson drugs and safety and receptor drug-binding profiles of antipsychotic agents. *Eur J Clin Pharmacol* 2009;65:1229-35.
- Gjerden P, Slørdal L, Bramness JG. The use of antipsychotic and anticholinergic antiparkinson drugs in Norway after the withdrawal of orphenadrine. *Br J Clin Pharmacol* 2009;68:238-42.
- Hartz I, Lundesgaard E, Tverdal A, Skurtveit S. Disability pension is associated with the use of benzodiazepines 20 years later: A prospective study. *Scand J Public Health* 2009;37:320-6.
- Hartz I, Tverdal A, Skurtveit S. A comparison of self-reported data on disability pension status with data from a nationwide administrative register. *Nor J Epidemiol* 2009;19:169-172.
- Hartz I, Tverdal A, Skurtveit S. Social inequalities in use of potentially addictive drugs in Norway – use among disability pensioners. *Nor J Epidemiol* 2009;19:209-218.
- Hauge S, Blix HS, Borgen K, Hungnes O, Dudman SG, Aavitsland P. Sales of oseltamivir in Norway prior to the emergence of oseltamivir resistant influenza A(H1N1) viruses in 2007-08. *Virology* 2009;6:54.
- Hausken AM, Furu K, Skurtveit S, Engeland A, Bramness JG. Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of predictors. *Eur J Clin Pharmacol* 2009;65:295-301.
- Håkonsen GD, Pettersen MH, Skurtveit S, Giverhaug T. Samtidig bruk av warfarin, analgetika og antiinflammatoriske midler. [Concomitant use of warfarin, analgesics and anti-inflammatory drugs]. *Tidsskr Nor Laegeforen* 2009;129:1217-20. In Norwegian.
- Kjosavik SR, Ruths S, Hunskaar S. Psychotropic drug use in the Norwegian general population in 2005: data from the Norwegian Prescription Database *Pharmacoepidemiol Drug Saf* 2009;18:572-8.
- Landmark CJ, Larsson P, Rytter E, Johannessen SI. Antiepileptic drugs in epilepsy and other disorders – a population-based study of prescriptions. *Epilepsy Res* 2009; 87: 31-9.
- Selmer R, Sakshaug S, Skurtveit S, Furu K, Tverdal A. Statin treatment in a cohort of 20 212 men and women in Norway according to cardiovascular risk factors and level of education. *Brit J Clin Pharmacol* 2009;67:355-62.
- Skurtveit S, Furu K, Kaasa S, Borchgrevink P. Introduction of low dose transdermal buprenorphine – did it influence use of potentially addictive drugs in chronic non-malignant pain patients? *Eur J Pain* 2009;13:949-53.
- Skurtveit S, Strøm H, Skriverhaug T, Mørland J, Bramness J, Engeland A. Road traffic accident risk in patients with diabetes mellitus, receiving blood glucose-lowering drugs. Prospective follow-up study. *Diabet Med* 2009; 26:404-08.
- Viktil K, Engeland A, Furu K. Use of antirheumatic drugs in mothers and fathers before and during pregnancy – a population-based cohort study *Pharmacoepidemiol Drug Saf* 2009;18:737-42.
- Winther RB, Bramness JG. Legemiddelshopping av vanedannende medikamenter i Norge [Prescription shopping of addictive drugs in Norway]. *Tidsskr Nor Laegeforen* 2009;129:517-20. In Norwegian.

2008:

- Bachs LC, Bramness JG, Engeland A, Skurtveit S. Repeated dispensing of codeine is associated with high consumption of benzodiazepines. *Nor J Epidemiol* 2008;18:185-90.
- Berg A, Furu K, Spigset O. Slimhinneavsvellende nesedråper og nesesypray hos barn [Nasal decongestants and nasal sprays in children]. *Tidsskr Nor Laegeforen* 2008;128:2582-3. In Norwegian.
- Bramness JG, Buajordet I, Skurtveit S. The role of pharmacoepidemiological studies in the market withdrawal of carisoprodol (Somadril®) in Europe. *Nor J Epidemiol* 2008;18:167-72.
- Bramness JG, Skurtveit S. Carisoprodol should be taken off the market. *South Med J* 2008;101:1074-5.
- Bramness JG, Skurtveit S, Neutel CI, Mørland J, Engeland A. Minor increase in risk of road traffic accidents after prescriptions of antidepressants. *J Clin Psych* 2008; 69:1099-1103.
- Brekke M, Rognstad, Straand J, Furu K, Gjelstad S, Bjørner T, Dalen I. Pharmacologically inappropriate prescriptions for elderly patients in general practice: How common? Baseline data from The Prescription Peer Academic Detailing (Rx-PAD) study. *Scand J Prim Health Care* 2008;26:80-5.
- Engeland A, Bramness JG, Daltveit AK, Rønning M, Skurtveit S, Furu K. Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106,000 pregnancies in Norway 2004-06. *Br J Clin Pharmacol* 2008;65:653-60.
- Engeland A, Bramness JG, Mørland J, Skurtveit S. Veitrafikkulykker knyttet til forskrivning av legemidler: en registerbasert kohortstudie. [Traffic accident risks associated with the prescription of medicinal drugs: a registry-based cohort study] *Nor J Epidemiol* 2008;18: 159-66.
- Fetveit A, Straand J, Bjorvatn B. Sleep disturbances in an arctic population: the Tromsø Study. *BMC Health Serv Res* 2008;8:117.
- Furu K. Establishment of the nationwide Norwegian Prescription Database (NorPD) – New opportunities for research in pharmacoepidemiology in Norway. *Nor J Epidemiol* 2008; 18:129-36.
- Gustavsen I, Bramness JG, Skurtveit S, Engeland A, Neutel CI, Mørland J. Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam. *Sleep Med* 2008;9:818-22.
- Hagen K, Stovner LJ, Skorpen F, Pettersen E, Zwart JA. COMT genotypes and use of antipsychotic medication: linking population-based prescription database to the HUNT study. *Pharmacoepidemiol Drug Saf* 2008;17:372-7.
- Litleskare I, Blix H, Rønning M. Antibiotikaforbruk i Norge [Antibiotic use in Norway]. *Tidsskr Nor Laegeforen* 2008;128:2324-9. In Norwegian.
- Olsen AS, Ottesen S. Varierende forskrivning av opioider til norske kreftpasienter [Variable prescription of opioids to cancer patients in Norway]. *Tidsskr Nor Laegeforen* 2008;128:1271-4. In Norwegian.
- Skurtveit S, Furu K, Bramness JG, Tverdal A. Benzodiazepine use in all alcohol consumers predicts use of opioids in patients 20 years later – a follow-up study of 13 390 men and women aged 40-42 years. *Pharmacoepidemiol Drug Saf* 2008;17:926-933.
- Skurtveit S, Selmer R, Tverdal A, Furu K. The validity of self-reported prescription medication use among adolescents varied by therapeutic class. *J Clin Epidemiol* 2008;61:714-17.
- Strøm H, Sakshaug S, Skurtveit S. Use of statins in patients receiving oral blood glucose-lowering drugs. *Nor J Epidemiol* 2008;18:191-94.

2007:

- Al-Haroni M, Skaug N. Incidence of antibiotic prescribing in dental practice in Norway and its contribution to national consumption. *J Antimicrob Chemother* 2007;59:1161-6.
- Blix HS, Engeland A, Litleskare I, Rønning M. Age- and gender-specific antibacterial prescribing in Norway. *J Antimicrob Chemother* 2007;59:971-6.
- Bramness JG, Engeland A, Furu K. Antidepressiver hos barn og ungdom – førte advarsler til færre forskrivninger? [The use of antidepressants amongst children and adolescents – did the warnings lead to fewer prescriptions?] *Tidsskr Nor Laegeforen* 2007;127:2653-5. In Norwegian.
- Bramness JG, Furu K, Engeland A, Skurtveit S. Carisoprodol use and abuse in Norway. A pharmacoepidemiological study. *Br J Clin Pharmacol* 2007;64: 210-8.

Bramness JG, Kornør H. Benzodiazepine prescription for patients in opioid maintenance treatment in Norway. *Drug Alcohol Depend* 2007;90:203-9.

Bramness JG, Skurtveit S, Mørland J, Engeland A. The risk of road traffic accidents after prescriptions of carisoprodol. *Accid Anal Prev* 2007;39:1050-5.

Engeland A, Skurtveit S, Mørland J. Risk of road traffic accidents associated with the prescription of medicinal drugs: a registry-based cohort study. *Ann Epidemiol* 2007;17:597-602.

Furu K, Skurtveit S, Langhammer A, Nafstad P. Use of anti-asthmatic medications as a proxy for prevalence of asthma in children and adolescents in Norway: a nationwide prescription database analysis. *Eur J Clin Pharmacol* 2007;63:693-8.

Hartz I, Sakshaug S, Furu K, Engeland A, Eggen AE, Njolstad I, Skurtveit S. Aspects of statin prescribing in Norwegian countries with high, average and low statin consumption – an individual-level prescription database study. *BMC Clin Pharmacol* 2007;7:14.

Nygard K, Schimmer B, Sobstad O, Walde A, Tveit I, Langeland N, Hausken T, Aavitsland P. A large community outbreak of waterborne giardiasis-delayed detection in a non-endemic urban area. *BMC Public Health* 2006;6:141.

Sakshaug S, Furu K, Karlstad Ø, Rønning M, Skurtveit S. Switching statins in Norway after new reimbursement policy – a nationwide prescription study. *Br J Clin Pharmacol* 2007;64:476-81.

Torkildsen O, Grytten N, Myhr KM. Immunomodulatory treatment of multiple sclerosis in Norway. *Acta Neurol Scand Suppl* 2007;187:46-50.

Åsheim H, Nilsen KB, Johansen K, Furu K. Forskrivning av sentralstimulerende legemidler ved ADHD i Nordland. [Prescribing of stimulants for ADHD in Nordland county]. *Tidsskr Nor Laegeforen* 2007;127:2360-2. In Norwegian.

2006:

Bramness JG, Skurtveit S, Furu K, Engeland A, Sakshaug S, Rønning M. Endringer i salg og bruk av flunitrazepam etter 1999. [Changes in the sale and use of flunitrazepam in Norway, 1999–2004]. *Tidsskr Nor Laegeforen* 2006;126:589-90. In Norwegian.

Gjelstad S, Fetveit A, Straand J, Dalen I, Rognstad S, Lindback M. Can antibiotic prescriptions in respiratory tract infections be improved? A cluster-randomized educational intervention in general practice--the Prescription Peer Academic Detailing (Rx-PAD) Study [NCT00272155]. *BMC Health Serv Res* 2006;6:75.

Mellingsæter T, Bramness JG, Slørdal L. Benzodiazepinlignende z-hypnotika: bedre og tryggere søvnmidler? [Are z-hypnotics better and safer sleeping pills than benzodiazepines?] *Tidsskr Nor Laegeforen* 2006; 126: 2954-6. In Norwegian.

Straand J, Fetveit A, Rognstad S, Gjelstad S, Brekke M, Dalen I. A cluster-randomized educational intervention to reduce inappropriate prescription patterns for elderly patients in general practice--The Prescription Peer Academic Detailing (Rx-PAD) study [NCT00281450]. *BMC Health Serv Res* 2006;6:72.

Strøm H, Engeland A, Eriksen E, Sakshaug S, Rønning M. Hvor mange og hvem behandles medikamentelt for diabetes mellitus? [How many and who are receiving medication for diabetes mellitus?] *Tidsskr Nor Laegeforen* 2006;126:768-70. In Norwegian.

2005:

Bramness JG, Hausken AM, Sakshaug S, Skurtveit S, Rønning M. Forskrivning av selektive serotoninreuptakshemmere 1990–2004. [Prescription of selective serotonin reuptake inhibitors 1990–2004]. *Tidsskr Nor Laegeforen* 2005;125:2470-3. In Norwegian.

2004:

Strøm H. Reseptbasert legemiddelregister: Et viktig verktøy for å oppnå detaljert legemiddelstatistikk [The Norwegian Prescription Database: An important tool for detailed information on drug use]. *Nor J Epidemiol* 2004;14:53-56.

2001:

Furu K. Drug utilisation in a public health perspective: Establishing a national prescription register in Norway. *Nor J Epidemiol* 2001;11:55-60.

